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Abstract 
 
This thesis addresses the signalling pathways and gene networks associated with 
melanoma cell motility in vivo and heterogeneity in tumour-associated vasculature.  
Melanoma metastasis begins with the acquisition of motility in the primary tumour, 
however, there is little characterisation of signalling pathways or 
microenvironments associated with melanoma motility in vivo.  Intra-vital imaging of 
clonal signalling reporter cell-lines showed heterogeneous cell behaviour in vivo 
and increased Notch, TGF-β and SRF dependent transcription in motile cells.  
Further investigations into Notch signalling in melanoma metastasis showed that 
Notch promotes metastasis through cell-autonomous and non-cell autonomous 
mechanisms.  The reporter cell-lines were used to enrich for the motile melanoma 
cell population and genes up-regulated in this population were identified.  Many 
cell-cycle regulators, including regulators of cytokinesis, were up-regulated in the 
B16 F2 melanoma population enriched for motile cells.  Bioinformatic analysis 
indicated that EZH2, a histone methyltransferase in the Polycomb repressor 2 
complex, can regulate the genes associated with motile cells and EZH2 depletion 
decreased melanoma cell motility in vitro and metastasis in vivo.  EZH2 was also 
shown to regulate cell morphology and the actin cytoskeleton through regulating 
activation of a subset of ERM proteins.  Due to association between melanoma 
metastasis and differentiation, the role of EZH2 in melanoma differentiation state 
was investigated.  EZH2 depletion did not significantly affect expression of 
melanoma differentiation markers but increased Oca2 mRNA expression leading to 
increased pigment.  
 
This thesis also investigates heterogeneity in the tumour microenvironment.  
Morphologically and dynamically distinct regions of the tumour vasculature were 
identified by intra-vital imaging and quantitative image analysis, and these regions 
could be followed over time using imaging windows.  The tumour vasculature 
showed a heterogeneous response to the anti-angiogenic drug, Sunitinib, possibly 
due to microenvironmental factors.  Aspects of vascular morphology and dynamics 
correlated with melanoma motility and may be used to describe microenvironments 
favourable for motility. 
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Images taken over a 51 minute time period.  Note singly motile cells in the middle 
and top right corner. 
 
Supplementary movie 2 B16 F2 melanoma streaming and collective cell 
motility in vivo  
Intra-vital movie of B16 F2 melanoma with cell membrane labelling shown in white.  
Images taken over a 19 minute time period.  Movie has been subject to smoothing 
with a Gaussian filter.  Note streaming cells and a group of cells moving collectively 
in centre. 
 
Supplementary movie 3 B16 F2 melanoma streaming motility in vivo 
Intra-vital movie of B16 F2 melanoma with cell membrane labelling shown in white.  
Images taken over a 22 minute time period.  Movie has been subject to smoothing 
with a Gaussian filter.  Note 2-3 streaming cells in the left centre. 
 
Supplementary movie 4 B16 F2 clonal Notch reporter in vivo 
Intra-vital movie of clonal B16 F2 Notch reporter cell-line.  Cell membranes shown 
in red and Notch reporter activity shown in green.  Autofluorescence also visible in 
green channel.  Images taken over a 19 minute time period.  Movie has been 
subject to smoothing with a Gaussian filter.  Note a GFP positive cell moving singly 
in top left and 3 GFP positive cells moving in the bottom left. 
 
Supplementary movie 5 B16 F2 clonal TGF-β reporter in vivo 
Intra-vital movie of clonal B16 F2 TGF-β reporter cell-line (with linker).  Cell 
membranes shown in red and TGF-β reporter activity shown in cyan.  Images taken 
over a 19 minute time period.  Movie has been subject to smoothing with a 
Gaussian filter. 
 
Supplementary movie 6 B16 F2 clonal SRF reporter in vivo 
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Intra-vital movie of clonal B16 F2 SRF reporter cell-line.  Cell membranes shown in 
red and SRF reporter activity shown in green.  Autofluorescence also visible in 
green channel.  Images taken over a 13 minute time period. 
 
Supplementary movie 7 B16 F10 motility in vitro 
B16 F10 cells were treated with control or EZH2 targeted siRNA, plated on 
Fibronectin coated glass bottomed cell cultre plates and stimulated with 5 ng/ml 
HGF.  Lowlight images were taken every 10 minutes.  Note tail retraction problems 
on EZH2 siRNA treatment. 
 
Supplementary movie 8 Normal vessels 
Movie of a 3D-reconstruction of a normal vessel.  Endothelial cell membranes 
shown in green and Collagen fibres shown in blue. 
 
Supplementary movie 9 Tumour vessels showing sprouting ends 
Movie of a 3D-reconstruction of tumour-associated sprouting vessels.  Endothelial 
cell membranes shown in green, Collagen fibres shown in blue and B16 F2 
melanoma cells shown in red.  Autofluorescent cells also visible in red channel. 
 
Supplementary movie 10 Tumour and associated vessels overview 
Movie of a 3D-reconstruction of a B16 F2 melanoma and associated vessels.  
Endothelial cell membranes shown in green and B16 F2 melanoma cells shown in 
red.  Autofluorescent cells also visible in red channel.  Angiosense, shown in 
purple, indicates the extent of blood flow. 
 
Supplementary movie 11 Endothelial cells with filopodia protrusions 
Intra-vital movie of tumour-associated vessels in a VE-Cadherin:GFPCAAX 
transgenic mouse.  Endothelial cell membranes labelled in green.  Images taken 
over a 51 minute time period.  Movie is a maximum intensity projection of 6 z-
stacks covering 24 μm.  Note filopodial protrusions. 
 
Supplementary movie 12 Endothelial cells with bleb-like protrusions 
Intra-vital movie of tumour-associated vessels in a VE-Cadherin:GFPCAAX 
transgenic mouse.  Endothelial cell membranes labelled in green.  Images taken 
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over a 40 minute time period.  Note blebbing behaviour of endothelial cells and 
bleb-like protrusions. 
 
Supplementary movie 13 Endothelial cells undergoing intra-vessel wall 
motility 
Intra-vital movie of tumour-associated vessels in a VE-Cadherin:GFPCAAX 
transgenic mouse.  Endothelial cell membranes labelled in green.  Images taken 
over a 38 minute time period.  Note group of endothelial vessels moving within the 
vessel wall.  Movie has been subject to smoothing with a Gaussian filter. 
 
Supplementary movie 14 Endothelial cells undergoing amoeboid-like 
motility distant to vessels 
Intra-vital movie of tumour-associated vessels in a VE-Cadherin:GFPCAAX 
transgenic mouse.  Endothelial cell membranes labelled in green.  Images taken 
over a 28 minute time period.  Note endothelial cells undergoing rounded 
amoeboid-like motility distant to vessels. 
 
Supplementary file 1 
List of genes used in overlap analysis of PRC2 regulated genes and the genes up-
regulated in the B16 population enriched in motile cells. 
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Chapter 1. Introduction 
1.1 Chapter overview 
This thesis describes investigations into heterogeneity in melanoma cell motility in 
vivo and examination of the signalling pathways that correlate with, and may act to 
control, melanoma motility and metastasis.  It also reports on analysis of the 
tumour vasculature in the melanoma microenvironment and response to anti-
angiogenic therapy.  The work uses melanoma cells, so this introduction will have a 
focus on melanoma and normal melanocyte biology.  It will also cover cell motility 
and metastasis in vivo and control of gene expression via the Notch, SRF and 
TGF-β pathways, together with chromatin mediated control of gene transcription.  
In addition, the tumour microenvironment will be discussed, including the tumour 
vasculature and the effects of the microenvironment on motility and invasion. 
 
1.2 Melanocyte and melanoma biology 
Melanoma is a skin cancer arising from the uncontrolled proliferation and invasion 
of melanocytes.  Melanoma is an aggressive disease, but if metastasis is limited to 
local invasion of the skin, surgical resection is adequate.  However, if distant 
metastasis has occurred, prognosis is poor and only 5 -22 % of patients survive 
beyond 5 years (http://info.cancerresearchuk.org/cancerstats/).  Therefore the 
study of melanoma metastasis is important to try to further understand the 
pathways involved and find novel treatments. 
 
1.2.1 Melanocytes 
Melanocytes are the pigment producing cells in the skin and exist in the lower 
levels of the epidermis at regular intervals.  They send out long dendritic processes 
into the epidermis which enable the transport and transfer of melanin to 
keratinocytes (Figure 1.2).  The extent of melanin production and transport 
determines skin colour.  Melanin is synthesised in a melanocyte specific organelle 
called the melanosome where tyrosine is processed into melanin in a number of 
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steps that require the enzymes Tyrosinase (TYR), DOPAchrome tautomerase 
(DCT) and 5,6-dihydroxyindole-2-carboxylic acid oxidase (TYRP1) (Kondo and 
Hearing, 2011).  The P-protein, encoded by Oca2, is localised to melanosomes, 
and although its specific role is currently unknown, it is thought to stimulate pigment 
production by regulation of melanosomal pH (Sitaram et al., 2009).  Melanosomes 
are transported to the cell periphery by kinesin motor proteins on the microtubule 
network.  Melanosomes are subsequently transferred to the actin network at the 
distal region of the dendrite by a complex containing Rab-27A and Myosin-Va 
(Hara et al., 2000) (Strom et al., 2002).  An interaction between Rab-27A, SLP2A 
and phosphatidylserine enables docking of melanosomes at the plasma membrane 
before melanin release and distribution through the epidermis (Kuroda and Fukuda, 
2004). 
 
1.2.2 Melanin production 
Melanin production is mainly stimulated by UV-induced secretion of α-Melanocyte 
Stimulating Hormone (α-MSH) by keratinocytes.  This activates Melanocortin 
receptor 1 (MC1R), a G-protein coupled receptor on melanocytes, which leads to 
an increase in melanocyte cAMP (Figure 1.1).  cAMP activates PKA, which in turn 
phosphorylates and activates cAMP response element-binding transcription factor 
(CREB) (Kondo and Hearing, 2011).  CREB activation results in increased 
transcription of Microphthalmia-associated Transcription Factor (MITF) which 
subsequently induces transcription of target genes such as TYR, DCT and TYRP1 
(Bentley et al., 1994) (Bertolotto et al., 1998) (Yasumoto et al., 1997).  Rab-27A 
expression is also increased by cAMP, which leads to an increase in the rate of 
melanosome transport and melanin export (Chiaverini et al., 2008).  cAMP can also 
affect the dendritic morphology of melanocytes by stimulating Rac and inhibiting 
RhoA activity (Scott and Leopardi, 2003).  Furthermore, the inhibition of RhoA is 
thought to be required for melanogenesis (Busca et al., 1998).  In this way, UV 
radiation acts to increase melanin in the skin and protect cells from further UV-
induced free-radicals and DNA damage. 
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Figure 1.1 Signalling downstream of α-MSH. 
α-MSH binds to and activates the G protein-coupled MC1R. The Gs family of G proteins 
subsequently transmits the signal to Adenylyl cyclase, which catalyzes the conversion 
of ATP to cAMP.   Increased levels of cAMP activate PKA, which in turn, translocates 
to the nucleus and phosphorylates CREB. Phosphorylated CREB then induces 
transcription of genes including MITF.  MITF can subsequently activate transcription of 
DCT, TYR and TYRP1. 
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1.2.3 Melanocyte natural history and differentiation 
Melanocytes are derived from the neural crest, a highly motile population of cells 
that arise from the neural tube in development.  Neural crest cells migrate 
extensively throughout the embryo to form neurons, glia, melanocytes, smooth 
muscle cells and cells of the craniofacial connective tissue (Sauka-Spengler and 
Bronner-Fraser, 2008).  Melanocytes are thought to arise from the migration of 
melanoblasts to the skin, however, recent work suggests that a significant 
proportion also originate from neural crest derived nerves in the skin (Adameyko et 
al., 2009).  The differentiation of neural crest cells into melanoblasts and 
subsequently melanocytes is dependent on the interactions between MITF, SOX-
10, Wnt signalling and Pax-3.  Mitf expression is specific to melanocyte lineages 
and is thought to promote melanocyte differentiation.  Mutation of Mitf results in a 
decrease in melanoblasts early in development and ectopic expression of Mitf 
promotes a pigment cell phenotype (Hornyak et al., 2001) (Tachibana et al., 1996).  
SOX-10, Pax-3 and β-catenin all activate Mitf expression and mutations in these 
genes leads to pigment defects and disease (Cooper and Raible, 2009).  The 
current model for melanocyte differentiation during development involves Pax-3 as 
both an activator of Mitf expression but also a competitor for MITF binding on the 
Dct promoter, such that it promotes MITF expression but prevents MITF dependent 
transcription of Dct.  On activation of Wnt signalling, Pax-3 is displaced from the 
Dct promoter and MITF drives Dct transcription and hence pigment production 
(Lang et al., 2005).  In this model Pax-3 acts to both determine cell fate and to 
maintain cells in a less differentiated state.   
 
1.2.4 Melanoma and metastasis 
Melanoma is largely attributable to somatic mutations caused by ultraviolet (UV) 
radiation exposure.  More than 80 % of melanomas arising in the skin have 
activating mutations in either Braf or Nras, highlighting the importance of MAPK 
pathway in melanoma (Curtin et al., 2005). However, these mutations rarely occur 
together (Gray-Schopfer et al., 2005).  Braf mutations are also found in benign 
melanocytic nevi (Pollock et al., 2003), but most nevi have undergone oncogene-
induced senescence (Michaloglou et al., 2005), suggesting that further mutations 
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are required to initiate melanoma.  Despite this, BRAF is a major regulator of 
oncogenic behaviour in melanoma including regulation of cell survival and invasion 
(Cartlidge et al., 2008) (Arozarena et al., 2011).  In addition, genetic polymorphisms 
in the Cdkn2a (Hussussian et al., 1994), Mc1r (Beaumont et al., 2005) and Mitf 
(Yokoyama et al., 2011) genes can result in a predisposition to the disease 
 
Melanoma progression and invasion is characterised by pathologists into a number 
of stages (Figure 1.2) (Miller and Mihm, 2006).  Initially dysplastic nevi are formed, 
the nevi proliferates within the epidermis and advances to a radial growth phase.  
Then the lesion switches to a vertical growth phase and invades into the lower 
epidermis, dermis and underlying basement membrane.  As the disease 
progresses, angiogenesis increases vascular density and promotes spread to 
distant organs, resulting in metastatic melanoma.  Invasion in the vertical growth 
phase represents acquisition of a metastatic phenotype as the melanoma cells 
move and invade their surroundings (Miller and Mihm, 2006).  Distant metastases 
are subsequently initiated through the motility and invasion of melanoma cells into 
lymphatic or blood vessels, transit in the vessels and successful growth at 
secondary organs.  Melanomas are not only comprised of melanoma cells but also 
stromal cells such as cancer-associated fibroblasts (CAFs), macrophages, T cells, 
adipocytes, blood and lymphatic endothelial cells and pericytes, which all form the 
melanoma microenvironment. 
 
Until the last five years, treatment for melanoma had not changed for decades, but 
the identification of mutant BRAF as a driver of melanoma provided a molecular 
target to inhibit melanoma growth (Davies et al., 2002).  Vemurafenib, a BRAF 
kinase inhibitor with specificity for mutant BRAF was approved in the US in late 
2011 after a phase III trial had to be stopped early when the overall survival benefit 
for vemurafenib became apparent (Chapman et al., 2011).  Despite the positive 
response almost all patients showed resistance with subsequent disease 
progression (Chapman et al., 2011) (Fedorenko et al., 2011).  Multiple mechanisms 
of resistance have been proposed, including increased receptor tyrosine kinase 
expression, Nras and Map2k1 mutations and a RAF kinase switch (Nazarian et al., 
2010) (Greger et al., 2012) (Villanueva et al., 2010). 
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Figure 1.2 Melanoma progression. 
Healthy melanocytes reside in the lower levels of the epidermis and extend dendritic 
protrusions to distribute melanin to keratinocytes.  Melanoma progresses through a 
series of steps starting with a nevus displaying uncontrolled growth.  The nevus initially 
grows radially but then switches to a vertical growth phase invading into the underlying 
dermis.  The last stage, metastatic melanoma, has increased vascular density and 
melanoma cells have colonised distant sites.  
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1.2.5 Melanoma differentiation and metastasis 
Melanoma is a particularly aggressive disease and once it has become metastatic 
it is difficult to treat.  A potential explanation for the aggressive nature of melanoma 
is melanocyte natural history.  Although melanocytes are stationary, they derive 
from highly motile neural crest cells and melanoma cells may revert to a neural 
crest-like state that promotes motility and metastasis.  When a panel of cell-lines 
from different origins were transformed with the same oncogenes, only the 
transformed melanocytes were metastatic (Gupta et al., 2005).  This correlated with 
slug expression, a transcription factor that drives neural crest motility, and slug was 
found to co-operate with oncogenic transformation to drive metastasis.  Nevi were 
also found to express a number of neural crest related motility factors suggesting 
that melanoma may retain characteristics of the less differentiated neural crest cells 
(Gupta et al., 2005). 
 
Reversion to a neural-crest-like state suggests changes in differentiation and there 
is a long standing interest in the relationship between differentiation and melanoma 
invasion and metastasis.  Work in the B16 murine melanoma model together with 
other models has argued that differentiation is associated with both increased and 
decreased metastasis (Bennett et al., 1994) (Kameyama et al., 1990).  The 
confusion may arise from the classification of differentiation.  Most studies used 
increased pigment as a read-out for increased differentiation as differentiated cells 
of the melanocyte lineage produce pigment.  However, as discussed in later 
chapters the two do not always correlate.  More recent work using intra-vital 
imaging of the B16 model has shown that the motile cells in the primary tumour are 
less pigmented and have increased Brn2 promoter activity, a transcription factor 
expressed in melanoblasts (Pinner et al., 2009).  This is suggestive of the motile 
cell population being less differentiated.   
 
MITF, an important transcription factor for melanocyte differentiation has also been 
associated with motile behaviour (Carreira et al., 2006).  Cells with low levels of 
MITF, suggestive of less differentiated melanoma cells, are more invasive and this 
is thought to be due to a decrease in the MITF target DIA1, and a subsequent 
increase in ROCK mediated contractility (Carreira et al., 2006).  In addition, hypoxia 
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results in a down-regulation of MITF and a subsequent increase in the metastatic 
potential of melanoma cells (Cheli et al., 2012).  Interestingly, Brn2 has been 
shown to repress MITF expression and analysis of human tumours showed distinct 
MITF+/Brn2- and MITF-/Brn2+ sub-populations (Goodall et al., 2008).  This has 
lead to the hypothesis that cells may switch between these different states, 
potentially as a result of extracellular signals, leading to changes in motility (Hoek 
and Goding, 2010).  Genome-wide analysis of melanoma cell-lines supports this 
model and proposes that melanoma cells can exist in two states, proliferative or 
invasive, and that a “phenotype switch” between the two may drive invasion and 
metastasis (Hoek et al., 2006) (Hoek et al., 2008).  The differentiation markers 
TYR, TYRP1 and DCT are up-regulated in the proliferative phenotype, indicative of 
high MITF (Widmer et al., 2012).  This implies that the invasive phenotype has low 
expression of differentiation associated genes and potentially represents a less 
differentiated state.   
 
Less differentiated cells in melanoma may arise from loss of the differentiation 
program (de-differentiation), possibly mediated by cell-autonomous factors or 
factors from the microenvironment.  Alternatively, less differentiated cells may 
represent the cancer stem cell population in melanoma.  The field of melanoma 
stem cells is complex due to a variety of reports describing different markers and 
using mice of various immune competencies to demonstrate melanoma stem-like 
cells (Fukunaga-Kalabis et al., 2011).  The proposed frequency of melanoma stem 
cells is also vastly different.  In addition, the identification of a population of slow-
cycling JARID1B positive cells that has stem-like properties in vivo suggests 
melanoma may not follow the classical hierarchy of stem cells and differentiated 
progeny, as JARID1B negative cells can give rise to JARID1B positive cells 
(Roesch et al., 2010).  Further support for a dynamic melanoma cell phenotype 
comes from the phenotype switching model discussed previously.  What is clear is 
that on a cell to cell basis, melanoma is a highly heterogeneous disease, however 
further investigation is required to determine the signalling pathways associated 
with, and regulating, heterogeneity and phenotype switching. 
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1.3 Metastasis and the microenvironment 
As discussed previously, metastasis is the spread of cancer cells from the primary 
tumour to distant organs and is the main cause of death in cancer patients (Figure 
1.3).  It requires a number of steps and thankfully is an inefficient process, which 
likely demonstrates the wide range of behaviours required for a cancer cell to 
initiate distant metastases.   
 
1.3.1 Exiting the primary tumour 
Metastasis starts with the acquisition of motility in the primary tumour.  A full 
discussion of cancer cell motility in vivo can be found in the next section, however, 
most of the cells in the primary tumour are non-motile and both extrinsic and 
intrinsic factors influence the acquisition of motility.  Extrinsic factors include signals 
from the microenvironment that promote cancer cell motility such as LPA, which 
can activate SRF signalling (Descot et al., 2009), TGF-β and HGF (Hanahan and 
Coussens, 2012).  Intrinsic factors may also influence the acquisition of motility, for 
example the mutations present or the differentiation state of the cell (Sahai, 2005).  
Furthermore, cancer cells have been observed to utilise a number of different 
modes of motility, including as single cells or as cohorts of cells (Friedl et al., 2012). 
To initiate distant metastases motile cancer cells must intravasate into either the 
lymphatics or blood vasculature and travel to secondary organs (Figure 1.3).  The 
mode of motility utilised by cancer cells may dictate the route of travel as TGF-β-
dependent single cell motility of breast cancer cells results in blood-borne 
metastasis whereas cells moving collectively only metastasise to local lymph-
nodes, presumably through the lymphatics (Giampieri et al., 2009).  Entry into the 
blood vasculature is likely to be more difficult than entry into lymphatics, as 
lymphatic vessels show pre-formed portals which can be used by dendritic cells for 
entry and may aid cancer cell intravasation (Pflicke and Sixt, 2009).  Intravasation 
into blood vessels is dependent on N-WASP mediated invadopodia and involves 
cancer cells squeezing between endothelial cells in a process called trans-
endothelial migration (Gligorijevic et al., 2012).  Defective endothelial basement 
membranes, loose pericyte coverage and a decrease in endothelial tight junctions 
induced by VEGF-A in the tumour environment, reduce the barrier to cancer cells 
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and may facilitate entry into the bloodstream (Baluk et al., 2003) (Yonenaga et al., 
2005) (Cooke et al., 2012).  Stromal cells within the microenvironment can also aid 
intravasation.  A subset of tumour-associated macrophages are found adjacent to 
blood vessels and using intra-vital imaging breast cancer cells were only found to 
intravasate adjacent to these peri-vascular macrophages (Wyckoff et al., 2007) 
(Figure 1.3).  An EGF-CSF-1 paracrine loop between the breast cancer cells and 
macrophages (described later) helps to attract the breast cancer cells to peri-
vascular macrophages and hence the vasculature. Furthermore, macrophages 
secrete VEGF-A, which can loosen endothelial cell contacts, and potentially aid 
cancer cell intravasation (Murdoch et al., 2008). 
 
1.3.2  Survival in the circulation 
Once in the lymphatics or blood vasculature, cancer cells must be able to survive 
the challenges of anchorage independence (Figure 1.3).  The shear stress, found 
particularly in the blood vasculature, is an additional challenge to cancer cells.  
Analysis of metastatic versus non-metastatic variants of the same cell-line 
indicated that both could interact with blood vessels but the non-metastatic cells 
showed increased fragmentation when associated with the vasculature (Wyckoff et 
al., 2000).  This suggests that the metastatic phenotype also provides protection 
from shear stress.  Evidence for this comes from the fact that Vimentin, which is 
up-regulated during cancer cell epithelial-to-mesenchymal transition (EMT), helps 
maintain leukocyte cell shape in the circulation (Brown et al., 2001).  Furthermore, 
cancer cells with high actomyosin contractility, associated with increased motility, 
show increased short-term survival after injection into the blood (Pinner and Sahai, 
2008).  In the blood stream cancer cells aggregate with platelets to form an 
embolus, which not only helps to protect against shear stress but also immune 
surveillance (Im et al., 2004) (Palumbo et al., 2007). 
 
1.3.3 Arrival and survival at secondary sites 
The location of cancer cell metastasis can in part be explained by cancer cells 
becoming lodged in the nearest capillary bed to the tumour.  However many 
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cancers show preferential metastasis to certain sites, for example breast cancer to 
the bone and lungs (Nguyen et al., 2009).  The long-standing “Seed and Soil” 
hypothesis proposes that successful organ colonisation depends on intrinsic 
properties of the cancer cell but also a permissive microenvironment for growth 
(Paget, 1989).  The cancer cell intrinsic expression of chemokine receptors 
mediates cancer cell “homing” to tissues which show increased expression of the 
ligand.  Bone metastases occur as a result of CXCR4 expression in breast cancer 
cells which attracts them to the bone marrow, a site rich in CXCL12, the CXCR4 
ligand (Muller et al., 2001).  Primary tumours also contain a heterogeneous 
population of cells with different intrinsic properties resulting in preferences for 
different secondary organs (Fidler, 1973).  Work using the MDA MB 231 breast 
cancer cells generated sub-lines with a propensity to metastasise to the lungs, 
brain or bone and described their associated gene expression profiles (Minn et al., 
2005) (Kang et al., 2003) (Bos et al., 2009).  ST6GALNAC5, a sialyltransferase, is 
up-regulated only in the cells showing brain specific metastasis and it enables 
specific adhesion to brain endothelial cells and passage through the blood brain 
barrier (Bos et al., 2009).  TGF-β enhances breast cancer metastasis to the bone 
and can act to increase expression of the genes highly expressed in cells which 
preferentially metastasise to the bone (Yin et al., 1999) (Kang et al., 2003). 
 
Formation of metastases in distant organs requires the adhesion of cancer cells to 
the endothelium, survival, extravasation and invasion of the endothelium 
associated basement-membrane (Figure 1.3).  A number of Integrins have been 
implicated in cancer cell adhesion to the vasculature including Integrin αVβ3, which 
binds PECAM-1, and Integrin α4β1 (Kikkawa et al., 2002) (Klemke et al., 2007).  
Both of these Integrins also increase trans-endothelial migration indicating a 
requirement for endothelial cell adhesion when traversing the vasculature wall.  
Cancer cells also release paracrine factors such as ANGPTL4 and CCL2 that 
disrupt endothelial cells cell-cell junctions and enhance trans-endothelial migration 
(Padua et al., 2008) (Wolf et al., 2012). Survival of cancer cells in the vasculature 
can be mediated by cell autonomous factors and interactions with stromal cells.  
The interaction of breast cancer cells and macrophages via VCAM-1 on the cancer 
cells and α4 Integrins on the macrophages enhances cancer cell survival by 
signalling through Ezrin and AKT (Chen et al., 2011).  Increased Ezrin expression 
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in metastatic cells can also enhance survival in the lung through AKT-mTOR 
signalling (Krishnan et al., 2006). 
 
1.3.4 Growth at secondary sites 
Once within the parenchyma at secondary sites, many cancer cells remain dormant 
(Naumov et al., 2002) (Figure 1.3).  Growth may be initiated either by a permissive 
microenvironment as suggested by the “soil and seed hypothesis” or through co-
option of the stroma, although these two possibilities may not be mutually 
exclusive.  Lung fibroblasts are induced to express Tenascin-C and VEGF-A, which 
promote the colonisation of breast cancer cells in the lungs (O'Connell et al., 2011).  
Additionally, breast cancer stem cells arriving at the lungs induce fibroblasts to 
secrete the matrix protein Periostin, which in turn recruits Wnt ligands to enhance 
cancer stem cell survival (Malanchi et al., 2012).   
 
The effects of cancer cells on secondary organs may occur even before 
metastasis.  Cancer cells in the primary tumour can direct recruitment of VEGFR-1 
positive bone-marrow derived cells to future metastatic sites.  The primary tumour 
induces expression of Fibronectin at future metastatic sites, enabling recruitment 
and adhesion of VEGFR-1 positive bone-marrow derived cells.  Matrix-
metalloproteases secreted by the bone-marrow derived cells subsequently induce 
release of active growth factors from the extracellular matrix (ECM) generating a 
pre-metastatic niche permissive for cancer cell growth (Kaplan et al., 2005).  Bone-
marrow derived cells are also attracted to the pre-metastatic niche through LOX 
dependent ECM remodelling (Erler et al., 2009).  Hypoxic cells in the primary 
tumour secrete LOX, which accumulates in the pre-metastatic niche leading to 
Collagen cross-linking and increased adhesion of bone-marrow derived cells.  In 
addition, the pre-metastatic niche may signal back to the cancer cells as up-
regulation of the chemokine CXCL12 has been observed in the pre-metastatic 
niche, which can promote the chemotaxis of CXCR4 positive cancer cells (Kaplan 
et al., 2005). 
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Figure 1.3 The metastatic process. 
Metastasis is the spread of cancer to distant organs and involves a cancer cell invading 
the local environment of the primary tumour and intravasating into either blood or 
lymphatic vessels.  On arrival at secondary sites, cancer cells adhere to the endothelial 
cell wall and extravasate.  Formation of metastases requires the cells to survive and 
grow in the novel environment. 
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1.4 Cell motility  
Cell motility is an important biological process that allows single-celled organisms 
to respond to differences in nutrient concentration and drives cell rearrangement 
and morphological changes in developing embryos.  It helps the immune system to 
locate pathogens but also enables cancer cells to move and metastasise.  The 
majority of research into cell motility has been carried out using cells on 2D 
surfaces, however, within the last decade the focus has shifted towards analysis of 
cells moving through 3D environments or tissues.  It is clear that cells behave 
differently in different environments.  Cells can move either as single cells or as 
groups or cohorts of cells (Friedl et al., 2012).  There are multiple modes of single 
cell motility ranging from mesenchymal-like to amoeboid-like or blebbing motility 
(Figure 1.4). 
 
Cell motility requires a cell to be able to make a protrusion in a forward direction, 
adhere to the surrounding matrix at the new position, and then retract the rear of 
the cell to turn the forward protrusion into bulk cell movement (Ridley et al., 2003).  
A pre-requisite for this set of processes is cellular polarity and the definition of a 
front and a back.  The actin cytoskeleton is thought to provide the driving force for 
cell motility, however, microtubules also play a role (Etienne-Manneville, 2004). 
 
1.4.1 The actin cytoskeleton 
The actin cytoskeleton is composed of highly dynamic filamentous actin (F-actin) 
polymers, composed of globular actin (G-actin) monomers.  G-actin can bind ATP 
in the cytoplasm and actin can hydrolyse ATP to ADP + Pi, although this reaction is 
faster when incorporated into F-actin filaments (Bugyi and Carlier, 2010).  
Following incorporation of G-actin-ATP into the barbed or plus end of the actin 
filament, ATP is hydrolysed leaving ADP + Pi.  Actin depolymerisation, the loss of 
actin monomers from the pointed end is increased by loss of the phosphate group 
(Bugyi and Carlier, 2010). The rate of G-actin-ATP monomer addition and G-actin-
ADP loss dictates the dynamics of the actin filament and actin treadmilling occurs 
when the rate of association of G-actin-ATP and the rate of loss of G-actin-ADP are 
balanced (Bugyi and Carlier, 2010). 
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Numerous processes control actin polymerisation (Nurnberg et al., 2011).  G-actin 
can bind a number of proteins in the cytoplasm and binding to Profilin promotes 
ADP/ATP exchange and so increases the amount of G-actin-ATP (Wolven et al., 
2000).  Furthermore, binding to Thymosin β4 sequesters G-actin in the cytoplasm 
(Safer et al., 1991).  Formins and Ena/VASP family members can increase the rate 
of actin monomer addition to barbed ends, whereas actin capping proteins prevent 
further actin monomer addition (Goode and Eck, 2007) (Chesarone and Goode, 
2009).  Actin filaments can also be branched and the Arp2/3 complex enables 
branching and the formation of new actin filaments, through mimicking the shape of 
actin dimers (Goley and Welch, 2006).  Cofilin is an actin severing protein which 
can lead to actin depolymerisation, but also acts to increase the number of barbed 
ends available and can thereby enhance polymerisation (Wang et al., 2007).   
 
Actin polymerisation can be stimulated downstream of the Rho family GTPases, a 
family of proteins regulated by binding to guanine nucleotides, that switch between 
an active GTP bound state and an inactive GDP bound state (Sahai and Marshall, 
2002).  Rho guanine nucleotide exchange factors (GEFs) are activated 
downstream of many receptors including receptor tyrosine kinases and G-protein-
coupled receptors (Schiller, 2006).  They promote the binding of Rho proteins to 
GTP, hence promoting an active state.  Although most family members do have 
GTP hydrolysing activity, the reaction is slow, and binding of Rho GTPase 
activating proteins (GAPs) increases the rate of switching to the inactive state 
(Tcherkezian and Lamarche-Vane, 2007).  Furthermore, Rho GDP dissociation 
inhibitors (GDIs) sequester GDP-bound Rho proteins in the cytoplasm, hence 
inactivating them (DerMardirossian and Bokoch, 2005).  Many Rho proteins are 
subject to membrane targeting in a similar way to Ras proteins, through lipid 
modifications initiated by recognition of a C-terminal CAAX motif (Adamson et al., 
1992).  At the membrane, active GTP-bound proteins bind actin regulators leading 
to downstream actin polymerisation (DerMardirossian and Bokoch, 2005). 
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1.4.2 The microtubule cytoskeleton 
The microtubule cytoskeleton is composed of polymers constructed from α and β-
tubulin dimers and similar to the actin cytoskeleton, the polymers are highly 
dynamic (Watanabe et al., 2005).  However, in contrast to the actin cytoskeleton, 
microtubules are nucleated and organised by a dedicated microtubule organising 
centre (MTOC).  Microtubule polymers are polarised and polymerisation occurs at 
the plus end whilst the minus end anchors the microtubules to the MTOC 
(Watanabe et al., 2005).  Microtubule disassembly also occurs at the plus end, so 
microtubules can switch between growing and shrinking phases dynamically, due 
to events at the plus end (Kirschner and Mitchison, 1986).  Microtubule 
polymerisation can generate force and the microtubule cytoskeleton is found in 
some cell protrusions during cell motility (Watanabe et al., 2005).  Furthermore, 
microtubules localise to focal adhesions and can regulate adhesion turnover 
(Stehbens and Wittmann, 2012).  During polarised cell migration the MTOC is 
repositioned to the front of the nucleus in a mechanism dependent on microtubule 
dynamics (Magdalena et al., 2003). 
 
The microtubule cytoskeleton also provides a platform for intra-cellular transport.   
Motor proteins such as Kinesins and Dyneins bind microtubules and convert 
chemical energy from ATP-hydrolysis into mechanical work to move along the 
microtubule polymers (Verhey et al., 2011).  Most kinesins move towards the plus 
end of the microtubule and hence transport intracellular cargo towards the cell 
periphery (Verhey et al., 2011).  During polarised cell migration, Kinesins may help 
transport protein complexes to the leading edge and by interacting with focal 
adhesions, they may bring molecules that promote adhesion turnover (Krylyshkina 
et al., 2002) (Stehbens and Wittmann, 2012).  However, not all Kinesins act as 
motor proteins.  KIF2C (also known as MCAK) is important for regulating 
microtubule dynamics and binds to the plus ends of microtubules causing 
microtubule depolymerisation (Hunter et al., 2003).  Over-expression of KIF2C 
results in an almost total loss of microtubules in the cell (Maney et al., 2001). 
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1.4.3 Cell protrusions 
Generation of protrusions is one of the first steps in cell motility (Ridley et al., 
2003).  Cells can generate a number of protrusions including filopodia, lamellipodia, 
invadopodia and blebs (Ridley, 2011).  Most protrusions are generated through 
polymerisation of the actin cytoskeleton, which pushes the plasma membrane 
forward.  However, cells can also generate forward motion through actomyosin 
contractility (Poincloux et al., 2011). 
 
1.4.3.1 Filopodia 
Filopodia are thin protrusions that contain parallel actin bundles.  The main Rho 
GTPase involved in filopodia formation is Cdc42 and this is thought to induce 
localisation of its targets including the formin mDIA1, N-WASP and IRSp53 (Ridley, 
2011).  The I-BAR domain of IRSp53 bends the plasma membrane outwards and 
mDIA1 can induce the straight actin filaments (Ahmed et al., 2010) (Campellone 
and Welch, 2010).  Fascin, an actin bundling protein, localises to filopodia and is 
important for their stability (Vignjevic et al., 2006) (Machesky and Li, 2010).  
 
Filopodia are observed in a number of cell-types including endothelial tip cells 
during angiogenesis (Gerhardt et al., 2003) and epithelial cells in Drosophila dorsal 
closure (Millard and Martin, 2008).  Furthermore, proteins important for filopodia, 
such as Fascin, are implicated in cancer cell invasion and metastasis (Machesky 
and Li, 2010). 
 
1.4.3.2 Lamellipodia 
Lamellipodia are broad protrusions and activation of the Rho GTPase Rac is 
sufficient to induce lamellipodium extension (Machacek et al., 2009).  Downstream 
of Rac, the SCAR/WAVE complex binds Arp2/3 to induce the formation of a 
branched actin network (Kunda et al., 2003).  However, there has been recent 
debate about the extent of branching within lamellipodia (Urban et al., 2010).  The 
cell-type, conditions and the relative activity of the Arp2/3 complex and more linear 
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actin nucleators, such as the Formins, may dictate the extent of branching (Ridley, 
2011).  Lamellipodia are most abundant in mesenchymal-like cells migrating on 
rigid 2D substrates including the migration of neural crest cells during development 
(De Calisto et al., 2005). 
 
1.4.3.3 Invadopodia 
Invadopodia are protrusions that have matrix degrading properties and are thought 
to help cells cross basement membranes (Schoumacher et al., 2011).  It is likely 
that invadopodia formation is initiated by co-ordination of Cdc42 and the tyrosine 
kinase, Src (Ridley, 2011).  Both the Arp2/3 complex and Formins are required for 
invadopodia and Fascin also helps stabilise these protrusions (Buccione et al., 
2009) (Lizarraga et al., 2009) (Li et al., 2010a).  In addition to being actin-rich, 
invadopodia contain microtubules and intermediate filaments and the intermediate 
filaments can provide mechanical stability (Schoumacher et al., 2010).  Matrix 
metalloproteases such as MT1-MMP are delivered to the ends of invadopodia by 
the Exocyst complex (Liu et al., 2009). 
 
1.4.3.4 Blebs 
Membrane blebs are not driven by actin polymerisation but instead through 
increases in hydrostatic pressure driven by actomyosin contraction (Charras et al., 
2005).  They are more often associated with cell motility in 3D environments rather 
than 2D surfaces and are utilised by migrating primordial germ cells in zebrafish, 
Dictyostelium and some cancer cell-lines (Blaser et al., 2006) (Langridge and Kay, 
2006) (Sahai and Marshall, 2003).  Blebs are thought to form at areas with weak 
attachments between the plasma membrane and actin cortex and once the bleb 
has extended the actin filaments polymerise to form a new actin cortex (Charras 
and Paluch, 2008).   
 
The four types of protrusions are not necessarily mutually exclusive as both 
lamellipodia and blebs have been observed at different regions on migrating cells 
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during zebrafish gastrulation (Diz-Munoz et al., 2010).  In addition, filopodia may 
emerge from the lamellipodial actin network (Gupton and Gertler, 2007). 
 
Cells undergoing collective motility also produce protrusions, although they are 
often limited to the leading cells in the group.  In 2D wound-healing models the 
front row of cells protrudes lamellipodia into the newly formed space (Vaughan and 
Trinkaus, 1966).  Drosophila tracheogenesis involves collectively motility and the 
leading cells, closest to the chemotactic cue, produce filopodia in the direction of 
movement (Ribeiro et al., 2002). 
 
1.4.4 Adhesions 
Cell motility often requires adhesion to the surrounding matrix, particularly during 
motility on 2D substrates.  This secures the new position of the membrane 
following protrusion and subsequently enables the generation of traction and force 
to move forwards (Ridley et al., 2003). Integrins are the main molecules that 
mediate adhesion to the ECM.  They are trans-membrane heterodimers consisting 
of a large extracellular domain that binds to specific matrix components and a short 
cytoplasmic tail that links to the actin cytoskeleton (Huttenlocher and Horwitz, 
2011).  Activation of Integrins through binding to matrix ligands results in Integrin 
clustering and formation of multiprotein complexes.  Nascent adhesions are small 
dynamic adhesions in the outer regions of protrusions that can mature into the 
larger focal adhesion complexes (Choi et al., 2008).  Focal adhesions contain 
proteins such as Talin, Vinculin and Alpha-actinin which bind the intracellular tails 
of Integrins and help link the ECM to the actin cytoskeleton, hence providing 
traction for cell motility (Huttenlocher and Horwitz, 2011).  Focal adhesions also 
contain the signalling molecules, Focal-adhesion kinase (FAK) and Src kinases, 
which control the turnover of focal adhesions and regulate cell motility (Webb et al., 
2004) (Mitra et al., 2005).  In order to move forward, cells must release the ECM 
attachments at the cell rear.  This is in part mediated by contractile force, but 
Integrin endocytosis and Calpain dependent proteolytic cleavage of adhesion 
proteins may also play a role (Webb et al., 2004) (Lawson and Maxfield, 1995) 
(Franco and Huttenlocher, 2005).    
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The role of adhesions in vivo is less defined.  Focal adhesions in cells on 3D 
substrates are more diffuse and have different molecular components, with fewer 
Integrins employed and less phosphorylated FAK (Cukierman et al., 2001).  
Furthermore, dendritic cells can migrate in vivo independently of Integrins and are 
thought to employ a mode of motility dependent on actomyosin contraction 
(Lammermann et al., 2008).  
 
Collectively motile cells use similar mechanisms to cells on 2D substrates in order 
to bind the ECM.  However, they must also maintain adhered to adjacent cells.  
Adherens junctions maintain cell-cell adhesions and are mediated by cadherins 
and catenins.  Cells migrating collectively during mammary gland morphogenesis 
maintain E-cadherin at cell-cell contacts and loss of E-cadherin is associated with a 
more single-cell mode of motility and epithelial to mesenchymal transition (Ewald et 
al., 2008) (Thiery, 2003).  
 
1.4.5 Contractile force 
Contractile force is required for cell migration as it drives retraction of the rear of 
the cell to enable a net forward motion.  The contractile machinery consists of the 
heavy and light chains of the motor protein Myosin II, together with actin filaments.  
Contractility is generated by multimeric Myosin II “walking” along multiple actin 
filaments in an ATP dependent process (Olson and Sahai, 2009).  This causes the 
actin filaments to move relative to one another generating contraction.  Contractility 
is regulated by the phosphorylation of Myosin light chain (MLC), which controls the 
conformation of the Myosin heads and hence increases ATPase activity (Vicente-
Manzanares et al., 2009).  MLC is phosphorylated by a number of kinases 
including ROCK1 and ROCK2 downstream of RhoA signalling and MRCK 
downstream of Cdc42 (Amano et al., 1996) (Wilkinson et al., 2005).  MLC is also 
the target of Myosin phosphatase (MYPT), which is itself negatively regulated by 
ROCK1 (Ito et al., 2004).  Hence RhoA signalling, leading to activation of ROCK, 
induces contractility through both MLC phosphorylation and inhibition of the MLC 
phosphatase.  In cells on 2D substrates the activation of RhoA leads to the 
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formation of stress fibres and this requires both ROCK and the Formin mDIA1 
(Watanabe et al., 1999). 
 
Single cells moving in vivo are highly dependent on actomyosin contractility.  As 
described earlier, some cell types can move independently of integrins instead 
using contractility to squeeze through gaps in the ECM.  In a similar manner, some 
cancer cells utilise amoeboid-like modes of motility to move through 3D matrices 
and the tumour environment in vivo.  During this form of motility, the contractile 
machinery is localised to the cell cortex and ROCK dependent contractility drives 
motility and local Collagen deformation (Wyckoff et al., 2006). 
 
Collectively motile cells have a supra-cellular actomysoin organisation, with 
increased contractility around the edge of the group and decreased contractility at 
cell-cell junctions (Hidalgo-Carcedo et al., 2011).  This enables the group to 
maintain cohesion, by stabilising cell-cell contacts.   Some systems of collective cell 
motility, such as branching morphogenesis in the mammary gland, may utilise 
contraction as a method to drive motility, rather than cycles of protrusion and 
adhesion.  Here, the leader cells are devoid of protrusions and the stiff stalk cells 
are thought to drive motility from the rear (Ewald et al., 2008).  
 
1.4.6 Cell polarity and directional cell motility 
Motile cells have a front, usually defined by active protrusions and the leading 
edge, and a rear, which is characterised by disassembly of adhesions and 
contraction.  This polarisation can be spontaneous or arise from the external 
environment as a result of soluble chemokines, changes in the ECM, or changes in 
the position or presence of adjacent cells.  The difference in localised cell 
behaviour in these regions is reflected by differences in the distribution or activation 
of signalling molecules.  During leukocyte and Dictyostelium migration PI3K 
signalling is polarised so that there is an increase in the PI3K product PIP3 at the 
leading edge (Ridley et al., 2003).  PI3K products can activate Rac through GEFs 
leading to an increase in Rac activity and protrusions at the leading edge.  PTEN, a 
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phosphatase that removes PIP3, is restricted to the sides of migrating cells, which 
helps prevent the formation of protrusions in these areas (Merlot and Firtel, 2003).   
 
The classical view of cell motility on 2D substrates involves increased Rac activity 
at the leading edge with RhoA activity restricted to the tail to promote tail retraction 
(Ridley et al., 2003).  However, recent studies with Rho protein biosensors have 
revealed a much more complex situation with both Rac and RhoA activity at the 
leading edge and a spatial and temporal regulation of their activity (Pertz et al., 
2006) (Machacek et al., 2009).  RhoA is activated at the cell edge at the same time 
as leading edge advancement, however, Rac1 and Cdc42 are activated behind the 
leading edge with a slight delay (Pertz et al., 2006) (Machacek et al., 2009).  Rac1 
activity is low at the onset of protrusion, whereas RhoA activity is high suggesting 
that Rac1 may not be responsible for advancement of the leading edge in the 
system analysed.  This is in contrast to reports showing that photo-activation of 
Rac is sufficient to drive protrusions (Wu et al., 2009). 
 
As mentioned previously, the environment can affect cell polarity, but it can also 
induce a directionality to migration.  Chemotaxis is the migration of cells towards a 
soluble factor such as the migration of Dictyostelium towards cAMP or leukocytes 
towards fMLP, a peptide derived from bacteria or damaged cells.  These 
chemokines regulate directional migration, although exactly how they do so is not 
yet clear.  Chemokine gradients may activate PI3K signalling to induce protrusional 
activity towards the source of the gradient.  Alternatively, soluble chemokines may 
help to stabilise protrusions pointing in the direction of the source, thereby 
regulating direction.  The chemokine CXCL12 is implicated in chemotaxis of 
primordial germ cells in zebrafish (Doitsidou et al., 2002).  Chemokine receptors 
are also implicated in cancer metastasis and increased expression of CCR7 in 
melanoma cells can increase metastasis to the lymph-nodes (Wiley et al., 2001).   
 
Cells moving collectively also have a polarity and move in a directed fashion.  
Usually there is a leader cell or cells, with distinct morphology, such as increased 
protrusions, but inputs must be integrated from the whole group of cells (Friedl and 
Gilmour, 2009).  Collective migration of the zebrafish lateral line is directed by 
CXCL12 (David et al., 2002).  In this system only the front cells respond to the 
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ligand but it is sufficient to drive directional migration of the group (Haas and 
Gilmour, 2006).  However, the leader cell is not always fixed, as tip and stalk cells 
can switch position during angiogenesis and photo-activation of Rac in Drosophila 
border cells is sufficient to change the polarisation and direction of motility 
(Jakobsson et al., 2010) (Wang et al., 2010b).  In some cases the leading cell is a 
different cell type.  Fibroblasts found at the leading edge of collectively migrating 
cancer cells remodel and degrade the ECM making tracks for the cancer cells to 
follow (Gaggioli et al., 2007). 
 
1.4.7 ERM proteins 
Ezrin, Radixin and Moesin are a family of proteins that link the actin cytoskeleton 
with the plasma membrane.  They contain a membrane associated FERM domain 
at their N-terminus and a C-terminal ERM-associated domain (C-ERMAD) (Fehon 
et al., 2010).  The C-ERMAD can bind both the FERM domain and F-actin.  In the 
inactive conformation, the C-ERMAD is bound tightly to the FERM domain, 
masking the F-actin binding site.  On activation, the affinity between the C-ERMAD 
and the FERM domain is reduced, the molecule opens and the C-ERMAD binds F-
actin (Simons et al., 1998).  The FERM domain can bind to cytoplasmic tails of a 
number of membrane associated proteins, such as CD44 and ICAM2, hence 
linking the plasma membrane and the underlying actin cytoskeleton (Yonemura et 
al., 1998). 
 
A number of signalling pathways contribute to ERM activation.  The first step is 
through binding of PIP2 enabling recruitment to the plasma membrane.  This may 
lead to a slight conformational change revealing a conserved threonine residue 
(Fievet et al., 2004).  Phosphorylation of the threonine results in the loss of intra-
molecular association, and a subsequent conformational change releasing the C-
ERMAD domain to bind F-actin (Simons et al., 1998).  Numerous kinases can 
phosphorylate and activate the ERM proteins including ROCK, PKCα, PKCθ 
(Matsui et al., 1998) (Ng et al., 2001) (Simons et al., 1998). 
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ERM proteins have important roles in cell motility (Arpin et al., 2011).  During 
amoeboid/bleb-like migration in 3D matrices, Ezrin accumulates at the cell rear 
together with actin and MLC.  Blebbing is decreased at this area, possibly due to 
increased linkage between the actin cortex and plasma membrane, and this directs 
blebbing and protrusions in the forward direction, hence driving cell motility 
(Lorentzen et al., 2011).  ERM proteins may act both upstream of RhoA by binding 
to Rho GEFs, GAPs and GDIs, and in addition they are activated by the RhoA 
substrate, ROCK (Fehon et al., 2010).  ERM proteins are activated downstream of 
receptor tyrosine kinases and Ezrin promotes cell motility downstream of HGF 
(Crepaldi et al., 1997).  
 
1.4.8 Different modes of single cancer cell motility in 3D 
Singly motile cells can be classified on a continuum between mesenchymal-like 
and amoeboid-like modes of motility (Figure 1.4).  Mesenchymal-like motility is 
slower and characterised by actin-rich protrusions such as filopodia or invadopodia 
(Friedl and Wolf, 2009).  It is dependent on peri-cellular proteolysis to degrade the 
surrounding ECM and make a path for the cell-body (Friedl and Wolf, 2009).  
Amoeboid-like motility is faster and uses contractility to squeeze the cell through 
gaps and deform the local extra-cellular matrix (Wyckoff et al., 2006).  This type of 
motility is more prominent in 3D environments.  Cells with high contractility 
generate blebs that protrude into the local environment and can generate traction 
for forward movement (Charras and Paluch, 2008).  Mesenchymal-like motility 
utilises adhesive structures such as focal-adhesions to generate traction, however, 
cells undergoing amoeboid-like motility may have weak or no attachment to the 
ECM (Schmidt and Friedl, 2010).  The type of single cell motility utilised by a cell 
may be pre-determined and expression of adhesion molecules, such as Integrins, 
may play a role.  Sarcoma and glioblastoma cells undergo a more mesenchymal-
like motility whereas leukocytes, leukaemia and prostate cancer cells undergo an 
amoeboid-like mode of motility (Friedl, 2004). 
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Figure 1.4. Modes of cell motility. 
Cells can move either collectively or as single cells and single cell motility may be 
further represented by amoeboid-like or mesenchymal-like motility.  Cells which move 
as a cohort but do not maintain strong cell-cell adhesions are considered to use a 
streaming form of motility. 
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Mesenchymal-like cell motility is utilised by many cell-types.  For example, during 
development the cells of the neural crest undergo EMT and migrate as single cells 
throughout the embryo using a protrusion-based mesenchymal mode of motility 
(Thiery et al., 2009).  EMT involves the loss of cell-cell adhesions through down-
regulation of E-cadherin, acquisition of a motile phenotype and a gene-expression 
signature reminiscent of mesenchymal cells.  It can be induced through soluble 
signals such as TGF-β and Wnts, which lead to a transcriptional response to up-
regulate proteins such as MMPs, Fibronectin and Vimentin and repress E-cadherin 
(Thiery et al., 2009).  EMT is thought to occur in cancer and there is a large body of 
evidence supporting EMT as a method of inducing motility of carcinoma cells in 
vitro (Thiery, 2003).  Long-term exposure to signals such as TGF-β may not only 
induce EMT, but may also lead to the acquisition of stem-like properties (Mani et 
al., 2008).  The role of EMT in vivo is less clear.  Histological sections of human 
cancer have revealed an increase in EMT markers and a loss of E-cadherin at the 
invasive edge of tumours (Brabletz et al., 2001).  However, these changes are not 
maintained in metastases, which could indicate EMT independent metastasis or 
rare and reversible EMT (Brabletz et al., 2001). 
 
Cells are plastic in their modes of motility and can switch between mesenchymal-
like and amoeboid-like modes of motility.  This switching was first observed when 
cells using a mesenchymal-like mode of migration in a 3D Collagen matrix were 
treated with a protease inhibitor cocktail resulting in a switch to an amoeboid-like 
form of motility (Wolf et al., 2003).  Furthermore, cells undergoing amoeboid-like 
motility switch to mesenchymal-like motility when treated with a ROCK inhibitor to 
inhibit contractility (Sahai and Marshall, 2003).  This highlights the versatility of 
motile cells and helps to explain why protease inhibitors have not been a 
particularly effective anti-cancer treatment (Lah et al., 2006).  However, total 
motility could be impaired by the joint use of protease and ROCK inhibitors, 
suggesting a combination of agents may be effective against invasion in vivo 
(Sahai and Marshall, 2003).  Switching can also occur in physiological situations 
and the mode of motility may be dependent on ECM density, and elasticity (Wolf 
and Friedl, 2011).  
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Levels of Rac activity control the nature of single cell motility and so Rac regulation 
is likely involved in the switching mechanism.  Rac activation by both NEDD9 and 
DOCK3 is required for mesenchymal-like motility and WAVE2 acts downstream of 
Rac to induce protrusions (Sanz-Moreno et al., 2008).  Rac activation also reduces 
MLC phosphorylation hence reducing contractility and amoeboid-like 
characteristics (Sanz-Moreno et al., 2008).  NEDD9 is another key regulator as it 
not only activates Rac, but also signals together with Integrin β3 and Src to 
promote mesenchymal-like motility whilst decreasing ROCK activity (Ahn et al., 
2012).  
 
During amoeboid-like motility ROCK signalling and contractility is high and Rac 
activation is low.  RhoA-ROCK signalling is promoted by cytokine signalling through 
the JAK-STAT pathway.  ROCK activation leads to an increase in STAT activation 
creating a positive feedback loop that may help to maintain amoeboid motility 
(Sanz-Moreno et al., 2011). Furthermore, ROCK activation leads to an ARHGAP22 
dependent inhibition of Rac activity and so inhibits the mesenchymal phenotype 
(Sanz-Moreno et al., 2008). 
 
A spatial localisation of RhoA signalling may also be important to regulate the 
mode of single cell motility.  The E3 ubiquitin ligase SMURF1 degrades RhoA at 
the leading edge  and SMURF1 depletion results in a mesenchymal to amoeboid 
transition due to the activation of RhoA at the cell cortex (Wang et al., 2003) (Sahai 
et al., 2007).  p27
Kip1 
inhibition of RhoA can also influence the mode of motility as 
loss of p27
Kip1 
results in amoeboid-like motility (Besson et al., 2004) (Berton et al., 
2009).  Activation of Cdc42 through the GEF DOCK10 promotes amoeboid-like 
motility whereas inhibition of Cdc42 by RASGRF inhibits amoeboid-like 
characteristics (Gadea et al., 2008) (Calvo et al., 2011).  Therefore the interplay 
between Rac, RhoA-ROCK and Cdc42 signalling helps to control the switch 
between mesenchymal- and amoeboid-like motility. 
 
The cytokine regulation of amoeboid-like motility suggests that the mode of motility 
may depend on the microenvironment.  However, many chemokines are known to 
activate Rac and so may lead to mesenchymal-like motility.  Furthermore 
Vitronectin, the Integrin β3 ligand, is required for the NEDD9 dependent promotion 
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of mesenchymal-like motility (Ahn et al., 2012).  This suggests that if cells with high 
NEDD9 encounter Vitronectin they may switch to a mesencymal-like mode of 
motility.  The trans-membrane receptor EphA2 promotes an amoeboid-like mode of 
motility in melanoma and prostate cancer cells and so regions with high Ephrin A 
ligands may promote amoeboid motility (Taddei et al., 2011) (Parri et al., 2009). 
 
1.5 Cancer cell motility in vivo 
1.5.1 Imaging approaches to study cancer cell motility in vivo 
There are a number of imaging based methods to study cancer cell motility and 
metastasis in vivo; from whole-body bioluminescence imaging to the sub-cellular 
resolution provided by intra-vital multi-photon microscopy.  The work in this thesis 
utilises single-photon and two-photon intra-vital microscopy in mice so these 
techniques will be the focus of this section. 
 
Single- and two-photon intra-vital microscopy use photons to excite a fluorophore 
into a higher energy state and collect the photons emitted on relaxation of the 
fluorophore.  The requirement for fluorophores means that cancer cells need to 
stably express fluorescent proteins for visualisation.  Two-photon microscopy 
excites fluorophores by simultaneous absorption of two low energy photons 
(Helmchen and Denk, 2005).  This uses wavelengths in the infra-red range which 
has the advantage of being able to penetrate further into tissues (Oheim et al., 
2001).  The infra-red wavelengths also create second-harmonic generation signal 
from structures with highly ordered repeats, such as Collagen I fibres, which helps 
visualise aspects of the ECM together with labelled cancer cells (Zipfel et al., 
2003).  An additional advantage of multiphoton microscopy is that only fluorophores 
in the focal plane are excited.  Outside of the focal plane the photon density is too 
low to allow simultaneous photon absorption (Helmchen and Denk, 2005).  This is 
in contrast to single-photon microscopy, which excites fluorophores outside of the 
focal plane and so requires a pinhole to remove out-of focus light (Beerling et al., 
2011).  Therefore multi-photon excitation not only reduces photo-toxicity by exciting 
only the fluorophores in the plane of interest, but also more of the emitted light can 
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be collected as all emitted light can be assumed to originate from the focal plane 
without the need for a pinhole. 
 
Exploring cancer cell motility using intra-vital imaging involves the generation of 
primary tumours with fluorescently labelled cancer cells.  This thesis uses sub-
cutaneous injection of fluorescent cell-lines into mice due to the ability to 
manipulate the cancer cells before injection.  However, there are a number of 
spontaneous cancer models in which the cancer cells are fluorescently labelled.  
Furthermore, zebrafish can be used as a model to study cancer metastasis due to 
the ease of imaging and amenable genetics (Ignatius and Langenau, 2011).  
 
Tumours can be imaged in different ways.  The skin-flap method allows one-off 
short-term imaging, typically 3-4 hours, although up to 30 hours can be achieved 
(Egeblad et al., 2008).  This method involves minor surgery immediately prior to 
imaging to expose the tumour, which may affect interstitial tissue flow and the 
tumour microenvironment.  Longer-term imaging without immediate surgery can be 
achieved with the use of an imaging window.  These were originally large, 
cumbersome structures surgically implanted on the back of the mouse (Lehr et al., 
1993) (Alexander et al., 2008).  However, recent refinement has resulted in a much 
smaller, lighter window that has been used for orthotopic imaging of mammary 
tumours in the mammary gland (Kedrin et al., 2008).  A challenge for long-term 
imaging of cancer is the dynamic rearrangements within the microenvironment that 
make imaging the exact same position day after day quite difficult.  Photo-
switchable fluorescent proteins, such as Dendra2, a green-to-red photoswitchable 
protein, enable the long-term labelling of a population of cells or region of interest 
and can help to overcome this problem (Gligorijevic et al., 2009).  This technique 
has also been used to determine the extent of cell motility by analysing the spread 
of the photo-switched cells after a defined time period (Canel et al., 2010).   
 
Detection of additional components of the microenvironment can be achieved by 
using transgenic mice and fluorescently-labelled probes, dyes and antibodies.  
Intra-venous injection of high molecular weight fluorescent dextran indicates blood 
vessels with flow whilst injected lower molecular weight fluorescent dextrans are 
taken up by macrophages (Wyckoff et al., 2007).  Intra-tumoural injection of 
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fluorescent dextran can also reveal the draining lymphatics (Giampieri et al., 2009).  
Transgenic mice with fluorescent protein expression under the control of a cell-
specific promoter allow the imaging of stromal cells in the tumour.  One example is 
the myeloid specific c-fms:GFP mice to visualise myeloid cells (Nakasone et al., 
2012).   
 
Intra-vital imaging can also be used to study the molecular processes associated 
with cell motility in vivo, such as signalling events and proteolytic cleavage.  Probes 
to study the protease activity of MMPs include an injectable substrate that 
fluoresces after cleavage (Weissleder et al., 1999).  Fӧrster resonance energy 
transfer (FRET) based probes can report on the activity status of a signalling 
molecule, such as the GTPase Rac1 (Hirata et al., 2012), or can be used to 
indicate substrate cleavage, as in the FRET Caspase probe (Bins et al., 2007).  
Fluorescent proteins can be fused to a protein of interest and have been used to 
study E-cadherin dynamics and regulation in vivo (Canel et al., 2010).  
Alternatively, cells expressing a fluorescent protein under the control of a 
transcriptional based reporter can visualise cells with active signalling and have 
shown heterogeneity in TGF-β signalling in breast cancer in vivo (Giampieri et al., 
2009). 
 
1.5.2 Different modes of cancer cell motility in vivo 
Intra-vital imaging has confirmed that cancer cells also use diverse mechanisms to 
move in vivo.  Amoeboid-like cancer cell motility in vivo is fast, with speeds of up to 
4 μm/min (Sahai, 2005).  Cells in some tumours also display chaotic blebbing forms 
of motility (Sanz-Moreno et al., 2008).  Similar to migration on 3D matrices, 
amoeboid-like migration is dependent on ROCK mediated contractility and imaging 
of MLC localisation revealed an accumulation at the cell cortex and behind the 
leading edge (Wyckoff et al., 2006).  Consistent with in vitro studies showing MMP 
independent amoeboid-like motility, inhibition of MMP activity does not decrease 
the number of motile cells in A431 squamous cell carcinomas or MTLn3 breast 
tumours (Wyckoff et al., 2006) (Wolf et al., 2003).  Mesenchymal-like cancer cell 
motility is also observed in vivo.  Mesenchymal-like motility, however, may be 
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confined to the more central tumour regions whereas cells at the tumour margins 
use amoeboid-like motility (Sanz-Moreno et al., 2008).  Although switching between 
modes of motility has not been addressed in vivo, the distinction between modes of 
motility based on location suggests that the microenvironment may play a part.   
 
Ex-vivo imaging of glioblastoma cells in a brain slice culture system identified two 
different modes of invasion, invasion through the brain parenchyma, mediated by 
multiple pseudopodia, and peri-vascular invasion, in which cells had a single 
pseuodopod (Hirata et al., 2012).  FRET probes revealed differences in Rho 
GTPase activation between cells.  Cells undergoing invasion into the brain 
parenchyma had increased Rac1 and Cdc42 activity and lower RhoA activity than 
cells undergoing peri-vascular invasion.  This shows that proteins known to be 
associated with motility have heterogeneous activity which correlates with 
heterogeneous motile behaviour of cancer cells.  Indeed, the authors argue that 
inter-cell heterogeneity in Rho GTPase activity dictates the method of cell invasion 
(Hirata et al., 2012). 
 
Cancer cells have been observed to move collectively in vivo in a number of 
different tumour types (Giampieri et al., 2009) (Alexander et al., 2008).  This has 
revealed distinct types of collective motility depending on the cohesive-ness of the 
group and contacts maintained by the cells (Friedl et al., 2012).  Streaming 
describes cells that are migrating in the same direction with weak cell contacts, 
perhaps following the same guidance cue, but each cell generates forward motion 
independently.  An isoform of MENA, an Ena/VASP family member, promotes cell 
streaming through affecting paracrine signals in vivo (Roussos et al., 2011).  
Cohesive collective cell migration is slower than streaming and cells maintain cell-
cell contacts over time (Giampieri et al., 2009) (Friedl et al., 2012). 
 
A common theme reported by intra-vital imaging is that motile cancer cells are 
relatively rare, with less than 10 % of cells in the primary tumour being motile 
(Giampieri et al., 2009).  Furthermore, some areas have no motile cancer cells 
whereas others have lots of motile cells (Condeelis and Segall, 2003).  As 
discussed previously, both cancer cell intrinsic and extrinsic factors affect the 
acquisition of motility in the primary tumour.  Purification of the motile cell 
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population in breast cancer using a microneedle of matrigel and EGF showed that 
motile cells have a distinct gene signature from the bulk of cancer cells.  Motile 
cells had differential regulation of genes associated with the actin cytoskeleton and 
the cell-cycle (Wang et al., 2004) (Goswami et al., 2004).  One explanation is that 
the motile cells may have intrinsic differences from the tumour mass and are a sub-
population of the tumour.  Alternatively, extrinsic signals from the local 
microenvironment could lead to a transient change in gene expression, resulting in 
the acquisition of motility and subsequent metastasis.  Consistent with local effects 
of the microenvironment, photo-switching of fluorescently labelled breast cancer 
cells revealed that cells near to blood vessels disperse and migrate more than cells 
distant to blood vessels (Kedrin et al., 2008).  This suggests that aspects of the 
microenvironment, such as blood vessels, may create a permissive environment 
and so affect the ability of cancer cells to migrate. 
 
1.5.2.1 Interplay between the microenvironment and cancer cell motility 
Extrinsic factors, such as signals in the microenvironment, can affect cancer cell 
motility.  Macrophages influence cancer cell motility in vivo and have been 
observed to migrate in streams together with breast cancer cells (Condeelis and 
Weissleder, 2010).  A paracrine loop between the two cell types operates to 
increase breast cancer cell motility and is an example of extrinsic factors regulating 
cancer cell gene expression and motility.  Breast cancer cells release CSF-1 that 
induces tumour associated macrophages to express EGF.  EGF then acts as a 
chemokine promoting the invasion of breast cancer cells, but also increasing CSF-
1 production so maintaining the paracrine loop (Goswami et al., 2005).  A subset 
tumour associated macrophages is found in peri-vascular regions, so this paracrine 
loop may be a reason for the increased motility near to blood vessels.  The peri-
vascular location of some macrophages also helps breast cancer cells to 
intravasate, as breast cancer cells are observed to migrate towards macrophages 
and only intravasate adjacent to peri-vascular macrophages (Wyckoff et al., 2007).  
This work starts to describe a permissive microenvironment for breast cancer cell 
motility, i.e close proximity to a blood vessel together with the presence of 
macrophages.  Patient sections were analysed for the presence of a macrophage, 
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blood vessel and invasive cancer cell (marked by increased MENA expression) 
within the same region, designated a tumour microenvironment of metastasis.  
Patients who developed distant metastasis showed a significant increase in the 
number of tumour microenvironments of metastasis, indicating the clinical 
relevance of perivascular macrophages for cell motility and metastasis (Robinson 
et al., 2009).  
 
Soluble signals from other cells in the microenvironment, such as CAFs, may also 
increase cancer cell motility in certain areas.  Numerous in vitro studies describe 
CAFs as promoters of cancer cell motility through factors such as HGF and TGF-β 
(Hanahan and Coussens, 2012).  TGF-β signalling is heterogeneous in breast 
cancer in vivo and correlates with single cell motility (Giampieri et al., 2009).  
Blocking TGF-β signalling in vivo blocks single cell motility suggesting that TGF-β 
mediates the induction of single cell motility.  Furthermore, consistent with 
heterogeneous motile behaviour, TGF-β signalling only occurs in some cells.  
Although the source of TGF-β was not explored, localisation of TGF-β expressing 
CAFs may contribute to the heterogeneity in induction of single cell motility. 
 
The ECM and physical environment of a tumour can also influence cancer cell 
motility.  Motile cancer cells interact with Collagen fibres and are often observed 
traversing the Collagen network at high speed using an amoeboid-like mode of 
motility (Condeelis and Segall, 2003).  Collectively invading strands of cancer cells 
associate with linear Collagen fibres suggesting that the ECM may help to provide 
a highway for migration (Alexander et al., 2008).  In addition, ECM remodelling by 
stromal cells such as CAFs helps to promote cancer cell motility, as indicated in 3D 
models of collective invasion in vitro (Gaggioli et al., 2007).  The different structures 
in the tumour microenvironment may affect whether cells are motile or which mode 
of motility they utilise.  Long-term tracking of fibrosarcomas revealed that areas of 
the tumour adjacent to fat storage adipocytes had an increase in singly motile cells 
(Alexander et al., 2008).  This correlates with in vitro reports that adipocytes 
promote cancer cell invasion and metastasis (Dirat et al., 2011) (Nieman et al., 
2011).   
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1.5.2.2 Heterogeneous activation in vivo of pathways associated with 
motility  
The varied behaviour of cancer cells in vivo probably reflects both internal and 
external differences, such as  
1. Genetic differences  
2. Differentiation or epigenetic changes 
3. External signals 
 
Motile melanoma cells in vivo were observed to be less pigmented and had higher 
activity of the promoter of the melanoblast transcription factor Brn2 (Pinner et al., 
2009).  This is suggestive of the motile cells being less differentiated, but whether 
this population represents the cancer stem cells is unknown.  However, imaging of 
a zebrafish model for rhabdomyosarcoma identified a cell population with tumour 
propagating properties, but these were not motile and instead a distinct, more 
differentiated, myogenin positive cell population potentiated invasion and 
metastasis (Ignatius et al., 2012). 
 
Heterogeneity in activation of signalling pathways associated with motility has been 
observed in human tumour slices, suggesting that intra-vital imaging of murine 
cancer models has relevance for the human disease.  Colon cancer sections show 
β-catenin localised to cell-cell junctions in the tumour bulk, but accumulated in the 
nucleus at the invasive tumour margin (Brabletz et al., 2001).  This pattern was 
also seen in the metastases.  This indicates that cells may undergo a transient 
increase in Wnt signalling that drives invasion but this signalling is not retained in 
the bulk of cells on reaching the metastatic site.  Further evidence for transient 
changes in signalling was revealed by intra-vital imaging of TGF-β reporter breast 
cancer cell-lines.  As discussed previously, TGF-β signalling was heterogeneous 
and correlated with single cell motility (Giampieri et al., 2009).  However, in lymph-
node metastases the majority of cells were non-motile and TGF-β signalling was 
low, suggesting a transient induction of motility and TGF-β signalling in vivo.  
Furthermore, cells showed increased lung colonisation after a pulse of TGF-β, 
whereas cells with constitutive activation of TGF-β signalling had reduced capability 
for lung colonisation, indicating the requirement for down-regulation of the signal.  
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This report also showed heterogeneity in TGF-β signalling in human breast tumour 
sections providing support for signalling heterogeneity in human tumours 
(Giampieri et al., 2009). 
 
In summary, intra-vital studies of cancer cell motility have shown that acquisition of 
motility is a rare and transient event that can be influenced by extrinsic factors in 
the microenvironment including macrophages and the presence of blood vessels.  
In addition, there are intrinsic differences between motile and non-motile cells in 
vivo such as differences in differentiation state and activation of certain proteins 
and signalling pathways.  
 
The next section will cover some key mechanisms by which extrinsic cues can 
affect gene expression and how stable patterns of gene expression may be 
maintained. 
 
1.6 Control of gene expression 
A cell’s phenotype and behaviour is dependent on the genes it expresses.  External 
signals, for example from the tumour microenvironment, can lead to gene 
expression changes and subsequent changes in cell behaviour, such as the 
acquisition of motility.  Gene expression can be controlled at many levels, including 
integration of external signals, transcription factor recruitment of RNA polymerase II 
complex components, remodelling of the higher order structure of DNA to increase 
polymerase access to genes, mRNA processing and mRNA stability.  In the 
nucleus, DNA is associated with Histone proteins to form chromatin.  For active 
gene transcription, the DNA must be accessible and RNA polymerase II complex 
must be recruited.  This section will address these initial steps of gene expression 
control.  There will be a focus on  
1. Upstream pathways that initiate transcription factor dependent RNA 
polymerase II (RNA pol II) recruitment  
2. Chromatin mediated control of gene expression, particularly gene silencing. 
 
Transcription factors can be general factors, such as TFIIA, that help to recruit the 
RNA pol II complex to the promoter of a gene.  Alternatively, specific transcription 
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factors mediate RNA pol II recruitment to a subset of genes through sequence 
specific DNA binding of key regulatory elements in gene promoters.  The next few 
sub-sections will address some of the key pathways regulating specific 
transcription factors. 
 
1.6.1 TGF-β signalling 
TGF-β signalling is activated in response to extracellular signals and is involved in 
the regulation of many cellular processes such as growth, adhesion, migration and 
differentiation (Schmierer and Hill, 2007).  It results in the nuclear accumulation of 
sequence specific transcription factors, called SMADS, that subsequently recruit 
other proteins and initiate transcription of target genes (Figure 1.5).   
 
The core TGF-β pathway has a large number of ligands in mammals, including 
bone morphogenetic proteins (BMPs), growth and differentiation factors (GDFs), 
Activins, Nodal and 3 TGF-β isoforms.  Some of the ligands, such as the TGF-βs, 
are secreted as latent forms and targeted to the ECM.  They require subsequent 
proteolysis to release the active ligand (Annes et al., 2003).  On release of active 
ligand, it binds to transmembrane serine-threonine kinase receptors to transfer the 
signal to inside the cell.  There are two classes of receptor, type I and type II, and 
on binding to ligand, dimers of the two types of receptors are brought together to 
form heterotetramers.  Type II receptors are constitutively active and so 
phosphorylate and activate the type I receptors.  Phosphorylation of the type I 
receptors recruits the receptor-regulated SMADs (R-SMADs), SMAD1,2,3,5 and 8.   
R-SMADs are subsequently phosphorylated by the activated type I receptors and 
this enables binding to the common mediator SMAD (Co-SMAD), SMAD4.  The 
receptor-R-SMAD interaction is specific due to differences in the amino-acid 
sequence of different type I receptors.  The type I receptors ALK 4,5 and 7 activate 
SMAD2 and 3 whereas ALK1,2,3 and 6 activate SMAD1,5 and 8 (Schmierer and 
Hill, 2007).  Active SMAD complexes accumulate in the nucleus and recruit other 
transcriptional regulators to activate transcription of target genes. 
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SMADs are continuously shuttling in and out of the nucleus, even in cells without 
receptor activation (Hill, 2009).  On activation of the signal, phosphorylated R-
SMADs, together with SMAD4, shuttle to the nucleus and activate transcription.  
The R-SMADs are also dephosphorylated in the nucleus leading to complex 
dissociation and R-SMAD nuclear export (Xu et al., 2002) (Inman et al., 2002).  If 
the receptors are still active R-SMADS will be phosphorylated again and shuttle to 
the nucleus, leading to an overall accumulation of SMADs in the nucleus and 
activation of target gene transcription.  TGF-β receptor activation can also lead to 
the SMAD independent activation of the MAPK, JNK, PI3K pathways and small 
Rho GTPases such as RhoA and Rac1 (Mu et al., 2012). 
 
All R-SMADs (with the exception of SMAD2) and SMAD4 can bind directly to DNA.  
The SMAD3-SMAD4 binding site was characterised as a single 5’-AGAC-3’ 
sequence known as a CAGA box, and promoters often consist of repeats of this 
sequence (Dennler et al., 1998).  The SMADs are thought to regulate transcription 
through chromatin re-modelling and recruitment of the SWI-SNF chromatin 
remodelling complex, BRG and the histone acetyltransferases p300 and CBP 
(Ross et al., 2006) (Janknecht et al., 1998).  This remodelling subsequently aids 
the recruitment of the general transcriptional machinery to activate transcription. 
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Figure 1.5 TGF-β signalling. 
Extracellular TGF-β ligands bind to a heterotetramer of type I and type II receptors.  
The type I receptors are phosphorylated by type II receptors, which recruits R-SMADs.  
The R-SMADs are phosphorylated by the activated type I receptors and then bind to 
co-SMADs.  The SMAD complexes accumulate in the nucleus resulting in transcription 
of TGF-β target genes.  I-SMADs are transcriptional targets which can inhibit the 
pathway through direct inhibition of active SMAD complexes on DNA and by indirect 
inactivation of receptor complexes. 
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Further regulation of the pathway can be achieved in a number of ways and 
ubiquitination plays a major role.  The inhibitor SMADs (I-SMADs), SMAD 6 and 7 
are transcriptional targets of TGF-β signalling and can feedback to inhibit the 
pathway.   SMAD7 is constitutively bound to the E3 ubiqutin ligases, SMURF1 and 
2.  Binding of SMAD-7 to receptor complexes targets the E3 ligases to the 
activated receptors leading to receptor degradation and signal inhibition (Kavsak et 
al., 2000).  In opposition to this, the de-ubiquitinating enzyme USP4 removes 
ubiquitin from TGF-β receptors, thereby maintain active signalling (Zhang et al., 
2012b).  SMAD7 also recruits protein phosphatase 1 (PP1) to active receptors 
resulting in de-phosphorylation and signal inhibition.  In addition, SMAD7 can 
directly inhibit binding of SMADs to DNA (Zhang et al., 2007).  In the absence of 
signal, transcriptional repressors such a SKI and SNON, bind CAGA box 
sequences (Stroschein et al., 1999).  TGF-β signalling results in degradation of 
SNON, which is dependent on the E3 ubiquitin ligase Arkadia, to allow 
transcriptional activation of target genes (Levy et al., 2007). 
 
1.6.1.1 TGF-β signalling in melanoma 
TGF-β signalling is implicated in many different cancers and has a complex role, 
acting as both a tumour supressor and invasion and metastasis promoter, even in 
the same cancer type.  Melanocytes are subject to growth inhibition by TGF-β. 
However, melanoma cells are less sensitive to TGF-β dependent growth inhibition 
and this correlates with stage, as metastatic melanoma cells show the least growth 
inhibition (Krasagakis et al., 1994).  Production of all 3 TGF-β isoforms is increased 
in melanoma compared to melanocytes (Krasagakis et al., 1999). 
 
TGF-β signalling also promotes invasion and metastasis in melanoma as inhibition 
of the pathway through over-expression of the inhibitor-SMAD Smad7, decreased 
invasion through decreasing MMP2 and 9 expression (Javelaud et al., 2005).  
Small molecule inhibition of TGF-β signalling also decreased experimental bone 
metastasis of melanoma cells (Javelaud et al., 2008).  Addition of TGF-β1 and 2 
increases B16 melanoma cell motility in vitro and decreases pigment, a 
characteristic of motile B16 cells in vivo (Pinner et al., 2009).  Other studies have 
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shown that TGF-β inhibits MITF expression through a decrease in PKA activation, 
and a subsequent loss of phosphorylated CREB and CREB dependent MITF 
expression (Pierrat et al., 2012). Given the role of TGF- β on MITF expression, 
TGF- β may promote switching to the more invasive MITF-/Brn2+ state.  This is 
consistent with genome-wide studies of melanoma cell lines in vitro that indicate 
that the invasive phenotype gene-signature is reminiscent of TGF- β induced gene 
expression (Hoek et al., 2006). 
 
TGF-β is known to drive a transcriptional program associated with melanoma 
invasion.  TGF- β drives GLI2 expression, a transcription factor associated with 
sonic hedgehog signalling (Dennler et al., 2007).  GLI2 can induce melanoma 
invasion through inhibition of E-cadherin and activation of MMP2 and 9 expression 
(Alexaki et al., 2010).  GLI2 was found to be heterogeneous in human melanoma 
sections, with increased GLI2 associated with decreased E-cadherin expression at 
the invasive front (Alexaki et al., 2010).   
 
Increased TGF- β in the melanoma microenvironment can also affect stromal cells.  
TGF-β activates normal fibroblasts and induces CAFs to produce ECM 
components, such as Fibronectin, Collagens and Tenascin-C (Xing et al., 2010).  
This can subsequently promote melanoma proliferation and invasion (Berking et 
al., 2001).  TGF- β can induce angiogenesis by directly affecting endothelial cell 
migration and through stimulating the production of the pro-angiogenic factors 
VEGF-A and IL-8 (Javelaud et al., 2008).  TGF- β can also influence immune cells 
in the microenvironment.  It is a potent inhibitor of T cells and together with IL-2, 
can induce differentiation towards immune-suppressive regulatory T-cells (Yang et 
al., 2010).  The high level of TGF- β found in melanoma likely increases invasion of 
melanoma cells, promotes tumour immunosuppression and angiogenesis and 
thereby promotes melanoma progression (Javelaud et al., 2008).  
 
1.6.2 SRF signalling 
SRF is a transcription factor that binds directly to DNA at 5’-CC(A/T6)GG-3’ 
sequences and associates with different co-factors to regulate transcription 
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(Treisman, 1986) (Olson and Nordheim, 2010).  There are two main classes of 
SRF transcriptional co-activators, the ternary complex factor (TCF) family and the 
myocardin-related transcription factor (MRTF) family.  These two families respond 
to different inputs and regulate distinct genes (Gineitis and Treisman, 2001).  As 
work in this thesis uses a transcriptional reporter dependent on the MRTF family of 
transcription factors, the focus will be on regulation of this branch of SRF signalling 
and gene transcription.   
 
MRTF-dependent SRF signalling links actin dynamics with gene transcription, 
thereby enabling cells to globally regulate transcription and cellular behaviour 
downstream of cytoskeletal rearrangement (Figure 1.6).  Most of the MRTF family 
transcription factors bind G-actin, acting as cytoplasmic G-actin sensors (Olson and 
Nordheim, 2010).  MRTF dependent SRF signalling is thus dependent on actin 
remodelling downstream of Rho GTPase activation (Sotiropoulos et al., 1999).  
Under conditions of low actin polymerisation, G-actin can bind MRTFs through 3 
RPEL motifs in the N-terminus of the transcription factors.  This leads to MRTF 
sequestration in the cytoplasm through obstruction of the nuclear localisation signal 
(Miralles et al., 2003) (Mouilleron et al., 2011).  On F-actin polymerisation the 
availability of G-actin in the cytoplasm decreases, which liberates MRTFs, allowing 
nuclear import and activating SRF dependent transcription.  Actin is also found 
within the nucleus and nuclear actin can further regulate the pathway.  MRTF 
bound to nuclear actin cannot activate transcription and has enhanced nuclear 
export (Vartiainen et al., 2007). 
 
Many external signals stimulate F-actin polymerisation from monomeric G-actin, 
leading either directly to Rho family GTPase activation, or activation of GEFs.  
Lysophosphatidic acid (LPA) and sphingosine-1 phosphate both activate RhoA 
leading to activation of SRF signalling (Descot et al., 2009) (Lockman et al., 2004).  
Multiple receptor tyrosine kinases activate GEFs and promote the switch to a GTP 
bound state of Rho proteins (Schiller, 2006).  Consistent with this VEGFR signalling 
activates MRTF dependent SRF signalling in endothelial cells (Chai et al., 2004).  
SRF signalling can also be activated downstream of Integrin signalling via Integrin-
linked kinase (ILK), FAK, Src and subsequent actin cytoskeleton remodelling 
(Huveneers and Danen, 2009) (Olson and Nordheim, 2010).  Furthermore, 
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Integrins are mechanosensors that transduce external mechanical stress and 
MRTF-dependent SRF signalling can be activated downstream of 
mechanotransduction (Zhao et al., 2007b).  This enables the cell to link gene 
transcription with external mechanical stress and tension. 
 
MRTF-dependent SRF target genes include genes involved in actin dynamics, cell 
motility and contractile force production and actin itself is an SRF target (Olson and 
Nordheim, 2010).  Therefore SRF signalling increases actin production leading to 
an increase in G-actin in the cell and an auto-regulatory negative feedback loop 
through G-actin dependent cytoplasmic sequestration of MRTF and MRTF nuclear 
exit (Olson and Nordheim, 2010).  
 
As MRTF dependent SRF signalling requires actin remodelling, drugs that target 
the actin cytoskeleton also affect SRF transcription activation.  Latrunculin B 
inhibits actin polymerisation and leads to an increase in SRF signalling.  
Alternatively, Cytochalasin D interacts with actin, disrupting the binding to MRTF 
and hence activates SRF signalling (Sotiropoulos et al., 1999).  
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Figure 1.6 MRTF-dependent SRF signalling. 
MRTF-dependent SRF signalling is activated downstream of F-actin polymerisation.  A 
number of stimuli activate actin polymerisation including signalling downstream of 
receptor tyrosine kinases (RTKs), G-protein coupled receptors (GPCRs) and Integrins. 
Actin polymerisation decreases cellular G-actin releasing MRTF to accumulate in the 
nucleus and together with SRF activate transcription. 
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1.6.2.1 SRF signalling in melanoma 
MRTF-dependent SRF signalling is required for melanoma invasion and 
metastasis.  Loss of MRTF in B16 melanoma cells does not affect primary tumour 
growth but decreases the number of motile cells in vivo.  MRTF depletion also 
decreases experimental metastasis to the lung (Medjkane et al., 2009).  This may 
be mediated through altered adhesion as adhesion to ECM components is also 
reduced by loss of MRTF.  Furthermore, expression of a constitutively active 
MRTF-A in poorly metastatic B16 F0 cells increased their metastastic potential by 
about 2-fold (Medjkane et al., 2009).  Depletion of the SRF targets Myosin light 
chain and non-muscle Myosin heavy chain also reduced invasion and metastasis 
suggesting these targets may be important for SRF dependent regulation of 
metastasis in melanoma.  Indeed, other studies have implicated myosin regulation 
in invasion and metastasis (Wyckoff et al., 2006). 
 
Many proteins involved in actin regulation, up-stream of MRTF-dependent SRF 
signalling, have also been implicated in metastasis.  Receptor tyrosine kinases are 
often over expressed in cancer, indeed increases in Receptor tyrosine kinase 
expression can lead to resistance to BRAF inhibitors (Nazarian et al., 2010).  
These receptors can lead to actin remodelling and activation of SRF signalling 
(Olson and Nordheim, 2010).  A polymorphism in the FGFR4 gene leads to 
prostate cancer progression and results in activation of SRF signalling and a 
subsequent increase in motility and invasion (Yu et al., 2011).  The Rho GTPases 
have an important role in invasion and metastasis and many are over-expressed in 
cancer (Sahai and Marshall, 2002).  RhoC is up-regulated in melanoma cells 
selected for increased metastatic potential (Clark et al., 2000).  RhoC can regulate 
the formins mDIA1 and Fmnl2 to potentiate actin polymerisation and increase 
amoeboid-like invasion of melanoma cells (Kitzing et al., 2010).  As RhoC induces 
actin polymerisation, its effects on metastasis may be in part through SRF 
signalling. 
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1.6.3 Notch signalling 
The Notch pathway controls differentiation and proliferation decisions in a number 
of cell-types by activation of a sequence-specific transcription factor (Andersson et 
al., 2011).  It has different roles in different cell-types and so the pathway must be 
able to respond in distinct ways in different cell contexts, possibly activating 
different sub-sets of target genes.  The core components and transduction pathway 
of Notch signalling are relatively simple, with only a small number of components 
required for pathway dependent transcription.   
 
Notch signalling is activated when a trans-membrane ligand binds a trans-
membrane receptor on an adjacent cell (Figure 1.7).  There are five canonical 
Notch ligands in mammals, Jagged 1,2 and Delta-like (Dll) 1,3 and 4, and four 
Notch ligands, Notch 1-4 (Andersson et al., 2011).  Following trans-activation of a 
Notch receptor, it is cleaved twice, once at site 2 (S2) and subsequently at sites 3/4 
(S3/4).  S2 cleavage is a key regulatory step in receptor activation and is mediated 
by extracellular ADAM proteases (Brou et al., 2000) (van Tetering et al., 2009).  S2 
cleavage releases the Notch extracellular domain (NECD) still bound to ligand, 
which is trans-endocytosed into the ligand expressing cell (Parks et al., 2000).  
After S2 cleavage the Notch extracellular truncated domain (NEXT) is subject to 
further cleavage by the γ-secretase complex, either at the plasma membrane or in 
endocytic vesicles (Andersson et al., 2011).  This releases the Notch intracellular 
domain (NICD), which translocates to the nucleus due to its nuclear localisation 
signals.  NICD cannot bind directly to DNA but instead binds to CBF-1 (also known 
as RBPJ-κ) and together with the co-activator MAML-1, initiates expression of 
target genes (Borggrefe and Oswald, 2009).  CBF-1 binds DNA via 5’-
CGTGGGAA-3’ motifs and is thought to act as a repressor of gene transcription in 
the absence of NICD (Hsieh et al., 1996).  On Notch activation, NICD and MAML 
displace co-repressors of CBF-1 and recruit co-activators, thereby bringing about 
transcriptional activation (Borggrefe and Oswald, 2009).  However, the DNA 
binding coefficient of CBF-1 has been found to be weaker than first thought and 
studies in Drosopila suggest CBF-1 is actively recruited to binding sites by NICD 
(Friedmann and Kovall, 2010) (Krejci and Bray, 2007).  Therefore, the interaction of 
CBF-1 with its DNA binding sites may be more dynamic than anticipated.  The 
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hairy/enhancer of split (HES) genes are Notch targets that have been identified in a 
number of cell contexts (Borggrefe and Oswald, 2009).   
 
Layered on top of the simple core Notch pathway are additional mechanisms to 
regulate and finely tune Notch signalling.  EGF repeats in Notch receptors can be 
glycosylated by Fringe proteins, which may affect the relative strength of ligand-
receptor interactions (Hicks et al., 2000).  Glycosylation has been shown to 
increase the levels of expression of Notch target genes, but not affect the set of 
genes activated (Andersson et al., 2011).  The final cleavage of the Notch receptor 
may occur at either site 3 or 4, which results in NICD fragments with different N-
terminal amino-acids.  The different NICD fragments generated have different half-
lives and so this could be a mechanism to regulate the duration of Notch signalling 
(Tagami et al., 2008).  Notch signalling is also regulated by the ubiquitin signalling.  
Numb-like is a negative regulator of Notch signalling, which recruits the E3 ubiquitin 
ligase, Itch, to promote Notch receptor degradation (McGill and McGlade, 2003).  
Furthermore, ubiquitination of NICD by the E3 ubiquitin ligase Fbxw7, can lead to 
rapid degradation of NICD and loss of Notch signalling (Oberg et al., 2001).  NICD 
is subject to other regulatory signals such as phosphorylation and acetylation.  The 
PEST degradation domain within NICD contains many phosho-sites and these are 
important in determining NICD stability as they are triggers for subsequent 
ubiquitination (Andersson et al., 2011).  The balance between acetlyation and de-
acetylation of NICD regulates its half-life and SIRT1, a de-acetylase, decreases 
NICD stability in endothelial cells (Guarani et al., 2011).  Notch target genes can 
also feedback to regulate the pathway.  The Notch target Nrarp, can form a 
complex with NICD and CBF-1 and decrease NICD stability (Lamar et al., 2001). 
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Figure 1.7 Notch signalling. 
Notch ligands on the signal sending cell bind to Notch receptors on the signal receiving 
cell, leading to two separate cleavage steps.  ADAM proteases first cleave at site S2 
followed by γ-secretase cleavage to release the Notch intracellular domain (NICD).  
NICD translocates to the nucleus and together with CBF-1 and MAML, activates 
transcription of target genes.  
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1.6.3.1 Notch in melanocytic cells and melanoma 
The Notch pathway has an important role in maintaining melanocyte stem cells and 
melanoblasts in vivo.  Conditional deletion of CBF-1 (RBPJκ) in melanocyte lineage 
cells results in a loss of hair pigmentation, characteristic of an absence of 
melanocytes and a loss of melanocyte stem cells.  In addition, treatment of mouse 
embryonic skin with the γ-secretase inhibitor DAPT, leads to melanoblast apoptosis 
and a loss of hair pigmentation (Moriyama et al., 2006).  Notch activation in mature 
melanocytes is sufficient to induce re-programming and de-differentiation to neural 
crest stem cell–like cells (Zabierowski et al., 2011).  This provides further evidence 
for the importance of Notch signalling in regulating the differentiation hierarchy of 
melanocytic cells. 
 
Notch signalling is also implicated in melanoma progression.  Notch1 and the 
Notch target, HEY1 are up-regulated in melanoma cells (Balint et al., 2005) (Pinnix 
et al., 2009) (Hoek et al., 2004).  Constitutive activation of Notch signalling by 
expression of NICD in melanocytes confers a transformed phenotype with 
increased proliferation and migration (Pinnix et al., 2009).  This suggests that Notch 
may be a driver of melanomagenesis.  Notch up-regulation in melanocytes also 
induces MCAM expression and decreases E-cadherin expression leading to 
changes in adhesion of melanocytes (Pinnix et al., 2009).   
 
Notch can drive proliferation of melanoma cells as γ-secretase inhibitors induce 
apoptosis in melanoma cells (Qin et al., 2004).  Furthermore, constitutive activation 
of Notch signalling in melanoma cells increases cell proliferation in vitro and tumour 
growth in vivo (Balint et al., 2005).  This Notch induced increase in tumour growth 
is dependent on β-catenin stability and β-catenin target gene expression, 
highlighting the importance of interactions between key signalling pathways in 
melanoma.  Notch signalling in melanoma can also increase proliferation through 
activation of the MAPK and PI3K/AKT pathways (Liu et al., 2006).  AKT is activated 
by the autocrine action of the Notch target NRG1, an ERBB3/4 ligand, resulting in 
increased proliferation (Zhang et al., 2012a).   
 
Chapter 1. Introduction 
68  
 
Notch signalling has also been implicated in invasion and metastasis.  Hypoxia 
induces Notch signalling in a number of different cancer cell-lines and Notch 
signalling induces EMT through directly up-regulating Snail expression (Sahlgren et 
al., 2008).  Snail can also feedback to increase Notch4 expression (Kuphal et al., 
2005).  The EMT regulator Slug, is a Notch target, which represses E-cadherin and 
induces invasion and metastasis (Leong et al., 2007).  Constitutive Notch signalling 
can also affect melanoma cell adhesion though increasing N-cadherin expression, 
which subsequently results in increased lung colonisation (Liu et al., 2006).   
 
Given the role of the Notch pathway in differentiation decisions, Notch may be 
involved in the phenotype switching between MITF+/Brn2- and MITF-/Brn2+ 
populations.  Brn2 can induce Notch signalling in neural progenitors and MITF 
down-regulation in melanoma cells increased Notch target genes (Castro et al., 
2006) (Thurber et al., 2011).  This suggests that Notch signalling may also be 
heterogeneous and increased in the potentially more motile MITF-/Brn2+ sub-
population. 
 
1.6.4 Interactions between signalling pathways 
Many signalling pathways in the cell interact, overlap and impinge on each other so 
that overall cell behaviour is regulated by a signalling network with many nodes and 
points of interaction.  The signalling pathways described above are no exception 
and this section will briefly discuss overlaps between Notch, TGF-β and SRF 
signalling.  
 
Notch signalling can be functionally enhanced by TGF-β.  NICD can bind to 
SMAD3 and this interaction increases expression downstream of both NICD and 
SMAD DNA binding sites (Blokzijl et al., 2003).  In addition, expression of HES-1, a 
Notch target, up-regulated after TGF-β addition in an NICD dependent manner 
(Blokzijl et al., 2003).  TGF-β also impacts on Notch signalling as TGF-β signalling 
induces HEY1 and Jagged1 expression during EMT and this is blocked if Notch 
signalling is inhibited (Zavadil et al., 2004).  In addition, HEY1 expression is bi-
phasic, showing an initial SMAD dependent peak, and a subsequent 
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Jagged1/Notch dependent transcriptional peak, highlighting the different levels of 
interaction between the Notch and TGF-β pathways (Zavadil et al., 2004).  
 
TGF-β induced EMT involves actin cytoskeleton rearrangements and so may 
activate MRTF-dependent SRF signalling as a result, indeed TGF-β can induce 
MRTF nuclear translocation in a Rho dependent manner in epithelial cells (Morita 
et al., 2007).  In a similar manner, hypoxia induced Notch-dependent EMT may 
also activate SRF signalling through changes in the G-/F-actin ratio.  MRTF also 
directly interacts with SMAD3 downstream of TGF-β signalling to activate slug 
transcription and drive EMT (Morita et al., 2007).  SMADs and MRTF share some 
of the same target genes such as Cyr61 and Ctgf (Olson and Nordheim, 2010) 
(Bartholin et al., 2007). However, SMADs and MRTF can also have inhibitory 
interactions as SMAD3 is thought to inhibit MRTF dependent smooth muscle actin 
expression under certain conditions (Masszi et al., 2010). 
 
1.6.5 Chromatin control of gene transcription 
1.6.5.1 Chromatin 
In the nucleus, DNA is packaged together with Histone proteins to form chromatin.  
The basic unit of chromatin is a nucleosome, which contains DNA wrapped around 
a Histone octamer (Kornberg and Lorch, 1999).  Linker Histones associate with 
nucleosomes and form higher order chromatin structures to further increase 
packaging of the DNA (Kornberg and Lorch, 1999).  However, the chromatin 
structure is highly dynamic and can unfold during transcription to allow easy access 
for RNA polymerases.  Together with compacting DNA, Histones also provide a 
mechanism for regulation of gene transcription.  Histone tails protrude from the 
nucelosome and are a target for multiple methods of modification.  There are over 
100 different sites recorded for Histone modification and numerous modifications 
including lysine methylation, acetylation, ubiquitination, arginine methylation and 
serine phosphorylation (Rando, 2012).  
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1.6.5.2 Histone modifications 
Histone modifications not only alter chromatin structure, potentially regulating 
access to DNA, but also recruit different proteins and complexes (Rando, 2012).  
The number of Histone residues available for modification and wide range of 
modifications gives the possibility for a huge complexity in Histone modifications 
and combinations.  However, studies report that patterns of modifications co-occur 
widely throughout the genome (Ernst et al., 2011).  Analysis at the single 
nucleosome level of 18 different histone modifications in Drosophila,showed 9 
distinct modification patterns, considerably smaller than the 2
18
 potential 
combinations (Kharchenko et al., 2011).  The distinct patterns, or chromatin states 
typically describe genomic locations such as promoters, intron, exons, enhancers 
and insulators.  Actively transcribed promoters are associated with tri-methylated 
lysine 4 of HistoneH3 (H3K4me3) and a range of acetylated modifications such as 
acetylated lysine 9 on Histone H3 (H3K9ac) (Mikkelsen et al., 2007).  Repressed 
genes are associated with tri-methylated lysine 27 of HistoneH3 (H3K27me3) and 
methylated lysine 9 on Histone H3 (Mikkelsen et al., 2007).  These distinct 
modification patterns enable or hinder RNA pol II recruitment, respectively.  Given 
the distinct roles for these modifications, it is surprising that they can also be found 
together.  Bivalent chromatin domains contain both repressive H3K27me3 marks 
and activating H3K4me3 marks.  Genes in these regions are thought to be 
repressed, but poised for activation, such that key genes can remain silenced but 
ready for transcription when required (Bernstein et al., 2006). 
 
1.6.5.3 Chromatin mediated gene silencing 
The remainder of this section will focus on chromatin mediated gene silencing and 
the H3K27me3 mark.  Around 15 % of Histone H3 is trimethylated at lysine 27 in 
ES cells and H3K27me3 enrichment is centred around the transcriptional start sites 
(TSS) of promoters (Zhao et al., 2007a).  H3K27me3 is usually associated with 
gene silencing and the mark is lost in actively transcribed genes (Simon and 
Kingston, 2009).  H3K27 tri-methylation is mediated by the polycomb repressor 
complex 2 (PRC2) (Margueron and Reinberg, 2011).  The core PRC2 complex 
consists of the Histone methyltransferases EZH1 and EZH2 and two other 
Chapter 1. Introduction 
71  
 
polycomb proteins, suppressor of zeste 12 (Suz12), which is essential for 
methyltransferase activity, and embryonic ectoderm development (EED) (Morey 
and Helin, 2010).  The PRC2 complex works together with the polycomb repressor 
complex 1 (PRC1).  PRC1 catalyses Histone H2A lysine 119 mono-ubiquitination 
(H2AK119Ub1), which is another repressive chromatin modification and is thought 
to compact chromatin (Morey and Helin, 2010).  RING1A and RING1B are the 
catalytic subunits of PRC1 and their activity is stimulated by BMI-1, an additional 
PRC1 component (Li et al., 2006).  PRC1 can bind H3K27me3, suggesting that 
PRC2 acts upstream to enable recruitment of PRC1 to repressed genes.  However, 
not all PRC2 bound genes show H2AK119Ub1 and PRC1 can catalyse H2AK119 
ubiquitination at polycomb target genes in the absence of PRC2 (Margueron and 
Reinberg, 2011) (Tavares et al., 2012).  This seems to be the minority of repressed 
genes and for the most part PRC2 and PRC1 are required to maintain gene 
repression.  
 
Exactly how PRC2 and H3K27me3 silence gene expression is under debate, it may 
be through regulation of chromatin structure or more likely recruitment of further 
regulatory factors (Simon and Kingston, 2009).  H3K27me3 may prevent proteins 
binding to DNA through steric hindrance, although RNA pol II can be detected at a 
subset of H3K27me3 enriched promoters (Stock et al., 2007).  RNA transcripts 
have been detected at low levels at these genes, suggesting that RNA pol II may 
be paused at H3K27me3 enriched genes (Zhao et al., 2007a) (Stock et al., 2007).  
Short transcripts generated from a paused RNA pol II may recruit PRC2 (Kanhere 
et al., 2010). Therefore PRC2 and H3K27me3 may regulate RNA pol II promoter 
escape and elongation rather than earlier steps such as recruitment and initiation 
(Margueron and Reinberg, 2011). 
 
Jarid2 is also found together with the core PRC2 components (Pasini et al., 2010).  
It is a member of the Jumonji Histone demethylation family of proteins, but it is 
thought to lack demethylase activity due to a lack of the key residues for co-factor 
binding (Cloos et al., 2008).  Jarid2 target genes overlap with 90 % of known PRC2 
core component target genes and it aids PRC2 core complex recruitment to target 
genes and regulates PRC2 activity (Pasini et al., 2010).  In addition, Jarid2 is 
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required for both PRC2 and RNA Pol II recruitment to bivalent genes in ES cells 
(Landeira et al., 2010). 
 
The mechanism of PRC2 recruitment to genes is currently unclear.  In Drosophila a 
specific DNA sequence named the polycomb response element targets polycomb 
proteins to chromatin (Margueron and Reinberg, 2011). Genome-wide studies in 
mammals have failed to find a similar sequence (Beisel and Paro, 2011).  However, 
Jarid2 is able to bind DNA with a bias towards GC rich regions and CHIP-Seq of 
other PRC2 components also shows a bias towards binding to GC rich regions (Li 
et al., 2010b) (Margueron and Reinberg, 2011).  Non-coding RNAs (ncRNAs) 
transcribed from the same DNA region (cis) or different DNA region (trans) may 
regulate H3K27me3 modifications and PRC2 recruitment.  X-chromosome 
inactivation involves H3K27me3 modifications and an increase in the more 
compact heterochromatin.  The ncRNA Xist is transcribed from the X-chromosome 
and is required for X-chromosome H3K27 methylation (Plath et al., 2003).  Xist can 
bind to PRC2 in vitro suggesting it may recruit PRC2 to the X-chromosome (Zhao 
et al., 2008).  Expression of the long ncRNA HOTAIR from the Hoxc locus leads to 
repression in trans of the Hoxd locus (Rinn et al., 2007).  HOTAIR binds to the 
PRC2 complex, recruiting it to the locus to bring about H3K27 methylation (Tsai et 
al., 2010).  PRC2 members can also bind to Histone modifications and EED has 
been shown to bind H3K27me3, increasing the enzymatic activity of EZH2 
(Margueron et al., 2009).  Therefore PRC2 recruitment may be through multiple 
interactions including Jarid2 binding to DNA, EED binding to H3K27me3 and other 
PRC2 components binding ncRNAs (Margueron and Reinberg, 2011). 
 
Some PRC2 members may have non-chromatin-related activities.  EZH2 has been 
shown to bind to Suz12 and EED to form a methyltransferase complex in the 
cytoplasm.  This complex is thought to co-localise with F-actin and control actin 
polymerisation through regulation Cdc42 (Su et al., 2005).  EZH2 can also bind and 
directly methylate a lysine residue within the transcription factor GATA4, resulting 
in a decrease in GATA4 dependent transcription (He et al., 2012).  Therefore, 
EZH2 and other PRC2 complex members may have additional roles other than 
chromatin mediated transcriptional control.   
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1.6.6 PRC2 complex during development and differentiation 
The PRC2 complex is important during differentiation and provides a memory 
function to maintain cellular identity and silence alternative transcriptional programs 
associated with other cell types (Prezioso and Orlando, 2011).  This function must 
also be dynamic to respond to environmental cues that induce differentiation but 
also to maintain the memory through the cell cycle.  In pluripotent ES cells, the 
PRC2 complex is thought to silence differentiation associated genes as loss of 
PRC2 components results in the up-regulation of differentiation associated genes 
(Boyer et al., 2006) (Lee et al., 2006).  In addition, binding of PRC2 components 
and H3K27me3 levels decreased at these genes on induction of differentiation 
(Boyer et al., 2006).  However, loss of Jarid2 in ES cells prevents differentiation 
and key differentiation associated genes are not primed for transcription (Landeira 
et al., 2010).  This suggests that Jarid2 dependent priming of differentiation 
associated genes is required for the cell to differentiate correctly.  Therefore, Jarid2 
may have a different role to the core PRC2 components during differentiation.  The 
requirement of core PRC2 components to silence differentiation associated genes 
and maintain cells in a less differentiated state is also highlighted in the epidermis, 
where EZH2 levels are high in epidermal progenitors but decrease with 
differentiation (Ezhkova et al., 2009).  Furthermore, loss of EZH2 in the developing 
skin increases differentiation. 
 
1.6.7 EZH2 in cancer 
EZH2 is up-regulated in a number of cancers including melanoma and lymphoma 
and is associated with aggressive breast and prostate cancer (McHugh et al., 
2007) (van Kemenade et al., 2001) (Kleer et al., 2003) (Varambally et al., 2002).  
Mutations in EZH2 are found in a number of cancers and a recent study identified 
EZH2 as a driver mutation in 3 % of melanomas (Chang and Hung, 2012) (Hodis et 
al., 2012).  Up-regulation of EZH2 in prostate cancer has been shown to be a result 
of genomic loss of microRNA 101, which represses EZH2 transcription (Varambally 
et al., 2008).  Additionally, EZH2 is regulated by the Rb-E2F pathway and 
increased expression is associated with cell proliferation (Bracken et al., 2003).   
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EZH2 can also affect cell proliferation acting as a typical oncogene, as loss of 
EZH2 in prostate and melanoma cells decreases proliferation (Varambally et al., 
2002) (Fan et al., 2011).  In melanoma, EZH2 expression increases from nevi to 
melanoma and is highest in metastatic disease.  As discussed previously, benign 
nevi often harbour Braf mutations but are in a state of senescence.  EZH2 up-
regulation is thought to silence the cell cycle inhibitor p21 and bypass the 
senescent state, driving cancer progression (Fan et al., 2011). EZH2 is also 
involved in driving breast cancer progression as breast cancer initiating cells show 
high levels of EZH2.  Hypoxia leads to an increase in EZH2 expression, which in 
turn decreases expression of the DNA damage protein RAD51 leading to increased 
DNA damage and subsequent activation of growth promoting pathways (Chang et 
al., 2011). 
 
In addition to driving tumour growth, EZH2 can promote invasion and metastasis in 
some cancer types.  An increase in EZH2 expression in prostate cancer results in 
silencing of the RasGAP, DAB2IP.  DAB2IP acts as a signalling scaffold to co-
ordinate both Ras and NF-κB signalling.  Epigenetic silencing of this protein leads 
to activation of both of these pathways, increasing tumour growth, EMT and 
metastasis (Min et al., 2010).  Increased levels of EZH2 in prostate cancer also 
lead to EMT and increased invasion through EZH2 silencing of the metastasis 
suppressor RKIP and direct silencing of E-cadherin (Ren et al., 2012) (Cao et al., 
2008).  In addition, EZH2 induces EMT in nasopharyngeal cancer by interacting 
with snail to repress E-cadherin expression (Tong et al., 2012).  Further implication 
of the PRC2 complex in cancer metastasis comes from the role of the long ncRNA 
HOTAIR, a PRC2 interaction partner, which targets PRC2 to the genome.  
Metastatic breast cancer cells show increased levels of HOTAIR resulting in 
genome-wide re-targeting of PRC2 and increased invasion and metastasis (Gupta 
et al., 2010). 
 
1.7 The tumour microenvironment and angiogenesis 
Tumours are comprised of a range of cell-types including CAFs, macrophages, T 
cells, adipocytes, blood and lymphatic endothelial cells and pericytes.  Interactions 
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between these different cell-types and cancer cells govern tumour progression and 
influence many of the hallmarks of cancer (Hanahan and Coussens, 2012).  In 
addition, therapeutic treatments must consider the tumour microenvironment as a 
whole as interactions between stromal cells and cancer cells can affect response to 
therapy and lead to drug resistance (Straussman et al., 2012) (Nakasone et al., 
2012).  Work in this thesis explores the blood vasculature in vivo, its relationship 
with motility in the primary tumour and response to angiogenic therapy.  This 
section will focus on the vasculature within the tumour microenvironment.  The 
effects of the microenvironment on motility and metastasis are discussed 
elsewhere. 
 
1.7.1 The tumour vasculature 
Blood vessels are formed from a layer of endothelial cells surrounded by pericytes 
and a basement membrane.  They provide tissues with oxygen and nutrients and 
help to remove carbon dioxide and waste metabolites (Potente et al., 2011).  This 
is also true for tumours and the growth of blood vessels into tumours sustains 
tumour growth.  Analysis of genetic mouse models of cancer revealed an 
“angiogenic switch”, a distinct event relatively early in cancer progression that 
described an increase in blood vessel density and enabled further tumour growth 
(Hanahan and Folkman, 1996).  The “angiogenic switch” was thought to be a rate-
limiting step in tumour growth, leading to the idea that targeted therapy against 
blood vessels in human tumours could halt cancer progression. 
 
The tumour vasculature is abnormal and compared to quiescent adult vessels, 
tumour vessels can be considered as in a state of hyper-activation.  They are 
highly branched and often enlarged and convoluted.  In addition, tumour vessels 
have uneven diameters, potentially as a result of pressure from tumour or stromal 
cells (Carmeliet and Jain, 2011b).   Pericytes are usually only loosely associated 
with the endothelial cells and the endothelial basement membrane is disordered 
(Baluk et al., 2003).  The result is leaky vessels that are poor at delivering oxygen 
and can hinder drug delivery to the tumour (McDonald and Baluk, 2002).  The 
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loose pericyte association and vessel leakiness may also aid cancer cell 
intravasation (Yonenaga et al., 2005).  
 
1.7.2 Induction of tumour angiogenesis 
Tumours can become vascularised in a number of different ways.  Vessels can 
sprout from existing ones and generate a new vascular network in a process called 
sprouting angiogenesis.  Alternatively tumours can co-opt pre-exitisting blood 
vessels without initial sprouting.  However, once the tumour outgrows the vascular 
network, hypoxia induces a sprouting angiogenic response (Potente et al., 2011). 
Vascular progenitor cells recruited to the tumour through paracrine signalling may 
form part of the tumour vasculature by intercalating with existing endothelial cells 
(Potente et al., 2011).  In a similar manner, tumour cells can insert themselves into 
the tumour vasculature in a process called vascular mimicry (Wang et al., 2010a). 
 
Sprouting angiogenesis is initiated by angiogenic factors in the environment, such 
as VEGF-A, PlGF, PDGF, FGF family members and Angiopoietins (Sakurai and 
Kudo, 2011).  Both cancer cells and stromal cells can contribute to angiogenesis.  
VEGF-A expression is up-regulated in cancer cells by both hypoxic conditions and 
oncogenic signalling, leading to an increase in tumour angiogenesis (Shweiki et al., 
1992) (Rak et al., 1995).  Tie2 positive macrophages in the tumour environment 
express an array of pro-angiogenic molecules such as VEGF-A and bFGF and 
large numbers of macrophages correlates with increased vessel density in human 
tumours (Murdoch et al., 2008). Paracrine interactions between CAFs and cancer 
cells can induce CAFs to express VEGF-A leading to sprouting angiogenesis 
(Fukumura et al., 1998).  Furthermore, CAFs can also promote angiogenesis 
through the CXCL12-dependent recruitment of endothelial progenitor cells (Orimo 
et al., 2005).   
 
The Vegfa gene product is subject to alternative splicing and results in a number of 
different isoforms (Harper and Bates, 2008).  Some isoforms contain a heparin 
binding domain enabling them to bind the ECM (Ferrara, 2010).  Other angiogenic 
factors, such as PDGF-BB can also bind to the ECM.  Stromal derived proteases 
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such as MMP9 release bio-active angiogenic ligands from the ECM hence 
promoting angiogenesis (Bergers et al., 2000) (Du et al., 2008).  Soluble and ECM 
bound ligands may have different effects on the tumour vasculature.  Soluble 
VEGF-A isoforms are thought to promote vessel enlargement whereas ECM bound 
VEGF-A isoforms induce vessel sprouting and branching (Lee et al., 2005). 
 
1.7.3 Sprouting angiogenesis 
VEGF-A stimulates endothelial sprouting and angiogenesis by binding to VEGFR-2 
and inducing filopodia formation in endothelial cells.  Cells responding in this way to 
angiogenic signals are labelled tip cells and these tip cells lead the nascent sprout 
(Gerhardt et al., 2003).  Stalk cells make up the rest of the vessel and these cells 
lack filopodia.  During developmental angiogenesis, further sprouting requires 
pericyte detachment and degradation of the basement membrane by MMPs 
(Potente et al., 2011).  Tip cells are enriched in MT1-MMP, which helps breakdown 
the basement membrane and also liberates ECM bound angiogenic factors (Yana 
et al., 2007).  As tumour vessels have weakly attached pericytes and an abnormal 
basement membrane, the importance of these steps in tumour angiogenesis is 
unknown. 
 
During developmental angiogenesis, tip cells interact with their neighbouring 
endothelial cells to induce a stalk cell phenotype in the adjacent cell, and prevent 
multiple tip cells and excessive sprouting.  VEGF signalling in tip cells, together 
with other external signals, such as Laminin α4 in the basement membrane, 
induces Dll4 expression (Phng and Gerhardt, 2009) (Stenzel et al., 2011).  Dll4 
expression on tip cells stimulates Notch signalling in adjacent cells.  High Notch 
signalling inhibits VEGFR-2/3 signalling and prevents sprouting creating a stalk cell 
phenotype (Benedito et al., 2012) (Phng and Gerhardt, 2009).  This situation is 
complicated by the switching of tip and stalk cell positions during sprouting 
(Jakobsson et al., 2010).  Nascent sprout growth is induced by stalk cell 
proliferation and endothelial cell migration (Potente et al., 2011).  High VEGF-A and 
other angiogenic molecules in the tumour environment are likely to stimulate 
multiple tip cells leading to increased vessel branching and increased vessel 
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density.  Whether filopodial sprouting is restricted to tip cells, and if lateral inhibition 
of sprouting occurs in tumour endothelium is unknown.   
 
During development, the vascular network grows through multiple cycles of 
sprouting and vessel fusion, forming new connections.  Vessel fusion occurs when 
two tip cells meet in a process known as anastomosis.  The tip cells make initial 
contact through filopodial extensions before forming new cell-cell contacts.  The 
process is aided by macrophages at the site of fusion (Fantin et al., 2010).  Vessels 
subsequently mature both at a cellular level and a network level.  On a cellular 
level, pericytes are recruited by endothelial expression of PDGF-B, which 
stimulates their proliferation and migration (Gaengel et al., 2009).  In addition, 
endothelial cells become quiescent and form cell-cell contacts to create a barrier 
between the blood and surrounding tissues.  VE-Cadherin is up-regulated during 
quiescence and localises to adherens junctions to regulate cell-cell adhesion and 
intracellular signalling (Harris and Nelson, 2010).  Mature endothelial cells also 
require survival signals and these include VEGF-A expressed by the endothelial 
cells themselves, and blood flow, which up-regulates the transcription factor KLF2 
(Lee et al., 2007) (Dekker et al., 2002).  Finally, the vascular network is subject to 
remodelling and pruning of vessels to generate an efficient network for blood flow 
(Potente et al., 2011).   
 
During tumour angiogenesis, many of these stages are disrupted.  High VEGF-A in 
the microenvironment means that growth factor gradients, which normally operate 
during developmental angiogenesis, are absent.  Disruption of the stages of normal 
sprouting angiogenesis is highlighted by the abnormal tumour vessel architecture.  
Analysis of vessel structures induced by acute VEGF-A treatment in vivo together 
with vessels observed in tumours, revealed heterogeneity in vascular structures.   
VEGF-A initially stimulates the formation of large, thin-walled, hyperpermeable 
sinusoids called mother vessels (MV).  These subsequently turn into capillary 
structures through sprouting, or vascular malformations (VMs) through proliferation 
of endothelial cells (Nagy and Dvorak, 2012).  This suggests that merely the 
increase is VEGF-A can lead to abnormal vasculature structures through 
endothelial cell proliferation and sprouting. 
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High VEGF-A levels lead to VEGFR-2 dependent signalling in endothelial cells and 
phosphorylation of VE-Cadherin.  This results in a loosening of endothelial cell-cell 
contacts and contributes to vascular leakage (Esser et al., 1998).  Tumour vessels 
often have poor blood flow and this can lead to an up-regulation of inflammation 
associated genes contributing to the inflammatory tumour microenvironment (Tozer 
et al., 2005) (Chiu and Chien, 2011).  As flow provides a survival signal to 
endothelial cells, presumably other mechanisms, potentially VEGF-A, provide 
adequate survival signals in the tumour context.  As discussed earlier, the tumour 
endothelium has a loose connection with pericytes. 
 
1.7.4 Targeting tumour angiogenesis 
Given that blood vessels are required to bring vital nutrients and oxygen to the 
tumour, a number of agents have been developed to target the tumour vasculature 
with the aim to starve the tumour and prevent growth.  The anti-VEGF-A antibody 
Bevacizumab, is approved in the US for combination treatment with chemotherapy 
for metastatic cancers.  A number of pan-VEGFR tyrosine kinase inhibitors have 
also been developed including Sunitinib and Sorafenib.  Sunitinib is approved in the 
US for treatment of metastatic renal cell carcinoma.  Both Sunitinib and Sorafenib 
also target other receptor tyrosine kinases and Sunitinib can additionally inhibit 
PDFR, CSF-1R and RET.  Clinical benefit of anti-angiogenic therapies is thought to 
be derived from both the inhibition of vascular expansion due to blockade of vessel 
branching, and vessel regression due to the inhibition of endothelial survival signals 
(Potente et al., 2011).  The loss of survival signals may also sensitise endothelial 
cells to chemotherapy or irradiation therapy, potentially explaining why anti-
angiogenic therapies are more effective in combination with other more traditional 
cancer therapies (Jain, 2005). 
 
Despite positive pre-clinical results, there have been a number of unsuccessful 
clinical trials with anti-angiogenic therapies and many trials indicated no benefit for 
overall survival in patients, (Allegra et al., 2011).  Some patients showed no 
response and other patients developed resistance later in disease progression.  
Furthermore, subsequent pre-clinical studies have suggested that anti-angiogenic 
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therapy creates a hypoxic environment that can act to increase cancer cell invasion 
and metastasis (Paez-Ribes et al., 2009) (Ebos et al., 2009). 
 
Resistance to anti-angiogenic therapy may arise through a number of mechanisms.  
Following anti-angiogenic treatment of experimental tumours, vascular density 
decreases but normal looking vessels with tightly associated pericytes remain 
(Bergers et al., 2003).  This suggests that pericyte coverage of tumour vessels may 
dictate the responsiveness to therapy.  Pericytes could protect endothelial cells by 
secreting VEGF-A and other growth factors, hence providing survival signals 
(Bergers and Hanahan, 2008).  It is likely that stromal cells have an important role 
in resistance to anti-angiogenic therapy.  Stromal cells may produce endothelial 
survival signals or VEGF/VEGFR independent pro-angiogenic ligands.  For 
example, CAFs from anti-angiogenic resistant tumours show an up-regulation of 
PDGF-C compared to non-resistant tumours (Crawford et al., 2009).  Furthermore, 
blocking antibodies against ANG2, another pro-angiogenic factor, together with 
anti-VEGF-A therapies improved anti-tumour activity (Brown et al., 2010).  
Alternatively, the cancer cells may up-regulate these non-VEGF “rescue” ligands 
such as PlGF and FGFs as a result of hypoxia (Potente et al., 2011).  Cancer cells 
may also recruit pro-angiogenic stromal cells.  Recruitment of CD11b+ Gr-1+ 
myeloid cells aids tumour growth in the presence of anti-angiogenic therapy 
(Shojaei et al., 2007a).  These cells have subsequently been shown to promote 
angiogenesis through secretion of Bv8, a G-protein receptor ligand that stimulates 
endothelial cells in a VEGFR independent manner (Shojaei et al., 2007b).  
 
Few, if any, of the receptor tyrosine kinase inhibitors inhibit all VEGFRs.  Sunitinib 
only inhibits VEGFR-1 and 2, whereas Sorafenib only inhibits VEGFR-2 and 3, and 
so pro-angiogenic signalling may occur through non-inhibited VEGF receptors 
(Azam et al., 2010).  Hypoxia is a key factor in resistance to anti-cancer therapies 
(Azam et al., 2010).  Generation of a hypoxic tumour environment after anti-
angiogenic treatment can induce autophagy in cancer cells, which aids survival (Hu 
et al., 2012).  Furthermore, investigation of the response of different tumour 
associated vessels, such as mother vessels or vascular malformations (described 
earlier) indicated that different vessels within the tumour may respond differently to 
anti-angiogenic therapy.  Vessel structures formed early in the response to VEGF-
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A, such as mother vessels, were sensitive to anti-VEGF therapy, whereas vessels 
formed later, such as vascular malformations, were resistant (Nagy and Dvorak, 
2012).  Therefore, different vessels in the same tumour may respond differently to 
anti-angiogenic therapy.   
 
Given the lack of success of VEGF-A or VEGFR targeting agents, other methods 
are being developed to target the tumour vasculature. Vascular normalisation aims 
to reduce vasculature permeability and abnormalities, hence improving cytotoxic 
drug delivery and therapeutic response (Carmeliet and Jain, 2011b).  This is in 
direct contrast to anti-VEGF and anti-VEGFR treatments which aim to reduce 
vascularisation and starve tumours of oxygen.  Treatments that affect macrophage 
polarisation may enable vessel normalisation as loss of M2 skewed macrophages 
results in vessel normalisation (Rolny et al., 2011).  M2 macrophages secrete a 
range of pro-angiogenic factors such as PlGF resulting in abnormal vessels.  In 
addition vessel normalisation increased response to chemotherapy and decreased 
metastasis in this study, highlighting the potential of vascular normalisation as a 
therapy (Rolny et al., 2011).  
 
In summary, the tumour vasculature is highly abnormal, with different mechanisms 
working together to increase tumour vasculature density and different vascular 
structures present in tumours.  This leads to heterogeneous vascular organisation 
and regulation in the tumour environment.  Anti-angiogenic therapies have not 
performed as well as predicted in the clinical setting and this may be due to the 
heterogeneous nature of the vasculature and adaptation in the tumour 
microenvironment. 
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Chapter 2. Materials and Methods 
2.1 Reagents and chemicals 
Potassium chloride (KCl), Tris base, Tris HCl, potassium phosphate (KH2PO4), 
sodium phosphate (Na2HPO4), ethylene diamine tetraacetic acid (EDTA), glycine, 
β-mercaptoethanol, sodium hydroxide (NaOH), hydrochloric acid (HCl), 
tetramethylethylenediamine (TEMED), ethanol (EtOH), methanol (MeOH), dimethyl 
sulfoxide (DMSO), Tween-20, TRITON X100, bromophenol blue, xylene cyanol FF, 
Ponceau S, bovine serum albumin (BSA), adenosine triphosphate (ATP), 
deoxynucleotides (dNTPs), paraformaldehyde (PFA), ethidium bromide, were all 
purchased from SIGMA.  Acetic acid, glycerol, 40 % acrylamide solution, sodium 
dodecyl sulphate (SDS), sodium acetate, sodium chloride (NaCl), and magnesium 
chloride (MgCl2) were purchased from Fisher Scientific.  UltraPure agarose was 
purchased from Invitrogen. 
 
2.1.1 Enzymes  
Restriction enzymes were purchased from New England BioLabs (NEB) and were 
supplied and used with the appropriate buffers.  PCR reactions were performed 
using Phusion polymerase from NEB in HighFidelity (HF) buffer. DNA polymerase 
1 (Klenow fragment) was purchased from NEB and was used to blunt DNA ends. 
Ligation reactions were carried out using T4 DNA Ligase, also from NEB. 
 
2.1.2 Buffers and solutions  
Some common buffers and solutions are listed below. 
 
Phosphate buffered saline (PBS) 
1.5 mM KH2PO4, 8 mM Na2HPO4, 2.7 mM KCl, 137 mM NaCl, pH 7.4 
 
Tris buffered saline (TBS) 
137 mM NaCl, 2.7 mM KCl, 20 mM Tris HCl, pH 7.4 
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TE buffer 
10 mM Tris HCl pH 7.5, 1 mM EDTA 
 
50 x TAE  
2 M Tris-acetate (242 g Tris base + 57.1 ml glacial acetic acid per litre), 0.05 M 
EDTA pH 8.0 
 
10 x Protein buffer 
1.92 M glycine, 0.25 M Tris Base 
 
SDS running buffer 
100 ml of 10 x protein buffer, 890 ml distilled water (dH20), 10 ml 10 % SDS 
 
Transfer buffer 
100 ml of 10 x protein buffer, 699 ml distilled water (dH20), 200 ml methanol, 1 ml 
10 % SDS 
 
Stripping buffer 
0.15 M glycine pH 2.5, 0.4 % SDS 
 
5 x SDS sample buffer 
0.32 M Tris pH 6.8, 10 % SDS, 50 % glycerol, 0.5 M β-mercaptoethanol, 0.05 % 
bromophenol blue  
 
6 x DNA loading buffer 
0.25 % bromophenol blue, 0.25 % xylene cyanol FF, 30 % glycerol 
 
2.1.3 Cell-culture reagents 
Fetal calf serum (FCS) was purchased from PAA.  Matrigel was purchased from 
BD Biosciences.  DMEM, Opti-MEM and Penicillin-Streptomycin (Pen-Strep) were 
purchased from Gibco.  Methyl cellulose was purchased from SIGMA.  Common 
growth factors, inhibitors or drugs used include 
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TGF-β1   (Peprotech) 
HGF    (SIGMA) 
α-MSH   (SIGMA) 
Cytochalasin D  (Tocris) 
H89    (Tocris) 
SB 431542  (Tocris) 
Sunitinib   (LC Laboratories) 
   
2.2 Cell culture manipulations 
2.2.1 Cell-lines 
Melanoma cell-lines used were the murine B16 F2 and F10 pigment producing 
lines and the 5555 and 4434 lines derived from the BRAF-V600E mouse 
melanoma model (Dhomen et al., 2009).  B16 F2 cells had been previously 
transduced with a retro-viral vector for mRFPCAAX or GFPCAAX expression to 
label the plasma membrane.  B16 F10 GFP and mCherry cells had been previously 
transfected and stably selected for constitutive GFP and mCherry expression.  All 
melanoma cells were cultured in DMEM with 10 % FCS and 1 % penicillin-
streptomycin in 10 % CO2.  Clonal B16 F2 reporter cell-lines, and the B16 F2 
polyclonal cell-line expressing NICD-GFP were also cultured under these 
conditions after selection with antibiotics (see later).  The more metastatic B16 F10 
were used for motility assays and short-term lung metastasis experiments unless 
stated. 
 
2.2.2 Cell culture 
Cells were removed from cell culture dishes with 0.1 % trypsin and 0.02 % versene 
after washing with PBS.  Trypsin was neutralised by addition of media containing 
10 % FCS. 
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2.2.3 Generation of B16 melanoma spheroids 
B16 F2 cells were removed from cell culture dishes with trypsin and resuspended 
in a sterile 0.25 % methyl cellulose solution in DMEM at 1 x10
6
 cells per ml.  20 μl 
droplets were plated onto the underside of a 10 cm culture dish and allowed to form 
spheroids in a 37 °C incubator overnight. 
 
2.2.4 Transient DNA transfections 
B16 F2 cells were transfected with Fugene6 (Roche). 60 000 B16 F2 cells were 
plated in 6-well plates 24 hours before transfection and the media changed to Opti-
MEM 30 minutes prior to transfection.  6 μl of Fugene6 was added to 100 μl of 
Opti-MEM followed by 1 μg DNA. The tube was mixed and incubated for 30 
minutes before being added dropwise to the 6-well plate. After 6-8 hours the media 
was changed to DMEM + 10 % FCS.  When cells were transfected with two or 
more plasmids, the constructs were mixed to give a total of 1 μg of DNA. 
 
2.2.5 Transfection of siRNA oligos 
siRNA oligos were ordered from Dharmacon and stock concentrations made up at 
20 μM.  Smart pools were generated by mixing an equal volume of each of the four 
siRNA oligos for a single gene.  The Allstars non-targeting siRNA oligo (Qiagen) 
was used as a control.  B16 F2 and F10 cells were transfected with Lipofectamine 
2000 using a final siRNA concentration of 100 nM.  For a 12-well plate, 35 000 B16 
cells were plated 24 hours before transfection and the media changed to 400 μl 
Opti-MEM 30 minutes prior to transfection.  On the day of transfection two tubes 
were prepared: 
 
Tube 1. 50 μl Opti-MEM and 1 μl Lipofectamine 2000.   
Tube 2. 50 μl Opti-MEM plus 2.5 μl of siRNA (20 μM stock).  
 
Tubes 1 and 2 were incubated separately for 5 minutes and then mixed and 
incubated for a further 30 minutes.  Finally the transfection complexes were added 
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dropwise to the cells.  After 6-8 hours FCS was added to the cells to a final 
concentration of 10 %.  The following day the cells were washed with PBS and 
transferred to DMEM + 10 % FCS.  If required, the cells were trypsinised and 
plated onto glass-bottomed cell culture dishes (MatTek) 24 hours after transfection 
and fixed a further 24 hours later. 
 
When cells were transfected with siRNA oligos and DNA plasmids, Lipofectamine 
2000 was used with a similar protocol to above.  The two tubes prepared for a 12-
well plate transfection were: 
 
Tube 1. 50 μl Opti-MEM and 0.5 μl Lipofectamine 2000.   
Tube 2. 50 μl Opti-MEM, 1.25 μl of siRNA (20 μM stock) and 0.5 μg DNA.  
 
The sequences used for transient knockdown experiments are shown below: 
 
EZH2  EZH2 #1 D-040882-01  GGAAAGAACUGAAACCUUA 
  EZH2 #2 D-040882-02  CAGAAGAGCUGAUGAAGUA 
  EZH2 #4 D-040882-04  GGAGGGAGCUAAGGAGUUU 
 
 
Jarid2   Jarid2 #1 D-054799-01  GCGGAAAGGUGGACACUAA 
  Jarid2 #2 D-054799-02  CGGCUAGCCUGCAUAAAGA 
  Jarid2 #4 D-054799-04  UAAGGUAAAUGGAGUCACU 
 
Suz12  Suz12 #1 D-040180-01  GGACCUACAUUACAAUUUA 
  Suz12 #2 D-040180-02  GAUGUAAGUUGUCCAAUAA 
  Suz12 #4 D-040180-04  GCACAGAACUCUUACUUAC 
 
BMI-1  BMI-1 #1 MU-065526-01 CAGCAAGUAUUGUCCUAUU 
  BMI-1 #2 MU-065526-02 GUAUGAAGAGGAACCUUUA 
BMI-1 #3 MU-065526-03 GUAAAUAAAGAGAAGCCUA 
BMI-1 #4 MU-065526-04 GAUAAAAGGUACUUACGAU 
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P protein P protein #1 MU-041297-01 GGACUUCGCUGGUUUCACA 
P protein #2 MU-041297-02 GCUCAAAGGUUGCACACUU 
P protein #3 MU-041297-03 AUACAGAGUUUGGCUCAUU 
P protein #4 MU-041297-04 UGUAAAGGCAUAUCAACUU 
 
Control Allstars 1027281  Sequence not specified 
 
2.2.6 Generation of stable cell-lines 
Clonal reporter cell-lines were generated by transient co-transfection of B16 F2 
mRFPCAAX cells with the reporter plasmid together with a pbabe-hygro plasmid at 
a ratio of 3:1.  pBabe hygro contains a hygromycin resistance cassette and so 
confers resistance to hygromycin.  After 48 hours, cells were transferred to 
selection medium containing DMEM + 10 % FCS + 500 μg/ml hygromycin and 
maintained in selection medium for 2-3 weeks.  Clones were derived by either 
1. Stimulating the reporter cell-lines (10 % FCS after serum starvation for SRF 
reporter, 2 ng/ml TGF-β1 for TGF-β reporter), FACS sorting 12-18 hours 
later and collecting responsive cells in 96 well plates.  
or  
2. Splitting the reporter cell-line sparsely and manually picking clones.   
 
Further testing of clones was undertaken to ensure transcription of fluorescent 
protein in response to stimulus and loss of fluorescent protein expression on 
inhibition of the pathway of interest.  
 
B16 F2 cells stably expressing NICDGFP were generated by transiently 
transfecting B16 F2 mRFPCAAX cells with a plasmid encoding Notch1-ICD-GFP.  
After 48 hours cells were transferred to selection medium containing DMEM + 10 % 
FCS + 1 mg/ml G418 and maintained in selection medium for 2-3 weeks.  Cells 
were subsequently FACS sorted to ensure expression of the NICD-GFP fusion 
protein. 
 
Chapter 2 Materials and Methods 
88  
 
2.2.7 Flow cytometry analysis and sorting 
Flow cytometry analysis and sorting was used to generate and test clonal reporter 
cell-lines, purify cells stably expressing fluorescent proteins, perform cell cycle 
analysis and collect reporter cell populations for microarray. 
   
To prepare cells for flow cytometry analysis or sorting, cells were trypsinised, 
washed in PBS, resuspended in sterile PBS and filtered through a 70 μm sterile cell 
filter (BD Falcon). The filtered cells were then transferred to a polystyrene FACS 
tube (BD Falcon) and kept on ice.  Sorted cells were collected in polypropylene 
FACS tubes (BD Falcon) or 96-well cell culture plates containing media + 10 % 
FCS.  After sorting into FACS tubes, cells were re-plated and cultured as normal. 
 
Reporter cell-lines were subject to cell sorting to collect the reporter high and 
reporter low populations for subsequent microarray analysis.  Cells grown in vitro 
were prepared as described above.  B16 F2 mRFPCAAX Brn2 reporter tumours 
were dissected and cut into small pieces.  The tumour pieces were incubated in 1 
mg/ml sterile Collagenase/dispase (Roche) in PBS (no Ca
2+ 
or Mg
2+
) for 40 minutes 
at 37 C and were pipetted up and down at intervals to generate a single cell 
suspension.  The cell suspension was filtered 2-3 times through 70 μm filters, once 
through a 40 μm filter and finally diluted with PBS.  The tumours cells were 
identified by expression of mRFP and sorted according to GFP expression.  As a 
control, B16 F2 mRFPCAAX cells grown in vitro were also analysed to help identify 
tumour cells and provide a GFP negative control.  For microarray analysis, 100 000 
cells were collected directly in 700 μl of RLT lysis buffer containing 1 % β-
mercaptoethanol.  Multiple tubes were collected to maximise yield and 
subsequently RNA was extracted using RNeasy micro kit (Qiagen). 
 
Most cell cycle analysis was performed by the FACS Laboratory using propidium 
iodide.  Cells were trypsinised, centrifuged and then fixed with 70 % ethanol before 
being taken to the FACS Lab.  Live Notch reporter cells for cell cycle analysis were 
incubated with 10 μg/ml Hoechst 33342 at 37 °C for 45 minutes before being 
analysed for GFP expression and Hoechst 33342 staining. 
 
Chapter 2 Materials and Methods 
89  
 
2.3 Nucleic acid manipulations 
2.3.1 Preparation of DNA 
Plasmid DNA was prepared from small overnight bacterial cultures transformed 
with the plasmid of interest using the QIAfilter Plasmid Midi kit (Qiagen) and 
QIAprep Miniprep kit (Qiagen).  Briefly, the bacteria were collected by 
centrifugation and subject to alkaline lysis.  For mini preps, the lysates were 
neutralised and adjusted to high salt binding in a single step and subsequently 
cleared by centrifugation.  Plasmid DNA was then purified on a silica membrane.  
For midi preps the lysates were applied to a QIAGEN Anion-Exchange Resin under 
low-salt and pH conditions.  Subsequent washes removed RNA, proteins, and low-
molecular-weight impurities.  The plasmid DNA was then eluted, precipitated with 
propan-2-ol and centrifuged to pellet the DNA.  The DNA pellet was washed with 
70 % ethanol and resuspended in TE buffer. 
 
2.3.2 Quantification of nucleic acids 
The concentration of nucleic acids from minipreps, maxipreps or RNA extraction 
was quantified using a Nanodrop Spectrophotometer (Nanodrop) to measure the 
absorbance at 260 nm. 
 
2.3.3 Polymerase chain reaction (PCR) 
Polymerase chain reactions were carried out according to the reagent mix and 
temperature cycles below. 
1 μl DNA template (10 ng) 
10 μl 5 x HF buffer (supplied with Phusion polymerase) 
2.5 μl Forward primer (25 pmol) 
2.5 μl Reverse primer (25 pmol) 
2 μl dNTPs (400 μM) 
0.5 μl Phusion polymerase (NEB) 
dH2O to 50 μl 
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Temperature cycles 
98 C 5 mins 
98 C 30 s  denaturing 
52 C 30 s  annealing 
72 C 30 -120 s  extension  return to denaturing x 18 - 25 cycles 
72 °C 10 mins 
4 C hold 
 
2.3.4 Agarose gels 
Agarose was melted in 1 x TAE buffer in the microwave at concentrations of 
between 0.7 and 2 % depending on the DNA fragments to be separated.  Ethidium 
bromide was added to a final concentration of 0.5 μg/ml before casting the gel.  
DNA samples were mixed with 6 x DNA loading buffer and loaded. A 1 kb ladder 
was also loaded to help identify DNA fragment sizes.  Gel electrophoresis was 
performed in TAE buffer at 70-100V.  DNA was visualised using a UV 
transilluminator and if required the band of interest was cut out from the gel. 
 
2.3.5 Purification of DNA from agarose gels 
DNA was purified from agarose gels using QIAquick Gel extraction kit (Qiagen).  
Briefly, the agarose band containing the DNA was dissolved at 65 °C in 3 volumes 
of Buffer QG.  Then, one volume of isoproponal was added and the solution 
applied to a Qiaquick column.  The column was subsequently washed, dried and 
the DNA eluted in dH2O.  
2.3.6 Restriction enzyme DNA digest 
DNA was digested according to the enzyme used. 
2 μg DNA 
5 μl 10 x buffer 
1 μl BSA (if required) 
1 μl Restriction enzyme 
dH2O to 50 μl 
Chapter 2 Materials and Methods 
91  
 
 
2.3.7 Klenow blunting of DNA ends 
If required, DNA ends were blunted using Klenow which has polymerization activity 
and 3'→ 5' exonuclease activity.  Following restriction enzyme digestion of DNA, 
the restriction enzymes were heat inactivated.  Subsequently 2 μl of dNTPs (400 
μM) and 1 μl of Klenow were added and the reaction incubated at 37 °C for 20 
minutes before a final heat inactivation at 75 °C for 5 minutes. 
 
2.3.8 Calf intestinal alkaline phosphatase treatment of DNA ends 
Following restriction enzyme digest of vectors intended for ligation reactions, the 
vectors were treated with calf intestinal alkaline phosphatase (CIP) to remove 5’ 
phosphate groups.  1 μl of CIP was added to the digestion reaction and incubated 
at 37 °C for 20 minutes. 
 
2.3.9 Ligation of DNA fragments 
Small volumes of the DNA fragments were run out on an agarose gel to roughly 
determine the relative amounts of vector and insert.  Ligation reactions were set up 
using a range of vector:insert ratios. Each 20 μl ligation reaction contained:  
2 μl T4 ligase buffer,  
x μl Vector DNA,  
y μl Insert fragment DNA,  
1 μl T4 ligase,  
dH2O up to 20 μl.  
 
Reactions were left at room temperature for at least 2 hours. The ligation reaction 
was then used to transform competent E.coli. 
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2.3.10 DNA sequencing 
DNA constructs were checked by sequencing before being used in cell-based 
assays. Big Dye terminator (BDT) kit (Applied Biosystems) was used and each 
sequencing reaction contained: 
8 μl BDT reaction mix 
1 μl DNA (100 ng) 
1 μl Primer (4 pmol) 
10 μl dH2O 
 
The temperature cycles were as follows:  
96 C 1 min 
96 C 10 sec -denaturing 
50 C 5 sec - annealing 
60 C 4 min -  extension  return to denaturing x 25 cycles 
4 C hold 
 
DNA from sequencing reactions was purified using ethanol/EDTA/sodium acetate 
precipitation.  Briefly, DNA was precipitated by adding 2 μl of 125 mM EDTA, 2 μl 
of 3M sodium acetate (pH 5.2) and subsequently 50 μl 100 % ethanol.  The 
precipitated DNA was centrifuged, the pellet washed with 70 % ethanol and 
allowed to dry at room temperature.  The purified DNA was then analysed by an in 
house research services laboratory. 
 
2.3.11 RNA extraction 
RNA was extracted from cells using the RNeasy mini and micro kits (Qiagen) in 
order to determine mRNA expression levels and to prepare samples for microarray.  
Briefly, cells were lysed in RLT buffer and the lysate homogenised by vortexing or 
by passing the lysate through a 21-gauge needle 5-10 times.  After addition of 70 
% ethanol, the sample was loaded onto a spin column.  DNA digestion was carried 
out on the column and then the column was washed and the RNA eluted in 
RNAase free water. 
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2.3.12 Preparation of cDNA 
Complementary DNA (cDNA) was prepared by reverse transcription of 1-2 μg of 
total RNA.  The reagents below were mixed and heated to 70 °C for 5 minutes 
before being incubated on ice for 5 minutes.  
1-2 μg total RNA 
2 μl Random primer mix (Promega) 
1 μl RNasin ribonuclease inhibitor (Promega) 
Nuclease-free water up to 14 μl 
 
Subsequently the reagents below were added and incubated at room temperature 
for 10 minutes before being incubated at 40 °C for 50 minutes. 
5 μl M-MLV RT 5 x buffer (Promega) 
2 μl dNTPs (400 μM) 
1 μl M- MLV Reverse Transcriptase (Promega) 
3 μl nuclease-free water 
 
Finally nuclease-free water was added up to 100 μl for a starting amount of 2 μg 
RNA, or 50 μl for a starting amount of 1 μg of RNA.  1 μl of this cDNA was used in 
subsequent Q RT-PCR reactions. 
 
2.3.13 Quantitative Real-Time PCR (Q RT-PCR) 
Q RT-PCR was used to determine the expression of mRNAs of interest relative to a 
control mRNA.  Platinum SYBR Green qPCR SuperMix-UDG with Rox (Invitrogen) 
was used in conjunction with a 7900HT Fast Real-Time PCR system (Applied 
Biosystems).  Reactions were set-up on ice in a 96 well optical reaction plate 
(Applied Biosystems) as outlined below: 
12.5 μl Platinum SYBR Green qPCR SuperMix-UDG with Rox 
0.5 μl Forward primer (0.5 pmol) 
0.5 μl Reverse primer (0.5 pmol) 
1 μl cDNA 
10.5 μl dH2O 
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50 °C 20 s 
95 °C 10 mins 
95 °C 15 s  Denaturing 
60 °C 60 s  Annealing/Extension return to denaturing x 40 cycles 
4 °C hold 
 
Commonly used DNA oligonucleotide primers are shown below: 
 
Gapdh  Forward GTGCAGTGCCAGCCTCGTCC 
  Reverse GCCACTGCAAATGGCAGCCC 
 
Actin  Forward CACCCGCGAGCACAGCTTCT 
  Reverse CGTTGTCGACGACCAGCGCA 
 
Hes-1   Forward TGGCTGCTACCCCAGCCAGT 
  Reverse CGCTGCAGGTTCCGGAGGTG 
 
Dct   Forward GCTTCAGGAATGCACTGGAAGGGT 
  Reverse TCGTTGGCTGCTGAGTGTGGC 
 
Tyr  Forward GCGATGGAACACCTGAGGGACC 
  Reverse GTGAGTGGACTGGCAAATCCTTCC 
 
Tyrp1  Forward GCGAAGCGCACAACTCACCC 
  Reverse CCTGCAGCATCTCCTGCATGTCT 
 
Ezh2  Forward ATTGCGCGGGACTAGGGAGTG 
  Reverse GCACCGAGGCGACTGCATTCA 
 
Jarid2  Forward GGCCGTCGAGGAAAAGGCCC 
  Reverse GGCAGCGCAGGAGAACCTCG 
 
Oca2  Forward GCCTGCCTGGGAGGTAATGGGA 
  Reverse TGCAAATGATGGCTGGCTGGCT 
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Sparc  Forward GTGTGTGCCAGGACCCCACC 
  Reverse CCAGGCAGGGGGCGATGTATTT 
 
Mcam  Forward CTCACGCTGACCTGCGAGGC 
  Reverse TGGGGACCCAAAAATGCCCACG 
 
Actn4  Forward TCGCAGGGAAGCCTTGGAGAAAACA 
  Reverse  GGCCAGGATGGCCTCACGCT 
 
2.4 Plasmids 
2.4.1 Mammalian expression constructs 
The Notch reporter pCBFRE:GFP construct was a gift from Julian Lewis. 
 
The Notch luciferase reporter pCBFRE:luciferase construct was purchased from 
Addgene. 
 
The TGF-β reporter pCAGA:CFP (with linker) was generated by Silvia Giampieri 
and on cloning of CFP downstream of the CAGA sequence, a 46 bp linker 
sequence was also introduced.  I subsequently removed this linker sequence by 
digestion with AgeI and HindIII, Klenow treatment and blunt-end ligation to 
generate pCAGA:CFP (no linker). 
 
The SRF reporter p3DA:2eGFP and p3DA:2eGFP Fos 3’UTR constructs were a 
gift from Richard Treisman. 
 
The pbabe Hygro construct was a gift from Gordon Peters. 
 
The constitutive renilla expression construct was a gift from Axel Behrens. 
 
The pNICD-GFP construct was a gift from Julian Lewis. 
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The peGFP C1 construct was purchased from Clontech. 
 
The pmCherry C1 construct was made by Steven Hooper by cloning in the 
mCherry expression sequence into the peGFP C1 clontech vector backbone. 
 
The full-length Ezrin-GFP and constitutively active mutant EzrinTD-GFP were 
generated by Erik Sahai. 
 
2.5 Bacterial techniques 
2.5.1 Bacterial media and plates 
Competent E.coli were grown in suspension in LB containing the appropriate 
antibiotic. Transformations were plated onto 10 cm dishes containing Agar and 
either ampicillin (75 ug/ml) or kanamycin (50 ug/ml) as appropriate. 
 
2.5.2 Bacterial strains 
Subcloning Efficiency DH5α Chemically Competent Cells (Invitrogen) were used for 
transformation of plasmids for midipreps.  One Shot TOP10 Chemically Competent 
Cells (Invitrogen) were used for transformation of ligation reactions. 
 
2.5.3 Bacterial transformation  
Bacteria were thawed on ice for 15 minutes. Bacterial suspension was mixed with 
plasmid DNA or ligated DNA fragments and incubated on ice for a further 20 
minutes. The bacteria and DNA were then heated to 42 C in a water bath for 45 s 
and returned to ice for 10 minutes.  250 μl of SOC media was added and the 
bacteria incubated for 45 min at 37 C with shaking.  The bacteria were then added 
to an agar plate containing the appropriate antibiotic resistance and spread over 
the surface. The plate was incubated overnight at 37 C. 
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2.6 Protein manipulations 
2.6.1 Preparation of cell protein lysates 
Plates containing cells for lysis were washed with cold PBS before 1 x SDS sample 
buffer was added and the cells scraped and collected.  The sample was boiled at 
95 C for 5 minutes before being used for western blotting. 
 
2.6.2 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
Poly-acrylamide gels were made with:  
0.1 % SDS  
375 mM TRIS HCl pH 8.8  
8-15 % poly acrylamide depending on protein molecular weights to be separated  
0.1 % APS  
0.001 % TEMED 
 
The gels were poured into mini-gel systems (BioRad) and over-laid with dH20 to 
ensure the gels were flat.  When set, the dH20 was removed and stacking gel was 
overlaid:  
0.1 % SDS  
125 mM TRIS HCl pH 6.8  
5 % acrylamide  
0.1 % APS  
0.001 % TEMED 
  
A 1.5 mm comb (10-15 wells) was inserted and the stacking gel left to set.  Set gels 
were inserted into a gel cassette in a running tank (BioRad) and the cassette and 
tank filled with SDS running buffer.  A prestained protein ladder (Benchmark, 
Invitrogen) was run and the remaining wells loaded with up to 50 μl of sample.  
Gels were run at 100-125 V. 
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2.6.3 Western blotting  
After SDS-PAGE, the proteins in the gel were transferred to PROTRAN 
nitrocellulose membrane (Whatmann).  The gel was placed on top of 2 sheets of 
3MM chromatography paper (Whatmann), the membrane, which had been pre-wet 
in transfer buffer, was then laid on top of the gel, followed by 2 more sheets of 3MM 
paper.  This “tower” was placed inside two sponges in a transfer cassette (BioRad).  
The tank was filled with transfer buffer and the gel was transferred for 2-3 hours at 
80-90 V on ice.  After transfer the membrane was subject to Ponceau red staining, 
washed with dH2O and blocked by incubating with TBS + 3 % milk (Marvel) + 2 % 
BSA for 1 hour.  Primary antibodies were generally incubated with the membrane 
overnight at 4 C at a dilution of 1:1000 in 3 % milk + 2 % BSA.  Primary antibodies 
were washed off with 3 x 5 minute washes in TBS + 0.05 % Tween-20.  HRP-
labelled secondary antibodies (Fisher Scientific) were used at a dilution of 1:100 
000 in TBS + 3 % milk + 2 % BSA and incubated with the membrane for 1 hour.  
Secondary antibodies were washed off the membrane in 3 x 5 min washes with 
TBS + 0.05 % Tween-20. The blot was then developed by rinsing for 1 minute in 
Luminata Western HRP Substrate (Millipore) before being exposed to 
chemoluminescent film (GE Healthcare). 
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Antibodies used: 
Target Source Product 
number 
Antibody type Dilution 
β-tubulin Sigma T7816 Mouse monoclonal 1:10000 
Vinculin Abcam ab18058 Mouse monoclonal 1:2000 
Notch1-ICD Abcam ab8925 Rabbit polyclonal 1:1000 
EZH2 Cell Signalling #5246 Rabbit polyclonal 1:1000 
Suz12 Abcam ab12073 Rabbit polyclonal 1:1000 
BMI-1 Abcam ab14389 Mouse monoclonal 1:1000 
Phospho-MLC 
(Thr18/Ser19) 
Cell Signalling #3674 Rabbit polyclonal 1:1000 
Phospo-ERM 
(Ezrin-Thr567, Radixin 
Thr564, Moesin 
Thr558) 
Cell Signalling #3141 Rabbit polyclonal 1:1000 
Ezrin Cell Signalling #3145 Rabbit polyclonal 1:1000 
Moesin Cell Signalling #3146 Rabbit polyclonal 1:1000 
 
2.6.4 Luciferase assays 
Luciferase assays were performed with the dual luciferase assay kit (Promega) in 
conjunction with an Envision Multilabel plate reader (Perkin Elmer).  12-well plates 
containing cells for lysis were washed with cold PBS before 100 μl passive lysis 
buffer (Promega) was added and the cells incubated with shaking for 15 minutes 
and collected.  30 μl of lysate was added to a white 96-well plate (Matrix 
Technologies), then 100 μl of luciferase assay reagent II (Promega) was added and 
a luminescence reading taken to measure luciferase activity.  Subsequenly 100 μl 
of Stop and Glo reagent (Promega) was added and another luminescence reading 
taken to measure Renillla activity. 
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2.7 In vivo techniques  
2.7.1 Injection of melanoma cells  
To generate tumours for skin-flap imaging or analysis of lymph-node metastasis, 
mice were injected sub-cutaneously on the flank with 1 x10
6
 B16 F2 cells or 2 x10
6 
5555 cells in 100 μl of sterile PBS. 
 
For short-term metastasis assays a 50:50 mix of 1.5 x 10
6 
red and green labelled 
B16 cells in 100 μl of sterile PBS were injected into the tail-vein of mice.  For 
metastasis assays lasting 10 days, a total of 1x 10
6 
cells were injected. 
 
2.7.2 Tumour measurements 
Tumour measurements were performed by technicians in the Biological Resources 
Unit.  Tumour volumes were calculated from the equation 
Volume = ½(Length x width
2
) 
 
2.7.3 Implantation of imaging windows 
Imaging windows were generated the day before implantation.  A 12 mm coverslip 
was glued to the titanium imaging frame using superglue (UHU) and allowed to dry 
before being sterilised in 70 % ethanol overnight.  Mice were also shaved on a 
small area on the lower back the day before window implantation.  On the day of 
window implantation, mice were injected sub-cutaneously with 5 mg/kg Rimadyl 1 
hour before being anaesthetised with isofluorane.  The skin around the area of 
surgery was sterilised with Hibiscrub (VetTech) and a small incision made in the 
skin, sufficient to fit the imaging window.  Mersilk sutures (VetTech) were used 
around the incision using a purse-string method, the imaging window was fitted and 
the sutures pulled tightly around the window and tied off.  B16 spheroids 
resuspended in 100% matrigel were injected underneath the window using a 19-
gauge needle.  The mouse was allowed to recover on a heat-pad and maintained 
in isolation for the duration of the imaging window experiment. 
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2.7.4 Drug administration 
Sunitinib was dissolved in DMSO to give a stock concentration of 40 mg/ml.  25 μl 
of the stock, together with 100 μl of sterile PBS, giving a final dose of 40 mg/kg, 
was administed to mice by oral gavage with the help of technicians from the 
Biological Resources Unit. 
 
2.7.5 Tumour fixation and immunohistochemical staining 
Following imaging or alternative tumour analysis the tumours were fixed either by 
snap freezing in OCT embedding matrix (Fisher Scientific) or by immersion in 10 % 
NBF (Experimental Histopathology Lab) overnight.  Frozen tumour sections were 
analysed by immunofluorescence (described later) and NBF fixed tumours were 
paraffin embedded and subject to immunohistochemistry by the internal 
Experimental Histopathology Lab.   
 
Antibodies used for immunohistochemistry:  
Target Source Product number 
Notch1-ICD Abcam ab8925 
Endomucin Santa Cruz sc-65495 
EZH2 Cell Signalling #5246 
NG-2 Millipore AB5320 
α-SMA Dako M0851 
F4/80 eBioscience 14-4801 
CD3 Dako a0452 
Cleaved Caspase-3 Cell signalling #9664 
 
2.8 Microscopy  
2.8.1 Immunofluorescence  
Samples were fixed using 4 % paraformaldehyde, washed with PBS and 
permeabilised using 0.2 % Triton X100.  Samples were subsequently blocked for 1 
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hour with PBS + 5 % BSA before incubation with primary antibody in PBS + 5 % 
BSA overnight at 4 ° C.  Primary antibody was washed off in 3 washes of 5 minutes 
with PBS containing 0.05 % Tween-20.  Fluorescent secondary antibodies 
(Molecular probes and Jackson) were diluted 1:500 in PBS + 5 % BSA and 
incubated with the samples overnight, then washed off using 3 washes of PBS 
containing 0.05 % Tween-20.  Samples only requiring staining for F-actin and 
nuclei were fixed and permeabilised as above but then treated with phalloidin and 
DAPI both at 1:500 dilution.  Otherwise, phalloidin and DAPI were added at 1:500 
at the secondary antibody stage.  If required, the samples were mounted on 
microscope slides using Mowiol.  Immunofluorescence of frozen tissue samples 
and cells in culture were carried out the same way.  Images were taken using 
confocal microscopy. 
 
Antibodies used in immunofluorescence 
Target Source Product 
number 
Antibody type Dilution 
EZH2 Cell Signalling #5246 Rabbit polyclonal 1:100 
H3K27me3 Abcam Ab6002 Mouse monoclonal 1:50 
Phospho-MLC 
(Thr18/Ser19) 
Cell Signalling #3674 Rabbit polyclonal 1:100 
 
F-actin was visualised using FITC, TRITC, or 633- phalloidin (SIGMA).  Nuclei were 
visualised with DAPI (SIGMA). 
 
2.8.2 Phase contrast timelapse microscopy 
24 hours before imaging, glass-bottomed cell culture plates (MatTek) were 
incubated with 10 μg/ml Fibronectin (SIGMA) in PBS for 30 minutes before the cells 
were plated on top.  Cells were incubated at 37 C with 10 % CO2 in DMEM media 
contain 10 % FCS and stimulated with 5 ng/ml HGF 2 hours before imaging.  
Imaging was carried out on a Nikon microscope with a motorised stage for multiple 
positions (controlled by Metamorph software) using 20 x phase1 and 10 x phase1 
lenses. 
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2.8.3 Skin flap tumour imaging 
Sub-cutaneous tumours (described previously) were imaged when they reached 
between 6-10 mm in diameter. The mice were anaesthetised using isofluorane 
carried on oxygen, and anaesthetic was maintained during imaging using a 
mouthpiece.  Minor surgery was performed to expose the tumour and the mice 
were placed on a heated stage and covered with a heated blanket maintained at 37 
°C.  The tumour was laid on a cover slip and imaged from underneath.  Imaging 
lasted up to 3 hours, during which time either z-stack images or timelapse movies 
were captured with a 20 x Plan Apochromat lens.  Timelapse movies involved 
capturing a z-stack image every 1-2 minutes.  After imaging, the mouse was 
sacrificed.  If needed, the tumour material was dissected and fixed as described 
previously. 
 
Imaging was carried out using both single photon and two-photon lasers.  A two-
photon femto-second-pulsed Ti-Sapphire laser (Coherent) was used to image 
pigment and Collagen fibres at 825 nm and occasionally GFP at 872 nm.  Second 
harmonic signal from Collagen was collected at half the wavelength of excitation.  
Pigment signal was collected between 500 and 550 nm.  Single-photon 458 nm, 
488 nm, 543 nm, 561 nm and 633 nm lasers were used to image CFP, GFP, 
mRFP, mCherry and injectable probes with fluorescence at 680 nm.  
 
Blood vessels remained intact during imaging and blood flow could be monitored 
by intravenous injection of 100 μl Angiosense 680 (Perkin Elmer) immediately prior 
to imaging.  MMP activity could be monitored by intravenous injection of 100 μl 
MMPsense 680 (Perkin Elmer) 6-8 hours before imaging.  Healthy blood vessels 
for comparison with tumour vessels were imaged in the skin on the opposite flank 
to the tumour. 
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2.8.4 Window imaging  
Mice with imaging windows were imaged everyday starting at 4 days subsequent to 
window implantation.  The mice were anesthetised using isofluorane carried on 
oxygen, and anaesthetic was maintained during imaging using a mouthpiece.  The 
mice were placed on a heated stage and the imaging window placed in a hole in 
the stage.  Windows were subsequently imaged from underneath.  Every imaging 
session a tile z-stack image of the whole window area was taken using a 10 x Plan 
Apochromat lens.  Subsequently the lens was switched to a 20 x Plan Apochromat 
lens and regions of interest imaged.  Lasers and injectable probes used were as 
described previously. 
 
2.8.5 Imaging of lungs for experimental metastasis assays 
Lungs were removed 48 hours or 10 days after injection of melanoma cells, 
washed in PBS and placed on a coverslip.  Lungs removed 48 hours after injection 
were imaged using a 10 x Plan Apochromat lens and images taken using a large 
pinhole size.  Images were taken randomly over the two lungs using single photon 
488 nm and 561 nm lasers and subsequently analysed for area of mCherry vs GFP 
cells.  At the time of injection, 10 μl of the injection mix containing mCherry and 
GFP melanoma cells was plated onto a cell culture dish with a glass bottom 
(MatTek), the cells allowed to adhere and subsequently fixed.  This was imaged 
using the same settings and hence provided a control for the ratio of mCherry and 
GFP cells injected.  Lungs removed 10 days after injection were analysed using the 
microscope eye-piece and 10 x lens and the number of colonies of each colour 
counted manually. 
  
2.8.6 Imaging of lymph-nodes for spontaneous metastasis assays 
Inguinal and axillary lymph-nodes on the same side of the tumour were removed 
when the tumour reached 1-1.2 cm in diameter.  Excess fat was trimmed away and 
the lymph-node placed on a coverslip and imaged from underneath using a 20 x 
lens.  Presence of fluorescent tumour cells indicated lymph-node metastasis. 
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2.9 Image and data analysis 
2.9.1 Quantification of signalling reporter activity 
Quantification of signalling reporter activity was performed using LSM510 Image 
Examiner (Carl Zeiss) and Zen (Carl Zeiss).  Cellular reporter intensity was 
measured by drawing around a cell to create a region of interest and noting the 
fluorescence intensity.  The background fluorescence intensity was measured by 
generating a region of interest in an area not covered by cells.  The average 
intensity for the whole image was measured by making a region of interest the 
same size as the entire image.  Cellular fluorescence intensity was corrected for 
background levels and then normalised to the average GFP intensity for the whole 
image to give reporter activity. 
 
2.9.2 Quantification of pigment intensity 
Pigment intensity was analysed in two ways.  Pictures of cell pellets were taken 
with a digital camera (Canon) after trypsinising the cells, washing in PBS and 
centrifugation to collect the cells.  Pigment intensity was quantified on a cell to cell 
basis by plating the cells on glass-bottomed cell culture dishes (MatTek), fixing and 
staining for F-actin.  The pigment was then imaged using a two-photon femto-
second-pulsed Ti-Sapphire laser (Coherent) tuned to 870 nm with fluorescence 
detection between 500 and 550 nm.  The pigment intensity was measured using 
Zen software (Carl Zeiss) by drawing around a cell to generate a region of interest 
and noting the fluorescence intensity.  Background fluorescent levels were 
measured by creating a region of interest in an area lacking cells and noting the 
fluorescence.  Cellular pigment intensity was calculated by subtraction of the 
background fluorescence.  Microscope settings were kept the same between 
imaging of control and siRNA depleted cells in the same experiment. 
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2.9.3 Quantification of EZH2 and Histone H3 lysine-27 tri-methyl 
(H3K27me3) staining intensity 
Quantification of EZH2 and H3K27me3 staining was performed using Volocity 
image analysis software (Perkin Elmer) and Prism (GraphPad).  Images stained for 
EZH2, H3K27me3, and nuclei were acquired on a confocal microscope.  Nuclei 
were identified using automatic nuclei detection in Volocity and used to form 
objects.  To calculate relative EZH2 intensity, the nuclear EZH2 intensity was 
normalised to DAPI intensity.  The average H3K27me3 nuclear intensity was 
compared between conditions. 
 
2.9.4 Quantification of immunohistochemical staining 
Quantification of vessel density, morphology and Caspase 3 staining was 
performed with Volocity image analysis software (Perkin Elmer).  RGB images 
were taken for analysis using a Nikon Eclipse light microscope.  For the vessel 
analysis, endomucin positive objects were identified using intensity in the red 
channel and any holes in the objects filled in.  The area of the objects was noted 
and for vessel density, total vessel area for an image was divided by the total area 
of the image.  For vessel lumen area, the area of each object was noted and 
compared between tumour conditions.  Analysis of cleaved Caspase-3 was similar, 
cleaved Caspase-3 positive objects were identified using intensity in the red 
channel.  To measure apoptosis in the tumour centre versus tumour margin, a 
region of interest was generated to cover roughly the outer 200 μm of tumour.  The 
total area of cleaved Caspase-3 positive objects was calculated in the region of 
interest and the remaining area (to give Caspase 3 activity in the centre of the 
tumour) for DMSO and Sunitinib treated tumours. 
 
2.9.5 Cell area analysis 
Measures of the cell area were obtained both manually and using Volocity (Perkin 
Elmer) image analysis software.  Analysis of the cell area on P protein depletion 
was performed by manually drawing around the cell to create a region of interest in 
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Zen imaging software (Carl Zeiss) and the area noted.  Volocity was used for the 
other analyses.  Images of cells were thresholded based on F-actin staining, for 
analysis after siRNA depletion of PRC2 components, or GFP intensity, after siRNA 
depletion and rescue with Ezrin-GFP DNA constructs.  Thresholding created 
objects and any holes in the objects were filled in to give the area covered by cells 
in the image.  Nuclei were detected using DAPI staining and automatic nuclei 
detection.  The area covered by cells was subsequently divided by the number of 
nuclei to give the average cell area.  A minimum of 5 images were analysed per 
condition in each experiment. 
 
2.9.6 Quantitative morphometric vessel analysis 
Quantification of vessel morphology and dynamics was performed in LSM510 
Image Examiner (Carl Zeiss) and Zen (Carl Zeiss).  For characterisation of different 
tumour areas, representative vessels from each area were quantified.  For 
correlation purposes morphological characteristics were determined per z-stack of 
images.  Tortuosity indices, variation in width and branch point measurements, 
were calculated as averages of representative vessels in the z-stack.  Tortuosity 
index was calculated as a ratio of the arc length and chord length for a vessel 
bend.  Variation in vessel width was determined by measuring vessel width every 
10 μm for a 150 μm stretch of vessel and calculating the coefficient of variance.  
Branch points were calculated by measuring vessel length and counting branch 
points in that length.  Blunt ends were determined by counting the number of blunt 
ends per image plane, and dividing by the area of vessels in an image plane.  
Multiple planes were averaged over the z-stack.  The vessel area was measured 
for a whole image plane by thresholding on the GFP intensity and noting the area 
of the thresholded region.  Correlation of cell motility with vessel area was 
performed by counting the number of motile cells in the field of view averaged over 
the z-stack and measuring the vessel area also averaged over the z-stack.  
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2.9.7 Cell tracking in vitro 
Tracking of B16 F10 cells plated on Fibronectin was carried out using data from 
phase contrast time-lapse movies captured using MetaMorph software (Molecular 
Devices).  Timelapse movies underwent automatic cell tracking, again using 
MetaMorph software (Molecular Devices).  Briefly, in the first frame the cells were 
selected with the mouse and an area around the cell identified.  Through each 
frame the software determined the new position of each cell.  If the software failed 
to identify the cell in the next frame, for example when a cell underwent division, or 
if the cell moved out of the frame, the user paused the analysis and instructed the 
program to the accurate position of the cell, or to terminate the track.  The tracking 
data was stored as a log file and was inputted in to a template in Mathematica 
(Wolfram research) designed by the Light Microscopy Facility to calculate cell 
speed. 
 
2.9.8 Motile cell analysis in vivo 
The number of motile cells was calculated manually using LSM510 Image 
Examiner software (Carl Zeiss).  Cells were classified as non-motile, moving singly, 
collectively or streaming and the number of cells in each category counted per field 
of view in a 20 minute timelapse movie.  For correlation of signalling reporter 
activity and motility, cells were classified as non-motile, moving singly or streaming 
and the signalling reporter activity calculated as described previously. 
 
2.9.9 Analysis of experimental lung metastasis assays 
Lung images were analysed using Volocity (Perkin Elmer) image analysis software 
to measure the area of mCherry and GFP cells in the lung.  Images were 
thresholded on either GFP or mCherry to generate objects and the area of 
thresholded objects measured in each image.  A minimum of 7 images were 
analysed from each mouse and the total area of mCherry or GFP objects 
calculated per mouse.  The ratio of mCherry and GFP areas was obtained.  This 
was also performed for images of the injection mix plated on cell culture dishes.  
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The mCherry:GFP ratio from the lungs was normalised to the ratio from the plated 
injection mix.  The relative colonisation ability of control to siRNA treated cells was 
finally normalised to the relative colonisation ability of control to control cells to 
account for differences in detection of mCherry and GFP cells. 
 
2.9.10 Microarray analysis 
Microarray analysis was carried out in collaboration with the Paterson institute 
using Affymetrix chips (MOE430 2.0) and The Genome Centre at Barts using Illumina 
chips (REF6V3).  Both chips included probes of the whole mouse genome.  
Microarray results were analysed by Phil East in the Bioinformatics department. 
The ranges of values for each chip were normalised to each other and then points 
with very low intensity were excluded from the analysis.  The fold change between 
conditions was then calculated and averaged for the replicates. 
 
2.9.11 Geneset enrichment analysis (GSEA) 
Geneset enrichment analysis was performed using free software from The Broad 
Institute (http://www.broadinstitute.org/gsea/index.jsp).  Microarray data was 
adjusted to contain only the gene symbols, a description column and numerical 
expression values and saved in .txt format.  A phenotype file was created to 
describe the columns in the expression data file and the layout of the experiment 
i.e number of repeats.  Genesets were obtained from the MSigDB (The Molecular 
Signatures Database), curated by The Broad Institute and also generated from 
personal microarray analysis and publicly available microarray data.  Briefly, the 
free software ranks the genes in the microarray data file according to expression 
changes between conditions.  It subsequently tests how a list of genes (geneset) is 
distributed within the ranked data and calculates an enrichment score that 
represents the degree to which the geneset is represented at the top or bottom of 
the ranked list.  The score is calculated by walking down the ranked list and 
measuring a running-sum statistic.  The score is increased on encountering a gene 
within the geneset and decreased on encountering genes not in the geneset.  The 
enrichment score is then the maximum deviation score achieved.  An estimate of 
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statistical significance is obtained and if multiple genesets are used an adjustment 
for multiple hypothesis testing is applied.  The data is displayed graphically by 
showing the running sum on the y-axis and the ranked list on the x-axis and black 
bars indicate the presence of genes in the geneset. 
 
2.9.12 Overlap analysis 
Free software available on the MSigDB website (Broad Institute) was used to 
calculate the degree of overlap between a list of genes generated from personal 
microarray analysis and the genesets in the MSigDB.  The number of overlapping 
genes was compared to the number of expected overlaps based on the size of the 
geneset and an estimate of statistical significance derived. 
 
The degree of overlap between two lists of genes both generated from personal 
microarray analysis was calculated in conjunction with Phil East in the 
Bioinformatics department.  The analysis carried out was similar to that of the free 
software.  The number of overlapping genes was compared to the number of 
expected overlaps based on the number of genes in the lists and the chip used in 
the microarrays.  An estimate of statistical significance was also derived. 
 
2.9.13 Cluster analysis 
Hierarchical clustering was performed in conjunction with Robert Jenkins using the 
free software R (http://www.r-project.org).  Z-stack images of tumour-associated 
vasculature were analysed to quantifiy the morphometric parameters as outlined 
previously.  Hierarchical clustering was carried out by attempting to minimise the 
Euclidean distance between groups using Ward’s linkage, whereby groups are 
clustered such that the total variance within the cluster is minimised at each step. 
 
2.9.14 Statistical analysis 
Most of the statistical testing including t-tests and analysis of variance (ANOVA) 
testing was performed using Prism software (GraphPad).  Correlations between 
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melanoma cell motility values and vascular morphometric and dynamic data using 
Spearman’s rank correlation co-efficient and linear regression were performed in 
conjunction with Robert Jenkins using R (http://www.r-project.org. 
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Chapter 3. Heterogeneous cell behaviour correlates 
with differences in Notch, TGF- β and SRF signalling 
3.1 Chapter introduction 
Previous intra-vital imaging studies of motility and invasion have revealed 
heterogeneous cancer cell behaviour in a number of different systems (Giampieri et 
al., 2009), (Pinner et al., 2009).  The majority of cancer cells in a tumour are non-
motile. However, there is a small population of motile cells that can move either as 
single cells, or using more cohesive modes of motility.  The acquisition of motility is 
also likely to be reversible as even in lymph node metastases most cells are non-
motile (Giampieri et al., 2009). 
 
There could be many reasons for heterogeneous cell motility.  Motile cells may 
have acquired additional mutations driving an invasive state or signals from the 
local environment may cause cells to become motile only in certain areas.  
Alternatively, differentiation state of the cell may influence whether or not the cell is 
motile.  However, the above are most likely over simplified and it may be a 
combination of reasons, together with a permissive microenvironment, that enables 
motility. 
 
Previous work in the B16 melanoma model suggests that the motile cells are less 
differentiated.  Motile cells had lower pigment levels and higher Brn2 promoter 
activity, a transcription factor down-regulated during melanocyte differentiation 
(Pinner et al., 2009).  Tgfb2 mRNA was up-regulated in the less pigmented cells 
and TGF-β2 increased motility in vitro.  However, little is known about which 
pathways are important in maintaining or driving these changes in differentiation in 
vivo.   
 
Therefore a number of signalling pathways were investigated in vivo to try and 
determine whether differences in signalling correlated with differences in motility 
and which pathways may be involved in the acquisition of motility and a less 
differentiated state. 
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3.2 B16 F2 melanoma cells exhibit heterogeneous cell 
behaviour in vivo 
To confirm that B16 F2 melanoma cells display heterogeneous motile behaviour in 
vivo, intra-vital imaging was performed on sub-cutaneous B16 F2 tumours.  B16 F2 
cells had stable expression of a red fluorescent membrane marker to enable 
visualisation.  Z-stack images were taken every 1-2 minutes for 20 minutes and 
analysed for motile melanoma behaviour.  This revealed that, similar to previous 
reports, melanoma cells utilised different modes of motility (Figure 3.1 and 
Supplementary movies 1-3).  Cells were seen moving as single cells with a 
rounded amoeboid morphology (Figure 3.1).  Cells utilising this mode of motility 
were seen interacting with Collagen fibres and changing morphology to squeeze 
through gaps in the ECM.  Cells were also seen moving collectively, either as 
groups, that on a macro scale maintained cell-cell contacts, or in streams (Figure 
3.1).  Streaming cells were chains of cells moving in a similar direction but they did 
not always maintain connections with the adjacent cells.  Unlabelled host cells, 
often termed ghost cells, were seen within the chains. These may correspond to 
the macrophage population that promote cancer cell motility through a paracrine 
feedback loop (Wyckoff et al., 2004).   
 
Quantification of multiple movies revealed that less than 10 % of B16 F2 melanoma 
cells in the primary tumour are motile (Figure 3.2A).  Out of the motile population 
56 % of cells used a rounded single cell mode of motility, 30 % were found in 
streams and the rest moved collectively as groups. 
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Figure 3.1 Examples of modes of motility used by B16 F2 melanoma cells in vivo. 
Stills taken from intra-vital movies of B16 F2 melanoma showing A. Single cell motility.  
Scale bar 50 μm.  B. Collective motility in groups.  Scale bar 50 μm.  and C. Streaming 
cells.  Scale bar 100 μm.  Cell membranes shown in white. 
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Figure 3.2 Quantification of B16 F2 melanoma cell motile behaviour in vivo. 
A. Graph showing percentage of motile cells in each movie.  Each point represents a 
single movie.  Bar indicates median with interquartile range.  B.  Analysis of different 
modes of motility. Time-lapse movies of B16 F2 melanomas were analysed and the 
number of non-motile and motile melanoma cells counted.  Motile cells were further 
classified in to using collective, streaming or single cell modes of motility.  Data from 18 
movies of 9 mice. 
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3.3 Clonal reporter cell-lines reveal heterogeneous signalling 
in B16 F2 melanoma in vivo 
Differences in cell behaviour imply differences in the signalling status of the cells.  
To test the hypothesis that differences in cell behaviour correlated with differences 
in signalling, a number of clonal B16 F2 reporter cell-lines were generated.  The 
Notch, TGF-β and SRF pathways were chosen for investigation due to the reasons 
outlined below. Transcription-based fluorescent protein reporter constructs were 
used to enable the visualisation of signalling status, as active signalling would drive 
fluorescent protein expression.  However, as the half-life of the fluorescent proteins 
used is around 24 hours, the presence of fluorescent protein would indicate that the 
cell had received the signal within the last 24 hours or so and does not necessarily 
denote current active signalling. The reporter constructs were co-transfected with a 
hygromycin selection vector into B16 F2 cells with a red fluorescent membrane 
marker so all cells could be visualised by the membrane marker in vivo.  Stable 
cell-lines were generated by selection in 500 µg/ml hygromycin.  The stable cell-
lines were then single-cell cloned and the clones tested for reporter sensitivity.  
Clones were generated to circumvent heterogeneity in signalling arising as a 
consequence of differences in mutational status. 
 
3.3.1 Notch signalling is heterogeneous in B16 F2 melanoma in vivo 
Notch signalling was chosen because it has been found to promote EMT and 
motility in numerous cancer types (Leong et al., 2007) (Sahlgren et al., 2008).  
Also, it is required for maintenance of the melanocyte stem cell population and is 
sufficient to confer neural crest stem cell-like properties on melanocytes (Moriyama 
et al., 2006) (Zabierowski et al., 2011).  As motile B16 melanoma cells are thought 
to be less differentiated, the hypothesis was that Notch signalling may drive or 
maintain melanoma cells in a less differentiated state thereby promoting motility. 
 
The Notch reporter construct consisted of 4 CBF responsive elements (CBFREs) 
and the minimal simian virus promoter upstream of eGFP (Figure 3.3A).  CBFREs 
have been shown to bind the transcriptional repressor CBF-1 (Hsieh et al., 1996).  
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Binding of the intra-cellular domain of Notch to CBF-1 releases the repression and 
activates transcription downstream of the CBF-1 binding sites.  Therefore activation 
of Notch signalling and cleavage of the receptor to generate the intra-cellular 
domain should promote transcription and translation of eGFP, allowing visualisation 
of cells with active Notch signalling. 
 
The Notch reporter construct was tested in a transient transfection assay to confirm 
the response to NICD.  The reporter construct was co-transfected with either a 
constitutive mCherry (Shaner et al., 2004) plasmid alone or in conjunction with 
NICD or the empty vector (E.V).  The ratio of cells expressing GFP, driven by the 
CBFRE promoter, to mCherry positive cells was then calculated to give a measure 
of CBFRE response.  The percentage of responsive cells was significantly higher in 
NICD transfected wells compared to both the empty vector and mCherry alone 
(Figure 3.3B), confirming the construct was a Notch reporter.  A mutant construct 
containing mutant CBFREs was also tested.  Both the empty vector and NICD 
increased the percentage of responsive cells compared to mCherry alone 
suggesting a non-specific response of the mutant reporter (Figure 3.3B).  
 
After stable selection of the B16 reporter cells and single cell cloning, one clone 
was found to be responsive to Notch signalling.  To test the clone’s response to 
Notch signalling, NICD or the empty vector was co-transfected with a constitutive 
mCherry plasmid in a ratio of 2:1.  The cells were then subjected to flow-cytometry 
analysis.  Gates were set to analyse only the mCherry positive cells as these 
should have been transfected with either the empty vector or NICD due to the ratio 
of the plasmids transfected.  Transfection of the clonal reporter cell-line with NICD 
caused a shift towards increased GFP intensity compared to transfection of the 
empty vector (Figure 3.3C).  This confirms that the clonal reporter cell-line is 
responsive to Notch signalling. 
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Figure 3.3 Generation and testing of a clonal Notch reporter cell-line. 
A. Schematic of the Notch reporter construct and CBF responsive element.  CBF-1 
binding site shown in red.  SV40 M.P denotes the simian virus 40 minimal promoter.  B.  
Graph showing percentage of responsive cells in a transient transfection assay to test 
the Notch reporter (CBFRE:GFP).  CBFRE:GFP or mutant CBFRE:GFP were co-
transfected with mCherry and either NICD or the empty vector (E.V) in a ratio of 2:1.  
The ratio of GFP positive responsive cells to mCherry positive cells was calculated and 
converted to a percentage.  Error bars show standard error.  Stars indicate a p-value 
<0.05 in an ANOVA test.  C.  The clonal Notch reporter cell-line was transiently 
transfected with constitutive mCherry and NICD or empty vector and then subjected to 
FACS analysis gating only on the mCherry positive cells. 
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Flow-cytometry analysis of the Notch reporter clone grown in vitro revealed a broad 
distribution of GFP intensities spanning two orders of magnitude (Figure 3.4), 
implying that Notch signalling in B16 F2 cells is heterogeneous in vitro.  To test 
whether endogenous Notch targets correlated with GFP expression of the reporter, 
Notch reporter high and Notch reporter low populations were purified by FACS and 
sorted directly into RLT lysis buffer (Qiagen RNAeasy minikit).  Subsequent Q RT-
PCR for Hes-1 mRNA levels revealed that Hes-1 transcript levels were higher in 
the Notch reporter high population than the reporter low population.  This confirmed 
that GFP expression correlated with expression of endogenous Notch targets and 
helped validate the reporter cell-line.  
 
Further validation of the clonal Notch reporter cell-line came following microarray 
analysis of the Notch reporter GFP high and Notch reporter GFP low populations 
and identification of Notch targets in B16 F2 melanoma cells (discussed further in 
chapters 4 and 5).  Geneset enrichment analysis (Subramanian et al., 2005) 
(Mootha et al., 2003) using freeware from The Broad Institute 
(http://www.broadinstitute.org/gsea/index.jsp) indicated that the Notch reporter GFP 
high population was significantly enriched for Notch target genes (Figure 3.5).  This 
provides more support for the reporter cell-line, as expression of endogenous 
Notch targets, identified in B16 melanoma cells, correlated with the GFP 
expression of the Notch reporter cell-line. 
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Figure 3.4 Notch signalling is heterogeneous in vitro. 
A. FACS plot of the clonal Notch reporter cell-line indicating heterogeneity in Notch 
signalling in vitro.  R3 and R4 represent the gates used to sort the Notch low and Notch 
high populations respectively.  B.  Q RT-PCR of Hes-1 mRNA levels in the Notch high 
and Notch low populations in vitro.  Graph shows 3 independent pairs. 
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Figure 3.5. Notch target gene expression is enriched in the Notch reporter GFP 
high population. 
Geneset enrichment analysis using free-ware from The Broad Institute.  Genes up-
regulated on average greater than 1.2 fold in B16 F2 NICD-GFP cells compared to B16 
F2 control cells are significantly enriched in the Notch reporter GFP high population. 
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As less than 10 % of cells in vivo are motile, if Notch signalling promotes a motile 
state then activity through the Notch pathway should also be heterogeneous in vivo 
and correlate with motility.  To investigate this, the clonal Notch reporter cell-line 
was injected sub-cutaneously into C57Bl6 mice.  Intra-vital imaging of the Notch 
reporter tumours revealed a small population of GFP positive cells (Figure 3.6A) 
indicating that indeed Notch signalling was heterogeneous in vivo.  This small 
percentage was in contrast to the in vitro data in which around 80 % of cells were 
GFP positive (Figure 3.4).  However, this may have been as a result of the region 
of the tumours imaged because intra-vital imaging can only provide an idea of the 
outer 200 μm of the tumour.  Collagenase-dispase digestion of the tumours and 
subsequent FACS analysis of the Notch reporter tumours allowed the whole 
tumour to be analysed.  This confirmed that throughout the tumour only a small 
percentage of cells were GFP positive and had active Notch signalling (Figure 
3.6B).   
 
Immunohistochemical staining of B16 F2 tumours with an antibody against the 
intracellular domain of Notch1 provided further evidence of heterogeneous Notch 
signalling in vivo.  It revealed cell populations with different staining patterns 
suggesting heterogeneous signalling activity (Figure 3.6C).  Most cells had nuclear 
or sub-nuclear staining, but some cells had no staining or staining in both the 
nucleus and cytoplasm (Figure 3.6C).  The frequency of cells stained in both the 
nucleus and cytoplasm was roughly similar to the frequency of GFP positive cells in 
the Notch reporter cell-line.  The cells with staining in both the nucleus and 
cytoplasm may have higher levels of signalling compared to the cells with only 
nuclear staining.  Perhaps the Notch reporter cell-line is only responsive to very 
high levels of Notch signalling.  
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Figure 3.6 Notch signalling is heterogeneous in vivo. 
A. Intra-vital still image of the clonal Notch reporter cell-line.  B16 melanoma cells have 
a red membrane marker.  Active Notch signalling is represented by GFP expression.  
Pigment and Collagen fibres in white.  Scale bar indicates 100 μm.   B.  Flow-cytometry 
analysis of tumours derived from the clonal Notch reporter cell-line.  Gates indicate 
Notch high and Notch low populations.  C.  Immunohistochemical staining of B16 
tumour with anti NICD antibody.  Labels show representative cells with different 
staining patterns.  Scale bar indicates 50 μm. 
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3.3.1.1 Notch signalling is increased in the B16 F2 singly motile cell 
population 
To try to determine whether Notch signalling correlated with motility, B16 Notch 
reporter tumours were subjected to intra-vital imaging (Supplementary movie 4).  If 
the hypothesis was correct then the motile cells should be GFP positive or have 
increased GFP expression compared to the non-motile cells.  The GFP intensity 
was measured in non-motile cells and cells using single cell and more collective 
modes of motility.  As it is difficult to distinguish between streaming cells and cells 
moving collectively and the number of cells moving collectively in groups is very 
low, cells displaying cohesive modes of motility were labelled “streaming”.  Cellular 
GFP intensity was corrected for background levels and then normalised to the 
average GFP intensity for the whole image.  This allowed comparison across 
different tumours and tumour areas.  Cells using the rounded single cell mode of 
motility had higher levels of GFP expression compared to non-motile or streaming 
cells indicating increased Notch signalling in singly motile cells (Figure 3.7A).  
Hence Notch signalling correlates with single cell motility in primary B16 
melanoma.  This provides support for the hypothesis that Notch promotes motility 
by maintaining cells in a less differentiated state.  However, a small number of non-
motile cells had active Notch signalling suggesting that Notch is not sufficient to 
initiate motility (Figure 3.7A). 
 
To test the relationship between Notch and differentiation, pigment levels were 
used as a surrogate indicator of differentiation status.  This is because pigment 
production in the melanocyte lineage is suggestive of differentiated cells.  The GFP 
intensity, giving a measure of Notch activity, and pigment intensity of cells in vivo 
was measured.  Notch reporter activity had a mutually exclusive relationship with 
pigment intensity (Figure 3.7).  Cells with high Notch reporter activity had low 
pigment and cells with high pigment had low Notch reporter activity.  The increase 
in Notch signalling in singly motile cells and the mutual exclusive relationship of 
Notch reporter activity and pigment agrees with the hypothesis that Notch signalling 
is associated with a less differentiated, more motile state.  However, pigment levels 
are not the same as differentiation state and a more thorough analysis of 
differentiation markers is required (see next chapter). 
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Figure 3.7 Notch signalling is increased in singly motile cells. 
A. Box and whiskers plot showing GFP intensity and hence Notch reporter activity in 
non-motile, singly motile or streaming cells.  Box indicates median and inter-quartile 
range.  Whiskers indicate 10th-90th percentile.  Outliers indicated by single points.  80 
non-motile cells, 25 singly motile cells and 15 streaming cells analysed.  Data from 9 
movies of 4 mice.  Background GFP intensity subtracted from cellular GFP intensity 
before normalising to the average GFP intensity for the image.  B.  Graph of pigment 
intensity vs GFP intensity and hence Notch reporter activity.  Pigment and GFP 
intensities measured in the same cell. First background intensity was subtracted and 
then the values normalised to the average signal for the channel in the whole image.  
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3.3.2 TGF-β signalling is heterogeneous in B16 F2 melanoma in vivo 
TGF-β signalling is interesting because it has been found to promote single cell 
motility in breast cancer (Giampieri et al., 2009) and it has a well-characterised role 
in EMT both in development and cancer (Nieto, 2011).  Tgfb2 mRNA levels were 
found to be up-regulated in the less pigmented B16 cell population in vivo and 
TGF- β2 could decrease pigment and increase motility in vitro (Pinner et al., 2009).  
As the motile cells in vivo are less pigmented, TGF- β may both promote motility 
and decrease pigment explaining why the motile cells are less pigmented.   
 
To test whether TGF-β signalling is associated with motility, two clonal TGF-β 
reporter cell-lines were generated.  The reporter constructs used were based on 
the well characterised CAGA12 luciferase reporter which has 12 Smad binding sites 
upstream of a minimal promoter and luciferase.  This reporter had been used 
previously in the lab to generate a fluorescence-based TGF-β reporter, with the 12 
Smad binding sites and minimal promoter upstream of CFP (Figure 3.8A).  
However, during cloning, a 46 base-pair linker sequence was introduced (black bar 
in Figure 3.8A).  Use of this reporter in zebrafish indicated that the linker sequence 
alone, without the Smad binding sites, may promote some CFP expression 
(Caroline Hill, personal communication).  For comparison I generated a second 
CFP TGF-β reporter without the linker sequence (Figure 3.9A). 
 
The two reporters were selected for stable expression in the B16 F2 melanoma 
cell-line with a red membrane marker.  Single cell-cloning generated clonal TGF-β 
reporter cell-lines that were subsequently tested for response to TGF-β by flow 
cytometry.  The clonal reporter cell-lines were treated overnight with either 1 ng/ml 
TGF-β, 10μM SB431542 the TGF-β receptor inhibitor, or vehicle control DMSO.  
Both reporter cell-lines had increased CFP expression in the TGF-β treated wells 
compared to the DMSO control (Figure 3.8B (+linker) and Figure 3.9B (no linker)) 
confirming that they did behave as TGF-β reporters.  However, the reporter cell-line 
generated from the construct with the linker contained a fraction of cells that did not 
respond to TGF-β (Figure 3.8B).  Therefore this reporter cell-line may slightly 
underestimate the extent of TGF-β signalling. This cell-line also showed a slightly 
larger increase in CFP expression, suggesting that the linker may increase the 
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sensitivity to TGF-β.  There was little difference in CFP expression between the 
DMSO vehicle control and SB treated wells for either reporter cell-line (Figure 3.8B 
(+linker) and Figure 3.9B (no linker)).  This implies that there is little basal TGF-β 
signalling in B16 F2 cells grown in vitro.    
 
To investigate patterns of TGF-β signalling in B16 melanoma in vivo and to test 
whether it correlated with single cell motility, the two clonal TGF-β reporter cell-
lines were injected sub-cutaneously into C57Bl6 mice and the resulting tumours 
subjected to intra-vital imaging.  This revealed heterogeneous CFP expression in 
both reporter cell-lines (Figure 3.10 A and B) implying B16 F2 melanoma cells have 
heterogeneous TGF-β signalling in vivo.  Both reporter cell-lines had a similar 
percentage of CFP positive cells suggesting that the linker did not adversely affect 
reporter response or promote non-specific CFP expression.  The reporter cell-line 
generated from the construct without the linker required more laser power to 
visualise the CFP, suggesting that the linker may increase the sensitivity of the 
reporter. 
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Figure 3.8 Generation of clonal TGF-β reporter cell-line from construct 
containing linker sequence. 
A. Schematic showing TGF-β reporter construct used.  Red indicates Smad binding 
sequences.  MLP indicates minimal promoter and black bar indicates the 46 base-pair 
linker sequence introduced previously.  B.  FACS analysis of the clonal TGF-β reporter 
cell-line treated overnight with 1 ng/ml TGF-β, 10 μM SB431542, the TGF-β receptor 
inhibitor, or DMSO vehicle control.  
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Figure 3.9 Generation of clonal TGF-β reporter cell-line from construct without 
linker sequence. 
A. Schematic showing TGF-β reporter construct used.  Red indicates Smad binding 
sequences.  MLP indicates minimal promoter.  No linker sequence present.  B.  FACS 
analysis of the clonal TGF-β reporter cell-line treated overnight with 1 ng/ml TGF-β, 10 
μM SB431542, the TGF-β receptor inhibitor, or DMSO vehicle control. 
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Figure 3.10 TGF-β reporters show heterogeneous TGF-β signalling in vivo. 
Intra-vital still images from the two clonal TGF-β reporter cell-lines.  B16 F2 melanoma 
cells have a red membrane marker.  CFP expression indicates active TGF-β signalling.  
Pigment and Collagen fibres in white.  Scale bar indicates 50 μm. 
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3.3.2.1 TGF-β signalling is increased in the B16 F2 singly motile cell 
population 
Having confirmed heterogeneous TGF-β signalling in vivo, the relationship between 
TGF-β signalling and motility was investigated, to test if signalling correlates with 
motility.  The CFP intensity of non-motile, singly motile and streaming cells was 
measured.  In a similar way to analysis of the Notch reporter, the background CFP 
intensity was subtracted and then the values normalised to the average CFP 
intensity for the image.  Both clonal TGF-β reporter cell-lines showed that singly 
motile cells had increased CFP expression compared to non-motile or cells using a 
streaming mode of motility (Figure 3.11 and Supplementary movie 5).  The reporter 
cell-line generated from the construct without the linker did not have as big an 
increase in CFP intensity in singly motile cells as the other reporter cell-line; 
however it was still a significant difference.  This correlates with the magnitude of 
response to TGF-β of the two reporter cell-lines in vitro.  Therefore both reporter 
cell-lines showed that TGF-β signalling correlates with single cell motility. 
 
The motile cells in the B16 melanoma model are less pigmented and TGF-β2 has 
been shown to decrease pigment in vitro (Pinner et al., 2009).  As TGF-β signalling 
is increased in the singly motile cells the relationship between pigment and TGF-β 
reporter activity was examined to see whether TGF-β correlated with decreased 
pigment in vivo.  Both clonal TGF-β reporter cell-lines showed a mutually exclusive 
relationship between pigment and TGF-β reporter activity (Figure 3.12).  Cells with 
higher TGF-β reporter activity showed lower pigment levels indicating that TGF-β 
signalling correlates with decreased pigment.  These results support the hypothesis 
that TGF-β signalling promotes single cell motility and decreases pigment, 
however, it is possible that the increased TGF-β signalling could be a downstream 
product of a different pathway that drives motility.  Additionally the decreased 
pigment may also be result of other signalling pathways that are concurrent with 
TGF-β signalling.  The reporters only suggest a correlation between TGF-β 
signalling, motility and decreased pigment.  
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Figure 3.11.  TGF-β signalling correlates with single cell motility. 
Box and whiskers plot showing TGF-β reporter activity in non-motile, singly motile or 
streaming cells in B16 tumours generated from A. TGF-β reporter containing linker 
sequence.  67 non-motile cells, 54 singly motile cells and 64 streaming cells analysed.  
Data from 6 movies of 3 mice.  B. TGF-β reporter without linker sequence.  118 non-
motile cells, 36 singly motile cells and 88 streaming cells analysed.  Data from 11 
movies of 3 mice.  Background CFP intensity subtracted from cellular CFP intensity 
before normalising to the average CFP for the image.  Box indicates median and inter-
quartile range.  Whiskers indicate 10th-90th percentile.  Outliers represented by 
individual points.  Star indicates p value < 0.05 in ANOVA test.   
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Figure 3.12.  TGF-β signalling is mutually exclusive with pigment levels. 
Graphs of pigment intensity vs CFP intensity and hence TGF-β reporter activity for A. 
TGF-β reporter containing linker sequence.  B. TGF-β reporter without linker sequence.  
Pigment and CFP intensities measured in the same cell. First background intensity was 
subtracted and then the values normalised to the average signal for the channel in the 
whole image. 
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3.3.3 SRF signalling is heterogeneous in B16 melanoma in vivo 
SRF signalling provides a link between actin cytoskeleton remodelling and gene 
transcription.  It has been shown to regulate metastasis in the B16 model and loss 
of MRTF, a SRF co-factor, was shown to decrease the number of motile cells in 
vivo (Medjkane et al., 2009).  Loss of MRTF may have decreased motility due to a 
lower basal level of MRTF targets such as Myosin light chain and Tropomyosin 
(Medjkane et al., 2009).  Alternatively, SRF signalling may be activated during 
induction of motility and required to maintain the motile state.  Based on this data, 
the prediction was that SRF signalling promotes motility and correlates with motile 
B16 cells.  
 
To test whether SRF signalling correlates with motility in vivo, two clonal SRF 
reporter cell-lines were generated from two different reporter constructs.  Both 
constructs were based on the 3D.A reporter, which contains three serum response 
elements (SREs) from the c-Fos promoter (Mohun et al., 1987).  The reporter only 
responds to the Rho-actin arm of the SRF pathway and not the MAPK arm (Hill et 
al., 1995).  One construct contained the three SREs upstream of two eGFP copies 
(Figure 3.13A).  The other construct had the 3’ UTR sequence of the c-Fos gene 
downstream of eGFP to try and couple the stability of eGFP mRNA to the mRNA 
stability of SRF targets (Figure 3.14A).  
 
The constructs were tested for responsiveness to SRF signalling by transient co-
transfection with a constitutive CFP plasmid in B16 F2 cells.  The cells were then 
serum starved and treated with either 15 % FCS or 5 μM cytochalasin D before 
being subjected to flow-cytometry analysis.  Cytochalasin D activates SRF 
signalling by preventing MRTF binding to monomeric actin, MRTF then 
accumulates in the nucleus and together with SRF, activates transcription 
(Vartiainen et al., 2007).  Flow-cytometry analysis was restricted to the CFP 
positive cells because those were the cells to receive the reporter constructs.  
Treatment of both reporters with 5 μM cytochalasin D increased the GFP positive 
population in a time-dependent manner; cells treated with cytochalasin D for 10 
hours had a larger GFP positive population, with increased GFP intensity 
compared to cells treated for 5 hours (Figure 3.13B and Figure 3.14B (with c-Fos 
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3’UTR).  There was a slight increase in the GFP positive population on treatment 
with 15 % FCS.  This confirmed that both reporters responded to SRF signalling. 
 
Co-transfection of the reporter plasmids together with a hygromycin selection 
plasmid and subsequent selection in hygromycin generated stable SRF reporter 
cell-lines.  These were then subjected to single cell cloning to generate clonal SRF 
reporter cell-lines.  The clonal reporter cell-lines were tested for response to both 
15 % FCS and 5 μM cytochalasin D.  Flow-cytometry analysis showed an increase 
in the GFP intensity of clonal reporter cell-lines generated from both constructs, 
confirming the cells were indeed SRF reporter cell-lines (Figure 3.13C and Figure 
3.14C (with c-Fos 3’ UTR)).  However, the reporter cell-line generated from the 
standard SRF reporter construct contained a proportion of cells that did not 
respond to cytochalasin D.  Therefore this cell-line may underestimate SRF 
signalling. 
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Figure 3.13 Generation of a clonal SRF reporter cell-line. 
A. Schematic showing SRF reporter construct used.  Red indicates SRF binding 
sequences.  xActin M.P denotes Xenopus type 5 Actin minimal promoter containing the 
TATA box and transcription start site.  B.  Flow-cytometry analysis after transient 
transfection assay to test the SRF reporter.  The SRF reporter construct was co-
transfected with a constitutive CFP plasmid.  The cells were serum starved and then 
stimulated with either 15 % FCS or 5 μM cytochalasin D for 5 or 10 hours.  Gates were 
set to analyse only the CFP positive cells.  C.  Flow-cytometry analysis of the clonal 
SRF reporter cell-line after serum starvation and treatment with 15 % FCS or 5 μM 
cytochalasin D for 12 hours. 
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Figure 3.14 Generation of a clonal SRF reporter cell-line with a construct 
containing the 3' UTR of the c-Fos gene.  
A. Schematic showing SRF reporter construct.  Red indicates SRF binding sequences.  
xActin M.P denotes Xenopus type 5 Actin TATA box and transcription start site.  
Construct contains 3’UTR of c-Fos downstream of eGFP.  B.  Flow-cytometry analysis 
after transient transfection assay to test the SRF reporter.  The SRF reporter construct 
was co-transfected with a constitutive CFP plasmid.  The cells were serum starved and 
then stimulated with either 15 % FCS or 5 μM cytochalasin D for 5 or 10 hours.  Gates 
were set to analyse only the CFP positive cells.  C.  Flow-cytometry analysis of the 
clonal SRF reporter cell-line after serum starvation and treatment with 15 % FCS or 5 
μM cytochalasin D for 12 hours. 
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3.3.3.1 SRF signalling is increased in the B16 F2 motile cell population 
To try to establish whether SRF signalling correlated with motility, the clonal SRF 
reporter cell-lines were injected sub-cutaneously into C57Black6 mice and the 
tumours subjected to intra-vital imaging (Supplementary movie 6).  Still images 
revealed that GFP intensity was heterogeneous, indicating heterogeneous SRF 
signalling in vivo (Figure 3.15).  The GFP intensity of non-motile, singly motile and 
streaming cells was measured.  The intensity was corrected for background levels 
and normalised to the average GFP intensity for the whole image.  This showed 
that in both SRF reporter cell-lines both singly motile cells and streaming cells had 
higher GFP intensity than non-motile cells, indicating SRF signalling correlates with 
overall motility (Figure 3.16).  These data support the hypothesis that SRF 
signalling drives motility, however, as there were some non-motile GFP positive 
and so SRF active cells, further gain of function experiments need to be performed 
to confirm that SRF signalling is sufficient to induce motility. 
 
As motile cells in the B16 melanoma model are less pigmented and SRF signalling 
is increased in motile cells, the expectation was that cells with high SRF signalling 
should have low pigment.  Pigment and GFP intensity were measured 
simultaneously and plotted against each other.  Both SRF reporter cell-lines 
exhibited a mutually exclusive relationship between pigment and reporter activity 
(Figure 3.17).  Cells with active SRF signalling had low pigment and vice-versa.  
This also suggests that the cells with active SRF signalling are more motile since 
cells with less pigment are more likely to be motile (Pinner et al., 2009). 
 
Previous data in a breast cancer model had suggested that acquisition of motility 
was a reversible process because cells in lymph-node metastases were non-
motile.  In line with this, TGF-β signalling, shown to be increased in motile cells, 
was low or inactive in breast cancer cells in the lymph node (Giampieri et al., 
2009).  To examine whether SRF signalling was also transiently activated, the GFP 
intensity of cells in the lymph-node was compared to both non-motile and motile 
cells in the primary tumour. The reporter cell-line generated using the standard 
SRF reporter construct was used as it was the brightest in vivo.  Comparison of 
histograms of cellular GFP intensity showed that cells in the lymph-node had higher 
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GFP intensity than non-motile cells in the primary tumour (Figure 3.18).  Lymph-
node metastases also had higher GFP intensity than motile cells in the primary 
tumour.  This suggests that SRF signalling is increased in motile cells of the 
primary tumour and once these cells arrive at the lymph-node, SRF remains active, 
potentially even increasing.  This is a different pattern to activity of TGF-β signalling 
seen in the breast cancer model, but it may be a result of the different ways of 
activating the two pathways.  TGF-β signalling is sensitive to the environment 
however SRF signalling is sensitive to changes in the actin cytoskeleton.  It is 
possible that the lymph-node has low levels of TGF-β signalling, explaining the 
decrease seen in the breast cancer model, but once cells reach the lymph node 
they still require actin cytoskeleton remodelling, hence SRF signalling, to cope with 
arriving at a site with different ECM geometries.  
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Figure 3.15 SRF signalling is heterogeneous in vivo. 
Intra-vital still images from clonal B16 F2 melanoma SRF reporter cell-lines. Reporter 
cell-line generated from A. Construct with no additional 3’UTR.  B.  Construct with c-
Fos 3’UTR.  B16 F2 cells have a red membrane marker.  GFP expression indicates 
active SRF signalling.  Pigment and Collagen fibres in white.  Scale bar indicates 100 
μm. 
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Figure 3.16 SRF signalling correlates with motile melanoma behaviour in vivo. 
Box and whiskers plots showing GFP intensity and hence SRF reporter activity in non-
motile, singly motile or streaming cells in B16 F2 tumours generated from  A. Standard 
SRF reporter.  79 non-motile cells, 79 singly motile cells and 27 streaming cells 
analysed.  Data from 8 movies of 4 mice.  B.  SRF reporter with c-Fos 3’UTR.  61 non-
motile cells, 51 singly motile cells and 17 streaming cells analysed.  Data from 9 
movies of 3 mice.  Background GFP intensity subtracted from cellular GFP intensity 
before normalising to the average GFP intensity for the image.  Box indicates median 
and inter-quartile range.  Whiskers indicate 10th-90th percentile.  Outliers indicated by 
single points.  Star indicates p value < 0.05 in ANOVA test.  NS denotes not significant. 
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Figure 3.17 SRF signalling correlates with decreased pigment production. 
Graphs of pigment intensity vs GFP intensity and hence SRF reporter activity for A. 
Standard SRF reporter.  B. SRF reporter with c-Fos 3’UTR.  Pigment and GFP 
intensities measured in the same cell. First background intensity was subtracted and 
then the values normalised to the average signal for the channel in the whole image. 
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Figure 3.18 SRF signalling is increased in motile cells and cells in lymph node 
metastases. 
Histograms of GFP intensity and hence SRF reporter activity for different populations 
of cells in the primary tumour and lymph-node metastases.  Cellular GFP intensities 
were corrected for background GFP intensity and then normalised to the average GFP 
for the image.  SRF reporter activity is categorised into bins of width 1. 
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3.4 Chapter summary 
Intra-vital imaging of B16 F2 melanoma confirmed heterogeneous cell behaviour in 
vivo as less than 10 % of cells were motile and of this 10 % more than 50 % used a 
rounded single cell mode of motility. Generation of clonal reporter cell-lines showed 
heterogeneous activity of the Notch, TGF-β and SRF signalling pathways.  Time-
lapse analysis of the reporter cell-lines in vivo showed that the singly motile cells 
had higher levels of Notch and TGF-β signalling than non-motile or streaming cells.  
This was in contrast to SRF signalling which was increased in all motile cells.  
Notch, TGF-β and SRF signalling all showed a mutually exclusive relationship with 
pigment, providing more evidence that these pathways were associated with 
motility since motile cells have lower pigment.  In addition, because pigment may 
be considered a surrogate readout for differentiation, these pathways may be 
involved in maintaining or promoting a less differentiated state.  The reporter 
analysis showed non-motile cells that had high levels of Notch, TGF-β and SRF 
signalling, suggesting that none of the pathways alone are sufficient for motility.  
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Chapter 4. Notch signalling is insufficient to drive 
motility but promotes metastasis through both cell-
autonomous and non cell-autonomous mechanisms 
4.1 Chapter introduction 
The results outlined in chapter three indicated that singly motile cells in the B16 F2 
melanoma model had increased levels of Notch, TGF-β and SRF signalling 
compared to non-motile cells.  Previous data also showed that motile cells have 
less pigment and have increased Brn2 promoter activity, which suggested that 
motile cells were less differentiated (Pinner et al., 2009).  Notch is required for 
maintenance of the melanocyte stem cell (Moriyama et al., 2006) and is sufficient 
to confer neural-crest stem cell-like properties on melanocytes (Zabierowski et al., 
2011).  Therefore the role of Notch signalling in melanoma motility and 
differentiation was investigated further.  The aim was to determine whether Notch 
signalling could drive or maintain melanoma cells in a less differentiated state, 
thereby promoting motility.  The data in chapter three only showed a correlation 
between Notch signalling, single cell motility and decreased pigment.  The plan 
was to generate B16 F2 cells with constitutive Notch signalling to ask whether 
Notch signalling alone was sufficient to drive motility in vivo and also to promote a 
less differentiated state. 
 
4.2 Generation of a B16 F2 cell-line with constitutive Notch 
signalling 
Canonical Notch signalling proceeds through engagement of the membrane 
spanning Notch receptor with a membrane bound Notch ligand on an adjacent cell 
(D'Souza et al., 2008).  The Notch receptor is subsequently cleaved twice to 
generate an intra-cellular domain (NICD) which translocates to the nucleus and 
activates transcription together with co-factors such as CBF-1 (Schroeter et al., 
1998).  A B16 F2 cell-line with constitutive Notch signalling was generated by 
transfection of a plasmid containing the Notch1 intracellular domain (NICD) fused 
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to GFP (Figure 4.1A) into B16 F2 melanoma cells with a red membrane marker.  
Subsequent growth of the cells in 1 mg/ml G418 for 2-3 weeks selected for cells 
which had stably inserted the construct into the genome.  These were then FACS 
sorted to collect the double-positive mRFP and GFP cell population to generate a 
pool of cells expressing both a red membrane tag and the NICD-GFP fusion 
protein.  This B16 F2 NICD-GFP cell-line enabled gain of function experiments to 
ascertain the sufficiency of Notch signalling in melanoma motility and metastasis. 
 
A number of experiments were performed to confirm that the B16 F2 NICD-GFP 
cells had increased Notch signalling compared to a control cell-line expressing 
GFP alone.  Western blot using an anti-NICD antibody confirmed that the B16 F2 
NICD-GFP cell-line had higher levels of NICD than the control (Figure 4.1B).  To 
test that NICD-GFP was driving Notch dependent transcription a CBFRE 
dependent Notch luciferase reporter was used.  The reporter was similar to the one 
used in chapter 1, but with expression of luciferase, not GFP, dependent on Notch 
pathway activation.  The B16 F2 NICD-GFP and B16 F2 control cell-lines were co-
transfected with the CBFRE:luciferase reporter and a constitutive renilla plasmid.  
Lysates were made two days after transfection and subjected to analysis of 
luciferase and renilla activity.  The CBFRE dependent luciferase signal was 
normalised to renilla to account for differences in transfection efficiency.  This 
showed that the B16 F2 NICD-GFP cell-line had more than twice the CBFRE 
dependent luciferase activity of the control cell-line, indicating increased Notch 
dependent transcription in the B16 F2 NICD-GFP cell-line (Figure 4.1C).  The cell-
lines were also tested for expression of the endogeneous Notch target, HES-1.  Q 
RT-PCR showed that the B16 F2 NICD-GFP cell-line had higher levels of Hes-1 
mRNA than the control cell-line (Figure 4.1D).  Together this indicates that the B16 
F2 NICD-GFP has increased Notch signalling. 
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Figure 4.1  Generation of a B16 F2 cell-line with constitutive Notch signalling. 
A. Plasmid encoding NICD-GFP fusion protein downstream of CMV promoter (denoted 
P-CMV).  B.  Western blot showing NICD levels in B16 F2 cell-lines generated from 
GFP (control plasmid) or NICD-GFP plasmid.  C.  Graph showing normalised luciferase 
signal in B16 F2 GFP (control) or B16 F2 NICD-GFP cell-lines.  B16 F2 GFP and B16 
F2 NICD-GFP cell-lines were co-transfected with a CBFRE:luciferase plasmid and a 
plasmid encoding constitutive renilla at a ratio of 5:1.  Lysates were made 48 hours 
after transfection and assayed for luciferase and renilla activity.  Luciferase signal was 
normalised to the renilla signal.  Data from 3 independent experiments.  Star indicates 
significance in t-test.  Error bars show standard error.  D.  Graph showing relative Hes-
1 mRNA levels as measured by Q RT-PCR.  Each pair indicates a single experiment. 
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4.3 Driving Notch signalling decreases pigment but may 
increase differentiation 
To test whether Notch signalling can drive cells towards a less differentiated state, 
pigment intensity, used as a surrogate for differentiation status, was measured in 
the B16 F2 NICD-GFP and control B16 F2 cell-line in vivo.  Tumours were 
generated from a 50:50 mix of B16 F2 NICD-GFP and control cells to enable 
analysis of the two different cell-lines in the same tumour environment.  Pigment 
intensity was measured, the background levels subtracted and finally values were 
normalised to the average pigment intensity for the image.  This allowed 
comparison of pigment levels between numerous tumours.  B16 F2 NICD-GFP 
cells had lower pigment levels than control cells in vivo, potentially implying that the 
NICD-GFP cells are less differentiated (Figure 4.2). 
 
To more thoroughly test whether Notch can promote a less differentiated state, 
expression of the melanoma differentiation markers, DCT, TYR and TYRP1 was 
analysed by Q RT-PCR.  These markers are transcriptional targets of MITF, and 
MITF is an important transcription factor in the melanocyte lineage whose 
increased expression is associated with differentiation (Cheli et al., 2011) (Carreira 
et al., 2006). mRNA was extracted from B16 F2 NICD-GFP and control cells 
growing in vitro.  Q RT-PCR showed that B16 F2 NICD-GFP cells had higher 
mRNA levels of all three differentiation markers (Figure 4.3).  However, this was 
not statistically significant in a paired t-test.  This implies that according to the 
known markers, driving Notch signalling may actually slightly increase the 
differentiation state, and is in contradiction to the pigment data.  Therefore pigment 
is probably not a good surrogate for differentiation.  The proposition that Notch 
signalling maintains cells in a less differentiated state, thereby promoting motility, is 
now unlikely since Notch signalling does not decrease melanoma differentiation 
markers.  However, Notch signalling may promote melanoma motility by other 
means, potentially by transcriptional control of genes that regulate motility.  As 
Notch signalling can decrease pigment in vivo and correlates with motility, the 
decrease in pigment seen in motile cells may be as a result of Notch signalling and 
unrelated to changes in differentiation. 
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Figure 4.2 Driving Notch signalling decreases pigment in vivo. 
A. Image of a mixed tumour with B16 F2 NICD-GFP with red membrane and B16 
control cells with green membrane.  Some B16 F2 NICD-GFP cells have lost the NICD-
GFP expression.  Pigment shown in white.  Scale bar indicates 100 μm.  B.  Graph 
showing pigment intensity in vivo for B16 F2 NICD-GFP and B16 F2 control cell-lines. 
Pigment intensity measured on a cell by cell basis.  Background intensity was 
subtracted from the cellular pigment intensity and then the values normalised to the 
average pigment intensity for the whole image.  Each data point represents a single 
cell.  Quantification of at least 100 cells from 4 mice.  Star indicates significance in 
statistical t-test.   
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Figure 4.3 Driving Notch signalling may increase differentiation in vitro. 
mRNA levels of the melanoma differentiation markers DCT, TYR and TYRP1 relative 
to GAPDH in B16 F2 NICD-GFP and control B16 F2 cells grown in vitro.  4 
independent experiments. NS indicates no significance in paired statistical t-test. 
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4.4 Notch signalling is insufficient to drive melanoma motility 
in vivo 
Although Notch did not drive cells into a less differentiated state it may still promote 
melanoma motility by other means.  To test if this was the case, a 50:50 mix of B16 
F2 NICD-GFP and control cells were injected sub-cutaneously into C57Bl6 mice.  
The tumours were subjected to intra-vital imaging and the number of motile cells 
per area of tumour was quantified.  The NICD-GFP and control cells could be 
distinguished because the control cells had a green membrane marker and the 
NICD-GFP cells had a red membrane marker and nuclear NICD-GFP expression.  
Tumours generated from a mix of the two cell-lines enabled comparison of the cells 
in the same tumour environment.  There was no difference in the number of cells 
moving either singly or using more collective modes of motility between the B16 F2 
control and B16 F2 NICD-GFP cell-lines in the mixed tumours (Figure 4.4).  This 
indicated that Notch signalling is insufficient to drive motility in the B16 melanoma 
model in vivo and invalidated the original hypothesis.  The previous chapter 
however, showed that Notch signalling correlated with melanoma motility in vivo.  
Therefore it is most likely that pathways driving acquisition of motility in vivo also 
activate Notch signalling and although this is unlikely to influence the motile 
behaviour it can still be used to mark the singly motile population. 
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Figure 4.4 Notch signalling is insufficient to drive melanoma motility in vivo. 
Box and whiskers plot showing the number of cells using different modes of motility per 
sq mm of tumour.  Tumours were generated from a 50:50 mix of GFP membrane 
labelled B16 F2 control and mRFP membrane labelled B16 F2 NICD-GFP cells.  Box 
indicates median and inter-quartile range.  Whiskers indicate 10th-90th percentile.  
Outliers represented by single points.  Atleast 25 cells analysed for each condition.  
Data from 12 movies of 6 mice. N.S indicates not significant in statistical t-test. 
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4.5 Cells with active Notch signalling can promote lymph-node 
metastasis in a non cell-autonomous manner 
Although Notch signalling is not sufficient to promote melanoma motility, Notch may 
have a role in other aspects of metastasis.  The B16 F2 melanoma cells can 
spontaneously metastasise to the lymph-node and fluorescently labelled melanoma 
cells can be visualised within the lymph-node using either confocal or 
epifluorescent microscopy.  Primary tumours were generated from B16 F2 control 
cells alone, B16 F2 NICD-GFP cells alone or a 50:50 mix of the two cell-lines.  
Each mouse was scored as either positive or negative for lymph node metastases.  
Single cells could be visualised in the lymph-node and so the presence of just a 
single cell counted as positive for lymph-node metastases.  Tumours generated 
from a 50:50 mix of B16 F2 control and B16 F2 NICD-GFP cells had the greatest 
percentage of mice with lymph-node metastases (Figure 4.5).  B16 F2 NICD-GFP 
tumours also showed increased lymph node metastasis compared to control 
however this was not statistically significant (Figure 4.5).  As previous data had 
shown no difference in motility between control and NICD-GFP cells (Figure 4.4), 
this hinted that cells with active Notch signalling in the tumour may promote 
metastasis in a non-cell autonomous manner. 
 
To further probe the potential non-cell autonomous role for Notch signalling in 
melanoma, the cells in metastases from the mixed tumours were examined to see 
if they were predominantly B16 F2 NICD-GFP, control or a mixture of both.  If cells 
with active Notch signalling promote metastasis in a non-cell autonomous manner, 
then the expected ratio of B16 F2 control to B16 F2 NICD-GFP cells in the lymph-
node would be the same ratio as the primary tumour, 50:50.  Indeed lymph-node 
metastases from mixed tumours contained about 50:50 B16 F2 control and B16 F2 
NICD-GFP cells (Figure 4.6A).  Still images of these tumours confirmed that they 
had maintained roughly the 50:50 ratio of control to NICD-GFP cells used at the 
time of injection (Figure 4.6B).  Tumour volume measurements showed no 
difference in tumour growth between B16 F2 control, NICD-GFP and mixed 
tumours indicating the increased metastasis was not from increased tumour size 
(Figure 4.7).  Therefore cells in the primary tumour with active Notch signalling 
promote metastasis to the lymph-node in a non-cell autonomous manner. 
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Figure 4.5 Notch signalling increases metastasis to the lymph node. 
Graph showing percentage of mice with B16 F2 control, B16 F2 NICD-GFP or B16 F2 
control plus NICD-GFP tumours with lymph-node metastases.  Mixed tumours were 
generated from injection of a 50:50 mix of both B16 F2 cell types.  12 mice in B16 F2 
control and B16 F2 NICDGFP cohorts, 14 mice in mixed tumour cohort.  Star indicates 
significance in Fishers exact test, NS indicates non significance. 
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Figure 4.6 Notch signalling promotes lymph-node metastasis in a non-cell 
autonomous manner. 
A.  Pie-chart showing proportion of B16 F2 control and B16 F2 NICD-GFP cells in 
lymph-node metastases from mice with mixed B16 F2 control and B16 F2 NICD-GFP 
tumours (The same tumours analysed as those in Figure 4.5).  B.  Still image of a 
mixed tumour generated from 50:50 mix of B16 F2 control (green membrane) and B16 
F2 NICD-GFP (red membrane).  Scale bar indicates 100 μm.  Quantification of volume 
of B16 F2 control and NICD-GFP cells in this image using Volocity image analysis 
software (Perkin Elmer). 
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Figure 4.7. Notch signalling does not affect B16 F2 melanoma growth in vivo. 
Graph showing tumour volume 10 days after injection of 1 x 106 B16 F2 melanoma 
cells for control, NICD-GFP and tumours containing a 50:50 mix of control and NICD-
GFP cells.  (The same tumours analysed as those in Figure 4.5).  Tumour volume 
calculated from ½(length x width2) with 8 mice in each cohort.  Error bars show 
standard error and NS denotes no significance in ANOVA statistical test. 
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Melanoma cells with active Notch signalling in the primary tumour could promote 
metastasis in a non-cell autonomous manner through a variety of mechanisms.  
They may increase the motility of other melanoma cells through secretion of 
chemokines, or affect aspects of the microenvironment such as the blood or 
lymphatic vessels, thereby increasing the spread of all cells in the tumour.  To try 
and address the first point regarding cells with active Notch signalling promoting 
motility in general, the number of motile control cells per mm
2
 in mixed tumours 
was compared to tumours generated from control cells alone.  The number of 
control cells using a single cell mode of motility was the same in control tumours 
and tumours generated from a 50:50 mix of B16 F2 control and B16 F2 NICD-GFP 
cells (Figure 4.8).  This indicates that cells with active Notch signalling do not 
promote metastasis through increasing the single cell motility of other melanoma 
cells in the tumour.  The number of control cells using more collective modes of 
motility was actually decreased in the mixed tumours compared to control only 
tumours (Figure 4.8).  This was unexpected and potentially counter-intuitive as in a 
breast cancer model collective motility enabled metastasis to the lymph-node 
(Giampieri et al., 2009), and here in tumours where metastasis to the lymph-node 
was increased, there was a decrease in collective modes of motility.  Overall the 
data suggested that melanoma cells with active Notch signalling do not promote 
metastasis in a non-cell autonomous manner through the induction of motility of 
other melanoma cells. 
 
An alternative explanation for the non-cell autonomous promotion of metastasis, is 
that the cells with active Notch signalling affect the microenvironment and thereby 
increase metastasis without influencing acquisition of motility in the primary tumour.  
Examples of this could include altering the endothelial cells resulting in increased 
extravasation, or signalling to the pre-metastatic niche to increase survival of 
melanoma cells at secondary sites.  To investigate the effects of cells with active 
Notch signalling on the microenvironment, B16 F2 control, NICD-GFP or mixed 
tumours were removed, fixed and subjected to immunohistochemical analysis of 
various stromal markers.  Analysis of the endothelial vessels using an anti-
Endomucin antibody revealed changes to the vessels in B16 F2 NICD-GFP and 
mixed tumours (Figure 4.9).  These were most likely blood vessels as staining with 
lymphatic markers revealed very few lymphatic vessels within the tumour bulk.  
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Volocity image analysis software was used to identify the vessels based on 
Endomucin staining.  Objects found by Volocity were subsequently “filled in” to 
include the vessel lumen and the area of each individual object or vessel 
calculated.  Analysis of the vessel density by calculating the percentage of tumour 
area covered by vessels indicated the B16 F2 NICD-GFP tumours had a higher 
density of vessels (Figure 4.9B).  However, B16 F2 NICD-GFP tumours also had 
larger vessel lumens than either mixed or B16 F2 control tumours (Figure 4.9C).  It 
is likely that the increased vessel coverage of the tumour is due to the increased 
lumen size of individual vessels.  The lumen size of vessels in tumours with a 50:50 
mix of B16 F2 control and NICD-GFP cells was also significantly larger than 
control, but significantly smaller than in B16 F2 NICD-GFP alone tumours.  This 
suggests that the more cells with active Notch signalling in the tumour, the larger 
the vessel lumen size, therefore implying that cells with active Notch signalling 
affect components of the tumour microenvironment. 
 
Metastasis to the lymph-node most likely occurs through lymphatic vessels, 
however, analysis of the lymphatics was complicated by technical issues.  A 
number of antibodies specific for LYVE-1, a lymphatic marker (Jackson et al., 
2001), were tested without success.  In addition, Podoplanin, an established 
marker for lymphatic vessels (Breiteneder-Geleff et al., 1999), gave potentially non-
specific lymphatic staining in the margins.  This was similar to published data in the 
B16 melanoma model describing a lymphoid-like stroma at B16 melanoma margins 
(Shields et al., 2010).  Therefore analysis of lymphatic vessel density or size was 
not possible. 
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Figure 4.8 Melanoma cells with active Notch signalling in the primary tumour do 
not promote a general increase in motility. 
Box and whiskers plot showing the number of motile cells per sq mm of tumour in 
mixed B16 F2 control plus B16 F2 NICD-GFP and B16 control alone tumours.  Same 
tumour denotes cells in mixed tumours generated from a 50:50 mix of B16 F2 control 
and B16 F2 NICD-GFP cells.  Control tumour denotes tumours made up of 100 % 
control cells   Box indicates median and inter-quartile range.  Whiskers indicate 10th-
90th percentile.  Outliers represented by single points.  6 mixed tumours analysed and 4 
control tumours.  Stars indicate p value < 0.05 in ANOVA statistical test and N.S 
indicates non-significance. 
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Figure 4.9 Cells with active Notch signalling promote an increase in vessel lumen 
size. 
A.  Immunohistochemical analysis of endothelial vessels in a subset of the tumours 
analysed in Figure 4.5 using anti-Endomucin antibody.  Scale bar indicates 150 μm.    
B.  Quantification of percentage area of tumour covered by vessels vessel in B16 F2 
control, NICD-GFP and mixed tumours.  C.  Quantification of the area of each 
individual vessel in B16 F2 control, NICD-GFP and mixed tumours.  Volocity image 
analysis software was used to identify vessel objects based on the Endomucin staining.  
The objects were filled in and the area of each object or vessel measured.  Analysis of 
3 images from 4 tumours for each condition.  Star indicates statistical significance in an 
ANOVA statistical test. 
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4.6 Notch signalling in B16 F2 melanoma cells increases 
experimental lung metastasis 
Although Notch signalling is insufficient to drive melanoma motility in vivo, the 
Notch reporter indicated that motile cells had increased Notch signalling and hence 
Notch correlated with motility.  As the motile cells in the primary tumour are 
believed to be those that metastasise to secondary sites, the effects of increased 
Notch signalling were investigated on lung colonisation.  The F2 sub-line of B16 
cells do not spontaneously metastasise to the lungs before the mouse needs to be 
sacrificed, so an experimental lung metastasis assay was used.  A 50:50 mix of 
B16 F2 control and NICD-GFP cells was injected into the mouse tail-vein and the 
ratio of cells in the lung examined by confocal microscopy after 48 hours or 10 
days.  The cells were distinguished by different fluorescent protein labelling of the 
plasma membrane.  A separate cohort of control mice received a 50:50 mix of 
control cells (red membrane) and control cells (green membrane).  The ratio of 
NICD-GFP (red membrane) to control cells (green membrane) was normalised to 
the ratio of red:green cells from control mice.  Mixing the cell-types accounted for 
differences in injection efficiency between mice.  This showed that both after 48 
hours and 10 days, NICD-GFP cells were more successful at colonising the lung 
than control cells (Figure 4.10).  Given that there are many steps involved in lung 
colonisation, such as survival in the bloodstream, adherence to vessel walls, 
intravasation and survival in the lung parenchyma, it is difficult to pinpoint the step 
at which Notch exerts its effects.  However, since Notch signalling promotes lung 
colonisation after only 48 hours it is likely to influence the initial steps of survival in 
the bloodstream, adhering to blood vessels or intravasation.  Therefore, although 
Notch signalling does not directly influence the motility of cells in the primary 
tumour, if motile cells have increased Notch signalling (as suggested by the 
reporter), they are then more able to colonise the lungs. 
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Figure 4.10 Notch signalling increases lung colonisation ability of B16 F2 cells. 
Graphs showing relative efficiency of lung colonisation for B16 F2 control and NICD-
GFP cells after A. 48 hours (5 mice per condition) and B. 10 days (9 mice per 
condition).  Star indicates statistical significance in t-test. 
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4.7 Microarray to identify Notch targets in B16 F2 melanoma 
To try and identify Notch targets in B16 F2 melanoma cells and to look for potential 
regulators of the increased lung and lymph-node metastasis, B16 F2 control and 
B16 F2 NICD-GFP cells were subjected to microarray analysis.  Biological 
triplicates of RNA extracted from cells grown in vitro revealed a number of genes 
up-regulated on NICD-GFP expression.  The list of these Notch targets can be 
found in the appendix.  Geneset enrichment analysis (Mootha et al., 2003; 
Subramanian et al., 2005), using software from The Broad Institute, was used to try 
and identify pathways and processes enriched in the Notch targets. The list of 
Notch targets was compared with over 3000 genesets in the Molecular Signatures 
Database (MSigDB) C2 category (compiled by The Broad Institute).  The C2 
collection contains curated genesets from online pathway databases, PubMed 
publications and knowledge of domain experts.  This showed an enrichment for 
interferon regulated genes in the Notch targets (Table 1). Stat1, Ifitm3, Ifit3, Irf9 and 
Ifi35 mRNA levels were all up-regulated greater than 1.5 times in the B16 F2 NICD-
GFP cells.  MYLK, a kinase that phosphorylates myosin light chain leading to 
increased actomysoin contractility, was also identified to be a putative Notch target 
by microarray.  Actomysoin contractility is important for extravasation and lung 
colonisation (Wyckoff et al., 2006) (Pinner and Sahai, 2008).  Vegfb mRNA is up-
regulated about 1.3 times in the B16 F2 NICD-GFP cell-line relative to control.  
VEGF-B is a vascular endothelial growth factor member and can promote 
endothelial survival (Zhang et al., 2009).  Further consideration of how these Notch 
targets may influence metastasis can be found in the discussion.  
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Table 1 Top 10 genesets of the MSigDB C2 category showing enrichment in 
Notch targets. 
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4.8 Chapter summary 
Contrary to the initial hypothesis, Notch signalling does not promote a less 
differentiated state, although it does reduce pigment levels in vivo.  In addition, 
driving Notch signalling is not sufficient to increase motility in the B16 melanoma 
model.  This implies that Notch does not maintain cells in a less differentiated state 
to promote motility.  As Notch has been found to correlate with motility, it is 
possible that the signalling/state that induces motility in vivo also increases Notch 
signalling.  The decrease in pigment observed in motile cells (Pinner et al., 2009) 
may be driven by the co-increase in Notch signalling.   
 
Cells with active Notch signalling increase metastasis to the lymph node in a non-
cell autonomous manner.  Primary tumours containing a mix of NICD and control 
cells showed increased metastasis and the cells that arrived in the lymph node 
were both NICD and control cells.  Analysis of the microenvironment confirmed that 
NICD cells could influence vascular phenotype and therefore potentially increase 
metastasis through effects on the endothelium.  Experimental lung metastasis 
assays showed that cells with active Notch signalling were favoured in lung 
colonisation.  An increase in Notch signalling may not affect the motility of cells in 
the primary tumour, but it is beneficial for later stages of the metastatic cascade. 
 
Notch target genes in B16 F2 melanoma cells were identified by microarray 
analysis.  This provided a number of potential regulators of the increased lung 
colonisation displayed by B16 F2 NICD-GFP cells, including Stat signalling, MYLK 
and VEGF-B.  Increased VEGF-B production by B16 F2 NICD-GFP cells may also 
explain the vascular phenotype seen in tumours containing these cells. 
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Chapter 5. Gene expression analysis to identify 
novel genes associated with B16 F2 melanoma 
motility 
5.1 Chapter introduction 
The metastatic cascade begins with the acquisition of motility and local cancer cell 
invasion in the primary tumour.  The motile cells as observed by intra-vital imaging 
are thought to be those that subsequently leave the primary tumour and form 
metastases.  To try to identify novel genes associated with melanoma motility, cells 
with high levels of Brn2 promoter activity and Notch signalling, both pathways 
associated with motility, were purified and their patterns of gene expression 
analysed.  Genes identified in this way may provide fresh ways of targeting cancer 
cell invasion and metastasis. 
 
5.2 Identification of genes up-regulated in populations 
enriched for motile cells 
Data in chapter 3 and previous data showed that the clonal B16 Notch reporter and 
Brn2 promoter activity in a Brn2 reporter cell-line (Pinner et al., 2009) correlated 
with B16 F2 melanoma motility in vivo.  The Brn2 promoter reporter was generated 
using the sequence between about -2.5 kb and -520 upstream of the ATG initiator 
codon of the human Brn2 gene, upstream of eGFP (Goodall et al., 2004).  
Therefore eGFP expression in the Brn2 reporter cells indicated cells with active 
Brn2 promoter expression.  Re-analysis of the Notch reporter data showed that 
cells in the top quartile of Notch reporter intensity were significantly enriched for 
motile cells compared to cells in the lowest quartile of Notch reporter intensity 
(Figure 5.1A).  The data collected from the Brn2 reporter cell-line presented in 
Pinner et al (Pinner et al., 2009) was also re-analysed and showed a significant 
enrichment of motile cells in the top quartile of Brn2 promoter reporter intensity 
(Figure 5.1A).  Therefore, FACS sorting of these reporters to purify the GFP high 
population in each case, i.e Notch high and Brn2 promoter high, should purify a 
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population enriched for motile cells.  To try to identify novel genes that regulate 
motility, the GFP high and GFP low populations from the two reporter cell-lines 
were subjected to microarray analysis. 
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Figure 5.1.  Notch reporter high and Brn2 promoter reporter high cells are 
enriched for motile cells. 
Graph showing percentage of non-motile and motile cells in the top and bottom quartile 
of cells based on A. Notch reporter activity.  Re-analysis of data in Figure 3.7.  (Data 
from 9 movies of 4 mice) and B. Brn2 promoter reporter activity.  Data from Pinner et al.  
Cells were categorised as motile or non-motile and their Notch reporter GFP intensity 
measured.  Background GFP intensity subtracted from cellular GFP intensity before 
normalising to the average GFP for the image.  Star indicates statistical difference in 
Fischer’s exact test. 
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5.2.1 Purification and microarray analysis of B16 F2 melanoma cells with 
high Brn2 promoter reporter activity 
The B16 Brn2 promoter reporter cell-line (Pinner et al., 2009) was injected sub-
cutaneously into C57Black6 mice.  When the tumours reached around 0.8 cm in 
diameter, the mouse was sacrificed, the tumour excised and fully digested in a 
Collagenase dispase solution.  The tumour digest was prepared into a single cell 
suspension and filtered numerous times before FACS sorting to purify the GFP 
high, high Brn2 promoter activity and GFP low, low Brn2 promoter activity 
populations (Figure 5.2).  The melanoma cells were distinguished from the stromal 
cells by a red fluorescent membrane marker.  RNA purified from two tumour 
samples was sent off for microarray to analyse gene expression differences 
between the high Brn2 promoter activity and low Brn2 promoter activity 
populations. 
 
Genes up-regulated in the high Brn2 promoter activity population were identified 
and can be found in the appendix.  To analyse these genes, geneset enrichment 
analysis was performed.  This utilised free software from The Broad Institute and a 
public database of genesets (MSigDB).  Over 3000 genesets from the C2 collection 
of the MSigDB were queried against the Brn2 reporter microarray.  The C2 
collection contains curated genesets from online pathway databases, PubMed 
publications and knowledge of domain experts.   
 
The top 20 genesets overlapping with the high Brn2 promoter activity gene list are 
shown in Table 2.  Within the top 10 were 2 genesets that correlated with the grade 
or outcome of cancer.  The second most significant geneset was genes up-
regulated in the more aggressive and metastatic grade 3 breast cancer versus 
grade 1 (Table 2).  Geneset 8 comprised of genes that were up-regulated in 
melanoma patients that went on to develop metastases within 4 years compared to 
patients whose melanoma did not spread (Table 2).  A number of other genesets 
outside of the top 20, but still showing significant overlap, were also associated with 
disease recurrence or metastasis.  This supports the notion that the high Brn2 
promoter activity population of cells is enriched for the more motile, more 
metastatic cells and also suggests that the genes up-regulated in this population 
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may have relevance outside of melanoma.  The geneset showing the most 
significant overlap was that containing genes associated with proliferation in 
cervical cancer.  In addition, a geneset containing genes associated with pro-
metaphase showed significant overlap with genes up-regulated in the high Brn2 
promoter activity population.   On examination of the genes up-regulated in the high 
Brn2 promoter activity population, a number of cell-cycle regulators and genes 
involved in mitotic progression and cytokinesis were identified.  This may suggest a 
link between the cell cycle and cell motility. 
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Figure 5.2. Purification of the high Brn2 promoter activity population in B16 F2 
melanoma. 
B16 Brn2 promoter reporter tumours were digested into a single cell suspension and 
subjected to FACS sorting.  FACS plots were generated after sorting.  A. B16 
melanoma cells with a mRFP membrane label grown in vitro were used to gate around 
cells in the tumour with forward and side scatter characteristics of B16 cells. mRFP and 
GFP labelled B16 melanoma cells were used to identify mRFP positive cells from the 
tumours and identify the Brn2:GFP high and low populations.  B. FACS plot showing 
the gates used to purify the Brn2:GFP high and low populations. 
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Table 2. Top 20 genesets from the MSigDB C2 collection showing significant 
overlap with genes up-regulated in high Brn2 promoter activity population. 
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5.2.2 Purification and microarray analysis of B16 F2 melanoma cells with 
high Notch reporter activity 
The Notch reporter high population, which is enriched for motile cells, is small in 
vivo (Figure 3.6).  Therefore the B16 clonal Notch reporter cells were grown in vitro 
before FACS sorting to collect the GFP high, Notch reporter high cells and GFP 
low, Notch reporter low cells (Figure 5.3).  RNA purified from one sample was sent 
off for microarray to analyse gene expression differences between the Notch 
reporter high and Notch reporter low populations.  Genes up-regulated in the Notch 
reporter high population were identified and can be found in the appendix. 
 
In a similar manner to analysis of the high Brn2 promoter activity population, 
geneset enrichment analysis was used to analyse the genes up-regulated in the 
Notch reporter high population.  The top 20 genesets overlapping with the Notch 
reporter high list are shown in Table 3.  Within the top 20 were a number of 
genesets containing genes associated with proliferation or genes encoding for cell 
cycle regulators and components.  This included the “REACTOME MITOTIC 
PROMETAPHASE” geneset which contains genes encoding for components 
required for pro-metaphase and also showed significant overlap with genes up-
regulated in the Brn2 reporter high population.  However, to test whether the Notch 
reporter high cells had a different cell-cycle profile to the Notch reporter low 
population, which may influence the expression analysis, the Notch reporter cell-
line was subject to DNA content analysis by flow cytometry.  Gating on the Notch 
reporter high and low populations showed little difference in the DNA profiles 
between the two populations (Figure 5.4).  Therefore the enrichment of cell cycle 
associated genes in the Notch reporter high population is unlikely due to 
differences in cell cycle status between the high and low populations. 
 
The geneset containing genes up-regulated in the more aggressive grade 3 breast 
cancer versus grade 1 breast cancer, which overlapped with the high Brn2 
promoter activity population, also showed significant overlap with the genes up-
regulated in the Notch reporter high population (Table 3).  In addition, genes up-
regulated in invasive breast cancer compared to normal tissue were also enriched 
in the Notch reporter high population.  These genes were not enriched in the high 
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Brn2 promoter activity population suggesting they may show specific co-regulation 
with Notch signalling rather than co-regulation with motility.   
 
Other genesets, not in the top 20 but also showing significant overlap, included 
genes up-regulated on breast cancer cell EMT and genes up-regulated in 
melanoma patients that had distant metastasis within 4 years compared to patients 
that did not.  Both of these genesets also showed significant overlap with genes up-
regulated in the high Brn2 promoter activity population.  This supports the notion 
that the Notch reporter high population is enriched for more motile, more metastatic 
cells.  Other interesting genesets that overlapped with genes up-regulated in the 
Notch high population included EGR2 targets and B-Myb targets.  Both of these 
genesets showed significant overlap with genes up-regulated in the high Brn2 
promoter activity population suggesting that these signalling pathways may 
regulate or be co-regulated with motility in melanoma. 
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Figure 5.3.  Purification of the Notch reporter high population in B16 F2 
melanoma. 
B16 F2 Notch reporter cells were grown in vitro and subjected to FACS sorting.  FACS 
plots were generated after sorting.  A. B16 melanoma cells with a mRFP membrane 
label were used to identify the mRFP positive cells and helped indicate the GFP 
negative population.  B. FACS plot showing the gates used to purify the Notch reporter 
high and low populations. 
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Table 3. Top 20 genesets from the MSigDB C2 collection showing significant 
overlap with genes up-regulated in the Notch reporter high population. 
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Figure 5.4. Notch reporter high and low populations have similar cell cycle 
profiles. 
B16 F2 clonal Notch reporter cell-line was grown in vitro and stained with 10 μg/ml 
Hoechst 33342 for 45 minutes at 37 °C.  Cells were subject to flow cytometry analysis 
and gated based on the GFP intensity of the Notch reporter as shown in the upper plot.  
Lower plots show raw DNA staining intensity data in the black line.  Overlaid blue lines 
show FlowJo predictions for G0/G1, S and G2/M phases of cell cycle. 
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5.2.3 Genes up-regulated in the Notch high and high Brn2 promoter 
activity populations show significant overlap 
There were a number of genesets that showed significant overlap with both the 
high Brn2 promoter activity population and the Notch reporter high population.  As 
both populations should be enriched for motile cells, a certain degree of overlap 
between the two populations is expected.  Geneset enrichment analysis was used 
to test if the genes up-regulated in the Notch reporter high population were 
significantly enriched in the high Brn2 promoter activity population and vice versa.  
This indeed showed that genes up-regulated by greater than 1.2 fold in the Notch 
reporter high population were significantly enriched in the high Brn2 promoter 
activity population, with a p-value of 0 (Figure 5.5A).  Genes up-regulated on 
average greater than 1.2 fold in the high Brn2 promoter activity population were 
also significantly enriched in the Notch reporter high population again with a p-
value of 0 (Figure 5.5B).  This indicates a very high degree of overlap between the 
two populations consistent with the fact that they are both enriched for motile cells.  
However, it may be that the high Brn2 promoter activity population also shows high 
Notch signalling or vice versa.  To try and address this, geneset enrichment 
analysis was used to test whether Notch target genes, as determined in the 
previous chapter, were enriched in the high Brn2 promoter activity population.  
There was no significant enrichment of Notch targets in the high Brn2 promoter 
activity population (Figure 5.6) signifying that the high Brn2 promoter activity 
population does not show high Notch signalling.  Therefore, the overlap in gene 
expression between the two populations is likely to suggest a similar phenotype 
between the two populations and is consistent with them both being enriched for 
motile cells.  Although the Notch reporter high cell population was purified in vitro 
and only one sample was used, the considerable overlap between the two 
populations increases my confidence in using this approach to identify novel genes 
associated with melanoma motility.  Another sample is being prepared for the 
Notch reporter high and low populations to further increase the robustness of the 
approach.  
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Figure 5.5. Geneset enrichment analysis shows significant overlap between the 
Brn2 reporter high and Notch reporter high populations. 
Geneset enrichment analysis using free-ware from The Broad Institute.  A.  Genes up-
regulated in the Notch reporter high population by greater than 1.2 fold are significantly 
enriched in the high Brn2 promoter activity population.  B.  Genes up-regulated in the 
high Brn2 promoter activity population on average by greater than 1.2 fold are 
significantly enriched in the Notch reporter high population.  
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Figure 5.6.  No enrichment of Notch targets in high Brn2 promoter activity 
population. 
Geneset enrichment analysis using free-ware from The Broad Institute.  Notch targets, 
as determined by an average 1.2 fold increase or greater on expression of NICD-GFP, 
are not enriched in the high Brn2 promoter activity population. 
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5.2.4 Identification of common genes up-regulated in the populations 
enriched for motile cells 
Genes up-regulated in both the Notch reporter high and high Brn2 promoter activity 
populations are likely to be associated with motility as both populations are 
enriched for motile cells.  Lists of genes up-regulated in these two populations were 
compared and overlapping genes identified (Figure 5.7).  These overlapping genes, 
up-regulated in both the Notch high and high Brn2 promoter activity populations, 
were postulated to be bona fide genes up-regulated in the motile cell population in 
B16 melanoma (Table 4).  For simplicity these genes will now be referred to as 
genes up-regulated in the motile B16 population, although formally are up-
regulated in the B16 population enriched for motile cells.  
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Figure 5.7. Approach to identify novel genes associated with motile cells in B16 
F2 melanoma. 
Schematic showing experimental approach to purify B16 F2 population enriched for 
motile cells and to identify novel genes associated with motility. 
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Symbol Genename 
2610039C10RIK RIKEN cDNA 2610039C10 gene 
4930432O21RIK NA 
6330503K22RIK RIKEN cDNA 6330503K22 gene 
Ada Adenosine deaminase 
Adh7 Alcohol dehydrogenase 7 (class IV), mu or sigma 
polypeptide 
Anln Anillin, actin binding protein 
Aurka Aurora kinase A 
Blm Bloom syndrome homolog (human) 
Bub1b Budding uninhibited by benzimidazoles 1 
homolog, beta (S. cerevisiae) 
Bub3 Budding uninhibited by benzimidazoles 3 
homolog (S. cerevisiae) 
Cacnb4 Calcium channel, voltage-dependent, beta 4 
subunit 
Casp7 Caspase 7 
Ccl5 Chemokine (C-C motif) ligand 5 
Ccnb1 Cyclin B1 
Ccng1 Cyclin G1 
Cdc20 Cell division cycle 20 homolog (S. cerevisiae) 
Cdca2 Cell division cycle associated 2 
Cdca4 Cell division cycle associated 4 
Cdca5 Cell division cycle associated 5 
Cdca8 Cell division cycle associated 8 
Cdkn2c Cyclin-dependent kinase inhibitor 2C (p18, 
inhibits CDK4) 
Cetn4 Centrin 4 
Chkb Choline kinase beta 
Clspn Claspin homolog (Xenopus laevis) 
Dbf4 DBF4 homolog (S. cerevisiae) 
Dcxr Dicarbonyl L-xylulose reductase 
Table .4  
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Symbol Genename 
Ddit4l DNA-damage-inducible transcript 4-like 
Depdc1b DEP domain containing 1B 
Depdc6 DEP domain containing 6 
E130306d19rik RIKEN cDNA E130306D19 gene 
E2f2 E2F transcription factor 2 
Ecm1 Extracellular matrix protein 1 
Esco2 Establishment of cohesion 1 homolog 2 (S. 
cerevisiae) 
Espl1 Extra spindle poles-like 1 (S. cerevisiae) 
Fen1 Flap structure specific endonuclease 1 
Gbp2 Guanylate binding protein 2 
Gpatch2 G patch domain containing 2 
Gsg2 Germ cell-specific gene 2 
Gtse1 G two S phase expressed protein 1 
Ifit2 Interferon-induced protein with tetratricopeptide 
repeats 2 
Incenp Inner centromere protein 
Irf1 Interferon regulatory factor 1 
Kif11 Kinesin family member 11 
Kif22 Kinesin family member 22 
Kif23 Kinesin family member 23 
Kif2c Kinesin family member 2C 
Kif4 Kinesin family member 4 
Mlf1 Myeloid leukemia factor 1 
Mpp5 Membrane protein, palmitoylated 5 (MAGUK p55 
subfamily member 5) 
Mtap2 Microtubule-associated protein 2 
Mxd3 Max dimerization protein 3 
Ncapd3 Non-SMC condensin II complex, subunit D3 
Ncaph Non-SMC condensin I complex, subunit H 
Table 4. 
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Symbol Genename 
Ndc80 NDC80 homolog, kinetochore complex 
component (S. cerevisiae) 
Nde1 Nuclear distribution gene E homolog 1 (A 
nidulans) 
Nup107 Nucleoporin 107 
Nusap1 Nucleolar and spindle associated protein 1 
Parp3 Poly (ADP-ribose) polymerase family, member 3 
Polh Polymerase (DNA directed), eta (RAD 30 related) 
Prc1 Protein regulator of cytokinesis 1 
Ptplad2 Protein tyrosine phosphatase-like A domain 
containing 2 
Rad51ap1 RAD51 associated protein 1 
Rad54l RAD54 like (S. cerevisiae) 
Rbms1 RNA binding motif, single stranded interacting 
protein 1 
Rdh5 Retinol dehydrogenase 5 
Rfwd3 Ring finger and WD repeat domain 3 
Serf2 Small EDRK-rich factor 2 
Sfrs3 Splicing factor, arginine/serine-rich 3 (SRp20) 
Sgol1 Shugoshin-like 1 (S. pombe) 
Slc22a18 Solute carrier family 22 (organic cation 
transporter), member 18 
Stk17b Serine/threonine kinase 17b (apoptosis-inducing) 
Tk1 Thymidine kinase 1 
Top2a Topoisomerase (DNA) II alpha 
Zcchc8 Zinc finger, CCHC domain containing 8 
Zfp41 Zinc finger protein 41 
Table 4. Genes up-regulated by >1.2 fold in both the B16 Notch reporter high and 
high Brn2 promoter activity populations.   
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5.3 Bioinformatic analysis to identify potential regulators of 
the genes up-regulated in the motile B16 F2 population 
Gene ontology (GO) analysis of the genes up-regulated in the B16 F2 population 
enriched for motile cells was performed using The Broad Institute’s MSig Database.  
The overlap between known genesets of GO biological processes, cellular 
components and molecular function, was calculated with the geneset consisting of 
genes up-regulated in the motile B16 population.  This revealed a striking 
association with the cell-cycle (Table 5) which had also been suggested by the 
genes up-regulated in the Notch reporter high population and also to a certain 
extent the high Brn2 promoter activity population.  The genesets were sorted 
according to statistical significance of the overlap and the top 7 genesets were all 
cell cycle processes.  The remainder of genesets in the top 20 were a mix of more 
cell cycle processes and components required for the cell-cycle.  This included the 
two cellular component genesets “microtubule_cytoskeleton” and 
“cytoskeleton_part”, indicating that, as you might expect, cytoskeletal components 
are up-regulated in motile cells.  The genes from these genesets that were up-
regulated in the motile B16 population included Anln, an actin binding protein, and 
a number of kinesins, including Kif2c.  The human homologs, of Kif2c and Anln, 
have been found to correlate with poor survival in breast cancer (Sadi et al., 2011) 
suggesting that these genes might have a wider relevance to cancer metastasis. 
 
The list of genes up-regulated in the motile B16 population was surprising and did 
not reveal any obvious pathways associated with cell motility.  To try and address 
this, geneset enrichment analysis was used to query a public database of over 
3000 genesets for significant overlap with the genes up-regulated in the motile B16 
population.  The aim was to identify potential regulators of B16 melanoma cell 
motility.  The 30 genesets with the most significant overlap are shown in Table 6. 
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Gene set name 
# of 
genes in 
geneset 
# of 
genes 
in 
overlap 
Fraction 
overlap 
p-value 
Cell_Cycle_Process 188 16 0.0851 1.24E-12 
Cell_Cycle_Go_0007049 306 19 0.0621 1.99E-12 
Mitotic_Cell_Cycle 148 14 0.0946 9.02E-12 
Cell_Cycle_Phase 168 13 0.0774 6.85E-10 
Mitosis 81 10 0.1235 7.91E-10 
M_Phase_Of_Mitotic_Cell_Cycle 83 10 0.1205 1.01E-09 
M_Phase 112 11 0.0982 1.28E-09 
Spindle 37 7 0.1892 1.51E-08 
Chromosome_Segregation 31 6 0.1935 1.49E-07 
Microtubule_Cytoskeleton 148 10 0.0676 2.80E-07 
Chromosome_Condensation 10 4 0.4 8.28E-07 
Cytoskeletal_Part 231 11 0.0476 2.25E-06 
Microtubule_Motor_Activity 16 4 0.25 6.92E-06 
Mitotic_Sister_Chromatid_Segrega
tion 
16 4 0.25 6.92E-06 
Microtubule_Cytoskeleton_Organi
zation_And_Biogenesis 
34 5 0.1471 7.29E-06 
Sister_Chromatid_Segregation 17 4 0.2353 8.99E-06 
Cytokinesis 19 4 0.2105 1.45E-05 
Cell_Division 21 4 0.1905 2.21E-05 
Mitotic_Spindle_Organization_And
_Biogenesis 
9 3 0.3333 4.25E-05 
Spindle_Organization_And_Bioge
nesis 
10 3 0.3 6.03E-05 
 
Table 5. GO analysis of genes up-regulated in the motile B16 population. 
Top 20 GO genesets showing overlap with genes up-regulated in the motile B16 F2 
population.  Genesets sorted based on statistical significance of the overlap (see last 
column). 
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Table 6. Top 30 genesets from MSigDB C2 showing overlap with genes up-
regulated in the B16 motile population. 
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The geneset enrichment analysis, similar to the GO analysis, also found genesets 
associated with the cell cycle.  However, there were also some transcriptional-
based genesets identified.  Interestingly, the third most significant geneset was 
genes regulated by EZH2 (Table 6).  EZH2 is a member of the polycomb repressor 
2 complex and is involved in gene silencing (Margueron and Reinberg, 2011).  In 
embryonic stem cells it is involved in silencing genes associated with differentiation 
(Ezhkova et al., 2009) (Lee et al., 2006) (Boyer et al., 2006), so it may maintain 
B16 cells in a less differentiated, more motile state.  In a similar vein, genes 
associated with both human and mouse embryonic stem cells were found to be 
enriched in the genes up-regulated in the motile B16 population (Geneset entitled 
“WONG EMBRYONIC STEM CELL CORE at rank 20).  This provides further 
support for the idea that the motile cells are less differentiated.   
 
Similar to the analysis of the Notch high and high Brn2 promoter activity 
populations individually, there were a number of genesets associated with poor 
prognosis within the top 30.  This included a geneset containing genes up-
regulated in melanoma patients that developed metastasis within 4 years 
compared to patients that did not.  This provides further support for the genes up-
regulated in the B16 melanoma population enriched for motile cells being 
associated with distant metastasis in melanoma. 
 
Two genesets within the top 30 were B-Myb target genes (SHEPARD CRUSH AND 
BURN MUTANT DN and SHEPARD BMYB TARGETS). B-Myb is a transcription 
factor involved in cell proliferation and survival (Sala, 2005) and this analysis 
suggests it may also play a role in regulating B16 melanoma motility.  Genes co-
regulated with Brca2 are also significantly enriched in the B16 motile cell 
population.  Although BRCA2 is classically thought of as involved in the DNA 
damage response it is also known to have transcriptional activities (Scully, 2000) 
and so may regulate motility through transcriptional changes.  Brca2 germline 
mutation is also associated with increased risk of malignant melanoma (1999). 
 
Genes up-regulated on transformation with a constitutively active RhoA Q63L 
plasmid were the sixth most significant geneset.  RhoA is important to initiate 
cytoskeletal changes and the induction of contractility required for motility (Ridley 
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and Hall, 1992) (Takaishi et al., 1994).  Although less is known about the 
transcriptional role of RhoA in motility, SRF, a transcription factor activated as a 
result of RhoA induced F-actin polymerisation, is involved in B16 melanoma motility 
and metastasis (Medjkane et al., 2009) (chapter 3.3.3).  The publication in which 
the RhoA regulated geneset was identified, shows that E2F is required for RhoA 
induced transcriptional changes (Berenjeno et al., 2007).  This is consistent with 
the up-regulation of E2F2 in the motile B16 cell population (Table 4).  
 
Data in chapter three showed that SRF signalling correlates with B16 melanoma 
motility and in addition loss of SRF has previously been shown to decrease B16 
melanoma motility in vivo (Medjkane et al., 2009).  If SRF signalling is a key driver 
of motility in this model, then SRF target genes would be expected to show overlap 
with the genes up-regulated in the B16 melanoma population enriched for motile 
cells.  To test this hypothesis, genesets were generated from genes up-regulated 
or down-regulated by MRTF loss in B16 F2 cells as published in Medjkane et al 
(Medjkane et al., 2009).  Overlap analysis showed that MRTF dependent SRF 
targets, i.e genes down-regulated on MRTF loss, showed significant overlap with 
the genes up-regulated in the B16 melanoma population enriched for motile cells 
(Table 7).  This is consistent with the data in chapter three showing that SRF 
signalling correlated with motility.  Also, by using an independent array dataset, it 
provided more evidence that the list of genes generated by FACS purification of the 
reporter cell-lines is representative of the genes up-regulated in the motile cell 
population. 
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Geneset 
Observed 
overlap 
Expected 
overlap 
p-value FDR 
Genes 
downregulated on 
MRTF loss 
15 1.05 3.87E-014 3.61E-013 
Genes upregulated 
on MRTF loss 
0 0.38625 0.320402 0.35885 
 
Table 7. MRTF-dependent SRF targets significantly overlap with genes up-
regulated in the B16 F2 melanoma population enriched for motile cells. 
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5.4 Chapter summary 
To identify novel genes associated with melanoma motility and metastasis, the B16 
high Brn2 promoter activity and Notch reporter high populations were purified as 
they are enriched for motile cells.  The gene expression profiles of the reporter high 
and low populations were compared.  Genes up-regulated in either the high Brn2 
promoter activity and Notch reporter high populations showed significant overlap 
with a number of genesets associated with disease progression and metastasis.  
This included a geneset containing genes up-regulated in melanoma patients that 
developed distant metastasis in 4 years compared to patients that did not.  Genes 
up-regulated in the high Brn2 promoter activity and Notch reporter high populations 
showed significant overlap with each other, consistent with them both being 
enriched for genes up-regulated in the motile cell population.  The individual genes 
overlapping between the high Brn2 promoter activity and Notch reporter high 
populations were identified and considered to be genes up-regulated in the B16 F2 
population enriched for motile cells.  Gene ontology analysis of these genes 
revealed a link with mitotic machinery.  A non-biased geneset enrichment analysis 
approach revealed potential regulators of the transcriptional program associated 
with B16 cell motility including the polycomb protein EZH2.  Further bioinformatic 
analysis confirmed that SRF targets showed significant overlap with genes up-
regulated in the B16 F2 melanoma population enriched for motile cells.  This is 
consistent with the data in chapter three and previous data that showed SRF 
regulates B16 F2 motility.   
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Chapter 6. PRC2 components regulate the actin 
cytoskeleton and metastasis 
6.1 Chapter introduction 
Geneset enrichment analysis of the genes up-regulated in the B16 F2 population 
enriched for motile cells suggested that EZH2 may regulate B16 motility, as genes 
positively regulated by EZH2 in prostate cancer cells were significantly enriched in 
genes up-regulated in the motile B16 population.  EZH2 is a member of the 
Polycomb repressor complex 2 (PRC2) and the other core members include EZH1, 
Suz12 and EED.  The PRC2 complex mediates gene silencing through regulation 
of chromatin modifications (Margueron and Reinberg, 2011) and during 
development it silences differentiation associated genes (Boyer et al., 2006) 
(Landeira et al., 2010) (Ezhkova et al., 2009).  Jarid2 is a more recently identified 
member of the PRC2 complex and is thought to regulate PRC2 activity and gene 
occupancy (Li et al., 2010b) (Peng et al., 2009) (Shen et al., 2009).  EZH2 is up-
regulated in melanoma (McHugh et al., 2007) and promotes metastasis in prostate, 
breast and squamous cell carcinoma (Min et al., 2010) (Wang et al., 2011).  
Therefore the hypothesis was that EZH2 may promote cell motility by silencing 
differentiation associated genes to maintain cells in a less-differentiated, more 
motile state.   
 
6.2 EZH2 levels are heterogeneous in melanoma 
The microarray analysis suggested that Ezh2 mRNA was up-regulated in the Notch 
reporter high population, a population enriched in motile cells.  To further explore 
heterogeneity in EZH2 levels and to confirm the microarray data, the levels of Ezh2 
mRNA were examined in the Notch reporter cell populations.  This confirmed the 
array analysis and showed that Ezh2 mRNA was increased in the Notch reporter 
high population, a population enriched for motile cells (Figure 6.1). 
 
Given that less than 10 % of melanoma cells are motile (Figure 3.2) and Ezh2 
mRNA is up-regulated in the B16 F2 motile cell population (Figure 6.1), if EZH2 
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regulates cell motility the levels should be heterogeneous in vivo.  To address this, 
tumours of the syngeneic Black6 melanoma models, B16, 4434 and 5555 were 
stained for EZH2 using immunohistochemistry and immunofluorescence.  EZH2 
immunohistochemistry of paraffin embedded B16, 4434 and 5555 tumours 
revealed heterogeneity of EZH2 staining on a cell to cell basis (Figure 6.2 A).   
4434 and 5555 tumours also showed increased EZH2 staining at the tumour 
margin, an area enriched for invasive cells (Figure 6.2).  This is consistent with 
increased EZH2 being associated with motility and invasion.  Immunofluorescent 
staining of frozen B16 tumours allowed quantification of the EZH2 staining 
intensity.  This showed that the majority of cells have similar levels of nuclear EZH2 
but a shoulder of the frequency histogram extended to higher EZH2 levels (Figure 
6.2 B and C).  The skewness of the distribution was calculated to be 0.97, 
indicating a positive skew and suggesting more cells than expected from a normal 
distribution, have high EZH2 staining.  The shoulder of cells with high EZH2 
staining contained about 7 % of cells, similar to the percentage of motile cells. 
 
Two frozen tissue samples of human melanoma metastases were also tested for 
heterogeneity in EZH2 expression using immunofluorescence.  EZH2 levels were 
also heterogeneous in human melanoma, and again the distributions had a positive 
skew.  The skewness value was 1.33 for human melanoma metastasis 1 and 2.02 
for human melanoma metastasis 2.  This suggests that an EZH2 high population of 
cells may also exist outside of murine melanoma (Figure 6.3). 
 
EZH2 catalyses the tri-methylation of histone H3 at lysine 27 (H3K27me3).  If EZH2 
regulates cell motility through histone modification and gene regulation then levels 
of H3K27me3 should also be heterogeneous.  The second human melanoma 
metastasis was co-stained for global levels of H3K27me3 together with EZH2.  This 
showed heterogeneity in the global levels of the tri-methyl mark catalysed by PRC2 
(Figure 6.3).  Image analysis software to measure the staining intensity of EZH2 
and H3K27me3, showed a significant correlation between the two, with a 
Spearman correlation coefficient of 0.34 (Figure 6.3 B).  This was consistent with 
data showing a significant decrease in global levels of H3K27me3 on PRC2 
component depletion (Figure 6.4 C). 
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Figure 6.1. Ezh2 mRNA is up-regulated in the Notch reporter high population. 
Q RT-PCR confirmation of Ezh2 transcript levels in the Notch reporter high and low 
populations of the clonal Notch reporter cell-line grown in vitro.  Data from 2 samples 
and error bars show the standard error.  FACS plots showing controls and the gates for 
collection of the Notch reporter high and low populations are presented in Figure 5.3. 
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Figure 6.2. EZH2 levels are heterogeneous in syngeneic mouse melanoma. 
A.  Immunohistochemical staining for EZH2 in B16 F2, 4434 and 5555 melanoma 
grown in syngeneic C57Black6 mice.  Tumours were excised and fixed at 0.7 cm 
diameter. Top row images have scale bar indicating 50μm, bottom row images have 
scale bar indicating 150 μm.  Arrows indicate nuclei with high EZH2 staining.  T 
indicates the tumour and M indicates the margin.  B.  Immunofluorecence staining of 
B16 frozen tumour sections for actin (green), nuclei (pink) and EZH2 (white).  Scale bar 
indicates 50 μm.  C.  Histogram showing the relative frequency of relative EZH2 
staining intensity in individual nuclei in B16 tumour sections. 
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Figure 6.3. EZH2 levels are heterogeneous in human melanoma metastases. 
Immunofluorecence staining of frozen sections from 2 human melanoma metastases 
for actin (green), nuclei (pink) and EZH2 (white).  Scale bar indicates 50 μm.  B.  
Histograms showing the relative frequency of relative EZH2 staining intensity in 
individual nuclei in sections from human melanoma metastases. 
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Figure 6.4. Levels of tri-methylated lysine 27 on histone H3 are heterogeneous in 
vivo. 
A.  Immunofluorecence staining of frozen sections of human melanoma metastasis 2 
for actin (green), nuclei (white) and EZH2 (blue) and tri-methylated lysine 27 on histone 
H3 (H3K27me3) (red).  Scale bar indicates 50 μm.  B.  Graph showing correlation 
between relative nuclear EZH2 and H3K27me3 intensities.  p-value indicates 
statistically significant correlation using Spearmans rank test.  C.  Graph showing a 
decrease in global H3K27me3 levels on PRC2 component depletion.  B16 F2 cells 
were transfected with control or PRC2 targeted siRNA and fixed for immunofluorescent 
staining of H3K27me3 48 hours after transfection.  Data from at least 5 images of 3 
independent experiments.  Error bars show the standard error and stars indicate 
significant decrease in H3K27me3 staining by ANOVA statistical test.  
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6.3 PRC2 components regulate cell morphology 
6.3.1 Loss of EZH2 leads to an increase in cell area 
To determine whether EZH2 may promote motility, cell morphology was examined 
following knockdown of EZH2 with targeted siRNA.  The idea was that regulators of 
motility should also regulate the actin cytoskeleton and hence cell morphology.  
B16 F2 cells were transfected with either control or EZH2 targeted siRNAs, plated 
on glass and fixed after 48 hours.  Three different EZH2 siRNAs gave a similar flat 
cell phenotype with an increased cell area (Figure 6.5).  EZH2 knockdown was 
confirmed using both Q RT-PCR and western blot (Figure 6.6).  Although all 
siRNAs increased the cell area, siRNA #2 had a slightly different phenotype to the 
other two siRNA.  siRNA #1 and 4 increased the cell area and many cells had long 
tails indicative of tail retraction problems (Figure 6.5), however, siRNA #2 resulted 
in very large and flat cells with F-actin cables at the cell edge. 
 
. 
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Figure 6.5. Loss of EZH2 leads to an increase in cell area. 
A.  B16 F2 cells were transfected with control or EZH2 siRNA and plated on glass.  
Cells were fixed 48 hours after knockdown.  Image shows cells with labelled plasma-
membrane.  Scale bar indicates 25 μm.  B.  Cells used for measuring cell area were 
first stained with DAPI and then imaged.  The cell area per image, measured with 
Volocity image analysis software, was divided by the number of nuclei.  Data from at 
least 5 individual images of 2 different experiments.  Stars indicate significance in 
ANOVA statistical test. 
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Figure 6.6 Confirmation of EZH2 knockdown. 
A.  Q RT-PCR analysis of Ezh2 mRNA levels 48 hours after knockdown with control or 
EZH2 targeted siRNA in B16 F2 cells.  Error bars show the standard error from 3 
independent experiments and stars indicate significance in ANOVA statistical test.  B.  
Western blot of EZH2 protein levels 48 hours after knockdown with control or EZH2 
targeted siRNA in B16 F2 cells.  
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6.3.2 Loss of the PRC2 components, Suz12, and Jarid2 also leads to an 
increased cell area 
To try and determine whether the change in cell morphology on loss of EZH2 was a 
PRC2 dependent or independent phenomenon, other members of the PRC2 
complex were subject to siRNA knockdown and the cell morphology phenotype 
analysed.  Depletion of the PRC2 core complex member, Suz12, led to an increase 
in cell area, although siRNA #2 also resulted in an increase in actin ruffles.  This 
was not seen with other Suz12 siRNA and so may be an off-target effect (Figure 
6.7).  Depletion of Jarid2 also resulted in a similar cell morphology phenotype to 
EZH2 loss, with a concurrent increase in cell area.  However, the increase in cell 
area with Jarid2 siRNA #2 did not reach significance compared to control (Figure 
6.7).  As knockdown of the PRC2 components EZH2, Suz12 and Jarid2 all gave an 
increase in cell area, this suggests that the PRC2 complex can regulate cell 
morphology and the actin cytoskeleton.  
 
The PRC2 complex works together with the PRC1 complex to mediate gene 
silencing (Simon and Kingston, 2009).  If the effects on cell morphology on PRC2 
component knockdown are through changes in gene regulation then loss of PRC1 
components should give a similar phenotype.  Loss of BMI-1 only resulted in a 
significant increase in cell area in 1 out of the 3 siRNAs that depleted BMI-1 levels 
(Figure 6.8).  This suggests that BMI-1 and the PRC1 complex does not regulate 
cell morphology, although analysis of further PRC1 components would help to 
confirm this. 
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Figure 6.7.  Loss of PRC2 components leads to an increase in cell area. 
A.  B16 F2 cells were transfected with control, Suz12 or Jarid2 siRNA and plated on 
glass.  Cells were fixed 48 hours after knockdown and stained with phalloidin.  Scale 
bar indicates 25 μm.  B.  Q RT-PCR analysis of Jarid2 mRNA levels 48 hours after 
transfection in B16 F2 cells.  Data from 3 independent experiments. C.  Western blot of 
Suz12 protein levels 48 hours after transfection in B16 F2 cells.  D. Graph of cell area 
on Jarid2 and Suz12 knockdown.  Cells were stained with DAPI and phalloidin.  The 
cell area per image, measured with Volocity image analysis software, was divided by 
the number of nuclei.  Data from at least 5 individual images of 2 different experiments.  
Error bars show the standard error and stars indicate significance in ANOVA statistical 
test. 
Chapter 6. Results 
 
204  
 
 
Figure 6.8. Loss of the PRC1 component BMI-1 does not increase cell area. 
A.  Western blot of BMI-1 protein levels 48 hours after knockdown with control or BMI-1 
targeted siRNA in B16 F2 cells.  B.  B16 F2 cells were fixed 48 hours after transfection  
with control or BMI-1 siRNA and stained with phalloidin.  Scale bar indicates 30 μm.  C.  
Graph of cell area on BMI-1 depletion.  The cell area per image, measured with 
Volocity image analysis software, was divided by the number of nuclei.  Data from at 
least 5 individual images of 2 different experiments.  Error bars show the standard error 
and stars indicate significance in ANOVA statistical test. 
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6.4 PRC2 regulates cell morphology through ERM protein 
activation 
6.4.1 PRC2 depletion does not decrease actomyosin contraction 
Cells depleted for EZH2 and other PRC2 components are flatter with an increased 
cell area and possible tail retraction problems (section 6.3).  This phenotype could 
be indicative of a loss of actomyosin contractility, as contraction is required to 
retract the rear of the cell during cell motility on a 2D surface and for maintenance 
of cell morphology (Levayer and Lecuit, 2012).  However, neither western blot nor 
immunofluorescence revealed a decrease in phospho-MLC levels on EZH2 
depletion (Figure 6.9 and Figure 6.10).  In fact, EZH2 siRNA #2 resulted in a slight 
increase in phospho-MLC by western blot and this could be visualised in the strong 
actin cables at the cell periphery using immunofluorescence.  Therefore the flat cell 
phenotype and increase in cell area is not as a result of a decrease in actomyosin 
contractility. 
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Figure 6.9. Loss of EZH2 does not decrease total phospho-MLC levels. 
A. Western blot of B16 F2 cells 48 hours after transfection with control or EZH2 
targeted siRNA.  B. Immunofluorescent staining for phospho-MLC.  B16 F2 cells were 
transfected with control or EZH2 targeted siRNA and plated on glass.  48 hours after 
transfection cells were fixed and stained with phalloidin and a phospho-MLC antibody.  
Scale bar indicates 25 μm. 
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6.4.2 Loss of PRC2 leads to a decrease in Ezrin and Radixin 
phosphorylation and activation 
Ezrin, Radixin and Moesin are a family of proteins that link the actin cytoskeleton to 
the plasma membrane and are involved in maintaining cell shape and polarity and 
regulating migration (Fehon et al., 2010).  Phosphorylation of ERM proteins by 
kinases such as ROCK, PKCα and PKCθ, leads to a conformational change and 
activation (Matsui et al., 1998) (Ng et al., 2001) (Simons et al., 1998).  This allows 
ERM proteins to bind both F-actin and membrane proteins, acting to link the two 
cellular components.  To investigate whether PRC2 components may exert their 
effects on cell morphology through regulation of ERM proteins, western blotting 
was performed for phosphorylated ERM proteins after PRC2 knockdown. 
 
Loss of EZH2 resulted in a decrease of a subset of phosphorylated ERM proteins 
(Figure 6.10), suggesting that EZH2 can regulate ERM activation.  The ERM 
proteins are closely related and the activating phosphorylation occurs on a 
conserved threonine residue (Mangeat et al., 1999).  The antibody recognises the 
phosho-site on all three proteins, however, the molecular weight of Moesin is 75 
kDa and Ezrin and Radixin are both around 80 kDa.  As Ezrin and Moesin have a 
very similar molecular weight, it is difficult to resolve the three bands on a gel.  
Figure 6.10A shows a loss in the upper phospo-band (indicated by an arrow) on 
EZH2 knockdown.  If the bands represent the individual ERM proteins according to 
molecular weight, this suggests a loss of phosphorylated Ezrin, Radixin or both.  To 
check that regulation of ERM activation is a PRC2 dependent mechanism 
phospho-ERM levels were also analysed after Suz12 and Jarid2 depletion.  In 
Figure 6.10B, 3 bands can just about be determined and loss of Suz12 and Jarid2 
leads to a loss of the two upper bands, indicative of a decrease in activity of both 
Radixin and Ezrin.  Suz12 siRNA #2 reproducibly resulted in a total loss of all 
phosphorylated ERM proteins, which correlates with it resulting in a slightly 
different cell morphology phenotype due to possible off-target effects (Figure 6.7). 
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Figure 6.10 Loss of PRC2 leads to a decrease in ERM phosphorylation. 
A.  Western blot of phospo-ERM levels 48 hours after transfection with control or EZH2 
targeting siRNAs.  Arrow indicates the upper phospho-ERM band lost on EZH2 
depletion.  EZH2 blot shows the efficiency of knockdown with each individual siRNA 
and β-tubulin is a loading control.  B.  Western blot of phospo-ERM levels 48 hours 
after transfection with control, EZH2, Jarid2 or Suz12 targeting siRNAs.  Lines show 
the two upper phospho-ERM bands decreased on PRC2 depletion.  Vinculin used as a 
loading control. 
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To further dissect which member or members of the ERM family were affected on 
loss of PRC2, lysates of control cells were run on the same gel, transferred 
together and then the membrane was cut to blot for total Ezrin, total Moesin and 
phospho-ERM.  The membranes were lined up before exposure to help identify 
which bands in the phospho-ERM blot corresponded to which ERM proteins.  The 
individual bands represented the individual phospho-proteins and were in order 
according to molecular weight (Figure 6.11).  The upper most band being Ezrin, 
followed by Radixin and the lowest band Moesin.  This suggests that loss of PRC2 
components leads to a decrease in activation of Ezrin and Radixin. 
 
To check that loss of PRC2 components lead to a decrease in activation of ERM 
proteins rather than a decrease in the total levels, western blots of total Ezrin were 
performed after knockdown of EZH2 and Jarid2.  This showed no change in total 
levels of Ezrin after PRC2 component depletion, indicating that PRC2 regulates 
Ezrin and Radixin phosphorylation and activation (Figure 6.12). 
 
 
 
Chapter 6. Results 
 
210  
 
 
Figure 6.11.  Confirmation of the identity of phospho-ERM bands on a western 
blot. 
Control cell lysates were run on the same gel and then the membrane cut before 
blotting for phospho-ERM, total Ezrin and total Moesin on separate membranes.  The 
membranes were lined up again before exposure.  β-tubulin acts as a control to check 
the efficiency of membrane line-up before exposure. 
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Figure 6.12 PRC2 component loss does not change total Ezrin levels. 
Western blot of total Ezrin levels 48 hours after transfection with control, EZH2 or 
Jarid2 smartpool siRNAs.  EZH2 blot shows the efficiency of knockdown and β-tubulin 
is a loading control. 
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6.4.3 Constitutively active Ezrin is sufficient to rescue the increase in cell 
area on PRC2 depletion 
Loss of PRC2 components causes an increase in cell area and a decrease in 
activation of ERM proteins (section 6.3 and 6.4.2).  As ERM proteins are known to 
regulate cell morphology, the hypothesis was that the increase in cell area on 
PRC2 depletion was due to a decrease in ERM protein activation and a 
subsequent decrease in the connection between the plasma membrane and 
underlying actin cytoskeleton.  To test this hypothesis, plasmids encoding Ezrin-
GFP and constitutively active Ezrin-GFP (EzrinTD-GFP) were used to try and 
rescue the cell area phenotype seen on PRC2 depletion.  The consitutively active 
Ezrin construct contained full-length Ezrin fused to GFP with a threonine to 
aspartate point mutation at Ezrin residue 567 to mimic phosphorylation. 
 
B16 F2 cells were co-transfected with either control or EZH2 targeted siRNA 
together with a plasmid encoding either Ezrin-GFP, EzrinTD-GFP or membrane 
targeted GFP (GFPCAAX).  Ezrin-GFP and GFPCAAX were used as controls for 
the increased Ezrin and GFP in the cells respectively.  Cells transfected with EZH2 
targeted siRNA showed an increase in cell area as expected, however, cells co-
transfected with EZH2 siRNA and EzrinTD-GFP had a similar morphology to 
control cells, indicating that constitutively active EzrinTD-GFP can rescue the 
phenotype (Figure 6.13 A).  No rescue was observed with the Ezrin-GFP or 
GFPCAAX constructs, confirming that the increase in cell area is a result of loss of 
ERM activation rather than loss of ERM levels (Figure 6.13A).  Quantification of the 
cell area using Volocity image analysis software confirmed that only the 
constitutively active Ezrin construct significantly rescued the EZH2 depletion 
phenotype (Figure 6.13 B).  The cell area after co-transfection of EZH2 targeted 
siRNA #2 and EzrinTD-GFP did not return to control levels but was significantly 
reduced compared to co-transfection with Ezrin-GFP. 
 
The experiment was repeated for depletion of Jarid2.  Constitutively active 
EzrinTD-GFP also significantly rescued the cell area phenotype seen on Jarid2 
depletion (Figure 6.14).  This indicates the increase in cell area seen on PRC2 
component depletion is most likely a result of decreased ERM protein activation. 
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Figure 6.13 Constitutively active Ezrin-GFP rescues the increase in cell area seen 
on EZH2 depletion. 
A.  Single confocal images of B16 F2 cells plated on glass 48 hours after co-
transfection with EZH2 targeted siRNA and either a GFPCAAX, Ezrin-GFP or EzrinTD-
GFP plasmid.  B16 F2 cells have a red plasma membrane marker and green indicates 
transfected cells.  B.  Quantification of B16 F2 cell area after co-transfection with EZH2 
targeted siRNA and GFPCAAX, Ezrin-GFP or EzrinTD-GFP plasmids.  Cell area was 
measured from at least 4 individual images of 3 different experiments using Volocity 
image analysis software.  Error bars show standard error and stars indicate significant 
reduction in cell area compared to GFPCAAX and Ezrin-GFP transfected cells.  
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Figure 6.14. Constitutively active Ezrin-GFP rescues the increase in cell area 
seen on Jarid2 depletion. 
A.  Single confocal images of B16 F2 cells plated on glass 48 hours after co-
transfection with Jarid2 targeted siRNA and either a GFPCAAX, Ezrin-GFP or EzrinTD-
GFP plasmid.  B16 F2 cells have a red plasma membrane marker and green indicates 
transfected cells.  B.  Quantification of B16 F2 cell area after co-transfection with Jarid2 
targeted siRNA and GFPCAAX, Ezrin-GFP or EzrinTD-GFP plasmids.  Cell area was 
measured from at least 4 individual images of 3 different experiments using Volocity 
image analysis software.  Error bars show standard error and stars indicate significant 
reduction in cell area compared to GFPCAAX and Ezrin-GFP transfected cells. 
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6.5 EZH2 positively regulates motility in vitro and metastasis 
As PRC2 components regulate cell morphology through ERM protein activation 
and Ezrin positively regulates metastasis (Hunter, 2004), the hypothesis was that 
EZH2 regulates melanoma cell motility and metastasis.  To test this hypothesis, the 
more metastatic sub-line B16 F10 was plated on Fibronectin in vitro to examine cell 
motility and also used in experimental metastasis assays.   
 
6.5.1 EZH2 depletion slightly decreases cell speed in vitro 
As an initial investigation into the role of EZH2 in regulating cell motility, B16 F10 
cells treated with control or EZH2 targeted siRNA were plated on Fibronectin 
coated glass plates and imaged following stimulation with 5 ng/ml HGF 
(Supplementary movie 7).  This indicated that EZH2 depletion resulted in cells 
having tail retraction problems, consistent with the increase in cell tails observed in 
fixed cells.  Cell tracking showed that cells depleted for EZH2 were also slower 
than control cells, although this only reached significance after 2 experiments for 
EZH2 siRNA #2. 
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Figure 6.15.  EZH2 depletion decreases cell speed in vitro. 
B16 F10 cells were transfected with control or EZH2 targeted siRNA and plated on 
Fibronectin coated glass.  Cells were stimulated with 5 ng/ml HGF for 2 hours before 
imaging with a Nikon lowlight microscope.  Cells were tracked using Metamorph 
software and cell speeds calculated.  Error bars show standard error of the mean for 
the average cell speeds from two experiments.  Star indicates significance in ANOVA 
statistical test. 
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6.5.2 EZH2 positively regulates metastasis 
Given that PRC2 components regulate Ezrin and Radixin activation and EZH2 
depletion resulted in altered cell motility, the role of EZH2 in metastasis was 
investigated using short term lung metastasis assays.  B16 F10 cells constitutively 
expressing mCherry or GFP were transfected with control or EZH2 targeted siRNA.  
A 50:50 mix of GFP expressing B16 F10 cells transfected with control siRNA and 
mCherry expressing B16 F10 cells transfected with EZH2 targeted siRNA was 
injected into the mouse tail-vein.  The ratio of green:red cells in the lung was 
examined by confocal microscopy after 48 hours.  A separate cohort of control 
mice received a 50:50 mix of B16 F10 GFP and B16 F10 mCherry cells both 
transfected with control siRNA.  The ratio of control transfected B16 F10 GFP to 
EZH2 siRNA transfected B16 F10 mCherry cells was normalised to the ratio of 
red:green cells from control mice.  Mixing the cell-types accounted for differences 
in injection efficiency between mice.  The control transfected B16 F10 cells were 
alternated between GFP and mCherry expressing to ensure that the cell-line or 
colour was not creating bias in the analysis. 
 
Loss of EZH2 in the metastatic B16 F10 sub-line decreased the lung colonisation 
efficiency in 2 out of the 3 siRNAs tested (Figure 6.16 A).  EZH2 siRNA #2, which 
gave the largest increase in cell area, dramatically increased the lung colonisation 
efficiency of B16 F10 cells.  As 2 out of 3 of the siRNAs tested decreased lung 
colonisation this suggests that EZH2 positively regulates metastasis and correlates 
with the increased EZH2 levels in the motile cell population of B16 melanoma.  
However, analysis of more siRNAs are required to be more confident of the data. 
 
To test whether the positive regulation of metastasis was a general PRC2 
mechanism the experimental metastasis assays were repeated for Jarid2 
depletion.  Depletion of Jarid2 with 2 out of the 3 siRNAs tested had no effect on 
the lung colonisation efficiency of the metastatic B16 F10 sub-line (Figure 6.16).  
However, siRNA #1 considerably increased lung colonisation efficiency.  This was 
surprisingly similar to EZH2 siRNA #2 as again the siRNA that induced the greatest 
increase in cell area promoted metastasis.  The fact that Jarid2 depletion in 2 of the 
siRNA had no effect on metastasis was also surprising because Jarid2 depletion 
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results in a change in cell morphology mediated by the loss of ERM protein 
activation, yet this had no effect on metastasis.  Ezrin has well characterised roles 
in different steps during metastasis (Hunter, 2004), yet it appears in B16 melanoma 
loss of Radixin and Ezrin activation does not affect metastasis.  As 1 out of 3 
siRNAs for both EZH2 and Jarid2 gave contradictory results, more siRNAs are 
required to confirm these observations. 
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Figure 6.16.  Analysis of PRC2 regulation of metastasis. 
Graphs showing relative efficiency of lung colonisation 48 hours after injection of B16 
F10 cells depleted for A. EZH2 and B. Jarid2 using 3 different siRNAs for each gene.  
Data from at least 5 mice over at least 2 experiments for each point.  Error bars show 
standard error and star indicates a statistically significant difference to control cells in 
ANOVA test. 
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6.6 PRC2 components regulate pigment production but do not 
significantly affect melanoma differentiation marker 
expression 
During development, the core PRC2 component EZH2, mediates silencing of 
differentiation associated genes and loss of EZH2 induces premature expression of 
differentiation markers (Boyer et al., 2006) (Lee et al., 2006) (Ezhkova et al., 2009).  
However, Jarid2 has a different role.  Jarid2 is essential for differentiation and 
depletion of Jarid2 leaves ES cells unable to differentiate in vitro (Landeira et al., 
2010) and leads to an arrest in gastrulation of xenopus embryos (Peng et al., 
2009).  
 
EZH2 levels decrease during murine epidermal differentiation (Ezhkova et al., 
2009), so to determine  whether EZH2 levels correlate with differentiation in B16 F2 
melanoma, the cells were subject to α-MSH treatment for 48 hours, as α-MSH is 
known to induce differentiation in this cell-type (Hunt et al., 1994) (Bennett et al., 
1994).  Treatment with 10 μM α-MSH significantly reduced Ezh2 mRNA levels and 
Jarid2 mRNA also showed a slight decrease (Figure 6.17).  This suggests that 
Ezh2 mRNA levels correlate with differentiation status in B16 melanoma. 
 
As motile cells in B16 melanoma are thought to be less differentiated (Pinner et al., 
2009) and EZH2 correlates with differentiation state, EZH2 may maintain cells in a 
less differentiated state to promote motility.  To test this hypothesis, pigment levels 
and expression of differentiation markers were assessed in cells depleted for EZH2 
and other PRC2 components.  Although discussion in previous chapters notes that 
pigment is not a good substitute for differentiation markers, decreased pigment 
correlates with motility in vivo and it is a simple assay to perform. 
 
Depletion of EZH2 in B16 F2 cells led to an increase in pigment levels as 
determined by both the colour of the B16 F2 cell pellet and quantification of 
pigment intensity on a cell by cell basis following imaging with a two-photon 
microscope (Figure 6.18).  To further explore the role of PRC2 in regulation of 
pigment levels, depletion of Jarid2 and Suz12 was performed.  Pigment levels on 
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loss of Jarid2 were dependent on the individual siRNA (Figure 6.18).  siRNA #1 
consistently decreased pigment levels as determined by the colour of the cell 
pellet.  siRNA #2 slightly increased pigment and siRNA #4 consistently increased 
pigment levels.  Due to the differences between siRNA oligos, a reliable conclusion 
of the effects of Jarid2 depletion on pigment levels could not be reached.  Depletion 
of Suz12 lead to a significant increase in pigment in 2 out of the three siRNAs 
tested (Figure 6.18).  This suggests that loss of PRC2 activity increases pigment 
production in B16 F2 cells, but this may or may not be Jarid2 dependent.  An 
increase in pigment after PRC2 loss implies that PRC2 activity maintains cells in a 
less pigmented state.   
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Figure 6.17. Ezh2 mRNA levels decrease on differentiation of B16 melanoma 
cells. 
B16 F2 cells were treated with 10 μM α-MSH or PBS control for 48 hours before Q RT-
PCR analysis of Ezh2 and Jarid2 mRNA levels.  Data points show 3 independent 
experiments.  Star indicates statistical significance in a paired t-test. 
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Figure 6.18.  PRC2 complex regulates pigment levels in vitro. 
A.  B16 F2 cells were transfected with control, EZH2, Jarid2 or Suz12 targeted siRNA 
and collected by centrifugation 48 hours after transfection.  B.  Quantification of 
pigment levels on a cell by cell basis following depletion of EZH2, Jarid2 and Suz12.  
B16 F2 cells were transfected with control, EZH2, Jarid2 or Suz12 targeted siRNA and 
plated on glass.  Cells were fixed 48 hours after transfection and imaged using a two-
photon microscope to detect pigment.  Cellular pigment intensity was measured and 
background levels subtracted.  At least 50 cells quantified from at least 2 experiments.  
Error bars show standard error and stars indicate significance in ANOVA statistical test. 
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To investigate the interplay between known regulators of pigment and 
differentiation and EZH2, B16 F2 cells depleted of EZH2 were treated with α-MSH 
or H89.  α-MSH results in an increase in B16 cell differentiation and pigment 
through stimulating MC1R (Hunt et al., 1994) (Kondo and Hearing, 2011).  H89 is a 
PKA inhibitor and decreases pigment levels through inhibition of the signal 
downstream of MC1R (Kondo and Hearing, 2011).  Stimulation of EZH2 depleted 
cells with α-MSH did not increase pigment levels further (Figure 6.19).  However, 
H89 treatment of EZH2 depleted cells prevented the increase in pigment normally 
seen on the loss of EZH2 (Figure 6.19).  This indicates that the increase in pigment 
on loss of EZH2 is dependent on PKA signalling.   
 
To test the requirements for EZH2 and Jarid2 in differentiation of B16 melanoma, 
cells were transfected with EZH2 or Jarid2 targeted siRNA and the mRNA levels of 
melanoma differentiation markers assessed by Q RT-PCR.  Basal levels of Tyrp1, 
Tyr and Dct mRNA did not change dramatically on EZH2 and Jarid2 loss (Figure 
6.20).  However, there was a trend towards increased mRNA levels of 
differentiation markers on EZH2 depletion and decreased mRNA levels of 
differentiation markers on Jarid2 depletion (Figure 6.20).  This trend is consistent 
with data from ES cells regarding PRC2 regulation of differentiation, however, 
given the small changes in differentiation markers there is not sufficient evidence to 
confirm a role for PRC2 in regulating B16 melanoma differentiation state. 
 
Overall, the data suggest that EZH2 regulates pigment independently of the 
differentiation associated MITF targets DCT, TYR, and TYRP1 as the increase of 
the MITF target genes on EZH2 depletion is not significant.  In addition, the 
changes in Dct, Tyr, and Tyrp1 mRNA levels between EZH2 siRNAs do not 
correlate with changes in pigment.  This is consistent with data discussed later in 
this chapter regarding a role for the P protein in EZH2 pigment regulation.  
Therefore, it is unlikely that EZH2 maintains cells in a less differentiated state to 
promote motility.    
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Figure 6.19. The increase in pigment observed on EZH2 depletion is dependent 
on PKA signalling. 
B16 F2 cells were transfected with control or EZH2 targeted siRNA.  24 hours after 
transfection PBS, 10 μM α-MSH or 10 μM H89 was added for a further 48 hours, 
before centrifugation to pellet the cells. 
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Figure 6.20.  Depletion of EZH2 and Jarid2 may have different effects on 
melanoma differentiation markers. 
Q RT-PCR analysis of the melanoma differentiation markers TYPR1, TYR and DCT in 
B16 cells 48 hours after transfection with control, EZH2 or Jarid2 targeted siRNA. Error 
bars show standard error. 
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6.7 PRC2 depletion decreases the number of cells in mitosis  
EZH2 up-regulation in melanoma is thought to suppress oncogene-induced 
senescence, a state associated with benign nevi, hence allowing the progression 
from benign nevi to melanoma (Fan et al., 2011) (Michaloglou et al., 2005).  
Senescence is usually associated with an up-regulation of cell-cycle inhibitors 
including p16, however B16 cells have lost the Ink4/ARF locus and so are p16 null 
(Campisi and d'Adda di Fagagna, 2007) (Melnikova et al., 2004).  EZH2 has been 
shown to regulate senescence in melanoma through suppression of the cell cycle 
inhibitor p21 (Fan et al., 2011) and microarray analysis discussed later (chapter 
6.8), identified p21 as an EZH2 target in B16 F2 cells.  Furthermore, senescent 
cells change morphology in vitro and have a large cell area (Campisi and d'Adda di 
Fagagna, 2007) so the change in cell morphology on PRC2 depletion may be as a 
result of senescence.  To test whether EZH2 and PRC2 suppresses senescence in 
B16 F2 cells, cell cycle profile analysis was carried out on cells depleted for PRC2 
components.  Loss of EZH2 and Jarid2 led to a decrease in the percentage of cells 
in S and G2 phase, however in all siRNAs tested there was a significant 
percentage of cells in mitosis (Figure 6.21). This suggests that PRC2 depleted cells 
are not senescent, however, β-galactosidase staining would help to confirm this.  
The siRNAs that induce the largest increase in cell area, EZH2 #2 and Jarid2 #1, 
also decrease the mitotic population the most, suggesting a link between cell 
morphology and cell growth. 
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Figure 6.21. PRC2 depletion reduces the percentage of cells in S and G2 phases 
of the cell cycle. 
B16 F2 cells were fixed in 70 % Ethanol 48 hours after transfection with control or 
EZH2 targeted siRNA.  Cells were then stained with propidium iodide and subject to 
flow cytometry and cell cycle profile analysis using FlowJo software. Plots show raw 
DNA staining intensity data in the black line.  Overlaid blue lines show FlowJo 
predictions for G0/G1, S and G2/M phases of cell cycle. 
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6.8 Genome-wide analysis of EZH2 and Jarid2 gene regulation 
6.8.1 Microarray analysis of EZH2 and Jarid2 depleted cells 
To try and establish how the PRC2 complex regulates ERM protein activation and 
how EZH2 may regulate cell motility and metastasis, microarrays were performed 
on depletion of EZH2 and Jarid2.  B16 F2 cells were transfected with EZH2 siRNA 
#1 and 4 and Jarid2 #1 and 4 as these showed the greatest similarity to each other 
in terms of cell morphology phenotype.   
 
To try and identify genes mediating the decrease in Ezrin and Radixin activation on 
PRC2 component depletion, genes showing a fold reduction of greater than 1.2 in 
all EZH2 and Jarid2 siRNAs were filtered from the microarray (found in appendix).  
This included Fscn1, and if the filters were relaxed to a reduction in 3 out of 4 
siRNAs, Rhoc.  Fascin is an actin cross-linking protein and RhoC is a small Rho-
GTPase protein with high sequence similarity to RhoA (Hashimoto et al., 2011) 
(Wheeler and Ridley, 2004).  However, western blot for both of these proteins did 
not reveal a loss in expression on EZH2 or Jarid2 depletion.  In addition, siRNA 
targeting Fascin and RhoC did not greatly decrease levels of phosphorylated ERM 
proteins.  A suitable candidate for loss of ERM protein activation on EZH2 and 
Jarid2 loss could not easily be found. 
 
6.8.2 EZH2 and Jarid2 can regulate genes up-regulated in motile B16 
population 
As work in chapter 5 had determined a list of genes up-regulated in the motile B16 
population, it would be interesting to test if EZH2 or Jarid2 could regulate these 
genes.  This may help to determine if either EZH2 or Jarid2 are chief components 
regulating B16 melanoma motility.  Overlap analysis was performed between 
genes up- or down-regulated on EZH2 or Jarid2 depletion and the genes up-
regulated in the motile B16 population.  In addition, genes that co-regulated with 
EZH2 in public datasets (oncomine) were analysed (all gene lists can be found on 
accompanying CD).  These genes co-regulated with EZH2 were shown to have the 
greatest overlap with the genes up-regulated in the motile B16 population (Table 
Chapter 6. Results 
 
230  
 
8).  This suggests that EZH2 may control expression of the genes up-regulated in 
B16 motile cells.  To further support this notion, genes that are down-regulated on 
EZH2 loss in B16 F2 cells show significant overlap with genes up-regulated in the 
B16 motile cell population (Table 8) (genes found in appendix).  As Ezh2 mRNA is 
increased in the motile cell population (Figure 6.1), this is consistent with EZH2 
positively regulating motility through positive regulation of the genes up-regulated in 
the motile cell population.  However, EZH2 is normally considered to silence genes, 
so these genes down-regulated on EZH2 loss may be indirect targets. 
 
To test if Jarid2 could regulate the transcriptional program associated with B16 
melanoma motility, Jarid2 target genes were analysed for overlap.  Genes up-
regulated after Jarid2 knockdown significantly overlapped with the genes up-
regulated in the motile B16 cell population (Table 8) (genes found in appendix).  
This may suggest that Jarid2 activity is low in the motile cell population.  Taken 
together this correlates with data from experimental metastasis assays in which 
loss of EZH2 decreased metastasis yet loss of Jarid2 had no effect.  If the gene 
expression pattern associated with motility is similar for metastasis, then genes 
positively regulated by EZH2 but Jarid2 independent should overlap with genes 
increased in motile B16 cells (gene lists found in Supplementary file 1).  Indeed, 
these genes show significant overlap (Table 8).  Therefore it is likely that control of 
the genes up-regulated in the motile cell population in B16 melanoma correlates 
with ability to regulate metastasis.  
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Geneset 
Observed 
overlap 
Expected 
overlap p-value FDR 
Genes that co-vary with Ezh2 
(oncomine) 16 0.42 3.96 x 10
-20
 3.96 x10
-19
 
Genes up-reg. by Jarid2  7 1.09 0.00014 0.00065 
Genes down-reg by EZH2 and 
Jarid2 independent (only oligo 4)  7 1.19 0.00024 0.00065 
Genes down-reg by EZH2 8 1.65 0.00031 0.00065 
Genes down-reg by EZH2 and 
Jarid2 independent (both Jarid2 
oligos) 5 0.78 0.00129 0.00215 
 
Table 8. Overlap analysis of EZH2 and Jarid2 regulated genes with genes up-
regulated in the B16 motile cell population. 
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6.8.3 Identification of PRC2 regulated genes that correlate with pigment 
EZH2 depletion resulted in an increase in pigment production and Jarid2 depletion 
gave mixed results, with siRNA #1 resulting in a decrease in pigment and siRNA #4 
resulting in an increase in pigment levels.  The microarray data was used to try and 
identify genes regulated by the PRC2 complex that control pigment production. 
Genes that correlated with changes in pigment levels were selected, i.e genes that 
were both up-regulated on EZH2 siRNA #1, 4 and Jarid2 siRNA #4 and down-
regulated on Jarid2 siRNA #1 depletion.  This resulted in a list of 31 genes that 
correlated with changes in pigment (Table 9).  One of the genes was Oca2 and 
mutations in this gene in humans are known to result in a form of albinism called 
oculocutaneous albinism type 2 (Donnelly et al., 2012).  In addition, polymorphisms 
in Oca2 result in most of the variation in human eye colour (Duffy et al., 2007) and 
can account for differences in skin and hair pigmentation (Han et al., 2008).  Oca2 
encodes a melanosomal membrane protein known as the P protein, which is 
thought to be involved in tyrosine transport and processing (Rosemblat et al., 1994) 
(Chen et al., 2002) (Toyofuku et al., 2002).  Therefore, changes in expression of 
this gene may affect pigment production.   
 
To confirm that PRC2 components could regulate Oca2 mRNA levels, B16 F2 cells 
depleted for EZH2 and Jarid2 were subject to Q RT-PCR for Oca2.  This validated 
the array results and showed an increase in Oca2 mRNA levels on depletion of 
EZH2 (Figure 6.22), in parallel with the increased pigment observed on EZH2 
depletion.  Oca2 mRNA levels decreased on knockdown of Jarid2 siRNA #1 
(Figure 6.22), correlating with a decrease in pigment levels in cells treated with this 
siRNA.  Depletion of Jarid2 with siRNA #2 and 4 increased Oca2 mRNA (Figure 
6.22).  This correlated with the quantification of pigment levels on a cell to cell basis 
as both these siRNA increased pigment levels in this assay.  
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Gene symbol Fold change 
  EZH2 #1 EZH2 #4 Jarid2 #1 Jarid2 #4 
1810014f10rik 1.23 1.44 -1.22 1.26 
1810058m03rik 1.33 1.40 -1.50 1.52 
Trnp1 1.53 2.38 -2.29 1.25 
A530050n04rik 2.10 2.48 -1.28 2.03 
Bace2 1.75 1.45 -1.88 1.34 
Capzb 1.60 1.34 -1.29 1.49 
Ccl5 1.69 1.39 -1.66 1.77 
E430003j01rik 1.42 1.28 -1.28 1.24 
Esrra 1.26 1.20 -1.75 1.42 
Gsta1 1.66 1.54 -3.66 1.37 
Hist1h1c 1.87 2.37 -1.39 2.57 
Hist1h2bc 1.30 1.53 -1.38 1.88 
Hist1h2be 1.23 1.64 -1.28 1.57 
Hist1h2bf 1.23 1.92 -1.30 1.75 
Hist2h2aa1 1.38 1.26 -1.36 1.24 
Irf9 1.31 1.53 -1.35 1.84 
L3mbtl2 1.47 1.98 -1.53 1.46 
Loc100038882 1.71 1.64 -1.69 1.87 
Loc100048346 1.55 1.63 -1.49 2.46 
Loc634731 1.31 1.56 -1.64 2.00 
Lrrc8a 1.25 1.22 -1.68 1.21 
Mpv17l 1.44 1.26 -1.29 1.30 
Oas1g 1.20 1.58 -1.35 1.93 
Oca2 2.38 2.08 -1.32 2.25 
Rab1 1.31 1.35 -1.92 1.23 
Rbks 1.26 1.25 -1.27 1.68 
Samd9l 1.28 1.67 -1.44 1.25 
Sepw1 1.30 1.43 -1.25 1.52 
St6galnac2 1.55 1.21 -1.41 1.37 
Tbrg4 1.24 1.25 -1.28 1.34 
Usp18 1.65 1.74 -1.77 3.13 
Table 9.  Genes correlating with changes in pigment levels. 
Genes selected showed a fold change of greater than 1.2 in EZH2 siRNA #1, 4 and 
Jarid2 #4 and a change of less than -1.2 in Jarid2 siRNA #1.  
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Figure 6.22. Oca2 mRNA expression on EZH2 and Jarid2 depletion. 
B16 F2 cells were transfected with control, EZH2 or Jarid2 targeted siRNA.  48 hours 
after transfection the cells were lysed and the total RNA extracted for Q RT-PCR 
analysis. Error bars show the standard error of the mean.  Data from at least four 
experiments.  Stars indicate statistical significance in ANOVA test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6. Results 
 
235  
 
To test whether the P protein could regulate pigment levels in B16 F2 melanoma, 
cells were depleted of P protein and the colour of the cell pellet analysed.  This 
showed a dramatic loss of pigment levels on loss of P protein expression (Figure 
6.23)  Even treatment with siRNA #3 and 4, which only slightly reduced mRNA 
levels, resulted in very little pigment in the cell pellets . 
 
As Oca2 mRNA levels are regulated by PRC2 components and P protein regulates 
pigment, the hypothesis was that PRC2 regulates P protein resulting in changes in 
pigment levels.  To investigate this hypothesis, P protein and PRC2 components 
were simultaneously depleted and the pigment levels of cell pellets examined.  B16 
F2 cells were transfected with equal amounts of control and EZH2 siRNA or P 
protein smart pool and EZH2 siRNA.  Control cells received control siRNA alone.  
The total amount of siRNA was kept constant.  EZH2 depletion resulted in an 
increase in pigment levels as expected, however concurrent loss of EZH2 and P 
protein decreased pigment compared to control cells (Figure 6.24).  This indicates 
that P protein is required for the increase in pigment observed on EZH2 depletion.   
 
Surprisingly, on depletion of P protein, changes to the cell morphology were 
observed.  P protein depleted cells appeared flatter and had a larger cell area 
(Figure 6.25).  Although the increase in cell area was similar to the EZH2 depletion 
phenotype, the actin phenotype was slightly different, as depletion of P protein 
resulted in an increase in actin cables in the cell.  The change in cell morphology 
was unexpected because although the motile cell population has less pigment, a 
direct link between pigment regulation and the actin cytoskeleton was not 
expected.  However, as P protein is involved in regulating pigment levels and 
depletion results in altered cell morphology, there may be a role for pigment 
associated proteins in control of the actin cytoskeleton. 
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Figure 6.23.  P protein regulates pigment levels in B16 F2 melanoma cells. 
A.  Image showing pigment levels in B16 F2 cell pellets after transfection with control 
or P protein targeted siRNA.  48 hours after transfection the cells were pelleted and 
imaged.  B.  Graph showing Oca2 mRNA levels (encoding for P protein) in B16 F2 
cells 48 hours after transfection with control or P protein targeted siRNA as determined 
by Q RT-PCR.  Error bars show the standard error for three experiments.  Stars 
indicate statistical significance in ANOVA test. 
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Figure 6.24. P protein is required for EZH2 pigment regulation in B16 melanoma 
cells. 
A.  Image showing pigment levels in B16 F2 cell pellets after transfection with 
individual or combinations of control, EZH2 or P protein targeted siRNAs.  Total siRNA 
was kept constant at 100 nmols.  48 hours after transfection the cells were pelleted and 
imaged. 
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Figure 6.25. P protein depletion results in a change of cell morphology. 
A. Images of B16 F2 cells transfected with control or P protein siRNA and plated on 
glass.  Cells were fixed 48 hours after knockdown and stained with phalloidin.  Scale 
bar indicates 25 μm.  B. Quantification of B16 F2 cell area after P protein or control 
knockdown.  Area was quantified manually by drawing around 20 cells in Zen imaging 
software.    
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6.8.4 Identification of PRC2 regulated genes that correlate with 
metastasis 
To try and identify which EZH2 target genes regulate metastasis, the microarray 
data was queried to identify genes that correlated with metastasis.  EZH2 depletion 
with siRNA #1 and 4 in B16 F10 cells resulted in decreased metastasis and Jarid2 
depletion with siRNA #2 and 4 had no effect on metastasis.  However Jarid2 
siRNA#1 resulted in a dramatic increase in metastasis.  Therefore, genes up-
regulated on Jarid2 siRNA #1 depletion and down-regulated on EZH2 siRNA #1 
and 4 depletion were filtered out from the microarray.  The microarray analysis was 
performed in the F2 sub-line and the metastasis assays with the F10 sub-line, but  
this analysis assumes that EZH2 targets will be maintained between the two lines.   
 
The expression of 40 genes correlated with metastasis (Table 10).  Out of these 40 
genes, Actn4, Mcam, Mybl2, Myl12b, Smarce1, Sparc and Srf were chosen 
because they were known cytoskeletal regulators or had previously been 
associated with metastasis.  Their expression levels after EZH2 and Jarid2 
depletion were analysed by Q RT-PCR to confirm the microarray results.  SPARC, 
Alpha actinin-4 and MCAM expression most closely correlated with metastatic 
potential of B16 F10 cells on knockdown of EZH2 and Jarid2 with the individual 
siRNAs (Figure 6.26).  Although the genes were initially chosen based on the 
expression after knockdown with EZH2 siRNA #1, 4 and Jarid2 #1, all genes 
showed an increase in expression after knockdown with EZH2 #2.  As shown 
previously, (Figure 6.16) this siRNA dramatically increases metastasis showing 
good correlation between regulation of these genes and metastasis.  However, only 
MCAM showed a significant reduction in expression on knockdown with EZH2 
siRNA #1 and 4 (Figure 6.26).  As both of these siRNA decrease metastasis, 
MCAM is the most likely candidate to regulate metastasis on PRC2 component 
depletion.   
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 Gene symbol Fold change 
 
EZH2 
#1 
EZH2 #4 Jarid2 
#1 
Jarid2 
#4 
Fam76b -1.26 -1.21 1.26 -1.34 
9430080k19rik -1.41 -1.30 1.26 -1.36 
9830001h06rik -1.24 -1.21 1.43 -1.13 
Actn4 -1.49 -1.21 1.24 -1.04 
Anp32a -1.52 -1.44 1.36 -1.44 
Ddx39b -1.35 -1.38 1.21 -1.02 
Casp2 -1.58 -1.38 1.32 -1.09 
Cdca4 -1.32 -1.24 1.23 -1.03 
Celf2 -1.30 -1.21 1.23 -1.54 
Dennd2a -1.29 -1.28 1.31 -1.30 
E030026i10rik -1.35 -1.32 1.40 -1.12 
Ehbp1l1 -1.22 -1.45 1.37 -1.02 
G3bp1 -1.33 -1.20 1.23 -1.00 
Gm22 -1.37 -1.32 1.44 -1.45 
Hmgb2 -1.24 -1.34 1.25 1.13 
Igfbp4 -1.41 -1.23 1.24 -1.30 
Loc381889 -1.34 -1.25 1.21 -1.02 
Mapre2 -1.41 -1.28 1.32 -1.45 
Mbnl1 -1.28 -1.24 1.58 -1.18 
Mcam -1.58 -1.53 3.66 -1.00 
Mybl2 -1.43 -1.24 1.25 -1.33 
Myl12b -1.30 -1.28 1.40 -1.06 
Ncapd2 -1.38 -1.41 1.24 -1.09 
Nfib -1.29 -1.36 1.80 1.04 
Nrm -1.47 -1.48 1.49 -1.08 
Hmgn5 -1.38 -1.20 1.22 -1.30 
Pabpc1 -1.72 -1.21 1.23 -1.12 
Pias1 -1.32 -1.25 1.30 -1.62 
Polr2a -1.22 -1.31 1.31 -1.02 
Zmynd8 -1.21 -1.21 1.55 -1.27 
Raly -1.26 -1.25 1.25 1.15 
Skp2 -1.50 -1.28 1.50 1.01 
Smarce1 -1.36 -1.43 1.25 -1.06 
Sparc -1.69 -1.28 2.41 -1.51 
Srf -1.41 -1.68 1.50 -1.29 
Suds3 -1.47 -1.49 1.25 -1.42 
Tmsb10 -1.20 -1.57 1.26 -1.06 
Tpm1 -1.35 -1.22 1.29 1.06 
Vgll4 -1.32 -1.56 1.53 -1.02 
Wnk1 -1.33 -1.20 1.23 1.04 
Table 10. PRC2 regulated genes that correlate with metastasis. 
Genes selected showed a fold change of less than -1.2 in EZH2 siRNA #1, 4 and a 
change of greater than 1.2 in Jarid2 siRNA #1.  
 
 
Chapter 6. Results 
 
241  
 
 
Figure 6.26. SPARC, Alpha-actinin-4 and MCAM expression closely correlates 
with individual EZH2 and Jarid2 siRNA effects on metastasis. 
Graphs showing Sparc, Actn4 and Mcam mRNA levels in B16 F2 cells 48 hours after 
transfection with control, EZH2 or Jarid2 targeted siRNA as determined by Q RT-PCR.  
Data from at least three experiments.  Error bars show the standard error and stars 
indicate statistical significance in ANOVA test. 
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6.9 Chapter summary 
Bioinformatic analysis of the genes up-regulated in the motile B16 F2 population 
identified EZH2 as a potential regulator of motility.  Consistent with EZH2 having a 
role in regulating the motile B16 F2 population, Ezh2 mRNA was up-regulated in 
the Notch reporter high population, a population enriched for motile cells.  EZH2 
levels were also heterogeneous in a number of syngeneic mouse melanoma 
models and in two human melanoma metastases.  EZH2 and other PRC2 
components including Jarid2 regulate B16 F2 cell morphology and the actin 
cytoskeleton through activation of the ERM proteins Ezrin and Radixin (Figure 
6.27).  To test whether EZH2 regulates cell motility and metastasis, the more 
metastatic B16 F10 sub-line was used.  Cells depleted in EZH2 showed tail 
retraction problems and a reduction in cell speed when migrating on Fibronectin in 
vitro.  EZH2 depletion also decreased metastasis although depletion of Jarid2 had 
no effect (Figure 6.27).  This indicates that the PRC2 dependent regulation of ERM 
proteins does not influence metastasis since Jarid2 depletion could decrease ERM 
activation yet had no effect on metastasis. Microarray analysis suggested that 
EZH2 regulation of MCAM may influence the metastatic ability of B16 F10 cells.  
Further support for EZH2’s role in regulating motility and metastasis came from 
overlap analysis of the genes up-regulated in the motile B16 F2 population.  Genes 
positively regulated by EZH2 showed significant overlap with the genes up-
regulated in the motile B16 F2 population.  As EZH2 is currently believed to 
suppress gene expression, EZH2 regulation of these genes may be indirect.  
CHIPSeq analysis is currently underway to differentiate between direct and indirect 
EZH2 targets.  EZH2 depletion resulted in an increase in pigment levels in B16 F2 
cells and this was mediated by an increase in P protein (Figure 6.27).  However, 
the role of the PRC2 component, Jarid2, in regulation of pigment levels was 
unclear.  Consistent with data from ES cells, loss of EZH2 slightly increased 
differentiation markers and loss of Jarid2 slightly decreased differentiation markers 
in B16 F2 cells, although the changes were not significant.   
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Figure 6.27. Summary. 
Schematic showing a summary of the role of EZH2 in B16 melanoma cells.  Details 
in black supported by data in chapter 6 and details in red remain speculative.  
EZH2 silences P-protein expression resulting in reduced pigment levels in EZH2 
high cells.  EZH2 regulates the cytoskeleton and cell morphology through 
regulation of Ezrin and Radixin activation.  EZH2 also positively regulates 
metastasis, possibly through positive regulation of MCAM expression or through 
regulation of the cytoskeleton. 
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Chapter 7. Intra-vital imaging reveals distinct 
tumour vascular zones with different responses to 
Sunitinib 
7.1 Chapter introduction 
The previous chapters have considered heterogeneous melanoma behaviour, in 
particular motility, and melanoma cell properties associated with it.  However, 
stromal components can also influence cancer cell invasion and metastasis 
(Gaggioli et al., 2007; Wyckoff et al., 2004).  The vasculature is an important 
component of the tumour microenvironment, and provides a route for cells to 
metastasise (Zetter, 1998).  It provides oxygen, metabolites and growth factors to 
the tumour and access to these may affect tumour cell behaviour (Folkman, 1971).  
Data from intra-vital imaging suggests breast cancer cells are more motile in 
regions with increased blood vessel density (Wang et al., 2005).  In addition the 
blood vasculature is a novel target for cancer therapy.  Mono-clonal antibodies 
targeting VEGF-A, such as Bevacizumab, or VEGFR-2 inhibitors, such as 
Sorafenib and Sunitinib, have been developed and licensed to treat a variety of 
cancers.  However, treatments have not performed as well as expected and 
numerous clinical trials have indicated no benefit for overall survival (Allegra et al., 
2011).  Furthermore, pre-clinical testing has indicated that anti-angiogenic 
treatments may cause tumours to relapse into a more aggressive state, increasing 
metastasis (Ebos et al., 2009; Paez-Ribes et al., 2009). Therefore the relationship 
between blood vessels and cancer cell motility was investigated further.  The aim 
was to determine whether cancer cell motility is associated with certain vascular 
morphologies or behaviours and whether anti-angiogenic treatments may perturb 
the relationship.  A transgenic mouse with GFP-labelled endothelial cells was used 
to analyse the tumour vasculature of the syngeneic B16 and 5555 models of 
melanoma. 
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7.2  Tumour vascular morphology and dynamic behaviour is 
heterogeneous in vivo 
7.2.1 Intra-vital imaging using VE-Cadherin:GFPCAAX mice provides a 
high resolution dynamic picture of the tumour vasculature 
Current methods to analyse the tumour vasculature include immunohistochemistry 
(Figure 7.1A) and injecting labelled probes into the blood.  Immunohistochemistry 
involves fixing the tumour and cutting thin slices.  Due to fixation any dynamic 
information is lost and artefacts may be introduced during the fixation process.  In 
addition, the technique does not easily allow 3-D analysis of the vasculature.  
Injectable probes, whether fluorescent or radiolabelled, only give information about 
perfused vessels and information about the endothelial cells themselves is not 
easily available. To circumvent these issues, intra-vital imaging was used to 
analyse the tumour vasculature.  Intra-vital imaging allows serial z-sections to be 
imaged to form a 3-D reconstruction.  Additionally time-lapse imaging enables 
dynamic information to be recorded.   
 
VE-Cadherin:GFPCAAX mice were used to visualise the vasculature.  These mice 
were generated by Ralf Adams and have GFP with a membrane targeting CAAX 
box under the control of the VE-Cadherin promoter.  Briefly, cDNA encoding for 
enhanced green fluorescent protein fused to a C-terminal CAAX box was 
introduced by recombineering into the start codon of VE-Cadherin in a PAC clone.  
The resulting construct was used in a circular form for pronuclear injection into 
fertilised mouse oocytes.  Founders, identified by PCR genotyping, were screened 
and, following successful validation, bred into a C57BL/6J background.  VE-
Cadherin expression is limited to endothelial cells and so only the vasculature is 
labelled with membrane GFP.  Sub-cutaneous injection of either B16 F2 or 5555 
melanoma cells with a red fluorescent membrane marker into VE-
Cadherin:GFPCAAX mice allowed visualisation of both the melanoma cells and the 
vasculature using either two-photon or single photon intra-vital microscopy.  This 
enabled analysis ranging from a large scale overview of the tumour 
microenvironment (Figure 7.1 B) to a high magnification look at individual sprouting 
vessels interacting with the ECM (Figure 7.1F).  However, due to the penetration 
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capabilities of single and two-photon lasers, the depth into the tumour that could be 
imaged was limited to around 200μm with a two-photon laser. This is indicated in 
Figure 7.1A by the dashed box showing the limit of intra-vital imaging on a 
immunohistochemical staining. 
 
Injection of the fluorescent probe Angiosense 680 immediately prior to imaging 
tumours in VE-Cadherin:GFPCAAX mice indicated that many of the nascent 
sprouting vessels in the tumour are not perfused. (Compare Figure 7.1C,D and E).  
This highlights the fact that injectable probes do not provide information about the 
entire tumour vasculature network.   
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Figure 7.1 Imaging the tumour vasculature. 
A. Immuno-histochemical staining of B16 F2 tumours using anti-Endomucin antibody to 
identify blood vessels.  Dashed area roughly represents the area possible to image 
with multi-photon intra-vital microscopy.  B. Intra-vital confocal tile image showing 
whole tumour and margin.  C-E. Intra-vital confocal image of angiogenic sprouting 
towards tumour. C. GFP channel showing only vasculature.  D. Infra-red channel 
showing extent of blood flow using Angiosense 680.  E. Merge of red melanoma cells, 
green vasculature and Angiosense 680.  F. Two-photon intra-vital image of a sprouting 
blood vessel with Collagen second harmonic in blue. Intra-vital images show B16 F2 
melanoma cells with red membrane marker in VE-Cadherin:GFPCAAX mice. 
Endothelial cells have green membrane marker.  Scale bar indicates 100μm. 
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7.2.2 Quantification of vascular morphologies reveals distinct zones in 
the tumour environment 
Tile images spanning several hundred microns of B16 F2 melanomas in VE-
Cadherin:GFPCAAX mice suggested that different vessels in the same tumour had 
different morphologies (Figure 7.1).  To further characterise the vessel 
morphologies, images of numerous vessel areas in several tumours were taken 
using a 20x objective (3D reconstructions shown in Supplementary movies 8 and 
9).  Images were characterised into tumour or margin depending on the presence 
or absence of tumour cells.  Healthy vessels were analysed on the alternative flank 
to the tumour as a control.  A number of morphometric parameters were analysed 
for each image.  The parameters chosen were based on conventional parameters 
used to define vascular morphology with a focus on aspects of morphology known 
to be abnormal in the tumour vasculature.  Tortuosity was calculated by measuring 
the arc length and chord length of a vessel and dividing the arc length by chord 
length (Figure 7.2A).  Branch points were measured by counting the number of 
branch points and dividing by the vessel length to get a number of branch points 
per vessel length (Figure 7.2A).  Blunt ends were measured by counting the 
number and dividing by the vessel area (Figure 7.2A). Vessel area was calculated 
by thresholding on the GFP signal for the image and using image analysis software 
to measure the area.  Variation in vessel width was calculated by measuring the 
vessel width every 15μm along a 150μm vessel section.  The mean and standard 
deviation of vessel width were determined for the 150μm section and variation in 
vessel width was calculated by dividing the standard deviation by the mean (Figure 
7.2A). 
 
The morphological data for individual vascular networks was then subject to 
hierarchical clustering to create a cluster dendrogram (Figure 7.2 B). The distance 
along the arms in the dendrogram represents the degree of similarity in morphology 
between vascular networks, with smaller distances indicating increased similarity. 
This analysis revealed three predominant classes of vascular organisation: one 
class was dominated by healthy tissue (Figure 7.2 B cluster 1), the second by 
vessels from the tumour margin (Figure 7.2 B cluster 2), and the third included both 
tumour vessels and some tumour marginal vessels (Figure 7.2 B cluster 3). The 
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margin vascular networks fell into two distinct clusters (cluster 2 and 3), which 
shows that there are two distinct types of vascular networks found at the tumour 
margin. The vascular networks at the tumour margin in cluster 2, were the least 
similar to any other group and were characterised by increased tortuosity and 
variation in vessel width. The margin networks in cluster 3 were characterised by 
increased branch points and vessel ends. 
 
Further analysis of tile images of B16 F2 tumours indicated that the distinct margin 
regions may be related to distance to tumour (Figure 7.3 and Supplementary movie 
10).  However, it is difficult to conclusively show the relationship between distance 
to tumour and vascular morphology due to the curvature of the tumour and the 
distance limit of imaging.  The distinct vascular zones were thereby labelled 
immediate margin and peripheral margin.  The peripheral margin refers to the most 
morphometrically abnormal zone (cluster 2 in Figure 7.2) and the immediate margin 
(cluster 3 in Figure 7.2) refers to the zone with similar morphology to tumour 
vasculature.   
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Figure 7.2 Quantification of vascular morphology reveals distinct margin 
regions. 
A.  Schematic showing parameters quantified; tortuosity, number of branch points per 
vessel length, number of blunt ended vessels (tip cells), variation in vessel width.  B.  
Hierarchical cluster dendrogram of vessels based on the four morphometric 
parameters.  3 individual clusters are designated by the dashed lines. Clustering using 
Ward’s criterion and Euclidean distance.  Multiple images for each region are shown by 
coloured letters, tumour regions with a red “T”, margin regions with an orange “M” and 
healthy regions with a green “H”.  Numerous representative vessels were quantified in 
each image and images from at least 3 mice used for each region. Healthy regions 
were imaged in skin on opposite flank to tumour growth. 
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Figure 7.3 Two zones with distinct vascular morphology exist within the tumour 
margin. 
Intra-vital tile image of B16 F2 melanoma in VE-Cadherin:GFPCAAX mouse.  B16 F2 
melanoma cells have red membrane marker.  Additional auto-fluorescent cells, 
potentially phagocytic macrophages, can be seen in the red channel in both margin 
zones. Endothelial cells have green membrane marker.  Scale bar indicates 50μm. 
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Images illustrating vascular morphology in the different zones are shown in Figure 
7.4.  The main characteristics of the peripheral margin are high tortuosity and a 
large variation in vessel width. The immediate margin has the most branch points 
and a high density of blunt ends, very similar to the tumour (Figure 7.5). 
 
To test if the vascular morphologies observed in B16 F2 melanoma were a more 
general phenomenon, vascular morphology was also quantified in different areas of 
sub-cutaneous 5555 melanomas.  This also indicated that there were differences in 
morphology in different margin areas, again highlighting the increased tortuosity 
and variation in vessel width in the peripheral margin (Figure 7.5). However values 
for tortuosity and variation in vessel width were not as high as in the B16 model.  
The 5555 model also had a high number of branch points and blunt ends in the 
intermediate margin and tumour (Figure 7.5).  In the 5555 model the intermediate 
margin had the most blunt ends whereas in the B16 model the tumour had the 
most blunt ends, potentially indicating a slower angiogenic response in 5555 
tumours. 
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Figure 7.4 Heterogeneity in vascular morphology in different tumour 
environments. 
 
Intra-vital images of vasculature from VE-Cadherin:GFPCAAX mice with sub-
cutaneous B16 F2 melanoma tumours.  A.  Healthy skin was imaged on adjacent flank 
to the tumour.  B. Peripheral margin.  C. Immediate margin. D. Tumour.  Endothelial 
cells have green membrane marker.  Scale bar indicates 50μm. 
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Figure 7.5 Quantifcation of vascular morphometric parameters in two melanoma 
models. 
Graphs of morphometric variables A. Tortuosity, B. Branch points, C. Blunt ends and 
D. Variation in vessel width.   Vessels were quantified in the four distinct vascular 
zones in both B16 and 5555 BRAFV600E melanomas grown in syngeneic C57Black6 
mice.  Numerous representative vessels were quantified in each image and images 
from at least 3 mice used for each region. Error bars show standard errors.  Stars 
indicate a p-value <0.05 in a one-way ANOVA with a post-test to compare against 
Healthy vessels. 
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7.2.3 Intra-vital imaging reveals heterogeneous dynamic endothelial cell 
behaviour 
To analyse the dynamic behaviour of tumour associated endothelial cells 3-D z-
stacks of the vasculature were taken every minute for a period of 20-30 minutes.  
Movies of healthy, peripheral margin, immediate margin and tumour vasculature 
were analysed.  This indicated a number of dynamic cellular behaviours (Figure 
7.6). Two different types of protrusions were observed; filopodia-like 
(Supplementary movie 11) and bleb-like (Supplementary movie 12), and these 
could be either intra- or extra-luminal.  Endothelial cells were observed moving 
within the vessel walls (Supplementary movie 13).  Unexpectedly, they were also 
observed using a rounded mode of motility (Supplementary movie 14), reminiscent 
of amoeboid cancer cell motility, to move within the tumour distant to vessels at 
speeds of about 35 μm/hour. 
 
Quantification of dynamic behaviour by counting the number of events and 
normalising to the vessel area revealed that, as expected, the healthy vessels were 
relatively quiescent with little dynamic behaviour.  The peripheral margin was the 
most dynamic (Figure 7.7A).  This correlates with the peripheral margin also having 
the most abnormal morphology.  Dynamic activity in the peripheral margin was 
characterised by cell protrusions (Figure 7.7).  The immediate margin and tumour 
had similar levels of dynamic activity, although the types of behaviours differed 
slightly.  Vessels in the immediate margin had more protrusions where as tumour 
vessels had increased motility both within the vessel and distant to it (Figure 7.7).  
The dynamic information confirms that vessels in distinct vascular zones based on 
morphology, also have distinct dynamic behaviour.   
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Figure 7.6 Dynamic endothelial cell behaviour in vivo. 
A Filopodia-like protrusions.  Stills taken from a movie at time 0, 4 and 9 minutes.  
Arrowheads indicate filopodia-like protrusion from tip cell and stars indicate filopodia 
retraction.  Scale bar indicates 20 μm.  B. Bleb-like protrusions. Stills taken from a 
movie at time 0, 13 and 25 minutes.  Arrowhead indicates a bleb-like protrusion from a 
vessel.  Scale bar indicates 20 μm. C.  Intra-vessel wall motility.  Stills taken from a 
movie at time 0, 18 and 38 minutes.  Arrow indicates collective movement of 
endothelial cells within the vessel wall and yellow dashed line indicates extent of 
movement.  Scale bar indicates 20 μm.  D. Endothelial cell motility distant to vessels.  
Stills taken from a movie at time 0, 12 and 28 minutes.  Arrowheads indicate two 
different motile endothelial cells.  Scale bar indicates 50 μm. Endothelial cells have 
green membrane marker.   
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Figure 7.7 Quantification of dynamic behaviours in different vascular zones. 
A.Graph showing total number of dynamic events in distinct vessel regions.  Dynamic 
events measured by intra-vital time-lapse imaging and given as an average over the z-
stack.  Graphs showing prevalence of different dynamic events; B. Protrusions, C. 
Intra-vessel wall motility, D. Endothelial cell motility distant to vessel, in distinct vessel 
regions. At least 8 movies analysed from 4 mice for each region.  Error bars show 
standard errors.  Stars indicate a p-value < 0.05 in ANOVA statistical tests and ns is 
not significant. 
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7.3 Melanoma cell motility correlates with aspects of vascular 
morphology and dynamics 
Chapter three discussed the heterogeneity in melanoma motility in vivo.  
Differences in motile behaviour could be a result of the microenvironment and after 
determining heterogeneity in morphology and dynamics of the vasculature in vivo, 
the correlation between vasculature and melanoma cell motility was investigated.  
Melanoma cell motility, vessel density and the previously described morphological 
and dynamic parameters were measured simultaneously in twenty different tumour 
time-lapse movies.  Parameters were averaged to get a value for the whole volume 
of the z-stack movie.  Z-stacks were typically 20μm deep.  Initially cancer cell 
motility was plotted against vessel area to determine if there was a simple 
correlation between the extent of vascularisation and melanoma motility.  Statistical 
tests did not reveal a significant correlation between melanoma cell motility and 
vessel area (Figure 7.8). 
 
To determine if melanoma cell motility correlated with morphological features of the 
vasculature, levels of cell motility was arbitrarily divided into six groups from no 
cancer cell motility to high (>120 cells moving per sqmm tumour) and given a 
colour from white, through pink to red for high melanoma cell motility.  This was 
then overlaid onto the dendrogram generated through hierarchical clustering of 
vascular morphology. Tumour areas in the dendrogram were thereby represented 
by a measure for melanoma cell motility in the same region.  This revealed that 
even though the clustering was performed using morphological parameters, tumour 
regions with high melanoma cell motility were within the same cluster (Figure 7.9). 
Furthermore, tumour vascular networks fell into two main sub-clusters based on 
morphology, sub-cluster A and B (shown in Figure 7.9) and sub-cluster A had 
statistically higher melanoma motility than sub-cluster B.  This suggests that there 
is a link between overall vascular morphology and levels of melanoma cell motility. 
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Figure 7.8 Melanoma cell motility does not correlate with vessel area 
Plot of cancer cell motility vs vessel area.  Cancer cell motility and vessel area 
measured in the same intra-vital z-stack time-lapse movie.  Cancer cell motility given 
as an average over the z-stack.  Vessel density measured by thresholding green 
endothelial cell channel and given as an average over the z-stack.  Time-lapse movies 
from 7 mice analysed. 
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Figure 7.9 Melanoma cell motility correlates with vascular morphology. 
A. Hierarchical cluster dendrogram of vessel morphology.  Tumour regions have been 
replaced with relative cancer cell motility metric on a white to red scale.  White 
represents no motile cancer cells and red represents high cancer cell motility with > 
120 motile cancer cells per sqmm of tumour.  Melanoma cell motility measured by 
counting the number of motile cells from a 20 minute intra-vital timelapse movie and 
averaging over the z-stack.  20 timelapse movies from 7 mice analysed. B. Graph 
showing average motile melanoma cells for tumour areas in sub-clusters A and B. Star 
indicates p-value <0.05 in t-test.  
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To determine which morphological, and in addition whether dynamic characteristics 
of the vasculature correlated with high melanoma cell motility, each parameter was 
correlated to melanoma cell motility using data from 20 tumour areas.  In addition, 
each morphometric and dynamic parameter was correlated with each other to look 
for interesting correlations between the characteristics.  The correlations used the 
Spearman co-efficient which is robust to non-parametric parameters.  The 
correlations showed potential links between melanoma cell motility and endothelial 
cell intra-vessel wall motility, endothelial bleb-like extra-luminal protrusions and 
variation in vessel width ( 
Table 11).  The correlation p-values are not corrected for the large number of 
correlations and due to the small sample size (20 data points) the correlations can 
only be considered as potential links between the two variables.  Interesting 
relationships from the matrix were subsequently plotted against each other (Figure 
7.10).  Endothelial intra-vessel wall motility and endothelial bleb-like extra-luminal 
protrusions both show correlation with melanoma cell motility, but also with each 
other.  To determine if there was a relationship between endothelial intra-vessel 
wall motility and endothelial bleb-like extra-luminal protrusions to melanoma cell 
motility, model fitting was carried out using both standard linear regression and 
robust linear regression, which is more robust to outliers.  Models that included 
various combinations of linear terms and quadratic and cubic interaction terms 
were considered.  Interaction terms suggest that the relationship between one 
interacting variable and the dependent variable is reliant on the second interacting 
variable.  Hypothesis tests using ANOVA were carried out to deduce which model 
is the most significant.  The model that fitted the data best is given by 
M = β0+ β1I + β2B +β3I
2B 
where M is the melanoma cell motility, I is the intra-vessel wall motility and B is the 
bleb-like extra-luminal protrusions. βs are fitted parameters.  The fitted model 
indicates that the effects between the two independent variables on melanoma cell 
motility are not additive, but that there is a cubic interaction between them. Hence 
these two variables may describe a permissive environment for melanoma motility. 
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The correlations suggested a link between endothelial cell intra-vessel wall motility 
and extra-luminal bleb-like protrusions ( 
Table 12).  Both protrusions and endothelial cell motility are driven by VEGF-A 
(Rousseau et al., 2000) (Gerhardt et al., 2003) and as both of these parameters 
correlate with melanoma cell motility, melanoma motility may be increased in 
regions of high VEGF-A (see Discussion for alternative hypotheses).  A further 
interesting point is that bleb-like and filopodia-like protrusions are negatively 
correlated.  This suggests that these distinct protrusions form in different 
microenvironments potentially as a result of different growth factor stimulation. 
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Variable One Variable Two Spearman Correlation 
Coefficient (Robust to 
non-Gaussian) 
Spearman 
Correlation p-
value 
Melanoma 
Cell Motility 
Intra-vessel Wall 
Motility 
0.59 0.006545 
Melanoma 
Cell Motility 
Extra Luminal 
Protrusions (Bleb-
like) 
0.55 0.01200 
Melanoma 
Cell Motility 
Variation in vessel 
width  
0.46 0.04423 
 
Table 11 Correlations between dynamic and morphological parameters and 
melanoma cell motility. 
Spearman correlations were performed for each variable against melanoma motility.  
Correlations with p-value <0.05 are shown.  No p-value correction for the number of 
correlations performed. 
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Variable 
One 
Variable Two Spearman Correlation 
Coefficient (Robust to non-
Gaussian) 
Spearman 
Correlation p-
value 
Intra-vessel 
Wall Motility 
Extra Luminal 
Protrusions (Bleb-
like) 
0.65 0.001942 
Extra 
Luminal 
Protrusions 
(Filopodia) 
Extra Luminal 
Protrusions (Bleb-
like) 
-0.56 0.009441 
Blunt Ends Sum of Extra 
Luminal 
Protrusions 
0.54 0.01384 
Extra 
Luminal 
Protrusions 
(Filopodia) 
Branch Points 0.51 0.02280 
Variation in 
vessel width 
Sum of Intra 
Luminal 
Protrusions 
0.49 0.02713 
 
Table 12 Correlation matrix for morphometric and dynamic parameters. 
Spearman correlations were performed for each dynamic and morphological variable 
against each other.  Correlations with p-value <0.05 are shown.  No p-value correction 
for the number of correlations performed. 
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Figure 7.10 Melanoma cell motility correlates with specific endothelial dynamic 
behaviour 
Graphs showing motile melanoma cells vs A. Endothelial cell intra-vessel wall motility, 
B. Endothelial cell bleb-like extra-luminal protrusions and C. Index of variation in vessel 
width.  Melanoma cell motility and dynamic behaviours measured in the same intra-
vital z-stack time-lapse movie and given as an average over the z-stack.  20 time-lapse 
movies from 7 mice analysed. 
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7.4 Sunitinib anti-angiogenic therapy decreases tumour 
growth but vascular response is heterogeneous in vivo 
7.4.1 Sunitinib decreases vascular density and tumour growth in the B16 
melanoma model 
Results outlined in the previous section indicated a correlation between vascular 
morphology and dynamics and melanoma cell motility.  Therefore Sunitinib, an anti-
angiogenic drug, was used to try and perturb the vasculature and look at the effects 
on melanoma cell motility.  B16 F2 melanoma cells were injected sub-cutaneously.  
When the tumour was palpable, 40 mg/kg of Sunitinib or DMSO vehicle control was 
administered daily by oral gavage.  During this time tumour length and width were 
measured using callipers and tumour volume was calculated.  Mice were treated 
for three to four days and then imaged immediately following a Sunitinib/DMSO 
injection.  After imaging, tumours were fixed in 10 % neutral buffered saline 
overnight and subjected to immunohistochemical staining to analyse vessel 
density. 
 
Treatment with 40 mg/kg Sunitinib treatment significantly decreased the vessel 
density of B16 F2 melanoma (Figure 7.11) confirming the anti-angiogenic 
capabilities of the drug.  Treatment also slowed the growth of sub-cutaneous B16 
melanomas and significantly reduced the increase in tumour volume during the 
treatment period (Figure 7.12).  
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Figure 7.11 Sunitinib decreases vessel density in B16 F2 melanoma. 
A. Representative immunohistochemical staining of vessels in DMSO vehicle control or 
40 mg/kg Sunitinib treated tumours. A subset of the tumours analysed in Figure 7.12  
B.  Graph showing tumour vessel area after 4 days treatment. Vessel area measured 
by immunohistochemical staining of paraffin fixed tumour sections using anti-
Endomucin and subsequent area analysis using Volocity software. 3 separate images 
analysed per tumour section and 4 tumours used for each treatment.  Star indicates p-
value of <0.05 in statistical t-test. Error bars show standard errors. 
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Figure 7.12 Sunitinib decreases B16 melanoma growth in vivo. 
A. Tumour growth for DMSO vehicle control tumours (black line) and Sunitinib treated 
tumours (red-line).  Tumours were treated from Day 10 when the tumour became 
palpable.  B. Change in tumour volume over the treatment period for DMSO vehicle 
control and Sunitinib treated tumours.  Tumour volume calculated from ½(length x 
width2) with 7 mice in each cohort. Star indicates p-value of <0.05.  Error bars show the 
standard error. 
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7.4.2 Sunitinib treatment does not affect B16 F2 melanoma cell motility in 
vivo 
To try to determine if there is a causal relationship between the vasculature and 
melanoma cell motility, the number of motile cells was determined in DMSO or 
Sunitinib treated tumours.  The number of motile cells in Sunitinib treated tumours 
was not significantly different to DMSO vehicle control tumours.  In addition the 
relationship between number of motile melanoma cells and vessel area did not 
differ between the treatments.  This suggests that at least in the relatively short-
term (three to four days) Sunitinib does not affect melanoma cell motility.  However, 
as discussed in the forthcoming sections, the response of the vasculature in 
regions image-able by intra-vital microscopy was not as expected.  Therefore it is 
difficult to comment on the link between vascular morphology and dynamics and 
melanoma cell motility. 
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Figure 7.13 Sunitinib does not affect melanoma cell motility. 
A. Number of motile cancer cells measured by intra-vital time-lapse imaging in DMSO 
vehicle control or Sunitinib treated tumours using a subset of the tumours analysed in 
Figure 7.12. Tumours treated for 3-4 days prior to imaging and immediately before 
imaging.  Each data point indicates a single movie.  NS indicates no significant 
difference in statistical t-test. Error bars show standard errors.  B. Plots of vessel 
density vs cancer cell motility for DMSO vehicle control tumours and Sunitinib treated 
tumours. Cancer cell motility and vessel density measured in the same intra-vital z-
stack time-lapse movie.  Cancer cell motility is given as an average over the z-stack.  
Vessel density was measured by thresholding green endothelial cell channel and is 
given as an average over the z-stack.  
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7.4.3 Vessels in the tumour margin are resistant to Sunitinib anti-
angiogenic therapy 
Time-lapse intra-vital movies of the vasculature after DMSO vehicle control or 
Sunitinib treatment enabled analysis of the response of tumour associated 
vasculture to anti-angiogenic treatment.  Although Sunitinib treatment significantly 
decreased vessel area and tumour growth, there was not a significant difference in 
dynamic behaviour on Sunitinib treatment.  However, there was a trend towards 
fewer protrusions, and less endothelial cell motility, whether within the vessels or 
distant to it (Figure 7.14). 
 
Previous data had shown distinct vasculature zones based on dynamics and 
morphology.  The response of the different zones to Sunitinib was assessed based 
on the number of endothelial cell protrusions.  This was used as a read-out of the 
angiogenic response because angiogenic factors are known to promote filopodia 
and tip-cell sprouting (Gerhardt et al., 2003).  Vessels in the tumour showed a 
significant decrease in endothelial cell protrusions on Sunitinib treatment (Figure 
7.15).  However, vessels in the two tumour margin zones, as well as vessels in the 
margin as a whole, did not show a significant difference in number of protrusions 
on Sunitinib treatment.  This suggests that vessels in the margin are still 
responding to angiogenic factors and exhibiting an angiogenic response, even in 
the presence of the anti-angiogenic drub Sunitinib.  It also explains why that when 
considering all vessels together there is no significant difference in the number of 
protrusions between DMSO and Sunitinib treated tumours. 
 
Immunohistochemistry revealed a decrease in tumour vessel area after Sunitinib 
treatment and this correlates with the decrease in protrusions in tumour vessels 
seen by intra-vital imaging.  A closer look at the immunohistochemical staining 
revealed similar Endomucin staining at the margins of both DMSO and Sunitinib 
treated tumours confirming these vessels may be resistant to Sunitinib (Figure 
7.16). 
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Figure 7.14 Quantification of endothelial cell dynamics in DMSO and Sunitinib 
treated tumours. 
A.  Extra and intra-lumenal protrusions, B. Endothelial cell intra-vessel wall motility  C. 
Endothelial cell motility distant to vessels. NS indicates no significant difference in 
statistical t-test. Endothelial cell dynamics measured using intra-vital timelapse 
imaging.  Quantification of at least 7 movies from 4 mice.  Error bars show standard 
errors. 
 
Chapter 7. Results 
 
273  
 
 
Figure 7.15 The tumour margin is resistant to Sunitinib anti-angiogenic therapy. 
Breakdown of endothelial cell protrusions based on vessel region. A Tumour regions, B 
immediate margin C. peripheral margin and D. Collation of margins.  Star indicates p-
value of <0.05 in statistical t-test and ns indicates no significant difference. 
Quantification of atleast 7 movies from 4 mice. Error bars show standard errors 
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Figure 7.16 Tumour margin vessels persist during Sunitinib treatment. 
Immunohistochemical staining of vessels in the margin using anti-Endomucin in DMSO 
vehicle control and Sunitinib treated tumours.  Scale bar indicates 100 μm. 
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One prediction of the heterogeneous vascular response to Sunitinib is that the 
tumour cell response would also be heterogeneous.  Melanoma cells at the edge of 
the tumour may still be receiving oxygen and nutrients due to the resistant vessels 
in the margin.  To test this prediction, DMSO vehicle control and Sunitinib treated 
tumours were stained for cleaved Caspase-3 to show melanoma cells undergoing 
apoptosis.  Quantification of the area of cleaved Caspase-3 staining demonstrated 
a decrease in melanoma cell apoptosis at the tumour edge in both DMSO and 
Sunitinib treated tumours.  However this was only significant in Sunitinib tumours 
(Figure 7.17).  In addition Sunitinib treated tumours showed a slight increase in 
apoptosis in the tumour centre when compared to DMSO vehicle control tumours, 
but apoptosis at the tumour edge was actually decreased in Sunitinib tumours 
(Figure 7.17).  This demonstrates that in Sunitinib treated tumours melanoma cells 
at the edge of the tumour are protected from apoptosis potentially due to the 
Sunitinib resistant vessels that are still able to provide oxygen and nutrients to the 
very outer parts of the tumour.  
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Figure 7.17 Heterogeneous melanoma response to Sunitinib. 
Immunohistichemical staining of cleaved Caspase 3 in A. DMSO vehicle control and B. 
Sunitinib treated tumours using a subset of the tumours analysed in Figure 7.12.  Scale 
bar indicates 250μm.  C. Caspase 3 signal area in tumour centre and tumour margin 
for DMSO vehicle control and Sunitinib treated tumours.  Immuno-histochemical 
staining of paraffin fixed tumour sections using anti-cleaved Caspase-3 and 
subsequent area analysis using Velocity software. Tumour edge defined as outer 
200μm of tumour area as visible by hematoxylin and eosin staining.  Caspase 3 
staining area normalised to area of margin or tumour centre for individual section. 3 
separate images analysed per tumour section and 4 tumours used for each treatment.  
Star indicates p-value of <0.05 in statistical t-test. Error bars show standard errors. 
Chapter 7. Results 
 
277  
 
7.4.4 Tumour margins are enriched for stromal cells and have increased 
MMP activity 
Previous reports indicate that response to anti-angiogenic therapy may depend on 
the pericyte coverage of vessels (Bergers et al., 2003).  To investigate whether 
vessels in the margin had different pericyte coverage, tumours were stained for the 
pericyte markers NG2 and α-SMA.  There was little difference between pericyte 
staining in the tumour margin and tumour interior (Figure 7.18) suggesting that 
differences in response to Sunitinib were not as a result of pericyte coverage. 
 
Many different cell-types in the tumour can promote angiogenesis and a 
heterogeneous distribution may provide a reason for the heterogeneous vascular 
response to Sunitinib.  To test whether there was an increase in stromal cells at the 
tumour margins, B16 melanoma tumours were stained for a variety of stromal cell 
markers using immunohistochemistry.  Endomucin staining helped to highlight the 
tumour margin due to the increase in vessels at the very edge of the tumour.  F4/80 
staining showed a concurrent increase in macrophages at the tumour margin 
(Figure 7.19).  Additionally, the tumour margin was enriched for both CAFs 
indicated by α-SMA positive cells not associated with vessels, and T-lymphocytes 
(Figure 7.19).  Both CAFs and macrophages are known to be pro-angiogenic and 
so these stromal cells in the tumour margin may provide VEGFR-2 independent 
pro-angiogenic signals.  Alternatively, the sheer number of cells pro-angiogenic 
cells in the margin may result in a less effectual inhibition of angiogenesis by 
Sunitinib.   
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Figure 7.18 Vessels in the tumour margin and tumour interior have similar 
pericyte coverage. 
Immunohistochemical staining of vessels in tumour margin and interior.  Endomucin 
indicates presence of vessels and NG2 and α-SMA indicate extent of pericyte 
coverage.  Scale bar indicates 100μm. 
 
Chapter 7. Results 
 
279  
 
 
Figure 7.19 Stromal cells are enriched at the tumour margin. 
Immunohistochemical staining of B16 melanomas for various stromal cells.  
Endomucin indicates blood vessels.  F4/80 is a marker for macrophages. α-SMA is a 
marker for both pericytes and cancer-associated fibroblasts. CD3 is a marker for T-
lymphocytes.  Scale bar represents 250 μm. 
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In vivo pro-angiogenic growth-factors, such as VEGF-A, bind the ECM and a 
common mechanism of activation is cleavage by proteases (Lee et al., 2005).  
Stromal cells, including CAFs and macrophages, secrete proteases and for this 
reason the level of protease activity was investigated in the different vascular zones 
in vivo.  Protease activity was determined with MMPsense 680, an injectable probe 
that is only activated after protease cleavage.  MMPsense 680 was injected 6-8 
hours before imaging and activity in different vascular zones was compared with 
healthy vessels on the alternate flank to the tumour.  Very little fluorescence was 
detected in and around healthy vessels (Figure 7.20).  However, high levels of 
fluorescence were found around the tumour, particularly in the peripheral margin 
zone and to a lesser extent in the intermediate margin.  Some signal in the 
peripheral margin looked to be coming from phagocytic macrophages.  
Fluorescence signal dropped off in the tumour itself (Figure 7.20).  This suggests 
that there is increased protease activity in the margins and supports the notion that 
stromal cells in the margin provide angiogenic signals, potentially by activating 
ECM bound factors through protease function, to enable an angiogenic response 
even in the presence of Sunitinib. 
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Figure 7.20 Tumour margins have increased protease activity. 
Confocal images of different vascular zones showing protease activity.  Endothelial 
cells have green membrane marker, B16 F2 melanoma cells with red membrane 
marker and protease activity shown in purple using MMPsense 680.  Extent of the 
tumour indicated by white dashed line.  First tile and immediate margin images the 
scale bar represents 250 μm. Peripheral margin and healthy vessel images the scale 
bar represents 30 μm. 
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7.5 Longitudinal analysis of the tumour vasculature 
Intra-vital imaging of sub-cutaneous tumours using the skin-flap method is limited 
to one imaging session per tumour. For that reason, information regarding the 
development of the tumour vasculature over a number of days is lost.  Imaging 
windows enable day-after day imaging of the tumour microenvironment and may 
help to provide temporal links between the different vascular zones.  In 
collaboration with Dr Jacco van Rheenen in Utrecht, I set-up the use of imaging 
windows for repeated imaging of sub-sutaneous melanoma. 
 
Imaging windows were made of titanium, a lightweight yet strong metal that is 
biologically inert.  Coverslips were glued on to the window frame the day before 
implantation (Figure 7.21).  After the glue had set the window was placed in 70 % 
ethanol overnight for sterilisation.  On the day of surgery, mice were given an 
analgesic and anaesthetised.  A small incision was made lengthways in the skin of 
the animal, large enough to accommodate the window.  Sutures were made around 
the outside of the incision, similar to a running stitch, so that when the ends were 
pulled tight the skin was drawn into a groove on the outside of the window.  This 
left the skin snug to the window.  Immediately following the surgery, B16 F2 
melanoma spheroids in 100 % matrigel were injected underneath the window.  4-5 
days after surgery the tumour environment underneath the window was imaged 
every day until the tumour became too large.   
 
Immunohistochemical staining for stromal cell markers revealed a similar 
microenvironment in tumours grown under the window and those grown sub-
cutuaneously (Figure 7.22).  There was a slight increase in the F4/80 staining in 
window tumours but this may be due to the initial surgical procedure.  The staining 
showed fewer Endomucin positive vessels in the tumour bulk, however, window 
tumours were smaller than sub-cutaneous tumours when removed.  It is likely that 
this difference in tumour size accounted for the decrease in tumour vessels as 
endomucin staining was seen around the margins of window tumours. 
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Figure 7.21 Imaging window experimental outline. 
A. Schematic of experimental approach for window imaging experiments.  B.  Image 
showing window implanted in VE-CADherin:GFPCAAX mouse with B16 melanoma 
growing under window. 
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Figure 7.22 Sub-cutaneous tumours and tumours grown under imaging windows 
have similar stromal components. 
A.  Haemotoxylin and eosin staining of a window tumour to show orientation.  White 
box indicates area represented in B.  Scale bar represents 200 μm.  B.  
Immunohistochemical staining of a sub-cutaneous tumour or tumour grown under 
imaging window for various stromal cell markers.  F4/80 stains macrophages.  α-SMA 
marks cancer associated fibroblasts and pericytes.  Endomucin stains endothelial cells 
and CD3 marks T cells.  Scale bar indicates 150 μm. 
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7.5.1 Tumour angiogenesis in the B16 model occurs through a similar 
mechanism to developmental sprouting angiogenesis 
The tumour vasculature is thought to arise through at least two possible 
mechanisms, sprouting of new vessels from existing ones, or co-option of existing 
vessels in to tumour vessels (Carmeliet and Jain, 2011a).  Although intra-vital 
imaging using the skin-flap method revealed blunt-ended vessels pointing in the 
direction of the tumour suggestive of vascular sprouting, this was not conclusive.  
To further investigate whether tumour vessels in the B16 melanoma model arise 
from sprouting angiogenesis, window analysis of B16 melanoma in VE-
Cadherin:GFPCAAX, involving repeated imaging of the same tumour area, was 
performed.  The same vessels could be tracked over time and this showed a clear 
angiogenic front, consisting of tip cells, growing towards the tumour and eventually 
totally surrounding the tumour (Figure 7.23).  This indicates that sprouting 
angiogenesis is the main source of tumour-associated vasculature in B16 
melanoma.   
 
A more detailed analysis of angiogenic front progression and sprouting 
angiogenesis in B16 melanoma revealed striking similarities to developmental 
sprouting angiogenesis.  Sprouting vessels were seen to extend and grow and 
were frequently seen to branch (sprouts a,b and f in Figure 7.24).  Individual 
sprouts were measured and the rate of extension was calculated to be 186 μm per 
day (Figure 7.25).  Vessel branching is a response to angiogenic factors such as 
VEGF or FGF family members and helps to increase the vascular network 
(Carmeliet and Jain, 2011a).  Therefore vessel branching in the tumour 
environment increases the tumour volume receiving oxygen and other factors from 
the blood.  Anastomosis is the process of connection between two branches of the 
vascular network (Fantin et al., 2010).  It helps to form a functional vascular 
network by forming new circuits.  Anastomosis was also observed between two 
neighbouring nascent sprouts during tumour angiogenesis (Figure 7.26).  Similar to 
developmental anastomosis (Fantin et al., 2010), the tip cells protruded filopodia 
towards each other before fusion ( 
Figure 7.27).   
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Later steps in developmental vascular patterning include vessel remodelling and 
pruning.  Branch point migration, a form of vessel remodelling, was observed in the 
B16 melanoma tumour vasculature (Figure 7.28).  Vascular remodelling is thought 
to be dependent on blood flow (Lucitti et al., 2007) and the vessels undergoing 
remodelling were large vessels within the tumour.  Therefore it is likely that blood 
flow was present in these vessels.  The process of vessel pruning was difficult to 
observe and the evidence for it was not clear.  This was due to the fast growth of 
B16 melanoma cells and the fact that it occurs later during vascular patterning.  
After just a day in the late stages of tumour development, it was not clear whether 
the same z-sections were being imaged.  However, a noticeable decrease in vessel 
density, suggestive of vessel pruning, was observed. 
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Figure 7.23 Advance of the tip-cell rich angiogenic front towards the tumour. 
Image series of tumour-associated vasculature from days 6 to 12 after injection of 
melanoma cells.  The dotted line indicates the angiogenic front, note the advancement 
towards the tumour over time.  B16 F2 melanoma cells in red and endothelial cells 
shown in green.  Images show a region 1000 μm by 800 μm. 
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Figure 7.24 Sprout extension and branching during angiogenesis in B16 
melanoma. 
Image series of tumour-associated vasculature from days 8 to 11 after injection of 
melanoma cells.  Letters indicate the same sprout in sequential images.  Note the 
increasing length of sprouts over time and branching behaviour of sprouts a,b and f.  
B16 F2 melanoma cells in red and endothelial cells shown in green.  Images show an 
area 1.3 mm by 2 mm. 
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Figure 7.25.  Quantification of the rate of sprout extension. 
6 individual sprouts were tracked between 2 and 4 days and their length measured 
every day.  Individual data points show daily extension rate.  Error bars show the 
standard error of the mean. 
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Figure 7.26 Anastomosis between two neighbouring vessels. 
Image series of tumour-associated vasculature from days 8 to 11 after injection of 
melanoma cells.  “A” marks sites of vessel anastomosis. B16 F2 melanoma cells in red 
and endothelial cells shown in green.  Images show an area 1 mm by 1 mm. 
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Figure 7.27 Tip cells protrude filopodia towards each other before anastamosis. 
Confocal image of B16 F2 melanoma spheroids in a VE-Cadherin:GFPCAAX mouse.  
B16 F2 melanoma cells have red membrane marker.  Endothelial cells have green 
membrane marker.  Yellow is overlap of two channels and most likely represents auto-
fluorescent phagocytic cells.  Scale bar indicates 100 μm.  
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Figure 7.28 Vessel remodelling during tumour angiogenesis. 
A. Image series of tumour-associated vasculature on days 9 and 10 after injection of 
melanoma cells.  Arrow marks vessel branch that migrates during remodelling. B16 F2 
melanoma cells in red and endothelial cells shown in green.  B. Schematic of vessel 
remodelling shown in A.  Each vessel marked in separate colour. 
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7.5.2 Analysis of the temporal relationship between the immediate and 
peripheral margins 
Although skin-flap imaging of sub-cutaneous B16 melanoma revealed two distinct 
vascular zones in the margin, how they develop and the relationship between the 
two is unknown.  Window imaging of B16 melanoma was used to try and address 
these points.  It revealed the development of the immediate margin from existing 
vessels, a process that involved the emergence of tip cells, or blunt ended vessels, 
and extension of these nascent sprouts to form similar vascular morphologies to 
those seen in the immediate margin (Figure 7.29).   
 
A key characteristic of the peripheral margin is increased vessel tortuosity.  
Analysis of similar areas day after day revealed that tortuous vessels arose in 
areas that had previously exhibited a more sprouting morphology, similar to the 
immediate margin (Figure 7.30).  This suggested a progression from an immediate 
margin phenotype to a peripheral margin phenotype, implying that the peripheral 
margin may arise out of the immediate margin.  To further analyse this, the number 
of blunt ends and vessel tortuosity was quantified in the same area of marginal 
vessels for a number of days.  An increase in blunt ends was observed over time in 
the tumour margins (Figure 7.31) indicating the development of the immediate 
margin.  This was then followed by a decrease in blunt ends, potentially as the 
angiogenic response stabilised and sprouts extended.  However, the number of 
blunt ends was still comparable to those measured using the skin-flap method of 
imaging.  Vessel tortuosity also increased over time (Figure 7.31), although this 
increase was delayed by 1 or 2 days in comparison to the increase in blunt ends.  
This shows that characteristics of the peripheral margin develop later than 
characteristics of the immediate margin and hints that the peripheral margin may 
develop from areas that had once been immediate margins.  It is possible that as 
the angiogenic front progresses regions further from the front develop increased 
tortuosity and characteristics of the peripheral margin. 
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Figure 7.29 Emergence of the immediate margin. 
A. Image series of tumour-associated vasculature between days 4 and 9 after injection 
of melanoma cells.  Letters indicate the same B16 F2 melanoma spheroid in sequential 
images.  Note the increasing number of tip cells over time.  B16 F2 melanoma cells in 
red and endothelial cells shown in green.  Images show an area 1.5 mm by 1.6 mm. 
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Figure 7.30 Margin vessels show an increase in tortuosity over time. 
A. Image series of tumour-associated vasculature between days 5 and 9 after injection 
of melanoma cells.  Letters indicate the same object in sequential images.  T indicates 
vessels with medium to high tortuosity.  B16 F2 melanoma cells in red and endothelial 
cells shown in green.  Images show an area 850 μm by 750 μm. 
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Figure 7.31  Increase in margin vessel tortuosity is delayed compared to the 
increase in number of blunt ends. 
Graphs showing number of blunt ends per vessel area and tortuosity of vessels in the 
tumour margins over time.  Each graph from a different tumour.  Individual data points 
are an average over the image stack for the day. 
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7.6 Chapter summary 
Intra-vital imaging of the tumour vasculature revealed heterogeneous vascular 
morphology and dynamics.  Two distinct vascular zones in the margin, named 
immediate margin and peripheral margin, were defined based on morphology and 
this also correlated with distinct dynamic endothelial cell behaviour.  Longitudinal 
analysis of the tumour vasculature using imaging windows revealed that the tumour 
vasculature in B16 melanoma stems from sprouting angiogenesis of existing 
vessels and proceeds with similar steps to developmental angiogenesis.  
Furthermore, day after day imaging of the same tumour environment suggested 
that the peripheral margin may arise from areas which previously had immediate 
margin characteristics, suggesting the two distinct vascular zones in the margin are 
temporally linked.  Melanoma cell motility, previously shown to be heterogeneous, 
correlated with aspects of vascular morphology and endothelial dynamics, in 
particular extra-lumenal bleb-like protrusions and endothelial intra-vessel wall 
motility.  The anti-angiogenic drug Sunitinib did not affect melanoma cell motility.  
However endothelial cell response to Sunitinib was heterogeneous and vessels in 
the tumour margin displayed resistance to Sunitinib anti-angiogenic therapy.  This 
correlated with an increase in stromal cells and protease activity in the margin.   
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Chapter 8. Discussion 
8.1 Chapter overview 
Many factors, intrinsic and extrinsic, influence melanoma motility in vivo.  Induction 
of motility in melanoma may be coupled to changes in gene expression, resulting in 
specific signalling pathways and gene expression patterns in motile melanoma 
cells.  The main section of this discussion will first address modes of motility in vivo 
and the contribution of the microenvironment on motility.  It will then address the 
regulation of gene expression in motile cells including the Notch, TGF-β and SRF 
pathways and chromatin mediated control of gene expression.  Later steps in the 
metastatic cascade and the vasculature in melanoma will then be discussed.  The 
final sections will discuss the broader relevance of this work to melanoma and 
clinical treatment. 
 
8.2 Melanoma motility and metastasis 
8.2.1 Melanoma behaviour is heterogeneous in vivo 
A benefit of intra-vital imaging is the possibility for analysis of cell to cell variation in 
behaviour and signalling.  Work in chapter 3 illustrates that motile behaviour of B16 
F2 melanoma is heterogeneous in vivo and that motility correlates with differences 
in signalling pathway activation.  Less than 10 % of B16 F2 melanoma cells are 
motile in vivo (Figure 3.2), a similar percentage to that found in murine breast 
cancer models (Giampieri et al., 2009).  B16 F2 cells also use similar modes of 
motility in vivo to those described previously.  More than 50 % of the motile cells 
use an amoeboid-like single cell mode of motility.  However, a significant fraction, 
30 %, use a streaming mode of motility.  The caveat to this quantification is that it is 
often difficult to categorise the mode of motility.  Singly motile cells often use the 
same path and, depending on their proximity, it can be difficult to determine if they 
are streaming or moving independently as single cells.  This can be compounded if 
non-labelled host cells, such as macrophages, are also present in the stream.  The 
difference between streaming cells and collectively motile cells is even more 
difficult to interpret as the main difference is the level of adhesion between cells.  
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Use of membrane-labelled cells, as in chapter 3, helps to ascertain whether the 
cells are in contact, however, the nature of the contacts is unknown.  Therefore 
work in this thesis to investigate signalling in different modes of motility considers 
streaming and collective motility together. 
 
Despite the difficulties in determing between modes of motility, streaming most 
likely represents a distinct mechanism of motility as the work in chapter 3 shows 
differences in the activation of TGF-β and Notch signalling pathways between 
single and streaming cells (discussed later).  Streaming cells also appear faster 
than singly motile cells and may be following pre-generated tracks in the ECM, 
potentially made by fibroblasts, as illustrated by in vitro studies (Gaggioli et al., 
2007).  Occasionally multiple streams of cells were observed travelling in the same 
direction, possibly as a result of interstitial flow.  Indeed, interstitial flow can 
increase the metastatic potential of melanoma cells and can direct cancer cell 
motility in a CCR7 dependent manner (Shields et al., 2007). 
 
8.2.1.1 Microenvironment contribution to melanoma motility 
The microenvironment may contribute to cancer cell motility and heterogeneity in 
motility through paracrine signalling, stromal cell ECM remodelling and other 
mechanisms to create a permissive environment for motility.  Imaging of melanoma 
cells together with the blood vasculature enabled analysis of morphological and 
dynamic features of endothelial cells that correlate with melanoma cell motility.  
Unlike previous reports, data in chapter 7 shows that cancer cell motility is not 
increased in areas with increased vessel density (Figure 7.8).  However, my work 
hints that melanoma cell motility is high in areas where endothelial cells show 
dynamic bleb-like protrusions, migrate within vessel walls and the vessels have 
increased variation in width (Figure 7.10).  In some cases of endothelial bleb-like 
protrusions, I found autofluorescent signal, believed to be from macrophages, 
adjacent to the vessel.  Previous reports have shown that peri-vascular 
macrophages attract cancer cells and are associated with sites of intravasation 
(Wyckoff et al., 2007).  As I observed increased melanoma motility in areas with 
endothelial bleb-like protrusions, this is consistent with a link between increased 
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melanoma motility, endothelial bleb-like protrusions and peri-vascular 
macrophages. 
 
The endothelial behaviours associated with melanoma motility, described in 
chapter 7, may indicate low pericyte coverage, as pericytes act to maintain 
endothelial cell quiescence and may impose a structure and hence limit the vessel 
width.  Therefore, areas with low vessel pericyte coverage may have increased 
melanoma motility.  The quantitative analysis of stromal components and cancer 
cell motility, such as described in this thesis, should help to describe a permissive 
environment for cancer cell motility. 
 
8.2.2 Regulation of gene expression in motile melanoma cells 
8.2.2.1 TGF-β, SRF and Notch signalling is heterogeneous and associated 
with motility 
In addition to a general description of motility, I took a more targeted approach to 
investigate the regulation of gene expression in motile cells.  Work in chapter 3 
shows that singly motile B16 F2 melanoma cells in vivo have increased activation 
of Notch, TGF-β and SRF signalling as assessed by transcriptional reporters.  
Consistent with previous work showing that the motile cells in B16 melanoma have 
decreased pigment (Pinner et al., 2009), Notch, TGF-β and SRF signalling are 
mutually exclusive with pigment levels (Chapter 3).  Streaming cells have increased 
activation of SRF signalling but do not show increased TGF-β or Notch signalling 
(Chapter 3).  This is interesting as it suggests that different pathways control the 
different modes of motility.  In addition, it implies that there may be mechanistic 
differences between single cell motility and streaming and that streaming cells are 
not just adjacent single cells following a similar track or chemokine gradient.  SRF 
signalling may be increased in both singly motile and streaming cells as a response 
to changes in the G-/F-actin ratio.  Actin polymerisation is likely to occur in both 
forms of motility, which would subsequently reduce the G-actin concentration 
releasing MRTF to accumulate in the nucleus and activate SRF dependent 
transcription. 
 
Chapter 8. Discussion 
 
301  
 
The data in chapter 3, showing that TGF-β signalling is increased in singly motile 
but not streaming cells, is consistent with previous work in the B16 model.  Pinner 
et al showed that TGF-β2 induces motility in vitro and hypothesised that TGF-β 
induces motility and decreases pigment of cells in vivo (Pinner et al., 2009).  The 
work by Pinner et al showed that the less pigmented cells, which are enriched for 
motile cells, had increased TGF-β2 expression, suggesting an autocrine 
mechanism for TGF-β induced motility (Pinner et al., 2009).  A similar study using 
intra-vital imaging of TGF-β reporters in breast cancer showed that TGF-β induces 
single cell motility in vivo (Giampieri et al., 2009).  This, together with my work, 
suggests that TGF-β may have a wider role in promoting single cell motility of 
cancer cells. 
 
In contrast to TGF-β signalling, work in chapter 3 shows that SRF signalling is 
increased in both the singly motile and streaming cells.  SRF has previously been 
shown to be required for B16 motility in vivo (Medjkane et al., 2009).  The earlier 
experiments required long-term MRTF-A depletion, which decreases expression of 
important actin regulators including actin itself.  Therefore there are two possibilities 
for the role of SRF in motility: 
1. Cells with high SRF signalling may be motile because SRF signalling is 
required for sufficient expression of actin regulators.   
2. SRF signalling may be activated during the induction of motility, due to the 
changes in the G-/F-actin ratio, and SRF signalling may be needed for 
maintenance of motility. 
 
Chapter 3 shows that some non-motile cells have high SRF-dependent 
transcription suggesting SRF signalling is not a consequence of motility.  However, 
given the half-life of GFP (~24 hours) it is not possible to rule out that these non-
motile, SRF high cells were motile previous to imaging (the kinetic limitations of 
reporters are discussed later).  Therefore it is difficult to determine whether SRF 
signalling is activated during or prior to motility. 
 
Although Notch is up-regulated in singly motile cells (Figure 3.7), further analysis in 
chapter 4 suggested that Notch is not sufficient for motility, as driving Notch 
signalling through expression of NICD does not increase the number of motile cells 
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in vivo (Figure 4.4).  This is in contrast to previous in vitro studies showing that 
Notch signalling increases motility of melanocytes (Pinnix et al., 2009).  Perhaps 
Notch signalling in melanoma does not increase motility because expression of the 
relevant target genes is already increased compared to melanocytes.  However, 
my analysis of motile cells after NICD expression does not address whether Notch 
signalling is required for motility.  Further loss of function analysis, for example 
using γ-secretase inhibitors or expression of dominant-negative MAML, could 
address this point.  If Notch signalling is not required for motility in vivo it may be 
co-activated with motility, indeed TGF-β has been shown to induce HES-1 
expression in a NICD dependent manner (Blokzijl et al., 2003).  This may explain 
the decrease in pigment observed in motile cells as expression of NICD was 
sufficient to decrease pigment in vivo (Figure 4.2).   
 
Chapter 3 showed using individual clonal reporters that Notch, TGF-β and SRF 
signalling is increased in motile cells.  However, it did not address whether the 
signalling pathways were co-activated or the relationship between cells with active 
Notch, TGF-β or SRF signalling.  Combinatorial reporter cell-lines, showing 
activation of more than one pathway, for example both TGF-β and SRF signalling, 
would help to address if activation of more than one of these pathways is required 
for motility. 
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Figure 8.1 Model of heterogeneity in melanoma in vivo. 
Notch, TGF-β and SRF signalling is heterogeneous in vivo and increased in the motile 
cell population.  The Notch high population can promote metastasis in a non-cell 
autonomous manner potentially through effects on tumour endothelium.  EZH2 
expression levels are also heterogeneous in vivo and EZH2 positively regulates 
metastasis.   
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8.2.2.2 EZH2 expression is heterogeneous in vivo and increased EZH2 
expression may be associated with the motile state 
Work described in chapter 6 shows that expression of EZH2, a PRC2 Histone 
methyltransferase, is heterogeneous in both murine and human melanoma (Figure 
6.2 and 6.3).  The proportion of EZH2 high cells is similar to the proportion of motile 
cells perhaps indicating an overlap of the two populations.  Bioinformatic analysis in 
chapter 5 (discussed later) provides further support that EZH2 may be associated 
with the motile state as EZH2 is co-regulated with Notch signalling and it may 
positively regulate the genes associated with the motile B16 population.   
 
Heterogeneity in chromatin modifying enzymes has previously been described in 
melanoma.  Reports have shown that expression of the JARID1B histone 
demethylase is heterogeneous with around 10 % of cells showing high JARID1B 
expression (Roesch et al., 2005) (Roesch et al., 2010).  The JARID1B positive cells 
were shown to proliferate slowly and be important for maintainance of melanoma 
growth (Roesch et al., 2010).  The work in chapter 6 describes an EZH2 high 
population of cells also around 10 % of the total, so it is interesting to speculate 
whether JARID1B levels would also be elevated in these cells.  I propose that the 
EZH2 high population in melanoma is more motile, however JARID1B was not up-
regulated in the motile cell population, and JARID1B siRNA knockdown had no 
effect on B16 F2 cell morphology.  This suggests that JARID1B is not implicated in 
motility and perhaps that the EZH2 and JARID1B population do not overlap.  It is 
interesting to note that the slow-cycling JARID1B positive population that maintains 
melanoma growth is reported to have increased expression of Notch targets 
(Roesch et al., 2010).  Therefore the sub-populations of cells in melanoma may be 
overlapping. 
  
EZH2 and motility have not been formally linked in melanoma, but a number of 
reports in other cancer types indicate a role for EZH2 in promoting cancer cell 
invasion and EMT (Ren et al., 2012) (Tong et al., 2012).  The next sections will 
discuss the links between EZH2 and melanoma cell motility. 
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8.2.2.2.1 PRC2 complex regulates cell morphology and motility in vitro 
Previously, a single publication had shown that EZH2 may control actin 
polymerisation (Su et al., 2005).  Work in chapter 6 shows that depletion of EZH2 
and other PRC2 components, such as Jarid2, in B16 F2 cells induces a flat cell 
phenotype with an increase in cell area (Figure 6.5 and 6.7).  Changes in cell 
morphology are likely to require changes in the actin cytoskeleton and so this 
provides additional evidence for EZH2-dependent regulation of the actin 
cytoskeleton.  Further investigation into the cytoskeletal associated changes 
showed that PRC2 components regulate cell morphology through regulating 
phosphorylation of the ERM proteins Ezrin and Radixin (Figure 6.10 and Figure 
6.13).  Intriguingly, depletion of the PRC1 complex member BMI-1, does not have 
consistent effects on cell morphology, suggesting a PRC1 independent role for 
PRC2 in regulating cell morphology (Figure 6.8).  However, analysis of further 
PRC1 components would confirm this.  How PRC2 may regulate Ezrin and Radixin 
phosphorylation is unclear.  The microarray analysis outlined in chapter 6 did not 
show a change in any of the well established ERM kinases.  However, it did 
suggest a decrease in expression of Fascin, an actin bundling protein, on EZH2 
and Jarid2 depletion.  This could lead to effects on actin binding of the ERM 
proteins.  However, decreases in Fascin expression could not be detected at the 
protein level.  As PRC2 regulation of Ezrin and Radixin activation may be PRC1 
independent, this may suggest PRC1 independent control of gene expression or a 
cytoplasmic protein methylation mechanism similar to that suggested by Su et al.  
Given the important roles for the actin cytoskleleton and ERM proteins in cell 
motility, this suggests that EZH2 may regulate melanoma motility.  Indeed, 
timelapse analysis of B16 cells in vitro showed a decrease in cell speed on EZH2 
depletion and an increase in tail retraction problems (Figure 6.15).  The presence 
of tail retraction problems is consistent with an increase in cell tails observed in 
fixed cells after EZH2 depletion (Figure 6.5).  It would be interesting to perform 
timelapse analysis of EZH2 depleted cells rescued with constitutively active 
EzrinTD-GFP to test whether the tail retraction problem is associated with a loss of 
ERM protein activation.  
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8.2.2.2.2 EZH2 and Jarid2 regulate the genes associated with B16 motility 
In chapter 3, the heterogeneous activation of transcriptional-based reporters 
correlating with motility indicates different patterns of gene expression in the motile 
population compared to the tumour bulk.  The genes up-regulated in the B16 
population enriched for motile cells, were identified using the Brn2 promoter and 
Notch reporters (discussed later).  Overlap analysis described in chapter 6 
suggests that EZH2 positively regulates genes associated with motility whereas 
Jarid2 negatively regulates the genes associated with motility (Table 8).  Therefore, 
EZH2 may have a positive role in motility, in opposition to Jarid2.  This is consistent 
with the effects of EZH2 and Jarid2 on short-term lung colonisation as determined 
in an experimental lung metastasis assay (Figure 6.16).  How EZH2 positively 
regulates the genes associated with melanoma motility is unknown as EZH2 and 
PRC2 are classically considered to silence gene expression.  Perhaps EZH2 
indirectly regulates these genes through silencing a transcriptional repressor.  
Further experiments involving long-term silencing of EZH2 and Jarid2 are required 
to test their roles in motility in the primary tumour in vivo.  In addition, genome-wide 
CHIP experiments could establish if EZH2 is directly regulating the genes 
associated with motility and could explore the contrasting effects of EZH2 and 
Jarid2 in this system. 
 
8.2.2.2.3 EZH2 regulates changes in pigment associated with motility 
Previous work has shown that the motile cells in B16 melanoma are less pigmented 
than non-motile cells (Pinner et al., 2009).  Work in chapter 6 shows that EZH2 can 
control this phenotype change associated with motility, potentially through regulation of 
P protein expression, as loss of EZH2 increases pigment in an P protein dependent 
manner (Figure 6.24).  EZH2 depletion results in increased Oca2 mRNA levels (Figure 
6.22) and previous reports have shown an increase in pigmentation with increased P 
protein expression (Sitaram et al., 2009).  To confirm the role of P protein in EZH2 
dependent pigment regulation, CHIP could be performed to test if EZH2 directly binds 
the Oca2 promoter and inhibits expression.  The role of Jarid2 in pigment regulation is 
unclear due to different results from different siRNA tested.  Further siRNA oligos are 
required to determine if Jarid2 also regulates P protein expression and hence pigment. 
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8.2.2.3 Overlapping heterogeneity in signalling activation 
Analysis of the reporter cell-lines in chapter 3 shows that a small proportion of non-
motile cells exhibit activation of TGF-β, SRF or Notch signalling, implying that none 
of these pathways alone are sufficient for motility.  Perhaps, activation of more than 
one signalling pathway is required for motility and interplay between all three 
pathways and additional ones, e.g Brn2 expression, together with a permissive 
microenvironment, is required for motility.  Combinatorial reporter cell-lines which 
show activation status of more than one pathway would help to address this point.   
 
I propose that EZH2 high cells are more motile, and we know that TGF-β, Notch, 
SRF dependent transcription and Brn2 promoter activity are increased in the motile 
cell population, but how do they all interact?  The epigenetic status of a cell may 
dictate how responsive it is to external signals such as TGF-β or indeed it may 
dictate the target genes transcribed.  Alternatively, an increase in EZH2 may 
sensitise the cells to activity through the TGF-β, Notch, SRF and Brn-2 pathways 
hence promoting motility, or an altered cytoskeleton, due to changes in EZH2 
expression, may activate SRF and potentially Notch signalling. 
 
Given the heterogeneity in Notch, TGF-β and SRF signalling described in chapter 
3, it is interesting to think about how these populations with active signalling of 
various pathways overlap.  The use of combinatorial reporter cell-lines showing the 
signalling status of multiple pathways would help and may enable the 
characterisation of further sub-populations within melanoma 
 
8.2.2.4 Sources of heterogeneity in vivo  
The reporter cell-lines outlined in chapter 3 indicate heterogeneity in Notch, TGF-β 
and SRF signalling activation in vivo and immunohistochemistry shown in chapter 6 
indicates heterogeneous expression of EZH2.  As the cell-lines are clonal in origin, 
the heterogeneity does not result from genetic differences but potentially from the 
local microenvironment or differences in the differentiation hierarchy.  Another 
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possibility is heterogeneity in gene expression as a result of noise in gene 
transcription (Marusyk et al., 2012).   
 
Heterogeneity in TGF-β signalling has also been reported in murine breast cancer 
in vivo (Giampieri et al., 2009).  TGF-β is secreted by many cell-types in the tumour 
microenvironment, such as fibroblasts and macrophages, so proximity to stromal 
cells may dictate levels of TGF-β signalling.  It would be interesting to image the 
TGF-β reporter cell-line together with other stromal components in the 
microenvironment to look for a correlation between the stroma and signalling status 
of melanoma cells.  Attempts early in my PhD to GFP-tag TGF-β failed, but may 
have enabled visualisation of paracrine signalling in the tumour microenvironment.  
SRF signalling is responsive to external physical tension (Zhao et al., 2007b) and 
so the heterogeneity in SRF signalling observed in chapter 3 may reflect local 
differences in ECM stiffness and tension.   
 
Chapter 3 shows that Notch signalling is heterogeneously active in melanoma in 
vivo (Figure 3.6).  This may be a result of differences in differentiation state 
between cells as Notch is known to regulate differentiation (Andersson et al., 2011) 
and is required for maintainance of melanocyte stem cells (Moriyama et al., 2006).  
Notch signalling is also sufficient to confer a neural-crest like state on melanocytes 
suggesting that cells with active Notch in melanoma may be less differentiated 
(Zabierowski et al., 2011).  However, work in chapter 4 showed that driving Notch 
signalling by expression of NICD slightly increased the differentiation associated 
genes TYR, TYRP and DCT, indicating that Notch did not promote a less 
differentiated state of B16 F2 cells (Figure 4.3).  Therefore it is unlikely that 
heterogeneity in Notch signalling is a result of differences in differentiation.   
 
Notch signalling is activated through cell-cell interactions (Andersson et al., 2011) 
so heterogeneous Notch activation may arise from heterogeneous expression of 
Notch ligands.  Alternatively, Notch ligands are expressed by different stromal cell 
types, such as endothelial cells, so for example, melanoma cells adjacent to blood 
vessels cells could have increased Notch signalling.  However, imaging of the 
Notch reporter cell-line in the VE-Cadherin:GFPCAAX mice did not reveal an 
obvious relationship between the vasculature and cells with active Notch signalling.  
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Notch signalling is also activated by hypoxia (Sahlgren et al., 2008), so regions of 
hypoxic tumour cells may have increased Notch signalling.  However, the pattern of 
Notch reporter high cells in vivo does not seem to match this hypothesis.  
Therefore the origin of Notch heterogeneity is unclear.  It is also interesting that the 
proportion of GFP positive cells in the Notch reporter cell-line changed vastly 
between in vitro and in vivo cultures (Chapter 3).  It suggests that Notch signalling 
is high in vitro but low in vivo, this highlights the difference between cells in vitro 
and cells in the tumour microenvironment and the importance of in vivo studies.  
 
Work in chapter 6 shows that EZH2 expression is heterogeneous in both murine 
and human melanoma and that it is increased at the invasive tumour margins in 
murine melanoma (Figure 6.2 and Figure 6.3).  Previous work in an arthritis model 
has shown that EZH2 is up-regulated by the inflammatory cytokine, TNF-α, in 
synovial fibroblasts (Trenkmann et al., 2011).  TNF-α is expressed by both 
melanoma cells and stromal cells in the microenvironment (Balkwill, 2002) and 
work in chapter 7 shows that the tumour margins are enriched for stromal cells 
(Figure 7.19).  Therefore, areas such as the tumour margin, with increased stromal 
cells and TNF-α, may have increased melanoma EZH2 expression leading to 
heterogeneity in EZH2 levels.  If EZH2 promotes motility and TNF-α induces 
increased EZH2 expression, then TNF-α should promote melanoma cell motility.  
Indeed TNF-α been reported to promote melanoma invasion in vitro (Katerinaki et 
al., 2003).   
 
Alternatively, EZH2 is an E2F transcriptional target (Bracken et al., 2003), so cells 
with high E2F activity may drive high EZH2 expression.  Chapter 4 indicates that 
E2F2 is up-regulated in the B16 motile cell population (Table 4), which correlates 
with a high E2F, high EZH2 motile population.  E2F activity is cell-cycle state 
dependent and so the cell cycle may be an additional source of heterogeneity 
(Verona et al., 1997). 
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8.2.2.5 Approach to analyse signalling in motile melanoma cells in vivo 
The approach to characterise signalling pathways associated with melanoma 
motility uses transcription-based reporter cell-lines, which depends heavily on the 
reliability of the reporter construct and subsequent cell-lines.  It is difficult to 
absolutely exclude that reporter promoters respond to other signals.  Preferably, 
multiple clones would be tested for each reporter cell-line, however, I only obtained 
one responsive Notch reporter clone.  A drawback of the fluorescent transcriptional 
based reporters is the kinetics of response.  Ideally, the fluorescent protein of the 
reporter should have a similar half-life to endogenous transcriptional targets of the 
pathway, so that expression of the fluorescent protein mirrors expression of 
relevant targets.  GFP has quite a long half-life of about 24 hours, so its expression 
may not closely follow targets of the relevant pathways.  How well GFP expression 
mirrored transcriptional target expression was not addressed for any of the 
reporters in this thesis.  Therefore we cannot be certain that a cell with GFP 
reporter expression has pathway dependent transcription at that exact moment, but 
potentially the pathway has been active within the last 24 hours.  To further validate 
heterogeneity in signalling of the SRF and TGF-β pathways I would perform 
immunohistochemical staining of the endogeneous transcription factors, in a similar 
manner to the NICD staining in Figure 3.6.  In addition, imaging fusion proteins of 
SMAD2 and MAL (MRTF-A) with fluorescent proteins in vivo would improve the 
kinetics of the reporter and would allow determination of transcription factor 
localisation and hence activity, in motile versus non-motile cells. 
 
8.2.3 Investigating the gene signature of motile cells 
Although the transcriptional reporters used in chapter 3 suggest a different 
transcriptional program of motile cells, they only report on a single signalling 
pathway.  Chapter 5 describes the genome-wide approach to analyse gene 
transcriptional programs associated with melanoma motility and will be discussed 
in this section.  The Notch reporter from chapter 3 and a Brn2 promoter reporter 
developed in Pinner et al were used to purify the B16 F2 population enriched for 
motile cells.  Subsequent microarray analysis enabled the derivation of a gene 
signature associated with motile cells (Chapter 5).   
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Analysis of the Brn2 promoter and Notch reporter microarrays revealed significant 
overlap between the high Brn2 promoter activity population and Notch high 
population, resulting in around 70 genes up-regulated in both populations.  Having 
confirmed that the high Brn2 promoter activity population did not have an increase 
in Notch signalling and Notch targets, these genes were assumed to overlap due to 
similar cell phenotypes and hence were used to define a gene signature associated 
with motile cells. The geneset enrichment analysis also showed a number of 
genesets enriched in both the high Brn2 promoter activity population and Notch 
reporter high population, such as genes up-regulated in melanoma patients that 
had distant metastasis within 4 years compared to patients that did not.  Although 
there was statistically significant overlap, the genes up-regulated in the high Brn2 
promoter activity population and Notch reporter high population were not identical.  
This could be because the Notch reporter cells were purified in vitro and so the 
cells were under different conditions to the Brn2 promoter reporter cells purified 
from the tumour environment.  In addition, data in chapter 3 shows that the 
proportion of cells in the Notch reporter high population is much larger in vitro and 
so the population in vivo may only be a subset and hence only have certain genes 
of the Notch reporter high list up-regulated.  Additionally, although these 
populations are enriched for motile cells, chapter 3 shows the presence of non-
motile Notch reporter high cells.  These cells contribute to the analysed population 
and may result in the identification of genes that are not co-regulated with motility 
and hence not present in both lists.  The acquisition of motility may not require the 
same gene expression changes each time.  Instead, activation of a core gene 
expression network may be required together with additional inputs, which may 
differ.  These additional inputs may come from the microenvironment and depend 
upon the local composition. 
  
Surprisingly, a number of genes regulating the cell-cycle, especially cytokinesis and 
spindle assembly were up-regulated in motile cells (Table 4).  However, this is not 
too dissimilar to previous expression analysis of the motile cell population of breast 
cancer cells collected by an in vivo chemotactic assay.   In motile breast cancer 
cells more than half of the differentially regulated genes were associated with the 
cell-cycle (Goswami et al., 2004).   
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There are a number of similarities between the genes up-regulated in the motile 
B16 F2 cells outlined in chapter 5 and previously identified genes up-regulated in 
the motile breast cancer cell population.  Geneset enrichment analysis in chapter 5 
revealed that B-Myb targets are enriched in the genes up-regulated in motile 
melanoma cells (Table 6).  B-Myb is also up-regulated in the motile cell population 
of breast cancer (Goswami et al., 2004).  Geneset enrichment analysis also 
revealed that genes positively regulated by EZH2 in prostate cancer are enriched in 
the B16 motile cell population.  Further analysis in melanoma described in chapter 
6 also points to EZH2 having a positive role in promoting motility (discussed 
earlier).  This is consistent with the other PRC2 components EZH1 and EED being 
up-regulated in the motile cell population of breast cancer (Goswami et al., 2004).  
Genes co-regulated with BRCA2 are enriched in the motile B16 population (Table 
6) and BRCA2 is itself up-regulated in the breast cancer motile cell population 
(Goswami et al., 2004).   
 
Kinesins are up-regulated in the motile population of both B16 F2 melanoma and 
breast cancer.  KIF2C (also known as MCAK) and KIF23 (also known as MKLP1) 
are up-regulated in the motile B16 population (Table 4).  Interestingly previous 
reports show that KIF2C is over-expressed in a number of human tumours and is 
associated with lymph-node metastasis and poor prognosis in colorectal cancer 
(Ishikawa et al., 2008).  Furthermore, overexpression of KIF2C in gastric cancer 
cells increases motility (Nakamura et al., 2007).  Therefore the reporter cell-line 
approach described in chapter 5 to identify genes up-regulated in motile cells in 
melanoma seems to have similar results to both previous reports identifying genes 
up-regulated in motile breast cancer cells and wider analyses of metastasis.  This 
helps to validate the approach taken in this thesis to identify novel genes 
associated with motility and metastasis. 
 
Due to the large proportion of genes involved in cell cycle control in the B16 F2 
motile cell gene signature (Table 4 and Table 5), it is interesting to speculate that 
melanoma cell motility is dependent on the cell cycle.  During development, neural 
crest cells synchronously delaminate and migrate in S-phase and migration can be 
blocked by blocking the G1/S transition (Burstyn-Cohen and Kalcheim, 2002).  As 
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melanocytes arise from the neural crest, aspects of neural crest migration 
regulation may still remain in melanoma cells.  A number of the genes increased in 
the motile cell population identified in chapter 5 regulate cytokinesis (Table 4).  As 
cytokinesis requires Kinesins and localised control of the actomyosin network, 
regulators of cytokinesis may also be controlling actomyosin during amoeboid-like 
motility in vivo. 
 
8.2.3.1 Approach to derive a gene signature associated with melanoma 
motility 
The gene signature associated with the B16 motile cell population described in 
chapter 5 was derived from the overlap of genes up-regulated in the high Brn2 
promoter activity population and Notch reporter high population.  The Notch high 
population was purified from in vitro culture, which is not ideal but in vivo 
purification did not yield enough cells.  Also only one sample of the Notch reporter 
was subject to microarray, compared to two samples of the Brn2 promoter reporter 
populations.  Work is ongoing to repeat the Notch reporter microarray and increase 
the strength of the analysis.  Despite these caveats, there was a surprising degree 
of overlap between the Notch and Brn2 promoter reporter cells.  Having shown the 
high Brn2 promoter activity population is not enriched in NICD targets (Figure 5.6), 
one can assume that the high Brn2 promoter activity and Notch high populations 
share a similar phenotype (increased motility) and subsequently gene expression 
pattern.  To further support the gene signature associated with the B16 F2 motile 
cell population, there is considerable overlap with a totally independent array 
performed in a different laboratory identifying MRTF-A targets (Table 7) (Medjkane 
et al., 2009).  Chapter 3 shows that MRTF dependent SRF signalling is increased 
in singly motile B16 cells and so the overlap between the gene signature 
associated with the B16 motile cell population and MRTF targets further validates 
the relevance of the approach.  
 
The majority of genes up-regulated in the B16 population enriched for motile cells 
have not been functionally validated.  Knockdown of the genes in an invasion 
assay would determine if they contributed to melanoma cell motility and invasion.  
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The kinesins CENPE and KIF2C are drug targets, some of which are in clinical 
trials (Rath and Kozielski, 2012). These drugs could be tested in vivo to determine 
if they reduce the number of motile B16 melanoma cells.  Furthermore, the 
potential regulators of the gene signature, such as B-Myb, identified by geneset 
enrichment analysis in chapter 5, should also be tested in invasion assays.  As the 
genes are up-regulated in the B16 motile cell population the protein expression 
should be heterogeneous.  Immunohistochemical staining of both mouse and 
human tumours would be able determine heterogeneity in expression and 
potentially highlight the relevance for human melanoma. 
 
8.2.4 SRF, TGF-β and EZH2 are associated with motility and metastasis in 
other melanoma models 
The work in this thesis characterising gene expression changes and signalling 
pathways associated with motile melanoma cells is confined to B16 F2 cells.  To 
investigate the relevance of the findings of this thesis to human melanoma motility 
and metastasis I have used publicly available microarray data and subsequent 
geneset enrichment analysis.  I will now present and discuss this analysis but 
stress that the original data is not my own.  
 
The A375 cell-line is derived from human melanoma and multiple sub-lines have 
been generated from the parental A375 P cells including the A375 M2 sub-line that 
is enriched for the more motile and metastatic cell population.  Geneset enrichment 
analysis indicates that TGF- β and MRTF-dependent SRF targets are enriched in 
the A375 M2 sub-line, compared to the parental line (Figure 8.2).  This is consistent 
with my data in chapter 3 showing an increase in activity of these pathways in 
motile murine melanoma cells.  Furthermore, similar to the results in murine 
melanoma presented in chapter 6, genes positively regulated by EZH2 and genes 
that co-vary with EZH2 are up-regulated in the A375 M2 sub-line compared to the 
parental population (Figure 8.2).  The consistency with my data from murine B16 
F2 cells suggests that SRF, TGF-β and EZH2 may have relevance for human 
melanoma.  This is also supported by my analysis of both murine and human 
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melanoma samples showing heterogeneous EZH2 expression (Figure 6.2 and 
Figure 6.3).   
 
The derivation of more metastatic sub-lines and subsequent gene expression 
analysis, as performed with the A375 P and M2 lines, documents stable changes 
associated with motility and metastasis.  Imaging of the SRF reporter cell-line in 
lymph-node metastases suggests that SRF signalling is up-regulated in motile cells 
and furthermore, is maintained in cells in metastases.  This maintenance of SRF 
signalling is consistent with the stable up-regulation of MRTF-dependent SRF 
targets in the more metastatic sub-line of A375 cells.  Geneset enrichment analysis 
indicated that Notch target genes are not up-regulated in the more motile and 
metastatic sub-line of A375 cells.  In addition, the genes up-regulated in the B16 
population enriched for motile cells are not up-regulated in the more motile and 
metastatic sub-line of A375 cells.  This could be because Notch signalling and 
regulation of the genes associated with motility is transient during induction of 
motility and metastasis.  
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Figure 8.2.  SRF, TGF-β and EZH2 regulated genes are enriched in the more 
motile and metastatic sub-line of A375 human melanoma cells. 
Geneset enrichment analysis using free-ware from The Broad Institute, using publicly 
available array data from A375 P and A375 M2 cell-lines grown on deformable 
Collagen gels (Sanz-Moreno et al., 2011).  The genesets used are MRTF dependent 
SRF targets in B16 cells, common TGF-β target genes, genes positively regulated by 
EZH2 in B16 cells (listed in appendix) and genes that co-vary with EZH2 in melanoma. 
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8.2.5 Differentiation state and melanoma motility 
Previous reports suggest that B16 melanoma motility and metastasis is associated 
with a less differentiated state (Gupta et al., 2005; Kameyama et al., 1990; Pinner 
et al., 2009).  Although the idea of a less differentiated, more motile state was very 
much at the forefront of my mind, my investigations do not reveal any further links 
between differentiation and melanoma cell motility.  Microarray analysis of the Brn2 
promoter reporter used in Pinner et al revealed that it is not a true differentiation 
reporter as there was little difference in differentiation markers between the reporter 
high and low populations.  However, it reports on some signalling pathways 
associated with differentiation. 
 
As Notch signalling is increased in the motile melanoma population and maintains 
melanocyte stem cells, I hypothesised that Notch maintains a less differentiated 
state and promotes motility.  However, as Notch neither increases motility nor 
decreases differentiation associated genes, this hypothesis was disproved.  
Despite this, Notch is sufficient to decrease pigment, suggesting that Notch may 
promote a less pigmented state unrelated to differentiation status. 
 
PRC2 silences differentiation associated genes in ES cells so I also hypothesised 
that EZH2 maintains cells in a less differentiated state to promote motility.  Work in 
chapter 6 shows that EZH2 transcript levels decrease on α-MSH mediated 
differentiation of B16 melanoma cells (Figure 6.17), consistent with data from the 
developing epidermis where EZH2 expression decreases with differentiation 
(Ezhkova et al., 2009).  Despite this, neither EZH2 nor Jarid2 depletion have 
significant effects on expression of the differentiation markers TYR, TYRP1 and 
DCT (Figure 6.20), suggesting that PRC2 levels do not dictate differentiation status 
of B16 melanoma cells.  Nonetheless, EZH2-mediated suppression of Oca2 
maintains EZH2 high cells in a less pigmented state. 
 
In chapter 5, geneset enrichment analysis supports the hypothesis that the motile 
cells are less differentiated, as genes associated with human and mouse ES cells 
were up-regulated in the B16 population enriched for motile cells (Table 6).  
However, genes associated with differentiation in melanoma did not change in 
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expression between populations enriched for motile or non-motile cells.  
Furthermore, geneset enrichment analysis suggested that transcription factors 
known to co-ordinate melanocyte differentiation, such as Pax-3, SOX-10 and MITF, 
did not regulate the genes associated with motile melanoma cells (data not shown).  
This potentially argues that there is little difference in the differentiation state of 
motile and non-motile melanoma cells. 
 
My work suggests that the motile cells in the B16 F2 melanoma model cannot 
simply be considered as a less differentiated melanocytic or melanoblast-like state.  
However, it is possible that increased EZH2 levels drive the cells into an altered 
differentiation state with some similarities to ES cells. 
 
8.2.6 The phenotype switching model to induce melanoma motility 
The phenotype switching model proposed by Hoek and Goding suggests that 
“phenotypic heterogeneity is driven by specific gene expression programs which 
are imposed by the cellular microenvironment rather than by the accumulation of 
genetic events” (Hoek and Goding, 2010).  Furthermore, it suggests the 
microenvironment potentiates switching (in either direction) between a proliferative 
MITF+/Brn2-, and migratory MITF-/Brn-2+, state.  My work highlights the 
importance of the microenvironment to gene expression and signalling 
heterogeneity as the reporter cell-lines used in chapter 3, which although clonal in 
origin, show heterogeneity in signalling and motile behaviour.  Therefore the work 
presented here supports the initial aspects of the phenotype switching model.   
 
The increased TGF-β signalling in singly motile cells observed in chapter 3 is also 
consistent with switching between proliferative and motile states as previous data 
from genome-wide melanoma cell-line analysis shows an increase in TGF-β targets 
associated with the motile phenotype (Hoek et al., 2006).  The role of Notch in 
phenotype switching is currently hypothetical and postulates that Notch signalling is 
increased in the motile state as Brn-2 has been shown to induce Notch signalling in 
neural progenitors (Castro et al., 2006).  Work in chapter 3 shows an increase in 
Notch signalling in motile B16 melanoma cells, which is consistent with a 
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concurrent increase in Notch signalling in the motile phenotype, although my work 
indicates that this is not sufficient for motility (Figure 4.4).  However, the relative 
abundance of cells with Brn-2 and Notch promoter activity is quite different as the 
Notch active population is small in vivo.  Co-staining of tumours for NICD, Brn2 and 
MITF would help to determine if Notch signalling was a characteristic of the 
Brn2+/MITF- phenotype.  
 
Geneset enrichment analysis of both the Brn2 promoter reporter and Notch 
reporter shows that MITF targets are not enriched in the populations enriched for 
non-motile cells or motile cells.  This is not consistent with the MITF+/Brn2- MITF-
/Brn2+ switching model (Hoek and Goding, 2010), which argues that MITF is a 
main regulator of the switch and that the non-invasive population should have 
increased MITF targets. 
 
Switching between the two states, Brn2+ and Brn2-, is thought to be quite stable 
and have a hierarchy.  Previous results have shown that Brn2+ cells are capable of 
producing Brn2+ and Brn2- cells in vivo but that Brn2- cells very rarely produce 
Brn2+ cells (Pinner et al., 2009).  The stability in phenotypes may be epigenetically 
regulated by EZH2 and PRC2, as EZH2 controls cell plasticity in a number of 
situations and epigenetic regulation is maintained over many cell generations 
(Prezioso and Orlando, 2011).  In the developing heart, EZH2 loss leads to 
hypoplasticity and impairment of EMT (Chen et al., 2012).  EZH2 may maintain 
cells in their current phenotypic state and I would hypothesise that increased EZH2 
maintains cells in the motile phenotype.  Overall, my work supports the role of the 
microenvironment in contributing to changes in phenotype and switching to a motile 
state.  It also raises interesting questions about the involvement of Notch and EZH2 
in the different phenotypes and switching between states. 
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8.2.7 Other stages of the metastatic process 
8.2.7.1 Notch signalling promotes metastasis through cell autonomous 
and non-cell autonomous mechanisms 
Subsequent to motility in the primary tumour, cancer cells intravasate into 
endothelial vessels, travel to secondary sites, extravasate and must survive and 
proliferate to form metastases.  In chapter 4, I investigated the role of Notch 
signalling in B16 melanoma metastasis as I had found it is increased in the motile 
cell population and previous reports had suggested Notch could increase 
metastasis (Liu et al., 2006).   
 
Data in chapter 4 shows that Notch signalling is not sufficient to promote motility in 
vivo but it increases the metastatic potential of B16 F2 cells.  Notch promotes 
spontaneous lymph-node metastasis in a non-cell autonomous manner as mice 
with tumours containing a mix of NICD and control cells had increased lymph-node 
metastases and the cells in the lymph-node were a 50:50 mix of control and NICD 
cells (Figure 4.6).  As the number of motile cells in mixed tumours was similar to 
control or NICD tumours, this suggests that changes to the microenvironment 
increase the ability of motile cells to metastasise.  Indeed, tumours containing 
NICD cells had an increase in blood vessel lumen size (Figure 4.9).  However, 
lymphatic metastasis likely occurs through the lymphatic system.  Unfortunately, 
staining of lymphatics using anti-podoplanin and LYVE-1 antibodies was not very 
successful.  Few lymphatic vessels were observed in the tumour mass, but there 
was increased staining around the tumour margins.  The margin staining looked to 
be non-specific, but was similar to the lymphoid-like stroma described previously 
for the B16 model (Shields et al., 2010).  Therefore I was unable to determine 
whether cells with active Notch signalling impacted the lymphatic endothelium.  
Given that tumours containing NICD cells had increased blood vessel lumen size, it 
is interesting to consider that if left longer, these tumours may show increased 
spontaneous lung metastasis.  
 
Consistent with previous data in other melanoma cell-lines, B16 F2 experimental 
lung metastasis was increased by active Notch signalling (Figure 4.10).  As Notch 
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signalling is increased in motile cells in vivo (Figure 3.7), active signalling in motile 
cells can also impact other steps in the metastatic process, even though it may not 
be sufficient for motility.  Microarray analysis of control versus NICD cells, 
described in chapter 4, suggests a number of possible reasons for the increase in 
metastasis.  Transcripts of the interferon regulated genes, Stat1, Ifitm3, Ifit3, Irf9 
and Ifi35 are all up-regulated greater than 1.5 times in the B16 F2 NICD-GFP cells.  
Interferon leads to an activation of Stat proteins by JAK kinases and a subsequent 
increase in Stat target genes (Stark and Darnell, 2012).  Previous studies have 
shown that B16 F1 cells have heterogeneous activation of Stat1 and cells with high 
Stat1 signalling have increased ability to colonise the lung (Khodarev et al., 2009).  
Furthermore, JAK kinases have been shown to induce actomyosin contractility in 
melanoma cells (Sanz-Moreno et al., 2011), which is important for short-term 
survival in the circulation and lung colonisation (Pinner and Sahai, 2008).  
Therefore the increase in Stat1 and interferon regulated genes on expression of 
NICD-GFP may explain the increase in lung colonisation seen in the B16 F2 NICD-
GFP cell-line in chapter 4. 
 
Mylk transcript levels were was also identified in chapter 4 as up-regulated in cells 
with increased Notch signalling. Actomyosin contractility is important for amoeboid 
cancer cell migration in vivo, extravasation and lung colonisation (Wyckoff et al., 
2006) (Pinner and Sahai, 2008).  Increased MYLK expression in the B16 F2 NICD-
GFP cells may lead to increased actomyosin contractility and help explain the 
increased ability to extravasate and colonise the lungs.  However, the increased 
MYLK would also be expected to increase amoeboid motility in the primary tumour, 
but this was not observed. 
 
The microarray analysis also indicated that Vegfb mRNA is up-regulated about 1.3 
times in the B16 F2 NICD-GFP cell-line relative to control.  VEGF-B is a ligand of 
VEGFR-1, a receptor expressed on endothelial cells, monocytes, and tumour 
associated macrophages (Fischer et al., 2008).  VEGFR-1 positive bone-marrow 
cells have been shown to initiate the pre-metastatic niche and promote metastasis 
(Kaplan et al., 2005).  Therefore increased VEGF-B secretion from the B16 F2 
NICD-GFP cells may increase the recruitment of VEGFR-1 positive bone-marrow 
cells to pre-metastatic sites, including the lymph-node, hence promoting 
Chapter 8. Discussion 
 
322  
 
metastasis.  The increase in lung colonisation seen by B16 F2 NICD-GFP cells in 
chapter 4 could be a result of a similar mechanism of recruitment of bone-marrow 
cells to the lung, which subsequently aid melanoma cell growth through paracrine 
interactions.  However, VEGFR-1 staining of sub-cutaneous tumours and lungs 
containing either B16 F2 control or NICD-GFP metastases did not reveal a 
difference in VEGFR-1 positive cell recruitment (data not shown).  This suggests 
that increased VEGF-B production by B16 F2 NICD-GFP cells does not act in a 
systemic way to increase metastasis, however, it does not rule out a paracrine 
effect on the vasculature.  VEGF-B is a member of the vascular endothelial growth 
factor family, however, it is unusual in that it has no activity under normal conditions 
and any activity it does have, is context dependent (Li et al., 2012).  It has a 
survival effect on both endothelial and neuronal cells (Li et al., 2008; Zhang et al., 
2009), so it is possible that increased VEGF-B expression in the B16 F2 NICD-GFP 
cells increases cell survival during lung colonisation.  Alternatively, VEGF-B may 
signal to the vasculature and, potentially through increased angiogenesis or 
paracrine interactions, lead to increased lung colonisation of B16 F2 NICD-GFP 
cells.  In addition the increase in vascular lumen size seen in tumours containing 
the B16 F2 NICD-GFP cells in chapter 4 may be a result of increased VEGF-B 
signalling.  
 
To determine if VEGF-B, MYLK or STAT promote lung metastasis, these proteins 
could be knocked down by siRNA and the cells used in short-term experimental 
lung colonisation assays.  Furthermore, to determine if they are required for Notch 
induced increase in lung metastasis, VEGF-B, MYLK or STAT could be knocked 
down in NICD cells and subject to experimental metastasis assays.  To further 
investigate the effect of NICD cells on the endothelium, sprouting angiogenesis and 
lymphangiogenesis assays could be performed in vitro in the presence of NICD or 
control cells.  This would determine if NICD cells had direct effects on endothelial 
sprouting or morphology. 
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8.2.7.2 EZH2 positively regulates metastasis 
Much of the hypothesis that EZH2 positively regulates melanoma motility is based 
on it’s role in lung colonisation and also it’s effects on motility in vitro.  Work in 
chapter 6 shows that loss of EZH2 decreases experimental metastasis whereas 
loss of Jarid2 has no effect (Figure 6.16).  This was surprising given that depletion 
of both EZH2 and Jarid2 results in a loss of Ezrin and Radixin phosporylation 
(Figure 6.10) and that Ezrin promotes metastasis (Hunter, 2004).  Therefore, ERM 
protein phosphorylation does not seem to affect metastatic potential of B16 F10 
cells.  However, phosphorylation of Moesin is not affected on PRC2 depletion and 
so Moesin may be compensating for loss of activation of the other ERM proteins.  
The observation that Jarid2 depletion does not affect metastasis suggests that 
PRC2 and EZH2 regulated genes but Jarid2 independent genes are the most likely 
to regulate metastatic potential of B16 melanoma cells.  EZH2 may promote 
metastasis through positive regulation of MCAM expression, as MCAM expression 
is decreased concurrent with decreased metastasis on EZH2 depletion (Figure 
6.26).  MCAM is an adhesion molecule whose increased expression is associated 
with metastasis in melanoma cells (Xie et al., 1997).  Decreased MCAM expression 
on EZH2 depletion may decrease B16 cell adhesion to endothelial cells on arrival 
to the lungs and hence decrease metastasis.  However, the mechanism of EZH2-
dependent MCAM regulation is unclear, as EZH2 is classically associated with 
gene silencing.  EZH2 may regulate MCAM indirectly by silencing a repressor of 
MCAM expression.   
 
8.2.8 Problems with siRNA mediated gene silencing 
Investigating the role of PRC2 components in melanoma motility, differentiation and 
metastasis relied heavily on siRNA mediated depletion of key PRC2 components.  
However, siRNA studies are sensitive to off-target effects of the siRNA.  This study 
encounters a number of problems associated with siRNA mediated depletion.  
Depletion of EZH2 with 3 different siRNA did not lead to the exact same phenotype 
with all three oligos.  Cells depleted with EZH2 siRNA #2 were much flatter, had a 
larger surface area and had actin cables at the cell periphery compared to cells 
depleted with EZH2 siRNA #1 and 4 which also had increased cell area, but to a 
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lesser extent, and had long tails (Figure 6.5).  This was a common problem as 
oligos silencing Suz12 and Jarid2 also resulted in slightly different phenotypes.  
The problem was accentuated in the analysis of the effects of Jarid2 on pigment to 
such a degree that no conclusion could be found (Figure 6.18).  In addition, one out 
of three oligos for both EZH2 and Jarid2 resulted in a vast increase in metastasis in 
contrast to the effects of the other two oligos (Figure 6.16).  In sections 6.8.3 and 
6.8.4 I attempted to utilise these problems, together with microarray analysis after 
different siRNA knockdown, to identify genes that correlated with various 
phenotypes such as pigment and metastasis.  This highlighted the role of P protein 
in the regulation of pigment and hinted that MCAM may regulate metastasis.  
Overall, the siRNA oligos which consistently gave the majority phenotype, such as 
EZH2 #1 and 4, were considered when drawing conclusions from the data.  Ideally, 
more siRNA oligos are required to test the role of Jarid2 in pigment and to confirm 
the roles of both EZH2 and Jarid2 in metastasis.  In addition, re-expression of 
siRNA resistant cDNA would help to confirm the roles of EZH2 and Jarid2 in the 
relevant phenotypes. 
 
8.3 Heterogeneity in the tumour vasculature 
In addition to analysis of the motile cell population in melanoma, this thesis 
describes investigations into the vasculature in the melanoma microenvironment, 
which will be discussed further in this section.  Intra-vital imaging of the tumour 
vasculature in melanoma, presented in chapter 7, revealed heterogeneity in 
vascular morphology and response to Sunitinib anti-angiogenic therapy.  Two 
morphologically and dynamically distinct vascular zones in the tumour margin were 
identified, the immediate margin, a region with increased branch points and blunt 
ends, and the peripheral margin, a region with increased tortuosity and variation in 
vessel width (section 7.2).  Chapter 7 also describes the use of imaging windows 
for long-term tracking of the tumour vasculature.  Vascularisation of the B16 
melanoma model was shown to mainly arise through sprouting angiogenesis, and 
involved many of the same steps as developmental angiogenesis, such as sprout 
formation, sprout elongation, anastomosis and potentially vascular remodelling 
(section 7.5.1).  Sprout formation in the tumour environment showed the greatest 
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differences to developmental angiogenesis as protrusions were not limited to the tip 
cell leading the sprout.  Interestingly, although the tumour was vascularised, there 
was higher vascular density around the tumour.  This has also been observed with 
B16 melanoma spheroids in vitro (personal communication, Holger Gerhardt).  
Perhaps the B16 melanoma is a dense environment that is difficult for endothelial 
cells to penetrate.  Long-term tracking also indicated that the peripheral tortuous 
margin may arise from immediate sprouting margin areas, as margin vessels 
initially showed an increase in blunt ends, followed by increased tortuosity (Figure 
7.31).  This suggests that the immediate and peripheral margins are temporally 
linked. 
 
The overall morphologies of tumour vessels described in chapter 7 are similar to 
previous reports showing that tumour vessels are tortuous, chaotic, often with large 
lumens and increased branching (Carmeliet and Jain, 2011b).  Heterogeneity in the 
tumour vasculature has been previously reported, however the analysis of vascular 
phenotypes was based on immunohistochemical sections (Nagy et al., 2010).  
Therefore comparison with the vascular morphologies described in chapter 7 is 
difficult.  The previous reports indicate that large, thin walled mother vessels are 
the first vessels to appear in tumours and that they arise from existing vessels by 
degradation of the basement membrane, pericyte detachment and vascular 
expansion.  However, my longitudinal imaging studies point towards the first 
tumour vessels arising from nascent spout growth.  Furthermore, the morphological 
analysis of the vessels described in chapter 7 suggests these vessels, created by 
nascent sprouting and characteristic of the immediate margin, are relatively 
“normal” (more so than the vessels in the peripheral margin) narrow vessels with a 
number of blunt ends and branch points.  This disputes the idea of large mother 
vessels as the first tumour associated vessels and highlights the power of imaging 
studies.  However, the differences could be dependent on the tumour type 
analysed. 
 
The previous analysis of tumour vessel heterogeneity also indicates that the initial 
mother vessels are transient and then evolve into various types of daughter vessels 
including capillaries, glomeruloid microvascular proliferations (GMPs) and vascular 
malformations (VMs) (Nagy et al., 2010).  The longitudinal analysis of tumour 
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vasculature in chapter 7 indicates that phenotypes associated with the peripheral 
margin vessels, such as vessel tortuosity, develop after phenotypes associated 
with the immediate margin.  Therefore the peripheral margin vessels may be 
somewhat similar to daughter vessels.  However, due to the different methods used 
to analyse the vasculature; intravital imaging vs immunohistochemistry, it is quite 
difficult to determine which type of daughter vessel the peripheral margin 
corresponds to.  Due to the increased tortuosity and chaotic nature of peripheral 
margin vessels, they most closely resemble GMPs. 
 
Although the different vessel morphologies and vascular zones described in 
chapter 7 do not easily correspond to previous reports of tumour vascular 
heterogeneity, the different vascular zones do correspond to previous reports 
describing vascular phenotypes dependent on availability and processing of VEGF-
A.  VEGF-A can bind the ECM and be cleaved by a subset of MMPs (Lee et al., 
2005).  Previous studies have indicated that expression of MMP cleavage resistant 
VEGF-A in tumours leads to highly branched narrow vessels, whereas expression 
of the cleaved form of VEGF-A leads to an enlargement of vessels (Lee et al., 
2005).  The enlarged vessel phenotype is similar to vessels found in the tortuous 
peripheral margin of melanomas and the increased branching and narrow vessels 
are reminiscent of vessels in the tumour and immediate melanoma margin.  Work 
in chapter 7 confirms that there is increased MMP activity in the margins indicating 
that the heterogeneity in vessel architecture may be as a result of differential 
VEGF-A cleavage. 
 
Time-lapse imaging of the tumour vasculature revealed interesting endothelial cell 
behaviour.  Endothelial cells were observed extruding bleb-like protrusions, 
however, typically endothelial cells are considered to respond to growth factors by 
producing filopodia (Gerhardt et al., 2003).  Interestingly, filopodia and bleb-like 
protrusions were both observed in vivo and correlation analysis suggested a 
negative correlation between the two behaviours (Figure 7.10).  Perhaps different 
environments or growth factors induce the different protrusions.  Bleb-like 
protrusions may be the initial events in another interesting tumour associated 
endothelial cell behaviour observed in vivo.  Endothelial cells were observed 
undergoing a rounded, amoeboid-like form of motility distant to tumour vessels 
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(Figure 7.6).  This may be similar to the Endothelial to mesenchymal transitions 
(EndMT) described during development and pathology (van Meeteren and ten 
Dijke, 2012).  In one movie (Supplemental movie 12), an endothelial cell extruded a 
bleb-like protrusion from the vessel wall and subsequently escaped the vessel 
using rounded amoeboid-like motility.  This is similar to events observed during 
zebrafish development when aortic endothelial cells contract to bend out of the 
aorta and subsequently migrate away from the vessel (Kissa and Herbomel, 2010).  
TGF-β has been shown to drive EndMT and as TGF-β signalling is increased in 
motile melanoma cells, endothelial and melanoma cells may be responding to the 
same signal to induce motility (van Meeteren and ten Dijke, 2012) 
 
Due to the links between endothelial behaviour, vessel morphology and melanoma 
cell motility (discussed earlier) tumours were treated with Sunitinib, a relatively 
broad receptor tyrosine kinase inhibitor with anti-angiogenic properties, in an 
attempt to perturb the vasculature (section 7.4).  However, the vasculature was not 
perturbed as expected.  Although vessel density and tumour growth was 
decreased, vessels in the tumour margin were resistant to Sunitinib and still 
displayed angiogenic protrusions (section 7.4).  This was concurrent with lower 
melanoma cell apoptosis in the margins compared to the tumour bulk (Figure 7.17).  
Although previous studies suggest that pericyte coverage may affect response to 
Sunitinib, there was no indication of differences in pericyte coverage between 
tumour and margin vessels (Figure 7.18).  Instead, margins had a higher density of 
stromal cells, such as macrophages and CAFs, compared to the tumour bulk 
(Figure 7.19).  These stromal cells may provide VEGFR independent pro-
angiogenic signals suggesting that the microenvironment may be a cause of the 
lack of response to anti-angiogenic therapies.  In vitro sprouting angiogenesis 
assays did not provide evidence for paracrine VEGFR independent pro-angiogenic 
signals between CAFs, macrophages and B16 melanoma cells (data not shown)  
However, they do not accurately recapitulate the tumour environment, for example, 
many angiogenic ligands bind the ECM and are released after MMP activity.  
Indeed MMP activity is increased in the tumour margins compared to the tumour 
bulk (Figure 7.20).  This suggests that increased MMP activity, together with 
increased stromal cells, may lead to increased availability of pro-angiogenic ligands 
at the margins resulting in vessel resistance to Sunitinib.   
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Interestingly, heterogeneity in response to anti-angiogenic therapy has been 
reported previously in a system to reproduce tumour-associated vasculature by 
over-expression of VEGF-A in vivo (Sitohy et al., 2011).  In this case, the later 
forming vessels such as vascular malformations, feeding arteries and draining 
veins were resistant to anti-VEGF therapy and the authors argue that a decrease in 
VEGFR-2 levels in these vessel types explains the independence to VEGF-A.  I 
tested this hypothesis by staining of B16 tumour sections for VEGFR-2, but found 
no difference in expression between vessels in the margin and tumour bulk, 
indicating that this is unlikely to be the reason for Sunitinib resistance in the margin. 
   
8.4 Tumour heterogeneity and implications 
My work has revealed signalling heterogeneity in murine melanoma in vivo.  Intra-
tumoural heterogeneity can result from intrinsic factors such as genetic differences.  
However, the clonal nature of the reporter cell-lines suggests that the heterogeneity 
may arise from the microenvironment, differences in differentiation state and noise 
in gene expression (Marusyk et al., 2012). In human tumours it is likely that a mix 
of all of these factors results in a complex heterogeneity in gene expression 
patterns over space and time.   
 
The implications of intra-tumour heterogeneity are readily observed in patient 
response to therapy.  Human tumours often have a small population of cells that 
are resistant to therapy and cancer stem cells have been reported to be resistant to 
standard therapies (Reya et al., 2001).  In addition, the different microenvironments 
within the same cancer may lead to different selective pressures within the same 
tumour and multiple resistant cell populations (Marusyk et al., 2012).  A further 
compounding factor with cancer therapy is that the drug needs to reach the cancer 
at an effective dose.  However, heterogeneity of the tumour vasculature, as 
described in this thesis, may result in poor drug delivery or heterogeneous drug 
delivery to the tumour. 
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Some of the genes identified in this study as up-regulated in the motile melanoma 
population are linked to drug resistance, suggesting that the motile state may also 
represent a more drug-resistant state (Eyler and Rich, 2008).  For example, Kif2c 
mRNA is up-regulated in motile B16 cells and its expression mediates resistance to 
the chemotherapeutic, paclitaxel (Ganguly et al., 2011).  Many other Kinesins are 
up-regulated in the B16 population enriched for motile cells and their increased 
expression is associated with docetaxel resistance (De et al., 2009).  Increased 
EZH2 expression is also associated with drug resistance and ovarian cancer cells 
resistant to cisplatin show EZH2 over-expression (Hu et al., 2010).  In addition, loss 
of EZH2 in pancreatic cancer cells sensitises the cells to the chemotherapeutics, 
doxorubicin and gemcitabine (Ougolkov et al., 2008).  Furthermore, heterogeneity 
in chromatin state and expression of the Histone demethylase JARID1A results in 
heterogeneity in drug response in non-small cell lung cancer (Sharma et al., 2010).   
 
Intra-tumour heterogeneity leads to interactions between the different populations 
in the tumour, which may further promote growth and metastasis (Marusyk and 
Polyak, 2010).  The work in this thesis describes heterogeneity in Notch signalling 
in B16 melanoma and further shows that heterogeneity in the status of the Notch 
pathway promotes lymph-node metastasis.  Although this is likely due to effects on 
the microenvironment, phenotypic heterogeneity in small cell lung cancer leads to 
increased metastasis through paracrine interactions between cell populations 
(Calbo et al., 2011).   
 
Heterogeneity is likely to be dynamic, with patterns of gene expression changing 
over time.  My work does not address dynamic heterogeneity in the primary 
tumour, however the combination of transcriptional reporter cell-lines and long-term 
imaging using imaging windows would start to address these issues.   
 
8.5 Concluding remarks 
This thesis covers investigation of gene expression regulation during melanoma 
motility in vivo and a study of the tumour vasculature in melanoma.  It finds that 
Notch, SRF and TGF-β signalling is heterogeneous in vivo and is increased in the 
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motile B16 F2 cell population.  Although Notch signalling is not sufficient for motility 
in vivo, it promotes metastasis through cell autonomous and non cell autonomous 
mechanisms.  Derivation of a gene-signature of the B16 F2 melanoma population 
enriched for motile cells suggests a role for the chromatin modifier EZH2, in 
regulation of motility.  Further analysis indicates that EZH2 also positively regulates 
melanoma metastasis.  Imaging of the vasculature in melanoma revealed 
morphological and dynamic heterogeneity, with the identification of two distinct 
vascular zones within the tumour margin.  Endothelial behaviours and vascular 
morphology were found to correlate with melanoma motility.  Endothelial bleb-like 
protrusions, endothelial cell motility and increased variation in vessel width 
correlate with melanoma motility and help to describe a permissive 
microenvironment for motility. 
 
This work highlights the involvement of cancer cell and microenvironmental 
heterogeneity in the clinically relevant problem of metastasis.  More investigation of 
genes in the gene-signature of the B16 F2 motile cell population may identify novel 
genes associated with motility and metastasis in vivo.  Furthermore, EZH2 and 
some of the genes up-regulated in the B16 population enriched for motile cells may 
provide therapeutic anti-invasion and metastasis targets for melanoma in the clinic. 
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Chapter 9. Appendix 
9.1 Notch targets 
Genes up-regulated >1.2 fold in B16 F2 NICD vs B16 F2 control cells 
 
Cck 
Mgll 
Usp18 
Ifitm3 
Gsta4 
Loc100038882 
Ifit3 
D12ertd647e 
Rsad2 
Lgals3bp 
Loc100048346 
Sgk2 
Irf9 
Fez1 
Cdkn1a 
Hs3st1 
Slc22a18 
Sspn 
Anxa11 
Dcxr 
Iigp2 
Irgm 
Stat1 
Ptp4a3 
Samd9l 
Ifi35 
Parp14 
Mgst1 
Ctsa 
Rpl7a 
Oas1g 
Mylk 
Pqlc3 
Sytl2 
Ddx24 
Phlda3 
Scotin 
Adh7 
Dennd2a 
Ptgds 
Trim21 
B2m 
Cpne4 
Hes1 
Pcbd2 
Ccng1 
Apobec1 
Ephx1 
Col4a1 
Entpd2 
Egfl7 
Insig2 
Scly 
Ubl7 
Pmm1 
C230021p08rik 
Ncald 
Trappc6a 
Pkia 
Mgat4b 
Gnpda1 
S100a1 
Pgpep1 
Eif2ak2 
Tead2 
Loc100048721 
Mrps12 
1810030n24rik 
E330034g19rik 
Bst2 
Pi4k2b 
Ssbp3 
Tmsb4x 
1500010j02rik 
Rpl22 
Ecm1 
Ddah1 
Smpd1 
Aaas 
Arl2 
Timp2 
1110008p14rik 
Agrn 
Itm2b 
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Nme4 
Flrt3 
Mcts1 
Capg 
Stx8 
Mrps6 
Ccdc53 
1500011h22rik 
Loc100045617 
Tmem9 
Pigp 
Sept8 
Rhox5 
0610006i08rik 
Sumo1 
Vegfb 
Ndufs4 
Nckipsd 
Prickle4 
Col4a2 
Tomm7 
Slc25a1 
Gsta2 
Cox6a2 
Mc1r 
Lmna 
Paqr6 
Rgl1 
Nol5a 
Prkaca 
Lhfpl2 
Fxyd5 
Mcoln2 
Sepw1 
Mras 
Pex2 
Cuedc2 
Sac3d1 
Acot1 
Stx3 
Smpdl3a 
1190007f08rik 
Gstm2 
Mlkl 
Leprel2 
Tceb1 
Ei24 
2810417h13rik 
Enc1 
Csrp1 
2310016c16rik 
Phpt1 
Txnip 
Endod1 
Dstn 
Bid 
Gsta1 
Trp53 
Atp6v1h 
Cyba 
Actr3 
Dci 
Cebpb 
Mrpl30 
X99384 
Ctsb 
1110058l19rik 
Josd2 
Apoa1bp 
Psme1 
Atp5d 
Mknk2 
Gpr137b 
Cdc42ep4 
Slc25a20 
Uchl3 
Haghl 
Oca2 
Tcfap2a 
Mrpl43 
Asna1 
Mrpl14 
Reep5 
Impa2 
Ddx25 
Ndufc1 
Tulp2 
Xrcc1 
Kdelr3 
Tbc1d2 
Stx7 
Eg436240 
Loc100044298 
Map3k11 
Psip1 
Gtse1 
Bckdk 
H2afx 
Laptm4a 
Agpat2 
Cd274 
Cetn4 
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Atp5l 
Loc100041500 
Tspan3 
Vps16 
Scand1 
1700023m03rik 
Ube2m 
Bace2 
Prelp 
C1qbp 
Pold4 
Cd59a 
Tk1 
Hist1h2bj 
Bcs1l 
Gnai2 
Sc4mol 
C230093n12rik 
1810049h13rik 
Taldo1 
Atp5g2 
Timp1 
5330431n19rik 
Marcks 
Cdk2 
Sumo2 
Ddx58 
Nagk 
Arsb 
Tmem25 
Rdh14 
Rbck1 
Ubl3 
Atp6v0d1 
Tmem179b 
Ndufb3 
Tst 
Cdca5 
Tpm3 
Mrps23 
Tspo 
Aldh3b1 
Tyrp1 
 
9.2 Brn2 promoter reporter high genes 
Genes up-regulated >1.2 fold in B16 mRFPCAAX population with high Brn2 
promoter activity. 
Lce3b 
Olfr441 
Olfr151 
Slc8a1 
Gm12669 
Bc003266 
Olfr676 
Olfr1238 
Eml5 
Vmn1r72 
Gal3st2 
Tcstv3 
Olfr435 
Olfr749 
Apol10a 
Rnf148 
Magea9 
Olfr295 
Olfr784 
Klk1b1 
Psmb11 
Olfr952 
Olfr38 
Slbp 
Vmn1r47 
Hsd3b3 
Olfr1252 
Olfr1154 
Olfr945 
Olfr111 
Ednrb 
Olfr776 
Ccl8 
Olfr231 
Lyve1 
Tas2r140 
Ifna13 
Olfr733 
Il22 
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Olfr1255 
Gbp4 
Olfr995 
Olfr97 
Otos 
D930046h04rik 
Olfr729 
Olfr519 
Olfr462 
Olfr285 
Olfr1165 
Olfr968 
Krtap16-8 
Cetn1 
9030203c11rik 
Taf9 
Olfr1188 
Olfr118 
Hist1h4h 
Gpr182 
Txn1 
Npl 
Oog2 
Tas2r129 
D3ertd751e 
Il11ra2 
Nusap1 
1700029p11rik 
Pdgfrb 
Hyls1 
Lmbr1 
1700010m22rik 
Olfr553 
Pdgfd 
9630013d21rik 
Neil3 
Gpr1 
Tmsb15b1-Tmsb15b2 
Olfr99 
Cstad 
Olfr1030 
Tuba8 
H2-Q6 
Olfr918 
1700019m22rik 
Casp4 
Olfr458 
Casp12 
Gm8979 
Sh3bp1 
Klk1b11 
Zfp474 
3110052m02rik 
Rab11b 
Olfr282 
Olfr1302 
Mrgpra3 
Kif11 
Olfr474 
Olfr136 
Tgtp1 
C79407 
Olfr659 
H2-T10 
5330416c01rik 
Olfr1396 
Klhl38 
Tdg 
Vmn1r62 
Cp 
Olfr68 
Zfp658 
Olfr433 
Fbxo5 
Psat1 
Speer3 
Magea4 
Prc1 
Zfp738 
Olfr895 
Olfr103 
Olfr530 
Rdh7 
Olfr702 
Gp5 
Stil 
Gcsh 
Mrfap1 
Vmn1r216 
Hist1h2ac 
Slc18a3 
Ak5 
Fam54a 
Tubb2a 
Olfr829 
Ifit1 
Olfr1383 
Klk1b9 
Il17rd 
Akr1b7 
Foxl1 
Kir3dl2 
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Olfr361 
Vmn1r18 
Aoc2 
Cdkn2c 
A930006j02rik 
6030452d12rik 
Olfr1339 
Gm3604 
Olfr657 
Hoxd3 
B3galt1 
Gm11428 
Esco2 
Gbp3 
Nhsl1 
Slc40a1 
Phxr4 
Olfr564 
Nfxl1 
Cdca5 
Fut2 
Olfr196 
Olfr13 
Hist1h2bp 
Defb20 
A630033h20rik 
Clec4d 
Pde7b 
Cetn4 
Vmn1r75 
Olfr684 
Spdya 
Prl7a2 
Gbp2 
Myoc 
Fgf21 
Olfr875 
F13a1 
Sln 
Mup21 
Ssx9 
Tas2r105 
Chek1 
Aurkb 
Cyct 
Hspb8 
Hist1h1t 
1500015o10rik 
B830004h01rik 
Top2a 
6720463m24rik 
Kif20b 
Olfr686 
8030498b09rik 
Plscr2 
Rad54l 
Olfr921 
Sult5a1 
Neto2 
Tex13a 
Trp53rk 
Sgol2 
A4galt 
Npff 
Lgals2 
Sp100 
Rdh5 
Cdca2 
Rab27b 
Fam71f1 
Raet1e 
Kir3dl1 
Fcna 
Olfr1208 
Fkbpl 
Gm4455 
Ankrd58 
Oas1a 
Olfr108 
Ncaph 
Olfr1009 
4631416l12rik 
Olfr1412 
Cep55 
Kbtbd3 
Adam34 
Wdr86 
Fbxo48 
Oasl2 
Ccne2 
Kif18a 
Olfr635 
Olfr849 
Ppp1r14a 
Spc25 
4930504o13rik 
5730577i03rik 
Calm5 
1700008p20rik 
Cdo1 
Dnajb7 
Zfp59 
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Rnasel 
Brip1 
Olfr297 
Af366264 
Nrgn 
Ocm 
Zfp74 
A130004g07rik 
Xpo7 
Uts2r 
Spdye4 
Atp6v0d2 
Incenp 
Gm4841 
Fam110c 
Hsd3b5 
Gstm6 
Igtp 
Ifi44 
Ccdc163 
Olfr776 
Mogat1 
Mrgprb4 
Olfr90 
Gm5111 
4921509c19rik 
1810019j16rik 
Rxfp3 
Gdap1l1 
Lbx1 
Gnat1 
Oasl1 
Serp2 
1700001g17rik 
Reps2 
Adam6a 
Klhl25 
Mrgprx1 
Obox5 
Igf1 
Defb50 
Vmn1r172 
Serpinb9d 
Lypd4 
Mx2 
Tk1 
Gk2 
Gm5105 
Ctf1 
Ube2t 
Wdr25 
Mybl1 
Kif23 
Tmem74 
Fcer1a 
Olfr792 
Marco 
Tuba1a 
Il9 
Olfr1163 
Smad9 
Sod3 
Msx1 
Abcc2 
H2-M1 
Mef2d 
Zfp101 
Diras2 
Pcdhb5 
Ucn3 
Ai836003 
Wdr65 
Dbil5 
Hist2h3c1 
4921517d21rik 
Dimt1 
Serpinb9f 
Olfr554 
Elfn2 
Fsd1l 
Gnrh1 
Folr2 
Zfp7 
Eif2c3 
Ubc 
Olfr1112 
Dyrk3 
Ensmust00000057700 
Il17d 
Olfr1323 
Mcts2 
Olfr194 
Prss23 
Gm3579 
C230066g23rik 
Pde4dip 
Lcat 
Ramp1 
Kif18b 
Opn1mw 
4930599n23rik 
Gsg2 
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Zfa 
Tas2r117 
A130066n16rik 
E130306d19rik 
Cdk1 
Mixl1 
Akr1c14 
Olfr1480 
Scgb3a1 
Larp7 
Hmox1 
Ccnb1 
Olfr347 
Gpr45 
Sgol1 
G2e3 
Cdc45 
Kctd12b 
2010111i01rik 
D17h6s56e-5 
Ncapd3 
F730047e07rik 
Olfr1202 
Hsd3b6 
9330175e14rik 
Ak033775 
Kif4 
Il25 
Nmbr 
Cenpe 
Rxfp4 
Cenpj 
5730590g19rik 
Folr4 
Slc7a9 
8430431k14rik 
Ubqlnl 
Olfr653 
Olfr235 
Vmn1r228 
Clec4g 
Tagap1 
Phospho1 
Prl5a1 
Tcfap2d 
Slc10a5 
E2f8 
9330175e14rik 
Casc5 
Zfp354b 
Hoxa11 
Fam83d 
Rad54b 
Gm9734 
5830403l16rik 
Lcn4 
Olfr486 
Cacnb4 
Actg2 
Fabp3 
Bc147361 
1700120k04rik 
Gm128 
Fam111a 
Prkg1 
Olfr669 
Dlx1 
Melk 
Ska1 
Adrb3 
Trim12 
Vmn2r60 
Foxc2 
Mlf1ip 
Amigo3 
1700001c19rik 
6030445d17rik 
Taf5 
Arf1 
Pmp22 
Pcdhb9 
Ear6 
Ercc6l 
Olfr801 
Olfr961 
2010003k11rik 
P2rx3 
Aurka 
Olfr493 
Grin3a 
A330049m08rik 
Trim59 
Gucy1b3 
Gas6 
9430031j16rik 
Hsfy2 
Ptgr1 
Kif2c 
Irf1 
Olfr821 
Gm5434 
Ppnr 
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Skint10 
Npr2 
Ndc80 
2610039c10rik 
Mastl 
Aspm 
Gsta3 
Epha5 
Rdh16 
4930422g04rik 
Olfr1214 
Cox8b 
Cenph 
H2afv 
Olfr1102 
Vmn1r35 
Serpina12 
Kif26b 
Ppil5 
Rhox11 
Rdh14 
Hist1h2be 
Wdr20b 
Dnajb3 
Cxcl17 
Cga 
Eu234013 
Pnliprp2 
Fam81a 
Olfr183 
Ubd 
Hsp90aa1 
A530079e22rik 
Best1 
Tusc5 
Olfr208 
Fkbp7 
Spata9 
Phlda2 
Gen1 
A230052g05rik 
Ckap2 
Zfp868 
1700007k13rik 
Ifi203 
Olfr649 
Nxt1 
Zfp846 
Rap1a 
Efna2 
Osbpl7 
Ptplad2 
Olfr199 
9330119m13rik 
Vsx1 
Chrm5 
Ccl5 
Cenpi 
Camk2n1 
4930432o21rik 
Rbm8a 
Olfr56 
Ctsg 
Paqr7 
Cenpc1 
B230340j04rik 
Ugt2b35 
Smarce1 
Rps18 
Hnrnpul2 
Kcna5 
Ankrd33b 
A330008l17rik 
Cyp3a41b 
Dyrk2 
H2-T9 
Rbm11 
Morn4 
Lrrtm1 
Ttk 
Cap2 
Nck1 
Dnajc2 
Crh 
Prim1 
Olfr247 
Rtp4 
D130058e03 
Smc2 
Cyp8b1 
Prr11 
Pxt1 
Olfr463 
Clec2g 
Psg22 
Apbh 
Enpep 
Fut1 
Gcfc1 
Tbcc 
Lrrc4c 
Rbbp5 
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Sord 
Prph 
Ckap2l 
Sac3d1 
Prdm15 
Gast 
Olfr1467 
Sftpc 
Zfp69 
Trpv3 
Morn5 
Gngt1 
Ccne1 
Gm4876 
9930104l06rik 
Semg1 
Olfr677 
Bub1b 
Fam123a 
Bc150970 
Lce1f 
Chrna3 
Unc13a 
Got1l1 
1700055d18rik 
Kcnc3 
Manbal 
Drd1a 
Kazald1 
Lingo4 
Gip 
Ubl4b 
Fam55b 
Xkr7 
2210012g02rik 
4833444g19rik 
Iqgap3 
Dscc1 
Kif15 
Sfrs8 
Ube2c 
Eri3 
Dbf4 
Pou3f2 
Olfr1104 
Flt3l 
Olfr938 
Gch1 
4932415g12rik 
Olfr1499 
Wnt5b 
Saa4 
Serpina7 
Htr6 
Cenpq 
Gpr84 
Adh7 
Bub3 
5031438a03rik 
Hist1h1a 
A730037c10rik 
Nlk 
9530091c08rik 
Tas2r134 
Gins1 
C130046b21rik 
Kif22 
4931417g12rik 
Kcna4 
Mageb3 
Rab3c 
Ccdc28a 
Pbk 
Cdca8 
Olfr102 
Glt28d2 
Casp7 
Zcchc7 
Atpaf1 
Rab33a 
Ifnz 
Bc147505 
Rpl39l 
Lin9 
Txndc12 
Snai1 
Copg2 
Pcdhb21 
Zfp783 
Vmn1r45 
Vamp5 
Ngf 
Chkb 
Cyp2c44 
Cyp4a12b 
Batf2 
Slc22a13 
Rad51 
Olfr652 
Tbrg3 
Magea2 
Hormad1 
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Rfwd3 
Cpsf4l 
Kdm4d 
Hsd11b1 
Haus6 
9330176c04rik 
Ankrd61 
Rapgef5 
Cit 
Gm5420 
Hes1 
Bc025446 
Fam178a 
Krt34 
Dclre1c 
Ppp2r3a 
Bcdin3d 
Gemin4 
Htr3a 
Pex11a 
Tctex1d1 
Nuf2 
Wdfy3 
Fbxw15 
A430057m04rik 
Apba1 
Myl4 
Gpr63 
Bnipl 
Kcnv2 
Pea15b 
Atad2 
Nostrin 
Zfp85-Rs1 
Olfr1459 
Vmn1r66 
Olfr1270 
Sucnr1 
Gbp6 
Rmnd1 
Aa415398 
Ctsq 
Bc089491 
Hmgb3 
Prim2 
Gpr158 
Rep15 
Tpx2 
Kcna6 
Rad51ap1 
Pnma3 
4632434i11rik 
5930403n24rik 
Olfr1099 
Bc049715 
Wnt1 
Sgms1 
Cd274 
Tnp2 
Fen1 
Socs2 
Chst8 
Anln 
Fkbp1b 
Emx2 
Npffr2 
Cd59a 
Slc1a6 
Mcam 
Hspb6 
Camk4 
Txndc9 
Tmem69 
Olfr446 
Hmmr 
Hells 
Ddit4l 
Vmn1r26 
Ankrd9 
Gimap3 
Olfr74 
Zdhhc16 
1110058l19rik 
Mnx1 
B3galt2 
Slc25a2 
Fsd2 
Mafb 
Avp 
Olfr160 
Mki67 
Gm5424 
Cts6 
B3galt6 
Lrrc49 
Ttc9b 
C87436 
Dlgap5 
Fam110a 
Zcchc7 
Olfr284 
Sost 
Chapter 9. Appendix 
 
341  
 
Clspn 
Serpina5 
Vpreb3 
Dopey1 
Gemin6 
F630043a04rik 
Gtse1 
6330407j23rik 
Vasn 
Ifit2 
Tspan1 
D330045a20rik 
Olfr1364 
Zfp605 
Ddx58 
Hpvc-Ps 
 
9.3 Notch reporter high genes 
Genes up-regulated >1.2 fold in B16 mRFPCAAX Notch reporter high population.
Cdkn1a 
H2afx 
Rpo1-4 
Fzr1 
E130306d19rik 
D10bwg1379e 
9430015g10rik 
Smtn 
Cenpl 
Prkcbp1 
Aurka 
3000004c01rik 
Incenp 
Kif23 
Sgol1 
Cdca2 
Kif11 
Depdc1b 
Vps16 
Top2a 
Ccnb1 
Chka 
Ptp4a3 
Ncaph 
Ezh2 
Tk1 
Slc22a18 
Ddx24 
Lrp11 
Pigt 
Hist1h1c 
Pif1 
Slc25a10 
Stard8 
Rpl23 
Nup160 
Taf15 
5830457o10rik 
Gtse1 
Ncor1 
Dcxr 
5430432m24rik 
Mllt3 
Adh7 
Gsg2 
Fen1 
Phlda1 
Cdca8 
Mmab 
Ifitm3 
A730008h23rik 
Tbx2 
Nfib 
Eif4ebp2 
Isg20l2 
Kif22 
Snrp70 
Tbrg4 
Rad54l 
Nedd4 
Cck 
Zfp36l1 
Espl1 
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Caprin1 
Cetn4 
Dbf4 
Samd9l 
Cdc2a 
Gpatch2 
6430706d22rik 
Nedd1 
Kif4 
Capns1 
Zcchc8 
Ckap5 
Mcm6 
Ifit3 
Loc667609 
Cib1 
Tmem176a 
Rad23a 
Nusap1 
Vezf1 
Bc030476 
Psg23 
Ccdc77 
Nde1 
Gsta4 
4933439c20rik 
2610039c10rik 
Nr1h2 
Csrp1 
Gbp2 
Aldoa 
Dok1 
Cstf3 
Rnf14 
Stim1 
Pfkl 
Tcf25 
Ncapd3 
Taf11 
Ncapd2 
3300001p08rik 
Myst4 
Prc1 
Gna13 
Rnf26 
Lsm2 
4931406p16rik 
Cdkn2c 
Ppp4r1 
Mysm1 
1500010j02rik 
Lmna 
Cdc42ep5 
Dennd2a 
Foxm1 
Mbd1 
Zfp41 
Gtf3c1 
Trmt1 
Pcyt2 
Sfrs5 
Rbm5 
Kif2c 
Timp1 
Prf1 
1500003o03rik 
Mpp5 
Cenpn 
Clk3 
Dynll2 
Rbms1 
Samd4b 
Scand1 
Sypl 
Polh 
Slc41a3 
Nup107 
Ubac1 
Impdh1 
C030011o14rik 
Prkx 
Wdr6 
Tspo 
Vps37b 
Sfrs3 
6330503k22rik 
Bscl2 
Usp52 
Mterfd1 
Tmod1 
Phf17 
Mid1ip1 
Zfp326 
4833446k15rik 
Dpm2 
Anapc5 
Ogdh 
Xrcc1 
Supt5h 
Bub3 
Cacnb4 
Cenpp 
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Pip4k2a 
Lrba 
Chkb 
Cdca5 
Sfrs1 
Npm1 
Stk17b 
1500001m20rik 
D14ertd231e 
Bcas3 
Birc5 
Wdr51b 
Blm 
Csnk1d 
Actn4 
0610012g03rik 
Akap9 
Fez1 
Tex9 
Spc24 
Atp6v0a1 
Rbm38 
Cugbp1 
Ganab 
Ruvbl2 
Irgm 
Rfc2 
Pcyox1l 
Suclg2 
Tssc1 
Rhbdl2 
Depdc6 
Loc675228 
Xrcc6 
Sox5 
Rapgef4 
Mlf1 
Gtf3c2 
Col5a3 
4933407p14rik 
Extl1 
Smad3 
Bud13 
Syngr2 
Fastk 
Slc38a2 
Mdm2 
Ada 
E2f2 
Alg10b 
Tigd2 
Mrps25 
Rfwd3 
2310005n01rik 
Ihpk1 
Tmem49 
Fbxo21 
Wiz 
Nipbl 
Clspn 
Crocc 
Tsga14 
2010003j03rik 
Elf2 
Phf12 
Ecm1 
Mcph1 
Ei24 
Mrps21 
Loc100038882 
Nrbp2 
Ccng1 
D12ertd647e 
Asb6 
Mxd3 
Lace1 
Ppp1r11 
Fadd 
Sh3rf1 
6030443o07rik 
Paqr6 
Ccl5 
Mtap2 
Cdc20 
3010026o09rik 
Rhbdd3 
Klhl30 
Ars2 
Nadk 
Hsf4 
9630058j23rik 
Wdr54 
Cryz 
Stat1 
Hmgb2 
Tmsb10 
Dgkz 
1700027j05rik 
Cdca4 
Serf2 
Phlda3 
2610021k21rik 
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Pofut2 
Clk2 
Parp3 
Srxn1 
Riok3 
6430510m02rik 
Adssl1 
Mapre2 
Bbs4 
Scamp5 
Tex264 
Prpf19 
Srebf1 
Rbm43
 
9.4 EZH2 and Jarid2 regulated genes 
Genes down-regulated by <-1.2 on EZH2 k.d using oligos 1 and 4.
Ezh2 
Fscn1 
Tpp1 
Igfbp4 
H2afx 
Rnf6 
C230021p08rik 
Tead2 
Rnf6 
Pabpc1 
Usp1 
Csda 
Sparc 
Ezh2 
Gnai2 
Cdca4 
2310040a07rik 
Mcam 
Casp2 
Mum1 
Pabpc4 
Gdi1 
2810417h13rik 
Anp32a 
Nt5dc2 
Agrn 
Cd8b 
Loc633016 
Skp2 
Alg8 
Isy1 
Ddx5 
Anapc5 
Top2a 
Actn4 
C230067o06rik 
9830169e20rik 
Nrm 
Kntc1 
B130015m16rik 
Suds3 
Ttyh3 
Gtf3c2 
Cdca4 
C230021p08rik 
Timp1 
Tmcc2 
Ptpn6 
Loc100042405 
Hdgf 
Rnps1 
1110007a13rik 
Mybl2 
Loc100044779 
Zcchc8 
Lmnb1 
Ets1 
Ptbp1 
Bcl2l2 
Slc6a6 
Loc100045677 
Mrps33 
E130016e03rik 
Setd8 
Acat2 
Marcksl1 
6230401i02rik 
Rpa3 
B230333e16rik 
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Srf 
Igfbp4 
Mapre2 
9430080k19rik 
5830434p21rik 
Loc280487 
Fubp3 
Eg666609 
Ppapdc1b 
Pabpc4 
Tmsb10 
2810417k24rik 
Rnps1 
3110001o07rik 
Hdlbp 
Zmiz2 
C79267 
Ncapd2 
Nsbp1 
4833426j09rik 
1110001n06rik 
Prpf4 
Tsc22d4 
9430088n01rik 
Cad 
Dpp9 
Luc7l2 
Mbtps1 
Npepl1 
Hsp90ab1 
Rhbdd3 
Nasp 
Chek2 
Hirip3 
D17h6s56e-5 
Zfp746 
Gm22 
0610037l13rik 
Rpl4 
Phf2 
Gtf3c2 
Thoc3 
Icmt 
Odz4 
Taf15 
1810055e12rik 
Smarce1 
E030026i10rik 
Loc671878 
Magoh 
Tpm1 
Pcyt2 
Bat1a 
Rnasen 
3930401e15rik 
Senp3 
Zmynd11 
Hdac3 
Dek 
Pdia3 
Smarcc1 
2610036l11rik 
Loc100046343 
Odc1 
Loc381889 
Txn1 
Ttll4 
Wiz 
Mcm3 
Gdi1 
Gdi1 
Tmed10 
Nap1l1 
2410014a08rik 
G3bp1 
Parp2 
Wnk1 
Tpm4 
Sf3b4 
H2afy 
Eg667190 
Vgll4 
Mfap3 
Rbmx 
Hist1h2af 
Dhcr7 
Ppm1g 
Rapgef1 
Magoh 
Prmt6 
2410014a08rik 
Bc085271 
Pias1 
Wipi2 
Hdgf 
Ilf3 
Pbx2 
Tmed10 
Fus 
4121402d02rik 
Mcm6 
Cdca4 
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Whsc1 
Afg3l1 
Hist1h2ao 
Nup205 
Ube2e3 
Hnrpa0 
Supt16h 
Atxn1l 
Kif22 
Itpripl2 
2310040a07rik 
Bcas2 
Bat1a 
2310021p13rik 
Cugbp2 
Emp1 
Top2a 
Hist1h2an 
Wdr76 
Pfas 
Cdc25a 
Ubtf 
Igsf3 
Riok1 
Zfp162 
Loc100046136 
Mta1 
Wipi2 
Mylc2b 
Kif23 
Smyd2 
Dennd2a 
Khdrbs1 
Smarce1 
Dlg3 
Dusp19 
Smek2 
Dus4l 
Loc380927 
Thoc4 
2410008k03rik 
Loc100043126 
Cnot3 
Sfrs11 
Nfib 
Llph 
Tmem110 
Fance 
Cbx3 
Mbnl1 
Ruvbl1 
Hn1l 
1190002h23rik 
Bat2 
Rnf4 
Nup210 
Camk1 
Loc545866 
Rbm5 
Bc031781 
Txndc11 
U2af2 
Hist1h2ad 
Rbm38 
Nup107 
Loc100046081 
Wbp5 
Sorbs1 
Snrpd3 
4933424b01rik 
Ncl 
Mtdna_Nd4l 
Snrpf 
Clspn 
Myst2 
Thra 
Nasp 
Ai481316 
Sf1 
Nola3 
Tcof1 
Inppl1 
Kif15 
Mapk1 
Sf1 
Rhoc 
Psmd11 
Rnpep 
Cdkn1b 
Wiz 
Dazap1 
2810485i05rik 
1110011c06rik 
Raly 
1110001n06rik 
Nsdhl 
Hnrnpf 
Cul4a 
Hmgn2 
Ing4 
Arpc5l 
2310005n03rik 
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Pacs2 
1110003o08rik 
Loc100046298 
6720463m24rik 
Med23 
Calr 
Usp1 
Tmed7 
Mex3a 
Copg 
Unc119 
Loc100044557 
Nol5 
Whsc2 
Dcps 
Smc1a 
Hcfc1 
Top1 
Nuak1 
Purb 
Sox11 
B130065g19rik 
Ensa 
Nfib 
Cops6 
Acadm 
Lonp1 
Gstk1 
Orai3 
Lig1 
Aph1a 
Irf2bp1 
Trim27 
Hmgb2 
Scn3b 
1110054h05rik 
Mmab 
9830001h06rik 
Hsp105 
Sf3b3 
Ccnb1 
Lsm2 
Dut 
Nacc1 
Chaf1a 
Rell1 
Mex3a 
D0h4s114 
B9d1 
Fabp5 
Snrp70 
Eif4a3 
Tmpo 
6720469n11rik 
Cep57 
Bc031781 
Setd8 
Fam129b 
Loc100047834 
Mysm1 
4833420g11rik 
Mmp28 
Mlp 
Maea 
Kpnb1 
Hnrpdl 
Ilf3 
2610207i05rik 
Trim27 
Bc025076 
Loc100047012 
Sgol2 
Rpl31 
Dhcr24 
Dhcr24 
Megf8 
Nadk 
Tfdp1 
Atic 
Mcm10 
Nup85 
Ehbp1l1 
Ears2 
Rnf4 
Nup50 
Gdi1 
Zfp553 
Gnaq 
Nmral1 
Abi1 
Ncaph2 
Uhrf1 
Ubqln4 
Ddx1 
Setd6 
A730042j05rik 
Polr2a 
Ncbp2 
Vezf1 
D030056l22rik 
Prelp 
Timp1 
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Gdi1 
Smc6 
Tmem97 
Elavl1 
Actb 
Ide 
2210016l21rik 
Ppapdc1 
Nup50 
Nob1 
Olfr996 
Prmt5 
Osgep 
Prpf40b 
Hnrpdl 
Timeless 
Rbm12 
Ubap2l 
Gnl2 
Tipin 
Prkcbp1 
Pols 
C730029f17rik 
Bc004012 
Loc666036 
Catns 
Hdgf 
Dhcr24 
Xpnpep3 
Rap2a 
Rbm8a 
Mafg 
Pdzrn3 
Zswim6 
Metap2 
Exosc10 
Plaur 
Mcm7 
Tmsb10 
Ahcy 
Polr2f
 
Genes up-regulated by >1.2 fold on k.d with EZH2 oligos 1 and 4. 
 
Mgll 
9930004g02rik 
Oca2 
5730588l14rik 
A530050n04rik 
St3gal1 
Tulp2 
Gsta4 
Ddx26 
Hist1h1c 
Loc380706 
Copg 
Cd72 
Asb2 
Eg232599 
Gpr158 
Bace2 
E130112e08rik 
Gjb2 
Mvp 
Tmem53 
Loc100038882 
Pla2g2e 
Spp1 
Fbxo36 
Loc668631 
Ccl5 
Pi4k2b 
Bst2 
Rsph1 
Usp18 
Scl0001849.1_2273 
Ppargc1a 
Scamp5 
Sat2 
Rhob 
Capzb 
Aa467197 
Atp6v0a1 
Araf 
Siat7b 
Angpt2 
Nus1 
Loc100048346 
Loc381770 
Rad50 
4931422a14rik 
Bb128963 
Cyp4f13 
Slc36a1 
Loc212390 
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Mapk8ip1 
2700046g09rik 
Gsta2 
Terf2ip 
L3mbtl2 
Slc2a6 
Stt3b 
Cmpk 
Creb3 
Loc100047261 
Rnf5 
Sspn 
Ptpre 
Axin2 
Tgfbr2 
5031436o03rik 
2300002d11rik 
Mtap2 
Arfgef2 
Mocos 
Spsb2 
Slc11a1 
Tnip1 
Txndc13 
Pold4 
D19wsu162e 
Pigt 
Iigp2 
Igtp 
E430003j01rik 
Prnp 
Rab7l1 
Fkbp14 
Myo5a 
Rcsd1 
Hisppd2a 
Gsta1 
2810032e02rik 
Wdr68 
Vwf 
Gyg 
Lrrc51 
Ctsz 
Tmem42 
Emp3 
Ahnak 
Slc4a8 
Bc029214 
Snx27 
Cttnbp2 
Dpm2 
Cetn4 
H2-Q5 
Rn18s 
Rgl1 
Tcn2 
Gm1446 
Def6 
Ccdc92 
Vamp5 
Gm26 
Nagk 
Dusp11 
Optn 
Akr1b8 
Nudt7 
Msi2 
Alg3 
Dph4 
Ramp2 
Camk2n2 
Irgm1 
Cd63 
Adh7 
Fbxo2 
Myo1e 
Aip 
Gstm2 
Myl4 
Dusp16 
Egfl7 
St6gal1 
Car13 
Wisp1 
Klf7 
Ephx1 
Il11ra1 
B230209c24rik 
Tuft1 
Cdc42 
Dhrsx 
2510002j07rik 
Hyi 
Cryl1 
Ufc1 
Myd88 
Cpne4 
Mapt 
Pomt2 
Snta1 
Zfp579 
Isoc2a 
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4732458o05rik 
Tpi1 
1810058m03rik 
Zfp238 
Stau2 
2410003p15rik 
1110070o15rik 
Abcc5 
Ppap2a 
Dkk3 
Cryab 
Lgals9 
Ctsh 
Mettl11a 
Gtrgeo22 
Scotin 
Scrg1 
Hmg20a 
Rbm15 
Etv1 
1700088e04rik 
Loc634731 
Sepn1 
Rab1 
Lrp10 
Efcab1 
Cox5b 
Loc100048622 
1700009p17rik 
Eg433865 
Mcoln1 
Adamtsl5 
Pole3 
S100a1 
1110008p14rik 
Cc2d1a 
Mpv17l 
Peci 
Serpinf1 
H2-T23 
Kif1c 
Irf9 
Psmb10 
Slc22a18 
Rusc2 
Pdpk1 
Pigo 
Mylk 
Hist1h2bc 
Ascc2 
Loc100043555 
Padi2 
Ndufaf1 
Nox4 
Sepw1 
Haghl 
Slc35b2 
Hist1h2bm 
Col4a2 
Wbp2 
Gbl 
Evi5l 
Loc100044298 
Loc331595 
Lonp2 
Sel1l 
Aven 
Sdf2 
Mrpl12 
Bfsp2 
Adssl1 
Tubb2c 
Kdelr3 
Hist1h2bn 
Gpr89 
Zfp672 
Large 
Gcs1 
Gramd1b 
Gcap14 
Loc100044159 
Tnfrsf19 
Tmem120a 
Slc19a2 
Sgcb 
Gpr108 
Pdcd5 
Atp5sl 
Dbp 
Ttc3 
Samd9l 
B930007l02rik 
Nfic 
Slc25a38 
Elovl1 
Wfdc12 
Smpd1 
Kctd1 
Commd9 
Loc100044103 
1190007f08rik 
Dnajc15 
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Smpdl3b 
Zfp691 
1110012o05rik 
Mrap 
Otud3 
Cml4 
Hist2h2aa1 
2010001h16rik 
Loc100045780 
Bpnt1 
Os9 
Med16 
Nat6 
Pex11a 
Creg1 
Agpat2 
Glrb 
Rbks 
Atp13a2 
Loc212556 
Grina 
Pgp 
Galnt10 
Por 
Acot1 
Cdkn1a 
9330186a19rik 
Entpd5 
Scarb2 
Ubl7 
Esrra 
Slc4a2 
Nr1h4 
Cutc 
Tyki 
5730472n09rik 
Exosc5 
Tmem192 
Lrrc8a 
Abcd3 
Mkln1 
A730086l23rik 
Aw212394 
Sh3bgrl 
Ptprd 
Sft2d2 
Cpt2 
Dtna 
Coq9 
Tmem120b 
1200003c05rik 
Tmem9b 
Kctd17 
C030027h14rik 
Stat3 
Pbx4 
Lman2l 
Aig1 
Mgst1 
2310047d13rik 
Eg623230 
4921507p07rik 
Prpsap1 
Golga2 
Fam108a 
Tk2 
Rhod 
5930434b04rik 
Wapal 
Sord 
Au040320 
Trpv2 
Dapk3 
1600002k03rik 
Tbrg4 
Med11 
Btbd6 
Bc022224 
Oxsr1 
Lamc1 
Gnptg 
Chpf 
Bace1 
Mboat2 
Gstt3 
D16h22s680e 
Tle2 
Scd2 
Klhl22 
Osbpl2 
Hist1h2be 
1810014f10rik 
Gpr155 
Hist1h2bf 
Loc100040525 
Tmem115 
Fut8 
Gng12 
Tec 
Mfge8 
Commd1 
Rap1gap 
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Apol9b 
Serhl 
Fabp3 
Commd6 
Mras 
Tbc1d15 
C78339 
Slco3a1 
Ap4b1 
Tacc1 
Atp6v1b2 
Slc44a3 
Stim2 
Lmf1 
Vti1a 
Rhobtb2 
Spg20 
D16bwg1494e 
Maged2 
Glrx1 
Polr1b 
Stx8 
Ak3 
Au022252 
Smurf1 
Nod1 
Arl6ip5 
Rnf213 
Acp1 
Phospho2 
Ly6g5c 
1500003o03rik 
Tex264 
Rcor1 
Acadvl 
Loc100045864 
Eif4e2 
Asb1 
3830402i07rik 
Dgcr6 
Arf2 
Slc39a13 
Mtap6 
Hist1h2bk 
Pvr 
Crat 
Hmg20b 
Klf6 
6720456h20rik 
Nkiras2 
1700021f05rik 
Gp38 
9330175b01rik 
Muted 
Cox19 
Thap7 
5730469m10rik 
Stat1 
Eg433224 
C030002b11rik 
Pik3ip1 
Tcfap2a 
Tmed1 
Armc8 
D4ertd22e 
Oas1g 
Cript 
Chchd10 
C530044n13rik 
Tmem126b 
Ndor1 
 
Genes down-regulated by <-1.2 fold on k.d with Jarid2 oligos 1 and 4
Mgll 
5730588l14rik 
Tulp2 
Gsta4 
6430548m08rik 
Hgsnat 
Sspn 
Aebp1 
Fez1 
Rn18s 
Gm1446 
Vamp5 
Hpse 
Rsad2 
Azgp1 
Scrg1 
Mylk 
Gbx2 
Wfdc12 
1110012o05rik 
D10bwg1379e 
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Syt9 
1110059g02rik 
Gcat 
Xbp1 
Tbcd 
Timp3 
V1rd21 
Entpd4 
Gstp2 
Loc638935 
Grhpr 
1700003f12rik 
Ptdss2 
Erlin2 
Dkk3 
Gpr125 
Arpc1a 
Cort 
4930455g09rik 
Elovl4 
4930402h24rik 
St3gal3 
D14ertd449e 
Aph1a 
Slc2a1 
4930583h14rik 
Ano10 
Tmem180 
Pkib 
Armcx2 
Metrn 
Cyp3a13 
1810013d10rik 
Tpcn1 
Specc1 
Psg23 
B230343a10rik 
Bcat1 
Ids 
Cck 
A830080h07rik 
Gjb2 
Golm1 
Ldha 
Mic2l1 
3830612m24 
Tex2 
Bc019806 
Ppib 
Tyr 
Car9 
5031439g07rik 
Mgst3 
Neo1 
3110001p07rik 
Wdfy1 
Fam134b 
Casp6 
Myo5a 
Gipc1 
Pdxdc1 
6720458d17rik 
P4hb 
Scn1a 
C630013b14rik 
Loc100047619 
Tubg1 
Commd8 
2900037o03rik 
S100b 
Slc35b1 
Gas7 
Edem2 
Galnt2 
Acot7 
Brp17 
1700021k14rik 
Loc100046996 
1810063b05rik 
Klhl30 
Tbc1d7 
2700038c09rik 
Fbxo10 
Gins1 
Nubp1 
A630053n20rik 
Zdhhc15 
A630054l15rik 
Aldh1a3 
Emb 
Xpr1 
Abi2 
Glrx5 
Unc84a 
Tmem50b 
Cmtm5 
Pfkm 
Fam125a 
Papss1 
Odf3l1 
Surf4 
4930524j08rik 
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1110001c20rik 
Gcdh 
Idh2 
Scl0002507.1_236 
Rab18 
Gmds 
Dag1 
Tmc6 
Txndc5 
Wnk4 
Pja2 
Ptprm 
Pak4 
Ddx19b 
Itpk1 
Plp1 
Cenpb 
Phactr1 
E2f5 
Dynlt3 
C1qtnf5 
Fam134a 
Abca3 
Mycbp 
Cldnd1 
Ai595366 
Reck 
Mmd 
Loc245892 
Tmem56 
Vps24 
5630401d24rik 
Fnta 
Scd1 
Dgkz 
Slc31a1 
Npc1 
1500032d16rik 
Herpud1 
Extl1 
Sybl1 
Mbp 
Hspg2 
Srd5a3 
Pdss2 
Cyp7b1 
Imp4 
Rhox5 
Dnajc16 
Lman1 
Epb4.1l4b 
Loc381140 
Tmem150 
Bc023829 
Hspb8 
Il10rb 
Zw10 
Loc100045522 
Ppme1 
Ccdc56 
Bc018371 
Ssr1 
1700052o22rik 
Loc100044475 
Cstf2 
Ppard 
Araf 
Fkbp4 
Zdhhc21 
Rnu6 
Tex261 
Cdc40 
Igf2bp3 
Hs2st1 
Si 
Aw549877 
5430417l22rik 
Loc100048083 
1500009l16rik 
Gng7 
Sort1 
Rabgap1 
Aldh3b1 
Cotl1 
Smtnl2 
Arsb 
Pacsin3 
Kif3a 
Prdm16 
Mrpl3 
Insig1 
A630084d02rik 
Mrps15 
Insc 
Wrb 
Sec23ip 
Loc100045280 
1810008a18rik 
Nxt2 
Lbh 
Agps 
Cse1l 
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Lrp4 
Mrpl37 
5133400g04rik 
Tnfaip1 
Scamp5 
Elovl6 
Selk 
Eg638695 
Pi4ka 
Bag3 
Irak1 
Tgfbr1 
2310061j03rik 
Acbd3 
Tsen34 
Tom1l2 
Pfkl 
C78339 
Rab11fip4 
Wipi1 
Dlx6 
Klhl21 
1110012d08rik 
Loc677317 
Zdhhc12 
Tspan14 
Atp2a2 
Rnf26 
Stx12 
Igsf11 
Gprc5b 
Slpi 
4930564d15rik 
Sidt2 
Il1rl1l 
Rnf10 
2410042d21rik 
Afg3l1 
Tm7sf3 
Rab34 
Fin15 
Bet1 
Col9a1 
Suclg2 
Slc25a26 
Ctsc 
3110082i17rik 
2310022m17rik 
Hsp90b1 
Loc385461 
Cyb5 
Gamt 
Sfrs6 
4833439l19rik 
Ube2l3 
Map3k11 
Cdr2 
Cmtm7 
Pcna 
Loc381386 
Tyrp1 
Loc234882 
Tmc8 
Hist1h3c 
Dpysl2 
Pdia6 
Nipsnap1 
Neto2 
Pkd1 
Wdr45l 
Apba3 
Hist1h2ah 
Ahcy 
Letmd1 
Hsd17b11 
Wsb2 
Akt3 
Lman2 
Prelp 
Tmem51 
Mrpl51 
Sec31a 
Megf8 
Dhcr24 
Mod1 
Celsr2 
Gtf2h1 
D0h4s114 
Rell1 
Hsp105 
B230380d07rik 
Loc675899 
Gstk1 
Ugcg 
Idh1 
Plod2 
Loc100045882 
Ptgds 
Copg 
2610035d17rik 
Tmed7 
Mast2 
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Pacs2 
Psmd11 
Napa 
Fbln1 
1810043g02rik 
Bc031781 
Tmem86a 
1190002h23rik 
Mapk11 
Mest 
Reep3 
Odz4 
Traf4 
Pdia4 
Hus1 
Iars 
Hexim1 
Arl2bp 
Nsdhl 
Josd2 
Tpm4 
Asah3l 
Wwp2 
Tmed10 
Hist1h3d 
6230416j20rik 
4432405b04rik 
Dek 
Snx13 
Peli1 
Hist1h3f 
Gtf3c2 
Gm2a 
Hdlbp 
Cyp51 
Loc280487 
5830434p21rik 
Hist1h3e 
Acat2 
2900041a11rik 
Lmnb1 
Ptpn6 
Cd8b 
Nt5dc2 
Pabpc4 
Arl10c 
Pfn2 
Tpp1 
Fscn1
 
Genes up-regulated >1.2 fold on k.d with Jarid2 oligos 1 and 4.
Ccl25 
Mvp 
Fbxo36 
Pi4k2b 
Tmod1 
Ppargc1a 
Rhob 
Araf 
Angpt2 
Tnfrsf12a 
Hs3st1 
Creb3 
Loc100047261 
Rnf5 
5031436o03rik 
Ccnd1 
Txndc13 
Nppb 
2810032e02rik 
Ncald 
Dpm2 
Rgl1 
Def6 
Ppm1k 
Dph4 
Cd63 
Adh7 
Myo1e 
Marcks 
Ass1 
Loc100046232 
Cdc42 
Dhrsx 
Gja1 
Myd88 
Dusp16 
Abcc5 
Lgals9 
1700009p17rik 
Eg433865 
Adamtsl5 
Gadd45a 
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2410016f01rik 
Nrp1 
Carhsp1 
Zfp672 
Pdpk1 
Slc19a2 
Gpr108 
B930007l02rik 
Nfic 
Dscr1 
Dusp8 
Rhobtb2 
Med16 
Anapc7 
Exosc5 
Ddit4l 
A730086l23rik 
Eg623230 
Rhod 
Upp1 
Klrg2 
Serhl 
Epha3 
Scl0002785.1_49 
2510012j08rik 
Spg20 
2810474o19rik 
Ly6g5c 
1500003o03rik 
Hist1h2be 
Loc100045864 
Arf2 
Slc39a13 
Klf6 
Hmgn3 
Gbl 
Loc280205 
Loc385825 
Use1 
Dusp3 
Slc25a29 
Apobec1 
4832420l08rik 
Ppp1r10 
1810032o08rik 
Eif2ak2 
2310005l22rik 
Bc031353 
Eg624124 
Cyhr1 
Adss 
Fam13b 
Glrx2 
Urb2 
Sipa1l1 
C430004e15rik 
Rhou 
1500001e21rik 
Ube2b 
Mttp 
Pmm2 
Suclg1 
Tbx2 
Slc25a38 
Loc100039346 
Ttc13 
Znrf1 
Syf2 
Triap1 
Loc100047093 
1110032e23rik 
Eg630499 
Zfp91-Cntf 
Bckdha 
2410006h16rik 
Loc100047419 
Psrc1 
Mrpl49 
R74862 
Pdlim1 
Tmem166 
Ccnd3 
Bloc1s2 
1810020d17rik 
C430002d13rik 
2410003k15rik 
1110057k04rik 
Ssbp2 
Iqgap3 
Wbp7 
Loc381212 
Pdcd10 
Pdrg1 
Uvrag 
Crem 
Nagk 
C230075m21rik 
Cdkn1a 
Atp5j 
Bc010462 
Bc032203 
Snx12 
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Id3 
Mdm2 
Peo1 
Tcf4 
Mat2a 
Cox18 
Polr2h 
H2-D1 
Bid 
Cox7a2l 
Smn1 
Trp53inp1 
Mrpl54 
Rabac1 
Luzp1 
Loc641366 
1110018j23rik 
Loc665181 
Six1 
Thap11 
Tigd2 
Fosl2 
Gabarap 
1500012f01rik 
Tprkb 
Xpc 
Cdkn2c 
Bc024537 
Vapb 
6030458c11rik 
Eed 
Bud13 
0610038f07rik 
Fam178a 
Ddx21 
Ifit2 
Aldh4a1 
Mrpl9 
Arl16 
2010015p12rik 
Dynlrb1 
Gmip 
Rap2c 
Amotl1 
Irf3 
Bc017612 
Plk2 
Cenpp 
Dhx9 
Dab2 
Rapgef2 
Ncapd2 
Sesn2 
6430706d22rik 
Cdc20 
Tarbp2 
Bbc3 
1700040i03rik 
Loc100046393 
Ccnd2 
Rassf1 
Loc100048445 
Mllt4 
Iah1 
Vkorc1 
Trio 
2010321i05rik 
E130309d02rik 
Mtf2 
Tg 
N6amt1 
Frmd6 
Pax3 
Rnaset2 
Btbd3 
Ndrl 
Polk 
Akap8 
Foxc1 
Pip5k1b 
Lhfp 
Aw548124 
Zfp367 
D4bwg0951e 
E2f6 
Adh5 
Dus3l 
Mrpl24 
Phgdh 
Loc100040243 
Tgs1 
Sox4 
Rnu65 
Gbp2 
Htra2 
2810026p18rik 
Eef2 
1810026b05rik 
5830457o10rik 
Loc100048436 
Snora65 
Gtse1 
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B230369l08rik 
Nola1 
Trp53 
Prkcq 
Pptc7 
9430029l20rik 
Vgll3 
Ifi30
 
Genes down-regulated <-1.2 fold both on k.d with Jarid2 oligos 1 and 4 and EZH2 
oligos 1 and 4. 
 
Dhcr24 
Ptpn6 
Dhcr24 
Prelp 
5830434p21rik 
Dhcr24 
Nt5dc2 
Fscn1 
Rell1 
Gstk1 
Nsdhl 
Acat2 
Bc031781 
1190002h23rik 
Hdlbp 
Lmnb1 
Tpp1 
Pabpc4 
D0h4s114 
Cd8b 
Pacs2 
Dek 
Tmed10 
Gtf3c2 
Tmed7 
Ahcy 
Copg 
Hsp105 
 
Megf8 
Loc280487 
Tmed10 
Psmd11 
Tpm4 
Bc031781 
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